WO 00/50639

Continued

12 of 12

11.00	1000 0 54 60		· · · · · · · · · · · · · · · · · · ·
metoprolol, (S)-; (S)		beta adrenergic	angina; hypertension;
metoprolol	methoxyethyl)phenox		arrhythmia
	y]-3-[(1-	adrenergic antagonist	
	methylethyl)amino}-		
	2-propanol		
sotalol; sotalol	N-[4-[1-hydroxy-2-	beta adrenergic	arrhythmia
hydrochloride; MJ	[(1-	antagonist; class II	
1999; BMY 05763;	methylethyl)amino]et		
SOTACOR;	hyl]phenyl]methanesi		Ì
SOTALEX;	Ifonamide	antiantifytimine	
SOTAZIDE;			
BETAPACE			
dexsotalol; sotalol,	(C) NI [4 [1 badeson.		
(d)-; (+) MJ 1999;	(S)-N-[4-[1-hydroxy-		arrhythmia
BMY 05763	2-[(1-	antagonist; class III	Ì
DIVI I U3/03	methylethyl)amino]et		
	hyl]phenyl]methanesu		İ
	lfonamide		
ivabradine; S 16257;	1 6 6 7	bradycardic agent	angina; arrhythmia
S 16257-2	dimethoxybenzocyclo		-
	butan-1(S)-ylmethyl)-	·	
	N		
	methylanimo]propyl]-		
	7,8-dimethoxy-		
	2,3,4,5-tetrahydro-		
	1H-3-benzazepin-2-		
·	one		
falipamil; AQ A39	2-[3-[[2-(3,4-	calcium antagonist	arrhythmia
CL; AG A 39	dimethoxyphenyl)eth		arring timinu
	yl]methylamino]prop		
	yl]-2,3-dihydro-5,6-		
	dimethoxy-1H-	·	
•	isoindol-1-one		
fantofarone; SR		- alain	
33557; SR 33700	1	calcium antagonist	angina; arrhythmia
2227, SK 22700	methyl-N-[3-[4-[[2-		
	(1-methylethyl)-1-		
•	indolizinyl]sulfonyl]p		
	henoxy]propyl]benze		
	neethanamine		
gallopamil; D 600;		calcium antagonist	nypertension; angina;
PROCORUM;	dimethoxyphenethyl)		arrhythmia
CORAPAMIL;	methylamino]-2-		
ALGOCOR	isopropyl-2-(3,4,5-		ļ
	trimethoxyphenyl)val		
	eronitrile		
	1		

Fr. 0.60	To 50 550 1	T	
KT 362	5-[3-[[2-(3,4-	calcium antagonist	arrhythmia
	dimethoxyphenyl)eth		
	yl]amino]-1-	,	
	oxopropyl]-2,3,4,5-		
	tetrahydro-1,5-		
	benzothiazepine (E)-		
	butenedioate (1:1)		
Ro 236152	(+)-cis-3-(acetoxy)-	calcium antagonist	arrhythmia
}	2,3-dihydro-2-(4-		
	methoxyphenyl)-5-(2-		
	dimethylamino)ethyl-		
	1-naphtho(1,2b)-1,4-		
	thiazepin-4-(5H)one		
EGIS 3966	(E,E)-(+/-)-2-	calcium antagonist;	arrhythmia
·	(phenylmethylene)-	5HT antagonist	
	[3-[bis(1-		
	methylethyl)amino]-		
	2-		
	hydroxypropyl]oxime		
	cyclohexanone (E)-2-		-
e ye et	butendionate		
BRL 32872	N-(3,4-	calcium antagonist;	arrhythmia
	dimethoxyphenyl)-N-	class III	airiiyaiinia
	[3[[2-(3,4-	antiarrhythmic; class	
	dimethoxyphenyl)eth		
	yl]methylamino]prop		
	yl]-4-nitrobenzamide		
AIT 110	Unspecified	Calcium channel	angina; arrhythmia
AIT 111	Unspecified	Calcium channel	angina; arrhythmia;
	F		hypertension
verapamil, (S)-; (S)-	(S)-alpha-[3-[[2-(3,4-	calcium channel	hypertension;
verapamil;	dimethoxyphenyl)eth		arrhythmia; angina
levoverapamil; D	yl]methylamino]prop	Olockoi	amiyuuma, angma
2024	yl]-3,4-dimethoxy-		
	alpha-(1-		
•	methylethyl)benzenea		
	cetonitrile	·	
EMD 60263	 	0.01-:	
CIVID 00203	ethylimino-3,4-	calcium sensitizer	arrhythmia
	dimethoxybenzyl)-		
	1,2,3,4-		
	tetrahydroquinoline-		
	6-yl)-6-methyl-3,6-		
	dihydro-2H-1,3,4-	'	
	thiadiazine-2-one		

AFDX 384	N-[2-[2-	cholinergic	- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 2 2 2 2 2 2 2	[(dipropylamino)meth	Cholineigic	arrhythmia; diagnosis
	yl]-1-	muscarinic	
	piperidinyl]ethyl]-5,6		
1	dihydro-6-oxo-11H-		
·	pyrido[2,3-		
	b][1,4]benzodiazepin	antagonist	
	e-11-carboxamide		
	monomethanesulfonat		
	nonomemanesumona	L	
otenzepad; AFDX	(+) 11 [[2	_1_ 1.	<u> </u>
116; AFDX 116BS	(+,-)-11-[[2-	cholinergic	arrhythmia
110, ALDY 110P2	[(diethylamino)methy		
	[]-1-	muscarinic	
		antagonist;	
	5,11-dihydro-6H-	muscarinic M2	
		antagonist	
	b][1,4]benzodiazepin		
	e-6-one		<u> </u>
acecainide; acecainide	4-(acetylamino)-N-(2-	class I antiarrhythmic	arrhythmia
hydrochloride; N-	(diethylamino)ethyl)b		
acetylprocainamide;	enzamide		
NAPA; ASL 601			
actisomide; SC 36602		class I antiarrhythmic	arrhythmia
	diisopropylamino)eth	:	
·	yl]-4,4a,5,6,7,8-		
	hexahydro-1-methyl-		·
	4-phenyl-3H-		
	pyrido[1,2-		
	c]pyrimidin-3-one		
barucainide	4-benzyl-1,3-dihydro-	class I antiarrhythmic	arrhythmia
	7-[4-		
, ·	(isopropylamino)buto		
	xy]-6-methylfuro[3,4-		
	c]pyridine		
berlafenone; bipranol;	1-([1,1'-biphenyl]-2-	class I antiarrhythmic	arrhythmia
GK 23G	yloxy)-3-[(1,1-	,, <u>,</u> ,	,
·	dimethylethyl)amino]		
	-2-propanol		
bidisomide; SC		class I antiarrhythmic	arrhythmia
	[acetyl(1-		
	methylethyl)amino]et		
	hyi]-alpha-(2-		
	chlorophenyl)-1-		
	piperidinebutanamide		
	Piperidinoutanamide		

ethyl)imino diethanol bis(butylcarbamate) dihydrochloride diprafenone; (+,-)-1-[2-[3-[1,1-dimethylpropyl)amino]-2-hydroxypropoxy]phen yl]-3-phenyl-1-propanone E 0747; E 747; L 29065 E 0747; E 747; L 29065 E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydro-l'-(3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydro-l'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-loroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-loroxy-1-piperidinyl)phenyl-2-piperidinyl)ethyl]phenyl-2-piperidinyl)ethyl]phenyl-2-piperidinyl)ethyl]phenyl-2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benza acetate; R 818; E piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benza mide PLECAINE; APOCARD; ECRINAL	CV (402	h 21 /2 :	T	
dipydrochloride diprafenone; butafenone (+,-)-1-[2-[3-[(1,1-diass I antiarrhythmic arrhythmia dimethylpropyl)amino]]-2-hydroxypropoxy]phen yl]-3-phenyl-1-propanone E 0747; E 747; L 29065 E 0747; E 747; L 6-chloro-2,3-dihydro-l'-(3-(4-hydroxy-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer; E E 0747 (-)isomer (-)-6-chloro-2,3-dihydro-l'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide (-)-(1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-	CV 6402	,		arrhythmia
diprafenone; (+,-)-1-[2-[3-[(1,1-dimethylpropyl)amino]-2-hydroxypropoxy]phen yl]-3-phenyl-1-propanone E 0747; E 747; L G-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylbethyl-ybenzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benza mide ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; (1y (isopropylamino)propyl]fluorene-9-yl]fluorene-9-yl]fluorene-9-yllfluorene-9-yllfluorene-9-yllfluorene-9-yllfluorene-9-yllfluorene-9-yllfluorene-9-yllfluorene-9-yllfluorene-gardinydro-class I antiarrhythmic arrhythmia				
butafenone dimethylpropyl)amino -2- hydroxypropoxy]phen yl]-3-phenyl-1- propanone 6-chloro-2,3-dihydro- 1'-[3-(4-hydroxy-1- piperidinyl)propyl]- 2,2- dimethylspiro[4H-1- benzopyran-4,4'- imidazolidine]-2',5'- dione E 0747 (-)isomer, E 747 (-)isomer E (-)-6-chloro-2,3- dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine]-2',5'- dione encainide; MJ 9067; MJ 90671; E-NKADE; ENKAID flecainide flecainide flecainide flecainide; flecainide flecainide; flecainide flecainide; flecainide flecainide flecainide; flecainide flecainide flecainide flecainide; flecainide flecaini	dinafanana			
]-2- hydroxypropoxy]phen yl]-3-phenyl-1- propanone E 0747; E 747; L 6-chloro-2,3-dihydro- l'-[3-(4-hydroxy-1- piperidinyl)propyl]- 2,2- dimethylspiro[4H-1- benzopyran-4,4'- imidazolidine]-2',5'- dione E 0747 (-)isomer; E (-)-6-chloro-2,3- dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- class I antiarrhythmic arrhythmia midazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- class I antiarrhythmic arrhythmia piperidinyl)phen yl]benzamide flecainide; flecainide acetate; R 818; E opiperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2- Trifluoroethoxy)benza mide ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; (isopropylamino)prop yl]fluorene-9-	, -			arrhythmia
yl]-3-phenyl-1- propanone E 0747; E 747; L 29065 E 06-chloro-2,3-dihydro- 1'-[3-(4-hydroxy-1- piperidinyl)propyl]- 2,2- dimethylspiro[4H-1- benzopyran-4,4'- imidazolidine]-2',5'- dione E 0747 (-)isomer; E 747 (-)isomer E 0747 (-)isomer E 0747 (-)isomer (-)-6-chloro-2,3- dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; L-[2-(1-methoxy-N- [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide N-(2- piperidinyl)ethyl)- 2,5-bis(2,2,2- trifluoroethoxy)benza mide Class I antiarrhythmic arrhythmia arrhythmia class I antiarrhythmic arrhythmia	butatenone		0	
propanone E 0747; E 747; L 29065 6-chloro-2,3-dihydro- 1'=[3-(4-hydroxy-1- piperidinyl)propyl]- 2,2- dimethylspiro[4H-1- benzopyran-4,4'- imidazolidine]-2',5'- dione E 0747 (-)isomer, E 747 (-)isomer E 0747 (-)isomer dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 2,5-bis(2,2,2- trifluoroethoxy)benza mide flecainide; flecain			וֹן	
E 0747; E 747; L 29065 G-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione E 0747 (-)isomer G-chloro-2,3-dihydro-1'-[3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067;		yl]-3-phenyl-1-		}
29065 1'-[3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)pthyl]phen yl]benzamide flecainide; flecainide necainide necainide; flecainide necainide; flecainide necainide necainide necainide; flecainide necainide necain				
29065 1'-[3-(4-hydroxy-1-piperidinyl)propyl]-2,2-dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)pthyl]phen yl]benzamide flecainide; flecainide necainide necainide; flecainide necainide; flecainide necainide necainide necainide; flecainide necainide necain	E 0747; E 747; L	6-chloro-2,3-dihydro-	class I antiarrhythmic	arrhythmia
2,2- dimethylspiro[4H-1- benzopyran-4,4'- imidazolidine]-2',5'- dione E 0747 (-)isomer; E 747 (-)isomer (-)-6-chloro-2,3- dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E 0735; DIONDEL; 735; DIONDEL; 736; Class I antiarrhythmic arrhythmia	29065			
dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione E 0747 (-)isomer, E (-)-6-chloro-2,3-dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-class I antiarrhythmic arrhythmia [2-[2-(1-methyl-2-piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benza mide flecAINE; APOCARD; ECRINAL indecainide; 9-[3-(isopropylamino)prop yl]fluorene-9- dimethylspiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione class I antiarrhythmic arrhythmia arrhythmia arrhythmia arrhythmia arrhythmia arrhythmia		piperidinyl)propyl]-	·	
benzopyran-4,4'- imidazolidine]-2',5'- dione E 0747 (-)isomer, E 747 (-)isomer (-)-6-chloro-2,3- dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 2,5-bis(2,2,2- trifluoroethoxy)benza ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 0-[3- (isopropylamino)prop yl]fluorene-9-		2,2-		
imidazolidine]-2',5'- dione E 0747 (-)isomer; E 747 (-)isomer (-)-6-chloro-2,3- dihydro-1'-(3-(4- hydroxy-1- piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide RNKADE; ENKAID flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 2,5-bis(2,2,2- TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- (isopropylamino)prop yl]fluorene-9-		dimethylspiro[4H-1-		
dione E 0747 (-)isomer; E 747 (-)isomer Class I antiarrhythmic arrhythmia dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)- 2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-class I antiarrhythmic arrhythmia E NKADE; ENKAID ENKADE; ENKAID flecainide; flecainide acetate; R 818; E 0735; DIONDEL; 2,5-bis(2,2,2-trifluoroethoxy)benza ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 9-[3-(isopropylamino)propyl]fluorene-9-		benzopyran-4,4'-		
E 0747 (-)isomer; E (-)-6-chloro-2,3-dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)-2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)-0735; DIONDEL; 2,5-bis(2,2,2-trifluoroethoxy)benza mide flecAINE; APOCARD; ECRINAL indecainide; recainide; LY (isopropylamino)propyl]fluorene-9-		imidazolidine]-2',5'-		
dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)- 2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-class I antiarrhythmic arrhythmia [2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2-trifluoroethoxy)benza mide flecainide; flecainide; p-[3-class I antiarrhythmic arrhythmia arrhythmia arrhythmia class I antiarrhythmic arrhythmia		dione		
dihydro-1'-(3-(4-hydroxy-1-piperidinyl)propyl)- 2,2-dimethyl-spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione encainide; MJ 9067; (+,-)-4-methoxy-N-class I antiarrhythmic arrhythmia [2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2-trifluoroethoxy)benza ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 9-[3-(isopropylamino)propyl]fluorene-9- yl]fluorene-9-	E 0747 (-)isomer; E	(-)-6-chloro-2,3-	class I antiarrhythmic	arrhythmia
piperidinyl)propyl)- 2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2- trifluoroethoxy)benza MLMARYTM; mide flecainide; p-[3- (isopropylamino)prop yl]fluorene-9- class I antiarrhythmic arrhythmia arrhythmia arrhythmia	747 (-)isomer	dihydro-1'-(3-(4-		
2,2-dimethyl- spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E 0735; DIONDEL; TAMBOCOR; TAMBOCOR; Trifluoroethoxy)benza ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- (isopropylamino)prop yl]fluorene-9- class I antiarrhythmic arrhythmia arrhythmia		hydroxy-1-		
spiro(4H-1- benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E 0735; DIONDEL; TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- (isopropylamino)prop yl]fluorene-9- class I antiarrhythmic arrhythmia class I antiarrhythmic arrhythmia		piperidinyl)propyl)-		
benzopyran-4,4'- imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; recainide; 09-[3- (isopropylamino)prop yl]fluorene-9- loss I antiarrhythmic arrhythmia		2,2-dimethyl-		·
imidazolidine)-2',5'- dione encainide; MJ 9067; (+,-)-4-methoxy-N- MJ 90671; [2-[2-(1-methyl-2- ENKADE; ENKAID piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 2,5-bis(2,2,2- trifluoroethoxy)benza ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- (isopropylamino)prop yl]fluorene-9- imidazolidine)-2',5'- dione class I antiarrhythmic arrhythmia arrhythmia class I antiarrhythmic arrhythmia		spiro(4H-1-		
dione encainide; MJ 9067; MJ 90671; ENKADE; ENKAID piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 2,5-bis(2,2,2- trifluoroethoxy)benza ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; 09-[3- (isopropylamino)prop yl]fluorene-9-		benzopyran-4,4'-		·
encainide; MJ 9067; (+,-)-4-methoxy-N- MJ 90671; [2-[2-(1-methyl-2- piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 2,5-bis(2,2,2- trifluoroethoxy)benza ALMARYTM; mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- (isopropylamino)prop yl]fluorene-9- class I antiarrhythmic arrhythmia class I antiarrhythmic arrhythmia arrhythmia class I antiarrhythmic arrhythmia arrhythmia				
MJ 90671; [2-[2-(1-methyl-2-piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2-trifluoroethoxy)benza mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3-class I antiarrhythmic arrhythmia class I antiarrhythmic arrhythmia class I antiarrhythmic arrhythmia		dione		
ENKADE; ENKAID piperidinyl)ethyl]phen yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2- TAMBOCOR; trifluoroethoxy)benza mide FLECAINE; APOCARD; ECRINAL indecainide; p-[3- recainide; LY (isopropylamino)prop yl]fluorene-9- piperidinyl)ethyl]phen yl]benzamide class I antiarrhythmic arrhythmia		1	class I antiarrhythmic	arrhythmia
yl]benzamide flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; TAMBOCOR; ALMARYTM; FLECAINE; APOCARD; ECRINAL indecainide; recainide; LY 135837; DECABID yl]benzamide class I antiarrhythmic arrhythmia class I antiarrhythmic arrhythmia	•			
flecainide; flecainide acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2- TAMBOCOR; trifluoroethoxy)benza mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- recainide; LY (isopropylamino)prop yl]fluorene-9- class I antiarrhythmic arrhythmia arrhythmia	ENKADE; ENKAID			
acetate; R 818; E piperidinylmethyl)- 0735; DIONDEL; 2,5-bis(2,2,2- TAMBOCOR; trifluoroethoxy)benza ALMARYTM; mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- recainide; LY (isopropylamino)prop yl]fluorene-9-				
0735; DIONDEL; 2,5-bis(2,2,2- TAMBOCOR; trifluoroethoxy)benza ALMARYTM; mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- recainide; LY (isopropylamino)prop yl]fluorene-9-	-	1 `	class I antiarrhythmic	arrhythmia
TAMBOCOR; trifluoroethoxy)benza mide ALMARYTM; mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- class I antiarrhythmic arrhythmia recainide; LY (isopropylamino)propyl] 135837; DECABID yl]fluorene-9-		piperidinylmethyl)-		
ALMARYTM; mide FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- class I antiarrhythmic arrhythmia recainide; LY (isopropylamino)propylamino)propylamino)propylamino)propylamino	_	2,5-bis(2,2,2-		
FLECAINE; APOCARD; ECRINAL indecainide; 9-[3- class I antiarrhythmic arrhythmia recainide; LY (isopropylamino)prop yl]fluorene-9-	1			
APOCARD; ECRINAL indecainide; 9-[3- recainide; LY (isopropylamino)prop 135837; DECABID yl]fluorene-9-		mide		
ECRINAL indecainide; 9-[3- class I antiarrhythmic arrhythmia recainide; LY (isopropylamino)prop 135837; DECABID yl]fluorene-9-			•	
indecainide; 9-[3- class I antiarrhythmic arrhythmia (isopropylamino)prop yl]fluorene-9-	APOCARD;			
recainide; LY (isopropylamino)prop 135837; DECABID yl]fluorene-9-	ECRINAL			
recainide; LY (isopropylamino)prop 135837; DECABID yl]fluorene-9-	indecainide;	, -	class I antiarrhythmic	arrhythmia
r - 1				-
carboxamide	135837; DECABID	F -		
		carboxamide		

rz 052	5	T	,	
K 953	3-amino-5'-ethoxy-2'	class I antiarrhythmic	arrhythmia	
	(3-pyridyl)		1	
i	butyranilide		1	
	dihydrochloride		1	
LG 6101	1-[3-[2-methoxy-3-	class I antiarrhythmic	arrhythmia	
	[(2-		1	
	methylpropyl)amino]			
	propoxy]-4-methyl-2-	1	1	
	thienyl]-3-phenyl-1-			
	propanone			
	hydrochloride			
LNC 834; LNC 409	(9S)-10,11-dihydro-	class I antiarrhythmic	arrhythmia	·
sulfate	6'-methoxycinchonan		arrinyumma	
	3,9-diol sulfate (1:1)			
	salt			
modecainide; MJ	(+,-)-4-hydroxy-3-	class I antiarrhythmic	omby there's	
14030	methoxy-N-[2-[2-(1-	Class I annamymmic	amiyuuma	
1 1050	methyl-2-			
	piperidinyl)ethyl]pher			
	yl]benzamide	4	[
moracizine;	ethyl 10-(3-	alaas Lantiambatharia	11	
moricizine;	morpholinopropionyl)	class I antiarrhythmic	arrnythmia	
ethmosine; ethmozin;				
etmozin; EN 313;	carbamate			
ETHMAZONE;	carbamate	·		
ETHMAZONE, ETHMOZINE				
	4 1'' 1 4 1			27 11
NS 2	4-diisobutylamino-	class I antiarrhythmic	arrhythmia	en gerien er en in
•	1,1-diphenyl-1-			
070.77	butanol maleate			
ORG 7797	(16alfa,17beta)-17-	class I antiarrhythmic	arrhythmia	
	(methylamino)-estra-			
	1,3,5(10)-triene-3,16-			
	diol (Z)-butenedioate			
	(1:1) salt			
pilsicainide;	N-(2,6-	class I antiarrhythmic	arrhythmia	
pilsicainide	dimethylphenyl)tetrah			
hydrochloride;	ydro-1H-pyrrolizine-			
pilzicainide; SUN	7a(5H)-acetamide			
1165; SUNRYTHM				ł
pirmenol; pirmenol	cis-(+,-)-alpha-[3-	class I antiarrhythmic	arrhythmia	
hydrochloride; CI	(2,6-dimethyl-1-			1
845; PIRMAVAR;	piperidinyl)propyl]-			
PIMENOL	alpha-phenyl-2-			
,	pyridinemethanol			
	P) TOTTO THOU			

quinacainol; RP	D (1 1 dim other lather)	Internal Laboration	
54272; PK 10139	alpha-[2-(4-	-class I antiarrhythmic	arrhythmia
54272, FK 10139	piperidinyl)ethyl]-4-		
	quinolinemethanol		
ino WV 42262		1. T (1. 1. 1. 1.	<u> </u>
recainam; WY 42362		class I antiarrhythmic	arrhythmia
WIN 42362	dimethylphenyl)-N'-		
	[3-[(1-		
	methylethyl)amino]pr		
	opyl]urea	<u> </u>	
bertosamil	3'-isobutyl-7'-	class I antiarrhythmic	;arrhythmia; angina
	isopropylspiro(cycloh	I .	
	exane-1,9'-	antiarrhythmic	
]	(3,7)diazabicyclo(3.3.		
	1)nonane)		
levosemotiadil; DQ	(S)-2-[2-[3-[[2-(1,3-	class I antiarrhythmic	arrhythmia
4824; DS 4824; SD	benzodioxol-5-	class III	
3212; SA 3212	yloxy)ethyl]methylam	antiarrhythmic	
	ino]propoxy]-5-		
	methoxyphenyl]-4-		
	methyl 2H-1,4-		
	benzothiazin-3(4H)-	%	- "
NID I 57500	one		
WIN 57600	Unspecified	class I antiarrhythmic;	arrhythmia
		class III	· .
		antiarrhythmic	
WIN 61773	Unspecified	class I antiarrhythmic;	arrhythmia
		class III	
		antiarrhythmic	
WIN 65802	Unspecified	class I antiarrhythmic;	arrhythmia
	<u>'</u>	class III	
		antiarrhythmic	
bisaramil; bisaramil		class I antiarrhythmic;	arrhythmia
hydrochloride; RGH	syn-3-ethyl-7-methyl-		
2957; YUTAC	1	antiarrhythmic	
٠	diazabicyclo[3.3.1]no		
	n-9-yl ester		
			arrhythmia
		antiarrhythmic; class	
		III antiarrhythmic	
	yl)phenoxy]ethyl]ami		
	no]propoxy]phenyl]m	,	
	ethanesulfonamide		

WO 00/50639 PCT/US00/01392

ambasilide; LU 4711	03-(4-aminobenzoyl)-	class III	arrhythmia
	7-benzyl-3,7-	antiarrhythmic	
1	diazabicyclo[3.3.1]no		
	nane		
AWD 160275	Unspecified	class III	arrhythmia
		antiarrhythmic	
AWD 23111	unspecified	class III	arrhythmia
	•	antiarrhythmic	
CK 1649C	1-[2-hydroxy-2-[4-	class III	arrhythmia
	[(methylsulfonyl)ami	antiarrhythmic	
	no]phenyl]ethyl]-3-		
	methyl-1H-		
	imidazolium chloride		
dronedarone; SR	N-[2-butyl-3-[4-[3-	class III	arrhythmia
33589	(dibutylamino)propox	antiarrhythmic	
	y]benzoyl]-5-		
	benzofuranyl]-		
	methanesulfonamide		
E 4031	N-[4-[[1-[2-(6-	class III	arrhythmia
	methyl-2-	antiarrhythmic	
	pyridinyl)ethyl]-4-		· .
	piperidinyl]carbonyl]		
I	phenyl]methanesulfon		
	amide		
	dihydrochloride		
EGIS 7229	5-chloro-4-[[3-[[2-	class III	arrhythmia
		antiarrhythmic	-
	dimethoxyphenyl)eth		
	yl]methylamino]prop		
	yl]amino]-3(2H)-		
	ругidazinone (Е)-2-		
	butenedioate (1:1)		
ibutilide; ibutilide		class III	arrhythmia
	(ethylheptylamino)-1-	antiarrhythmic	
70226E; CORVERT	hydroxybutyl]phenyl]		
•	methanesulfonamide		
pazilide; ipalizide	1 - 1		arrhythmia
fumarate; WIN	(diethylamino)propyl]		· •
- 4177 33773 7 - 44 - 4	/ / / / / / / / /		1
54177; WIN 541774	-4,5-diphenyl-1H-	.,	

L 691121	NI 511 52 75	L1 YEY	
12 091121	N-[1'-[2-(5-	class III	arrhythmia
	benzofurazanyl)ethyl	antiarrhythmic	
	-3,4-dihydro-4-		
	oxospiro[2H-1-		
	benzopyran-2,4'-		
	piperidin]-6-		
	yl]methanesulfonami		
	de		
	monohydrochloride		
L 768673	(R) N-[2,3-dihydro-	class III	arrhythmia
	2-oxo-5-phenyl-1-	antiarrhythmic	
	(2,2,2-trifluoroethyl)-		
	1H-1,4-		
	benzodiazepin-3-yl]-		1
	2,4-		
	bis(trifluoromethyl)be		
	nzeneacetamide		
nifekalant; MS 551	6-[[2-[(2-	class III	arrhythmia
	hydroxethyl)[3-(4-	antiarrhythmic	
	nitrophenyl)propyl]a		
	mino]ethyl]amino]-		
	1,3-dimethyl-		
	2,4(1H,3H)-		
	pyrimidinedione		
	monohydrochloride		
ORG 20781	unspecified	class III	arrhythmia
		antiarrhythmic	aimyumna
SB 237376	N-[3-[[2-(3,4-	class III	arrhythmia
	dimethoxyphenyl)eth		amyuuma
··· : .		IV antiarrhythmic	
	nitrobenzamide		
KCB 328		class III	arrhythmia
102 320	methanesulfonamidop		armyuuma
		potassium channel	
		^	
	dimethoxyphenethyl)- N-	DIOCKET	
	methylaminolethaneh		
	ydrochloride		
TTF 1300			
11 1300		=	thrombosis;
		antiarrhythmic	arrhythmia

selenotifen; BN	4,9-dihydro-4-(1-	histamine antagonist;	ave disease: eathers
52256	methyl-4-	histamine H1	arrhythmia; rhinitis
	piperidinylidene)-	antagonist	armytiuma, miinus
	10H-	anagomst	
	benzo[4,5]cyclohepta		
	[1,2-b]selenophen-10		
	one		
atrial fibrillation	Unspecified	Ion channel	arrhythmia
therapy	1	modulator	
ion channel	Unspecified	Ion channel	arrhythmia; asthma
modulators	1	modulator	arinyanina, asumia
ecdisteron; ecdisten	Unspecified	Membrane	arrhythmia
		stabilization	arriyumna
mexiletine; KO 1173;	1-methyl-2-(2.6-	Na+ channel	neuropathy;
MEXITIL	xylyloxy)ethylamine	induction of native	arrhythmia; diabetes
	hydrochloride	open state and first	aimyumina, madeles
!		step of open channel	
5HT4 human	Unspecified	neuroreceptor, 5HT4	irritable bowel
neuroreceptor;			syndrome; cognitive
			defect; anxiety;
			arrhythmia; stroke;
·			urinary incontinence;
			migraine; research
			tool
AAP 10	6-L-tyrosinamide-		arrhythmia
	retro-antiarrhythmic		
	peptide (cattle atrium)		
kappa-conopeptides	Unspecified	peptide; potassium	heart ischemia;
			arrhythmia;
			gastrointestinal
<u>. </u>	·		disorder
cloricromen;	[[8-chloro-3-[2-	platelet antiaggregant;	arrhythmia:
cloricromene; AD 6;			thrombosis
PROENDOTEL	4-methyl-2-oxo-2H-		<i></i>
•	l-benzopyran-7-		
	yl]oxy]acetic acid		
	ethyl ester		
almokalant; H 234/09	(+,-)-p-[3-[ethyl[3-	Positive inotropic;	arrhythmia
	(propylsulfinyl)propyl		·
]amino]-2-	•	İ
	hydroxypropoxy]benz		
	onitrile		

r			
pentisomide;	(+,-)-alfa-[2-[bis(1-	potassium channel	arrhythmia
penticainide;	methylethyl)amino]et	activator; class I	
propisomide; CM	hyl]-alfa-(2-	antiarrhythmic	
7857; ME 3202;	methylpropyl)-2-		
RYTHMATE	pyridineacetamide		
AWD 12260; AWD	6-[[3-	potassium channel	arrhythmia
122-60	(diethylamino)propyl		
İ	amino][3,4'bipyridine		·
]-5-carbonitrile		
HMR 1098	unspecified	potassium channel	arrhythmia
	1 ^	blocker	
HMR 1883	Unspecified	potassium channel	arrhythmia
		blocker	arriyumia
potassium channel	Unspecified	potassium channel	arrhythmia
blocker,		blocker	ailiyuulla
WAY 123398	N-methyl-N-[2-	potassium channel	arrhythmia
	[methyl(1-methyl-1H-		aimytiima
	benzimidazol-2-	DIOCKCI	
	yl)amino]ethyl]-4-		
	[(methylsulfonyl)ami		
	no])benzensulfonami		
	de		
azimilide; azimilide	1-[[[5-(4-	potassium channel	ischemia; arrhythmia
dihydrochloride;	1 '	blocker; class III	ischenna, armyumna
	furanyl]methylene]am	antiarrhythmic	
STEDICOR	ino]-3-[4-(4-methyl-	and an iny diffic	
	1-piperazinyl)butyl]-		
	2,4-		
	imidazolidinedione		. • •
dofetilide: UK 68798:	N-[4-[2-[methyl[2-[4-	notaccium channel	arrhythmia
XELIDE: TIKOSYN	[(methylsulfonyl)ami	blocker: close III	amynuma
, moon	no]phenoxy]ethyl]ami		
	no]e thyl]phenyl]-	·	
	methanesulfonamide		
MK 499; L 706000			
MIX 433, L 700000	1 -		arrhythmia
		blocker; class III	
nometilid		antiarrhythmic	
sematilide; sematilide	1 -		arrhythmia
hydrochloride; CK		blocker; class III	
1752; RU 752; SH		antiarrhythmic	
506; ZK 110516	[(methylsulfonyl)ami		
<u> </u>	no]benzamide		

			
WAY 123223	N-[4-[2-hydroxy-3- [methyl(2- quinolinylmethyl)ami no]propoxy]phenyl]n ethanesulfonamide		arrhythmia
WAY 125971	N-(2-((methyl(3-(4- ((methylsulfonyl)ami no)phenoxy)propyl)a mino)methyl)-6- quinolinyl)methanesu lfonamide	antiarrhythmic	arrhythmia
KW 3407	5-[[(2-diethylamino)ethyl]a mino]-5,11-dihydro-7-methoxy-(1)-benzoxepino-[3,4-b]pyridine fumarate (2:3)	sodium channel blocker	arrhythmia
antiarrhythmic, acute,		sodium channel blocker; potassium channel blocker	arrhythmia
cariporide; cariporide mesilate; HOE 642; HOE 642A	N- (aminoiminomethyl)- 4-(1-methylethyl)-3- (methylsulfonyl)benz amide	sodium/hydrogen exchange inhibitor	arrhythmia; myocardial infarction; angina; restenosis
KBR 9032; KB-R 9032	N- (aminoiminomethyl)- 3,4-dihydro-2,2- dimethyl-4-(1- methylethyl)-3-oxo- 2H-1,4-benzoxazine- 6-carboxamide monomethanesulfonat e	exchange inhibitor; anti-ischemic	arrhythmia; heart ischemia; reperfusion injury
KB 130015	l ·	thyroid hormone antagonist	arrhythmia
thyroid hormone receptor alpha antagonists	unspecified		arrhythmia

RS 2135	(3aR,12R,12aR,12bS)	vasodilator	arrhythmia
	-12-amino-		
	2,3,3a,4,11,12,12a,12		
ł	b-octahydro-10-		
	hydroxyisoquino[2,1,		
	8-lma]carbazol-		
	5(1H)-one		
	hydrochloride 1:5		
	hydrate	:	
milacainide;	(R)-2-amino-N-(2,6-	vasodilator; sodium	arrhythmia
xilacainide; Ro		channel blocker; class	
229194	[3-(3-	I antiarrhythmic	
	pyridinyl)propyl]prop	_	
	anamide [S-(R*,R*)]-		
	2,3-		
	dihydroxybutanedioat		
	е		

Table 60. Current Candidate Therapeutic Interventions for the Treatment of Hypertension

Product Name	Chemical Name	Action	atment of Hypertension Indication
	6-[[3-[4-(2-	5HT agonist; 5HT1A	
MU	methoxyphenyl)-1-	agonist	
	piperazinyl]propyl]a		
	mino]-1,3,5-		
	trimethyl-2,4(1H,3H)-		
	pyrimidinedione		
A 74283		5HT agonist; 5HT1A	hypertension
		agonist; vasodilator	
U 86192A		5HT antagonist;	hypertension
	phenylpropyl)amino]	5HT1A antagonist	
	methyl]-7H-1,4-		
	dioxino[2,3-e]indole-		,
	8-carboxylic acid		
	methyl ester	<u> </u>	
AHR 16303B	1-[4-[3-[4-[bis(4-	5HT antagonist;	hypertension; angina
	fluorophenyl)hydroxy		
	methyl]-1-		
	piperidinyl]propoxy]p		
	henyl]-2-methyl-1-		
	propanone		
	ethanedioate (1:1)		

ketanserin; R 41468;	3-[2-[4-(4-	5HT antagonist;	hypertension
SEREFREV;	fluorobenzyl)-1-	5HT2 antagonist	1.
SUFREXAL;	piperidinyl]ethyl]-		
SEREFREX	2,4(1H,3H)-		
	quinazolinedione		
lidanserin; ZK 33839	(+,-)-4-[3-[3-[4-(p-	5HT antagonist;	hypertension
	fluorobenzoyl)piperid	5HT2 antagonist;	
	ino]propoxy]-4-	alpha adrenergic	
	methoxyphenyl]-2-	antagonist; alpha1	`
	pyrrolidinone	adrenergic antagonist	
SUN 9221	2-(4-chlorophenyl)-	5HT antagonist;	hypertension
	1,4-dihydro-	5HT2 antagonist;	
	[1]benzothiopyrano[4	alpha adrenergic	
	,3-c]pyrazol-3(2H)-	antagonist; alpha1	
·	one 5-oxide	adrenergic antagonist;	,
		platelet antiaggregant	
AB 47	(S)-1-[N-(8-amino-1-	ACE inhibitor	hypertension
	carboxyoctyl)-L-		
	alanyl]-L-proline		
ACE inhibitor	1-(2-((1-carboxy-6-	ACE inhibitor	hypertension
	(4		
••	piperidinyl)hexyl)ami		
	no)-1-		
,	oxopropyl)octahy		
and and take	dro-1H-indole-2-		•
# 1 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	carboxylic acid		
alacepril; DU 1219;		ACE inhibitor	hypertension
CETAPRIL	(acetylthio)-2-methyl-	•	
	l-oxopropyl]-L-		
	prolyl]-L-		
	phenylalanine		
benazepril; benazepril		ACE inhibitor	hypertension
hydrochloride;	(ethoxycarbonyl)-3-		• 1
	phenylpropyl]amino]-		
	2,3,4,5-tetrahydro-2-		,
LOTENSIN; BRIEM;	,		
	benzazepine-1-acetic		
	acid		
CIBACENE		1	· · · · · · · · · · · · · · · · · · ·

captopril; SQ 14225;	1-(3-mercapto-2-	ACE inhibitor	
ACENORM;	methyl-1-oxopropyl)-		hypertension; kidney
ACEPRIL;	L-proline		disease; heart failure;
1	L-pronne		diabetes
ANTIPRESS;			
CAPLOLANE;			
CAPOTEN;			
CAPOZIDE;			
CAPTEA;			
CAPTORIL;			
LOPIRIN;			
TENSOBON			
ceronapril; ceranapril		ACE inhibitor	cognitive defect;
SQ 29852	[[hydroxy(4-		hypertension; anxiety
	phenylbutyl)phospiny		
	l]oxy]-1-oxohexyl]-L-		
	proline		·
cilazapril; Ro	(1S,9S)-9-[[(1S)-1-	ACE inhibitor	hypertension
312848; Ro 312848	ethoxycarbonyl-3-		
006; INHIBACE;	phenylpropyl]amino]		
VASCACE;	octahydro-10-oxo-		
DYNORM	6H-pyridazino[1,2-		
	a][1,2]diazepine-1-		
	carboxylic acid		
CV 5975	(R)-3-[(S)-1-carboxy-	ACE inhibitor	hypertension
	5-(4-		
	piperidyl)pentyl]amin		
	o-4-oxo-2,3,4,5-	,	
[.	tetrahydro-1,5-		
	benzothiazepine-5-		
	acetic acid		
delapril; alindapril;	(S)-N-(2,3-dihydro-	ACE inhibitor	hypertension
CV 3317; REV	1H-inden-2-yl)-N-[N-		.
6000A; ADECUT;	[1-(ethoxycarbonyl)-		
CUPRESSIN;	3-phenylpropyl]-L-		
KEDAPRIL;	alanyl]glycine		in in a comment of the particle of the particl
DELAKET			
drug delivery system,	Unspecified	ACE inhibitor	hypertension
controlled release	•		- J
captopril; captopril			
drug delivery system,	Unspecified	ACE inhibitor	heart failure;
SODAS captopril;	k		hypertension
captopril SODAS			itypertension
1777			

nicotinoyl-L-lysyl- alpha-D- glutamyoctahydro- 1H-indole-2- carboxylic acid enalapril; MK 421; INNOVACE; (COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril; sodium; fosenopril; prodrug; MONOPRIL; DYNACIL; Phenylbutyl)phosphin yl]acetyl]-L-proline FUSINORM; FOSITENS; STARIL; FOZITEC fosinoprilat; f	DU 1777	(20.2-0.7.0) 1.010	A CELL 1	
alpha-D- glutamyoctahydro- 1H-indole-2- carboxylic acid enalapril; MK 421; (S)-1-[N-[1- (ethoxycarbonyl)-3- phenylpropyl]-L- alanyl]-L-proline RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril; sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; POSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; PIL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (MCE inhibitor hypertension hypertension hypertension hypertension ACE inhibitor hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension			ACE inhibitor	hypertension
glutamyoctahydro- 1H-indole-2- carboxylic acid enalapril; MK 421; INNOVACE; (ethoxycarbonyl)-3- phenylpropyl]-L- alanyl]-L-proline RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; ptynACIL; pt				
IH-indole-2- carboxylic acid enalapril; MK 421; (S)-1-[N-[1- (ethoxycarbonyl)-3- phenylpropyl]-L- alanyl]-L-proline ACE inhibitor hypertension hypertension ACE inhibitor hypertension hypertension hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension		, <u>-</u>		
carboxylic acid enalapril; MK 421; INNOVACE; COVERTEN; COVERTEN; ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; POSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprili; osinopril; osinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline Trans-4-cyclohexyl-1- [[hydroxy(4- phenylbutyl)phosphin yl]acetyl]-L-proline ACE inhibitor hypertension hypertension hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension				
enalapril; MK 421; (S)-1-[N-[1- (ethoxycarbonyl)-3- phenylpropyl]-L- alanyl]-L-proline RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; Phenylbutyl)phosphin yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline PL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)) ACE inhibitor hypertension hypertension ACE inhibitor hypertension ACE inhibitor hypertension				
INNOVACE; COVERTEN; ENAPREN; ENAPREN; RENITEN; VASOTEC; VASCRETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; Phenylbutyl)phosphin yl]acetyl]-L-proline FUSINORM; FOSITEN; STARIL; FOZITEC fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; fosinoprilat; fosfenopril; f				
COVERTEN; phenylpropyl]-L- alanyl]-L-proline RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline ACE inhibitor hypertension hypertension ACE inhibitor hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension ACE inhibitor hypertension hypertension			ACE inhibitor	hypertension
ENAPREN; RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; Phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosin	1			
RENITEN; VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril; SQ 2855; SQ 27519 prodrug; MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; trans-4-cyclohexyl-1- [[hydroxy(4- phenylbutyl)phosphin yl]acetyl]-L-proline FOSIenopril; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))	1			
VASOTEC; VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 [[[2-methyl-1-(1- oxopropoxy)propoxy] (4- DYNACIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilic; acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)) ACE inhibitor hypertension hypertension hypertension hypertension	1	alanyl]-L-proline		
VASERETIC; AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril; sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosinoprilat; fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline	-			
AMPRACE; RECA; GLIOTEN; HIPOARTE fosinopril; fosinopril; sodium; fosenopril; SQ 28555; SQ 27519 prodrug;	VASOTEC;			
GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 [[[2-methyl-1-(1- oxopropoxy)propoxy] MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline	VASERETIC;			
GLIOTEN; HIPOARTE fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 [[[2-methyl-1-(1- oxopropoxy)propoxy] MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline fosinoprilat; fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline	AMPRACE; RECA;	1		
fosinopril; fosinopril sodium; fosenopril; SQ 28555; SQ 27519 prodrug; MONOPRIL; DYNACIL; Phenylbutyl)phosphin FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; fosfenopril; fosfenopril; fosfenopril; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fosfenopril; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline fPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (IS,2R)-2- (((hydroxycarbamoyl))	GLIOTEN;			
sodium; fosenopril; eta]-4-cyclohexyl-1- [[2-methyl-1-(1- oxopropoxy)propoxy] [A- phenylbutyl)phosphin yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; trans-4-cyclohexyl-1- fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))	HIPOARTE			
sodium; fosenopril; eta]-4-cyclohexyl-1- [[2-methyl-1-(1- oxopropoxy)propoxy] MONOPRIL; (4- phenylbutyl)phosphin yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; (1		[1[S*(R*)].2alpha_4h	ACE inhibitor	hypertension
SQ 28555; SQ 27519 [[[2-methyl-1-(1-oxopropoxy)propoxy] (4-phenylbutyl)phosphin yl]acetyl]-L-proline [hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline [hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline [TPL 66564] TPL 66564 GR)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid [IS,2R)-2-(((hydroxycarbamoyl))] GRAFIL; FOZITEC ACE inhibitor hypertension hypertension [IS,2R)-2-(((hydroxycarbamoyl))]			I TOO MANOROI	ryportonsion
prodrug; MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (IS,2R)-2- (((hydroxycarbamoyl))	1			
MONOPRIL; DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; fosfenopril; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))		·		
DYNACIL; phenylbutyl)phosphin yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC Fosinoprilat; trans-4-cyclohexyl-1- [[hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3- (methylthio)-propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))	r •			
FUSINORM; yl]acetyl]-L-proline FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC Fosinoprilat; trans-4-cyclohexyl-1- [hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3- (methylthio)-propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))		 	·	
FOSITENS; TENSO STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; trans-4-cyclohexyl-1- [hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))	,			1
STOP; FOSITEN; STARIL; FOZITEC fosinoprilat; fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)) trans-4-cyclohexyl-1- ACE inhibitor hypertension ACE inhibitor hypertension		bijacotyij-15-pioniic		
FOSTARIL; FOZITEC Fosinoprilat; trans-4-cyclohexyl-1- [hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))	•			
fosinoprilat; trans-4-cyclohexyl-1- [hydroxy(4-phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid drapril; LG 32001 (1S,2R)-2-(((hydroxycarbamoyl)) trans-4-cyclohexyl-1- ACE inhibitor hypertension hypertension hypertension hypertension hypertension hypertension hypertension				
Fosinoprilic acid; SQ phenylbutyl)phosphin yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- 0xopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))		trans 4 cyclobayyl 1	ACE inhibitor	1
phenylbutyl)phosphin yl]acetyl]-L-proline PL 66564 (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)-propanoic acid drapril; LG 32001 (1S,2R)-2-(((hydroxycarbamoyl))			ACE HUNDROF	hypertension
yl]acetyl]-L-proline FPL 66564 (R)-2-(3-mercapto- 2(S)-methyl-1- 0xopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)) ACE inhibitor hypertension		,		
(R)-2-(3-mercapto- 2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)) ACE inhibitor hypertension	-		•	
2(S)-methyl-1- oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl))			AOD 1 1 1 1	
oxopropoxy)-3- (methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)) ACE inhibitor hypertension			ACE inhibitor	hypertension
(methylthio)- propanoic acid drapril; LG 32001 (1S,2R)-2- (((hydroxycarbamoyl)				
propanoic acid drapril; LG 32001 (1S,2R)-2- ACE inhibitor hypertension (((hydroxycarbamoyl)	•			
drapril; LG 32001 (1S,2R)-2- ACE inhibitor hypertension (((hydroxycarbamoyl)		, .		
(((hydroxycarbamoyl)				
	idrapril; LG 32001		ACE inhibitor	hypertension
mathyd) mathydaeth au				
		methyl)methylcarbam		
oyl)cyclohexane		oyl)cyclohexane		
carboxylic acid		carboxylic acid	· · · · · · · · · · · · · · · · · · ·	

imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]- 3-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1- methyl-2-oxo-4- imidazolidinecarboxy lic acid		hypertension; heart failure; diabetes
libenzapril; CGS 16617	[S-(R*,R*)]-3-[(5- amino-1- carboxypentyl)amino] -2,3,4,5-tetrahydro-2- oxo-1H-1- benzazepine-1-acetic acid		hypertension
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL; LONGES; ACERBON	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline	ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
SPM 925; CI 925; RS 10085197; UNIVASC; FAMPRESS; MOEX; PERDIX; FEMPRESS; PRIMOXIL; FEMIPRESS; FEMPRES	(ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1,2,3,4- tetrahydro-6,7- dimethoxy-3- isoquinolinecarboxyli c acid		hypertension
perindopril erbumine; S 9490; S 94903; SED 9490; MCN A2833109; DW 7950; COVERSYL;	(2S,3aS,7aS)-1-[(2S)- 2-[[(1S)-1- (ethoxycarbonyl)butyl]amino]-1- oxopropyl]octahydro- 1-1H-indole-2- carboxylic acid	· ·	hypertension; coronary artery disease; heart failure

perindoprilat; S 9780;	[2S-	ACE inhibitor	hypertension
S 9490 diacid	[1[R(R*)],2alfa,3abet	i	arypertension
	a,7abeta]]-1-[2-[(1-		
	carboxybutyl)amino]-		
	li-		
·	oxopropyl]octahydro-		
	1H-indole-2-		
	carboxylic acid		
quinapril; quinapril	[3S-	ACE inhibitor	hamartanaian
hydrochloride; CI	[2[R*(R*)],3R*]]-2-	ACE IIIIIIIIII	hypertension
906; PD 1094522;	[2-[[1-	1	
ACCUPRIL;	(ethoxycarbonyl)-3-		
CONAN;	phenylpropyl]amino]-		
ACCUPRO;	l-oxopropyl]-1,2,3,4-		·
ACUITEL;	tetrahydro-3-		
ACEQUIN;	isoquinolinecarboxyli		
ACCUZIDE;	c acid		ĺ
OUINAZIDE	c aciu		
	(20, 200, 600) 1 [(0)	ACE in Library	
ALTACE; TRIATEC;	(2S,3aS,6aS)-1-[(S)-	ACE inhibitor	hypertension; heart
			failure
	phenylpropyl]alanyl]o		
· ·	ctahydrocyclopenta[b]		,
4	pyrrole-2-carboxylic		
CARASEL; ACOVIL			
RL 6134; EQUATEN			hypertension
RL 6207; PRENTYL		ACE inhibitor	hypertension
RL 6893; SYNECOR			hypertension
1	[8S-[7[R*(R*)]]8R*]-	ACE inhibitor	hypertension
	7-[2-[[1-		
r .	(ethoxycarbonyl)-3-		,
	phenylpropyl]amino]-		
	l - oxopropyl]-1,4-		
	dithia-7-		Y
CARDIOPRIL	azaspiro[4.4]nonane-		
	8-carboxylic acid		
temocapril;	[2S-	ACE inhibitor	hypertension
	[2alfa,6beta(R*)]]-6-	'	
hydrochloride; CS	[[1-(ethoxycarbonyl)-	ļ	
622; ESCOL;	3-		
ACECOL; ACECOR	phenylpropyl]amino]t		
	etrahydro-5-oxo-2-(2-		
	thienyl)-1,4-		į
	thiazepine-4(5H)-	}	
	acetic acid		·

temocaprilat;	[2S-	ACE inhibitor	himortonaian
	[2alpha,6beta(R*)]]-	ACE IIIIIOIOI	hypertension
5139	6-[(1-carboxy-3-		
	phenylpropyl)aminol	.[
	etrahydro-5-oxo-2-(2-		
•	thienyl)-1,4-		
	thiazepine-4(5H)-		
	acetic acid		,
utibapril; FPL 63547	(S)-2-tert-butyl-4-	ACE inhibitor	1
unoapin, 112 055 17	[(S)-N-[(S)-1-	ACE MINURO	hypertension; heart failure
	carboxy-3-		ranure
	phenylpropyl]alanyl]-		
	delta2-1,3,4-		
	thiadiazoline-5-		
	carboxylic acid, 4-		
	ethyl ester		
WY 44655	(2S-	ACE inhibitor	hypertension
	(1(R*(R*)),2R*))-1-		rypertension
	(2-(1-		
	(ethoxycarbonyl)-3-		
	phenylpropyl)amino)-		
	1-oxopropyl)-2,3-		
]	dihydro-1H-indole-2-		
	carboxylic acid		
Y 23785	unspecified	ACE inhibitor	hypertension
zofenopril; SQ	[(R*),2alfa,4alfa]-1-	ACE inhibitor	hypertension;
26991; ZOPRACE	[3-(benzoylthio)-2-		myocardial infarction
<u>.</u>	methyl-1-oxopropyl]-		
	4-(phenylthio)-L-		
	proline		
zofenoprilat; SQ	(4S)-1-((S)-3-	ACE inhibitor	hypertension
1	mercapto-2-	•	
	methylpropionyl)-4-		
1	(phenylthio)-L-		
	proline		
quinapril + diltiazem;	-		hypertension
diltiazem + quinapril;		calcium antagonist	·
CI 975			
spirapril + isradipine;	-		hypertension
isradipine + spirapril;		calcium antagonist	
ISPRI			
delapril + manidipine;	•		hypertension
manidipine + delapril;	1	calcium channel	
CHF 1521		olocker	

	L	T	
trandolapril +	Unspecified	ACE inhibitor;	hypertension
verapamil; verapamil		calcium channel	
+ trandolapril; RU		blocker	
44570A; TARKA;			
VERATRON			
telmisartan+lacidipine	Unspecified	ACE inhibitor;	hypertension
ļ;		calcium channel	"
lacidipine+telmisartar	ı ı	blocker; angiotensin	
		II antagonist	
benazepril +	Unspecified	ACE inhibitor;	hypertension
hydrochlorothiazide;		diuretic	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hydrochlorothiazide +			
benazepril;	ľ		
CIBADREX;			
LOTENSIN HCT			
delapril +	Unspecified	ACE inhibitor;	hypertension
indapamide;		diuretic	hypertension
indapamide +			
delapril; CHF 1513;	:		
DELAPRIDE		j	
fosinopril +	Unspecified	A CD : 1 '1 '4	
hydrochlorothiazide;	Onspectited	ACE inhibitor;	hypertension; heart
hydrochlorothiazide,		diuretic	failure
fosinopril;		[
TENSOZIDE;		• "	
MONOPRIL-HCT;			
FOSICOMP			
lisinopril +	Unspecified		hypertension
hydrochlorothiazide;		diuretic	
hydrochlorothiazide +		·	
lisinopril; PRINZIDE;			
PRINIVIL PLUS;			
CARACE;			
ZESTORETIC;	·		
ACECOMB;			·
ACERCOMP			
	Unspecified	ACE inhibitor;	hypertension
hydrochlorothiazide;		diuretic	
hydrochlorothiazide +			
moexipril;			
UNIRETIC;			
FEMPRESS PLUS			
	·		

quinapril + hydrochlorothiazide; hydrochlorothiazide + quinapril;	Unspecified	ACE inhibitor; diuretic	hypertension
ACCURETIC; ACEQUIDE			
fasidotril; valadotril; alatriopril; BP 1.137	(S)-N-[3-(acetylthio)- 2-(1,3-benzodioxol-5 ylmethyl)-1- oxopropyl]-L-alanine	enkephalinase inhibitor	hypertension
glycopril	phenylmethyl ester N-[(2S)-3- (acetylthio)-2-(1,3- benzodioxol-5- ylmethyl)-1- oxopropyl]glycine phenylmethyl ester	ACE inhibitor; enkephalinase inhibitor	hypertension
BMS 189921	[S-(R*,R*)]- hexahydro-6-[(2- mercapto-1-oxo-3- phenylpropyl)amino]- 2,2-dimethyl-7-oxo- 1H-azepine	ACE inhibitor; matrix metalloproteinase inhibitor; neutral endopeptidase inhibitor; proteinase inhibitor	hypertension; heart failure
	(S,S)-2-[3-(2- mercapto-3- phenylpropionamide)- 2-oxo-2,3,4,5- tetrahydro-1H-1- benzazepin-1- yl]acetic acid	ACE inhibitor; neutral endopeptidase	hypertension
ER 3295	Unspecified	ACE inhibitor; neutral endopeptidase inhibitor	hypertension; heart failure
mixanpril	- -	ACE inhibitor; neutral endopeptidase inhibitor	hypertension
81252	2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl] amino]carbonyl]cyclopentyl]methyl]-N-[N2-(methylsulfonyl)-L-lysyl]-beta-alanine [S-(R*,R*)]-	neutral endopeptidase	hypertension; heart failure

Z 13752A	Unspecified	ACE inhibitor;	hypertension; heart
		neutral endopeptidase	failure
		inhibitor	
MDL 100240; MDL	[4S-	ACE inhibitor;	heart failure;
100173 pro	[4alpha,7alpha(R*),1		
	2bbeta]]-7-[[2-	inhibitor; diuretic	
	(acetylthio)-1-oxo-3-	,	
	phenylpropyl]amino]	-	
	1,2,3,4,6,7,8,12b-		
	octahydro-6-oxo-		
	pyrido[2,1-		
	a][2]benzazepine-4-		
	carboxylic acid		
C 111	Gly-Val-Tyr-Pro-His-	ACE inhibitor;	hypertension
	Lys	peptide	
C 112	Ile-Arg-Pro-Val-Gln	ACE inhibitor;	hypertension
	<u> </u>	peptide	
moveltipril; altiopril	[R-(R*,S*)]-1-[3-[[2-		hypertension
calcium; MC 838;	[(cyclohexycarbonyl)	vasodilator	
LOWPRES	amino]-1-		
· .	oxopropyl]thio]-2-	anesi" e	
	methyl-1-oxopropyl]-	'	
	L-proline		
spiraprilat; SCH	(8S)-7-[(S)-N-[(S)-1-	1 ' 1	hypertension;
33861	carboxy-3-	vasodilator	glaucoma
·	phenylpropyl]alanyl]-		
	1,4-dithia-7-	·	
	azaspiro[4.4]nonane-		
trandalamili CI 007.	8-carboxylic acid	1.00	
trandolapril; CI 907; RU 44570; RU 570;	[2S-		hypertension; heart
ODRIK; UDRIK;	[1[R*(R*)],2alpha,3a	l I	failure; myocardial
	alpha,7abeta]]-1-[2- [[1-(ethoxycarbonyl)-		nfarction
ODRIC; MAVIK	f[[1-(emoxycaroonyl)-		
ODICC, WAVIK	phenylpropyl]amino]-		
	phenyipropyrjamnoj- 1-		
	oxopropyl]octahydro-		
	1H-indole-2-		
	carboxylic acid		1
AGR 529		Adenosine A1	nypertension;
	1		rypertension;
	hydrochloride	coopiois in lat cens	Apernplueillia
		Adenosine A1	umortonoi o r
	`.		rypertension;
	2',3',5'-tripropanoate	receptors in rat cens	yperlipidemia
	= ,5 ,5 -u.proparioate		

RPR 100579	Unspecified	adenosine agonist	hypertension; heart failure;
			hyperlipidemia
antihypertensive	2-hexynyladenosine	adenosine agonist;	hypertension
	(2-H-Ado)	adenosine A2 agonist	
antihypertensive	2-octynyladenosine	adenosine agonist;	hypertension
	(2-O-Ado)	adenosine A2 agonist	rypertension
CGS 21680	4-[2-[[6-amino-9-(N-	adenosine agonist:	hypertension
	ethyl-beta-D-	adenosine A2 agonist	·
	ribofuranuronamidos	adenosine A3 agonist	"
	1)-9H-purin-2-		
	yl]amino]ethyl]benze		
L	nepropanoic acid		
CGS 22492	2-[(2-	adenosine agonist;	hypertension
	cyclohexylethyl)amin		, , , p e rension
	o]adenosine		
YT 146	2-(1-	adenosine agonist;	hypertension
	octynyl)adenosine	vasodilator	
KS 341; RKS 0341	Unspecified	adenosine antagonist	hypertension
FK 453; FR 113453	[R-(E)]-1-[1-oxo-3-	adenosine antagonist;	
	(2-	adenosine A1	in per tension
	phenylpyrazolo[1,5-	antagonist	
	a]pyridin-3-yl)-2-		
•	propenyl]-2-		
	piperidineethanol		
FK 838		adenosine antagonist;	hypertension
	phenylpyrazolo[1,5-	adenosine A1	- J P = 1 C I I I I
	a]pyridin-3-yl)-1(6H)-		
	pyridazine butyric	<i>G</i> ,	
	acid		
CVT 124; BG 9719;	3,7-dihydro-8-(3-	adenosine antagonist;	heart failure
ADENTRI	1		hypertension
		A1 antagonist	JF
	dipropyl-1H-purine-	3	
	2,6-dione		
eplerenone;	(7.alpha.,11.alpha.,17.	aldosterone	heart failure;
epoxymexrenone;			hypertension
CGP 30083; SC	17-hydroxy-3-	· ·	71
66110	oxopregn-4-ene-7,21-		
	dicarboxylic acid		
	.gammalactone		
	methyl ester		

drug delivery system, transdermal clonidine; clonidine transdermal; M 5041T	Unspecified	alpha adrenergic agonist	hypertension
apraclonidine; p- aminoclonidine; aplonidine; ALO 2145; NC 14; IOPIDINE	2,6-dichloro-N'-(4,5- dihydro-1H-imidazol- 2-yl)-1,4- benzenediamine		glaucoma; hypertension
moxonidine; BE 5895; BDF 5895; LY 326869; CYNT; PHYSIOTENS	4-chloro-N-(4,5- dihydro-1H-imidazol- 2-yl)-6-methoxy-2- methyl-5- pyrimidinamine	alpha adrenergic agonist; alpha2 adrenergic agonist; imidazoline agonist	hypertension; heart failure; diabetes
indoramin; WY 21901; DORALESE; TILTAB; BARATOL; WYDORA; WYPRESIN; VIDORA	N-[1-[2-(1H-indol-3-yl)ethyl]-4- piperidinyl]benzamid e	alpha adrenergic antagonist	hypertension; benign prostate hypertrophy
CL 870801	2-methyl-4-chloro-5- ((2-(4-(2- methoxyphenyl)piper azinyl- 1)ethyl)amino)- 3(2H)-pyridazinone hydrochloride	antagonist; 5HT	hypertension
alfuzosin; alfuzosin hydrochloride; SL 77499; SL 7749910; ALFOTEN; XATRAL; BENESTAN; BENESTAIN; XATRAL-MAG; DILOTEX; URION; UROXATRAL	N-[3-[(4-amino-6,7- dimethoxy-2-	alpha adrenergic antagonist; alphal adrenergic antagonist	benign prostate hypertrophy; hypertension
-	dimethoxy-2-		hypertension; glaucoma; benign prostate hypertrophy

[Ţ	T
CR 2991	Unspecified	alpha adrenergic	hypertension
		antagonist; alpha1	
		adrenergic antagonist	
cyclazosin	Cis-1-(4-amino-6,7-	alpha adrenergic	hypertension
	dimethoxy-2-	antagonist; alpha1	
	quinazolinyl)-4-(2-	adrenergic antagonist	
	furanylcarbonyl		
)decahydroquinoxalin		
	e monohydrochloride		
dicentrine; d-	(S)-6,7,7a,8-	alpha adrenergic	hypertension
dicentrine; (+)-	tetrahydro-10,11-	antagonist; alpha1	-) F
dicentrine; eximine;	dimethoxy-7-methyl-	adrenergic antagonist	
O,N-	5H-benzo[g]-1,3-		
dimethyllitseferine	benzodioxolo[6,5,4-		
	de]quinoline	1	
doxazosin; UK	1-(4-amino-6,7-	alpha adrenergic	benign prostate
33274; UK 3327427;		antagonist; alpha1	hypertrophy;
CARDURA;	quinazolinyl)-4-[(2,3-		hypertension
CARDENALIN;	dihydro-1,4-	and one give antagoing	ilypertension
SUPRESSIN;	benzodioxin-2-		
CARDURAN:	yl)carbonyl]piperizine		
DIBLOCIN;) .) care on Julpipor Emic		
DOXABEN;			
NORMOTHEN;			
DEDRALEN;			
ALFADIL			·
drug delivery system,	Unspecified	alpha adrenergic	hypertension
OROS prazosin;	1 -	antagonist; alpha l	riypertension
prazosin OROS; CP		adrenergic antagonist	
122991; MINIPRESS		adionorgic antagonist	
XL; ALPRESS LP			
HSR 175	R-(-)-5-[2[2-(5-	alpha adrenergic	
11510 175			hypertension; urinary
,	methoxyphenoxy)ethy		incontinence
		aurenergic antagonist	
	lamino]propyl]-2- meth		
	i i		•
	oxybenzenesulfonami		
	de		
metazosin; metasozin;			hypertension;
metazocin;	1		glaucoma; benign
KENOSIN			prostate hypertrophy;
	methoxy-1-		heart failure
	oxopropyl)piperazine		

QF 301	2-[2-(N4-O-	alpha adrenergic	hypertension
	methoxyphenyl-N1-	antagonist; alpha1	rypertension
	piperazinyl)ethyl]-1-	adrenergic antagonist	
	tetralone	- and gold and gold of	
SGB 1534	3-[2-[4-(2-	alpha adrenergic	hypertension
	methoxyphenyl)-1-	antagonist; alpha1	- Jp - crosson
	piperazinyl]ethyl]-	adrenergic antagonist	
	2,4(1H,3H)-		
	quinazolinedione		
	monohydrochloride	,	
SNAP 5150	N-[3-(4,4-diphenyl-1-	alpha adrenergic	benign prostate
	piperidinyl)propyl]-	antagonist; alpha1	hypertrophy;
	1,4-dihydro-2,6-	adrenergic antagonist	hyperlipidemia;
	dimethyl-4-(4-	3	hypertension
	nitrophenyl)-3,5-		-51
	pyridinecarboxamide		
urapidil; B 66256;	6-[[3-[4-(2-	alpha adrenergic	hypertension; benign
BY 05068;	methoxyphenyl)-1-	antagonist; alpha1	prostate hypertrophy;
EBRANTIL; ALPHA	piperazinyl]propyl]a	adrenergic antagonist	dysuria
DEPRESSAN	mino]-1,3-dimethyl-		
	2,4(1H,3H)-		
	pyrimidinedione	1	
AT 112	2,3-dihydro-2-[(4-	alpha adrenergic	thrombosis;
		antagonist; alpha1	hypertension
		adrenergic antagonist;	,
		platelet antiaggregant	
	c]quinazolin-5(6H)-		
	one	·	
terazosin; A 45975;			benign prostate
MY 208; HYTRIN;			hypertrophy;
HEITRIN;		adrenergic antagonist;	hypertension
VASOMET;		vasodilator	·
	furanyl)carbonyl]pipe		
URODIE;	razine		
HYTRINEX;			
TERAPROST;			
ISONTYN			
A 65265	1		hypertension
		antagonist; alpha2	
		adrenergic antagonist	

amosulalol; YM	5-[1-hydroxy-2-[[2-	alpha adrenergic	hypertension
09538; LOWGAN	(2-	antagonist; beta	
		yadrenergic antagonist	
	l]amino]ethyl]-2-		
	methylbenzenesulfon		
. C. 1.1. DDF 010.	amide		
brefonalol; BDF 8186		alpha adrenergic	hypertension
	dimethyl-3-	antagonist; beta	
		adrenergic antagonist	
	l-hydroxyethyl]-3,4-		
N. 1510	dihydrocarbostyril		
N 1518	4-[2-hydroxy-3-[[2-	alpha adrenergic	hypertension
	(2-methoxyphenoxy)-		
	-	adrenergic antagonist	
	methylethyl]amino]pr	İ	
	opoxy]-1(2H)-		
A C (25	isoquinolinone	<u> </u>	
AC 625	Unspecified	amylin antagonist;	hypertension
11.2		peptide	
adrenergic alpha2	Unspecified	analgesic	research tool; pain;
human			hypertension;
neuroreceptors;	·		glaucoma
neuroreceptors,			
adrenergic alpha2 human			
EMD 61650	2 1-1-1 2 5 4:1-1-1	A · YY	
ENID 01030	2-butyl-3,5-dihydro- 5-(phenylmethyl)-3-	Angiotensin II	hypertension
	[[2'-(1H-tetrazol-5-		
-	yl)[1,1'-biphenyl]-4-		
	yl]methyl]-4H-		
	imidazo[4,5-		
	c]pyridin-4-one		
EMD 66684		Angiotensin II	hamortonoion
7000	4-oxo-3[[2'-(1H-	ruigiotelisiii ii	hypertension
	tetrazol-5-yl)-4-		
·	biphenylyl]methyl]-		
• .	3H-imidazo[4,5-		
	C]pyridine-5-(N,N-		
	dimethylacetamide)		Ì
		angiotensin II	hypertension
		antagonist	туропоняюн
	biphenyl]-4-	wind Sound	
	yl]methyl]amino]-5-		
	pyrimidinecarboxylic		İ
	acid		
		1	,

			•
A 81988	Unspecified	angiotensin II antagonist	hypertension
angiotensin II	Unspecified	angiotensin II	hypertension
receptor antagonist		antagonist	L'yportonsion
BIBR 363	Unspecified	angiotensin II	hypertension
·	1	antagonist	Jp Creension
BIBS 222	2-[[[4-[[2-butyl-6-	angiotensin II	hypertension
	[[(methylamino)carbo		I pertunsion
	nyl]pentylamino]-1H-	g	
	benzimidazol-1-	İ	
	yl]methyl]phenyl]ami		
	no]carbonyl]-3,6-		
	dichlorobenzoic acid		
BIBS 39	4'-[[(2-n-butyl-6-	angiotensin II	hypertension
	cyclohexylaminocarb		
	onylamino-		
	benzimidazole-1-		
	yl)methyl]biphenyl]-		
	2-carboxylic acid		
BMS 180560		angiotensin II	hypertension
~ .	[[1-[2-(1H-tetrazol-5-		
	yl)phenyl]-1H-indol-	J	
	4-yl]methyl]-1H-	:	
	imidazole-5-		
	carboxylic acid		
candesartan cilexetil;	(+,-)-2-ethoxy-1-[[2'-	angiotensin II	hypertension; heart
TCV 116; H 21291;	(1H-tetrazol-5-		failure; restenosis;
BLOPRESS;	yl)[1,1'-biphenyl]-4-		kidney disease
ATACAND; AMIAS;	yl]methyl]-1-H-		
KENZEN	benzimidazole-7-		
	carboxylic acid 1-		
	[[(cyclohexyloxy)carb		
	onyl]oxy]ethyl ester		
CI 996	2-propyl-1-[[2'-(1H-	angiotensin II	hypertension
		antagonist	
	biphenyl]-4-		
	yl]methyl]-4-[2-		
	(trifluoroacetyl)-1H-		
	pyrrol-1-yl]-1H-		
	imidazole-5-		
	carboxylic acid	ļ	
DA 2079	Unspecified	angiotensin II	hypertension
	-	antagonist	-

	γ		
DUP 532	4-(pentafluoroethyl)- 2-propyl-1-[[2'-(1H- tetrazol-5-yl)[1,1'- biphenyl]-4-	angiotensin II antagonist	hypertension
	yl]methyl]-1H-		
	imidazole-5-		
	carboxylic acid		
E 4177	4'-[(2-cyclopropyl-7-	angiotensin II	hypertension
	methyl-3H-	antagonist	71
	imidazo[4,5-		
	b]pyridin-3-		
	yl)methyl]-[1,1'-		
	biphenyl]-2-		
	carboxylic acid		
embusartan; BAY	6-butyl-1-[[3-fluoro-	angiotensin II	hypertension
106734	2'-(1H-tetrazol-5-	antagonist	7,
	yl)[1,1'-biphenyl]-4-		
	yl]methyl]-1,2-		,
	dihydro-2-oxo-4-		
	pyridinecarboxylic		
	acid methyl ester		
EMD 66397	Unspecified	angiotensin II antagonist	hypertension
eprosartan; eprosartan	(E)-alfa-[[2-butyl-1-	angiotensin II	hypertension
mesylate; SB 108566;		antagonist	
SKF 108566; SKF	carboxyphenyl)methy		
108566 J; TEVETEN	l]-1H-imidazol-5-		
	yl]methylene]-2-		
	thiophenepropanoic	•	
	acid		·
EXP 3174; E 3174	2-butyl-4-chloro-1-	angiotensin II	hypertension
		antagonist	<i>"</i>
	yl)[1,1'-biphenyl]-4-		
	yl]methyl]-1H-	÷	
	imidazole-5-	•	
	carboxylic acid		
		angiotensin II	hypertension
	carboxyphenyl)methy		
	l]-4-chloro-1H-	J.	İ
	imidazole-5-acetic		
	acid disodium salt		·
			5

EXP 6803 2-butyl-1-[[4-[(2-carboxybenzoyl)amin o]phenyl]methyl]-4-chloro-1H-imidazole-5-acetic acid alfamethyl ester monosodium salt FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist hypertension antagonist forasartan; SC 52458 5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-1)] hypertension II hypertension antagonist	
o]phenyl]methyl]-4- chloro-1H-imidazole- 5-acetic acid alfa- methyl ester monosodium salt FK 739; FR 130739 Unspecified angiotensin II antagonist forasartan; SC 52458 5-[(3,5-dibutyl-1H- 1,2,4-triazol-1- angiotensin II hypertension antagonist	
chloro-1H-imidazole- 5-acetic acid alfa- methyl ester monosodium salt FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist hypertension forasartan; SC 52458 5-[(3,5-dibutyl-1H- 1,2,4-triazol-1- antagonist	
5-acetic acid alfamethyl ester monosodium salt FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist hypertension forasartan; SC 52458 5-[(3,5-dibutyl-1H-angiotensin II antagonist hypertension antagonist	
methyl ester monosodium salt FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist forasartan; SC 52458 5-[(3,5-dibutyl-1H-l,2,4-triazol-1- antagonist hypertension antagonist	
methyl ester monosodium salt FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist forasartan; SC 52458 5-[(3,5-dibutyl-1H-l,2,4-triazol-1- antagonist hypertension antagonist	
monosodium salt FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist forasartan; SC 52458 5-[(3,5-dibutyl-1H-1,2,4-triazol-1- antagonist hypertension antagonist	
FK 739; FR 130739 Unspecified angiotensin II hypertension antagonist forasartan; SC 52458 5-[(3,5-dibutyl-1H-1,2,4-triazol-1- antagonist hypertension antagonist	
forasartan; SC 52458 5-[(3,5-dibutyl-1H-angiotensin II l,2,4-triazol-1-antagonist hypertension	
forasartan; SC 52458 5-[(3,5-dibutyl-1H- angiotensin II hypertension 1,2,4-triazol-1- antagonist	
1,2,4-triazol-1- antagonist	
) -)	
tetrazol-5-	
ylphenyl)]pyridine	
GA 0056 2-[6-[(2-ethyl-5,7- angiotensin II hypertension	
dimethyl-3H- antagonist	
imidazo[4,5-	
b]pyridin-3-	
yl)methyl]-2-	
quinolinyl]benzoic	
acid	
HN 65021 2-butyl-4-chloro-1- angiotensin II hypertension	
[[2'-(1H-tetrazol-5- antagonist	
yl)[1,1-biphenyl]-4-	
yl]methyl]-1H-	.
imidazole-5-	
carboxylic acid 1-	[
(ethoxycarbamoyl)eth	İ
yl ester potassium salt	
HR 720; HOE 720 2-butyl-4- angiotensin II hypertension	
(methylthio)-1-[[2'- antagonist	i
[[(propyl)amino]sulfo	ł
nyl](1,1'-biphenyl)-4-	l
yl]methyl]-1H-	. [
imidazole-5-	
carboxylic acid	
dipotassium salt	.
	1
ICI D6888 Unspecified angiotensin II hypertension	İ

TOT DOZZI	b .1 1 4 222 227	· · · · · · · · · · · · · · · · · · ·	
ICI D8731	2-ethyl-4-((2'-(1H-	angiotensin II	hypertension
	1,2,3,4-tetrazol-5-	antagonist	
	yl)biphenyl-4-yl)-		
	methoxy)quinoline		
	hydrochloride		
irbesartan; SR 47436	, \	angiotensin II	hypertension; kidney
BMS 186295;	tetrazol-5-yl)[1,1'-	antagonist	disease; heart failure
APROVEL;	biphenyl]-4-		
KARVEA; AVAPRO	yl]methyl]-1,3-		
	diazaspiro[4.4]non-1-		
	en-4-one		
KRH 594	2-[[[5-ethyl-3-[[2'-	angiotensin II	hypertension
	(1H-tetrazol-5-	antagonist	71
	yl)[1,1'-biphenyl]-4-		
	yl]methyl-1,3,4-		
	thiadiazol-2(3H)-		
	ylidene]amino]carbon	ı	
	yl]-1-cyclopentene-1-		
	carboxylic acid		
	dipotassium salt		
KT 3671; DA 727;	5,6,7,8-tetrahydro-2-	angiotensin II	hypertension
KT 3-671	propyl-3-[[2'-(1H-	antagonist	
	tetrazol-5-yl)[1,1'-		
	biphen yl]-4-		
	yl]methyl]-4(3H)-		
	cycloheptimidazole		
KW 3433	Unspecified	angiotensin II	hypertension
		antagonist	
L 158978	Unspecified	angiotensin II	hypertension
		antagonist	
L 159282; MK 996	N-[[4'-[(2-ethyl-5,7-	angiotensin II	hypertension
		antagonist	
	imidazo[4,5-		
	b]pyridin-3-		
	yl)methyl][1,1'-		
	biphenyl]-2-		
	yl]sulfonyl]-		
	benzamide		
L 159689		angiotensin II	hypertension
	• •	antagonist]
	(1H-tetrazol-5-	<i>5</i>	
	yl)[1,1'-biphenyl]-4-		1
	yl]methyl]-6-		
	quinazolinyl]-N-		
	pentylbenzamide		
	p-injioonzamido		

L 161177	2-ethyl-5,7-dimethyl-	hngiatanain II	h
L 1011//	3-[[2'-(2-oxido-3H-	1 -	hypertension
	1,2,3,5-oxathiadiazol	antagonist	
	4-yl)[1,1'-biphenyl]-		
	4-yl]methyl]-3H-		
	imidazo[4,5-		
T 160154	b]pyridine		
L 162154	N-[[4'-[[3-butyl-1,5-	-	hypertension
	dihydro-5-oxo-1-[2-	antagonist	
	(trifluoromethyl)phen		
	yl]-4H-1,2,4-triazol-		
	4-yl]methyl][1,1'-		
	biphenyl]-2-		
	yl]sulfonyl]-3-chloro-		
	2-		
ì	thiophenecarboxamid	B	
	e		
L 162234	[[4'-[[3-butyl-1,5-	angiotensin II	hypertension
	dihydro-5-oxo-1-[2-	antagonist	
	(trifluoromethyl)phen		
	yl]-4H-1,2,4-triazol-		
	4-yl]methyl][1,1'-		
	biphenyl]-2-		
	yl]sulphonyl]carbami		
·	c acid 1,1-		
	dimethylethyl ester		
L 163017		angiotensin II	hypertension
,		antagonist	
	[[2'-(N-(3-methyl-1-		
	butoxy)c		
	arbonylaminosulfonyl		
	[1,1']-biphenyl-4-		
	yl]methyl]-3H-		
	imidazo[4,5-		
	b]pyridine		
L 692429	3-amino-3-methyl-N-	angiotensin II	hypertension
	[2,3,4,5-tetrahydro-2-		arypertension
	oxo-1-[[2'-(1H-	Bomor	
	tetrazol-5-yl)[1,1'-	•	
	biphenyl]-4-		
	yl]methyl]-1H-1-		
	benzazepin-3(R)-yl]-	•	
	butanamide	·	
	putanamide		

losartan; losartan	2-butyl-4-chloro-1-	angiotensin II	hypertension; anxiety:
potassium; DUP 753;	[[2'-(1H-tetrazol-5-	antagonist	stroke; heart failure;
MK 954; DUP 89; E	yl)[1,1'-biphenyl]-4-	gomet	myocardial infarction
3340; AVASTAR;	yl]methyl] -1H-		inyocaidiai iiiaiction
COZAAR;	imidazole-5-methano	1	
LOORTAN;	- mountaino	1	
NULOTAN			
LR B139	Unspecified	angiotensin II	1
	•	antagonist	hypertension; angina
LY 235656	Unspecified	angiotensin II	hypertension
		antagonist	-
LY 285434	Unspecified	angiotensin II	hypertension
		antagonist	
LY 301875	(4S)-4-[4-	angiotensin II	hypertension
	(carboxymethyl)phen	antagonist	31
	oxy]-1-[(2R)-1-oxo-		
	2-[4-[(2-sulfoben		
	zoyl)amino]-1H-		
	imidazol-1-yl]octyl]-		
	L-proline		
LY 302289	Unspecified	angiotensin II	hypertension
·		antagonist	•
LY 315995	Unspecified	angiotensin II	hypertension
		antagonist	- 1
ME 3221	3-methoxy-2,6-	angiotensin II	hypertension
	dimethyl-4-[[2'-(1H-	antagonist	
	tetrazol-5-yl)-1,1'-		1
	biphenyl-4-		
	yl]methoxy]pyridine		
milfasartan; LR	2-[[4-butyl-2-methyl-	angiotensin II	hypertension
		antagonist	- J.F
	tetrazol-5-yl)[1,1'-		
	biphenyl]-4-		
	yl]methyl]-1(6H)-		
	pyrimidinyl]methyl]-		
	3-		·
-	thiophenecarboxylic		i
	acid methyl ester		·

almasartani CC 966	4 (1 1 1 1		
olmesartan; CS 866	4-(1-hydroxy-1-	angiotensin II	hypertension
	methylethyl)-2-	antagonist	
	propyl-1-[[2'-(1H-		
•	tetrazol-5-yl)[1,1'-		
	biphenyl]-4-		
	yl]methyl]-1H-		
	imidazole-5-		
	carboxylic acid, (5-		
	methyl-2-oxo-1,3-		
	dioxol-4-yl)methyl		
	ester		
PD 123177; EXP 655	1-[(4-amino-3-	angiotensin II	hypertension
	methylphenyl)methyl]	antagonist	'
	-5-(diphenylacetyl)-	_	
İ	4,5,6,7-tetrahydro-1-		
	H-imidazo[4,5-	<u> </u>	
	c]pyridine-6-		
	carboxylic acid		·
PD 123319	(S)-1-[[4-	angiotensin II	hypertension
	(dimethylamino)-3-	antagonist	- J P = 1 = 0 = 1 = 1
	methylphenyl]methyl]		. . .
	-5-(diphenylacetyl)-		
	4,5,6,7-tetrahydro-		
	1H-imidazo[4,5-		
	c]pyridine-6-		
	carboxylic acid		
PD 150304	(Z)-4-[[2-butyl-5-[[1-	angiotensin II	hypertension
	butyl-3-[(5-methyl-3-		J,
	thienyl)methyl]-2,5-di	,,	
	охо-4-		
	imidazolidinylidene]		
	methyl]-1H-imidazol-		
	1-yl]methyl]benzoic		İ
	acid		
	5-methyl-7-propyl-8-	angiotensin II	hypertension
		antagonist	-7 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -
	yl)[1,1'-biphenyl]-4-		
1	yl]m ethyl]-[1,2,4-		,
	triazolo[1,5-		
	c]pyrimidin-2(3H)-		
1	one (S11)	İ	

RWJ 46458	2-	ongiotancia II	
10450	carbethoxymethylide	angiotensin II	hypertension
	e-4-methyl-4-ethyl-2		
	[4-(2'-tetrazolo)-	-	
	phenyl]benzylpiperid	i	
annino-to-	n-6-one	<u> </u>	
saprisartan;	1-[3-bromo-2-[2-	angiotensin II	hypertension
saprisarian potassium	; (trifluoromethylsulfo		
GR 138950; GR	ylamino)phenyl]benz		
138950X; GR	o[b]furan-5-		
138950C	ylmethyl]-4-		
1	cyclopropyl-2-ethyl-		
Ì	1H-imidazole-5-		
	carboxamide		
saralasin; saralasin	1-(N-methylglycine)-	angiotensin II	hypertension;
acetate; aralasin; P	5-L-valine-8-L-	antagonist	contraception;
113; P 113 (peptide);	alanineangiotensin II		diagnosis
SARENIN			
SC 51316	2,5-dibutyl-2,4-	angiotensin II	hypertension
	dihydro-4-[[2'-(1H-	antagonist	, perconsion
. 62	tetrazol-5-yl)[1,1'-		
	biphenyl]-4-		
	yl]methyl]-3H-i,2,4-		
	triazol-3-one		
SK 1080; KR 31080	2-butyl-5-methyl-6-	angiotensin II	hypertension
	(1-oxido-2-pyridinyl)-		any portonision
	3-[[2'-(1H-tetrazol-5-	3	
	yl)[1,1'-biphenyl]-4-		
·	yl]methyl]-3H-		
	imidazodo[4,5-		
	b]pyridine		
SL 910102		angiotensin II	hypertension
	ł -	antagonist	hypertension
TAK 536			hv == 0========
		angiotensin ii antagonist	hypertension
	3-yl)[1,1'-biphenyl]-	amaguiusi	
	4- yl]methyl-2-		
	ethoxy-1H-		
	benzimidazole-7-		ļ
			· ·
	carboxylic acid		

tasosartan; ANA 756;	5,8-dihydro-2,4-	angiotensin II	hypertension
WAY ANA 756;	dimethyl-8-[[2'-(1H-		- Jp
VERDIA	tetrazol-5-yl)[1,1'-		
	biphenyl]-4-		
	yl]methyl]-		
,	pyrido[2,3-		
	d]pyrimidin-7(6H)-		
	one		
telmisartan; BIBR	4'-[(1,4'dimethyl-2'-	angiotensin II	hypertension
277; BIBR 0277SE;	propyl[2,6'-bi-1H-	antagonist	Ilypertension
MICARDIS; PRITOR		gv	
·	yl)methyl]-[1,1'-		
	biphenyl]-2-		
	carboxylic acid		
U 97018	2-butyl-3,6,7,8,9,11-	angiotensin II	hypertension
	hexahydro-6,9-	antagonist	half berreitsion
	dimethyl-3-[[2'-(1H-	and gomes	
	tetrazol-5-yl)[1,1'-		
	biphenyl]-4-		
	yl]methyl]-6,9-		
	ethano-4H-		
	imidazo[4,5-		
	d]pyridazino[1,2-		
	a]pyridazin-4-one		}
	5-propyl-6-[[2'-(1H-	angiotensin II	hypertension
į –	tetrazol-5-yl)[1,1'-	antagonist	in ypertension
	 biphenyl]-4-	- Gomot	·
	yl]methyl-		
	[1,2,4]triazolo[1,5-		
	a]pyrimidin-7-ol		
		angiotensin II	hypertension; heart
		antagonist	failure
	tetrazol-5-yl)[1,1'-	- Somot	
	biphen yl]-4-		
	yl]methyl]-1H-		
	pyrazole-4-carboxylic		
	acid		
	3-(1,1-dimethylethyl)-	angiotensin II	hypertension
		antagonist	ary per regision
	tetrazol-5-yl)[1,1'-	Bonnor	
	biphenyl]-4-		
	yl]methyl]-1H-		
	pyrazole-4-carboxylic	,	
T T	acid		
·····			

CCD	h. /1	T	
valsartan; CGP	N-(1-oxopentyl)-N-	angiotensin II	hypertension; heart
48933; DIOVAN	[[2'-(1H-tetrazol-5-	antagonist	failure
	yl)[1,1-biphenyl]-4-		
	yl]meth yl]-L-valine		
WK 1360	Unspecified	angiotensin II	hypertension
		antagonist	
WY 126227; WAY	N-[[2'-(1H-tetrazol-5-	angiotensin II	hypertension
126227	yl)(1,1'-biphenyl)-4-	antagonist	
	yl]methyl]-2-		
	(trifluoromethyl)-4-		
	quinazolinamine		
YM 31472	Unspecified	angiotensin II	hypertension
	1	antagonist	ary per tension
YM 358	2,7-diethyl-5-[(2'-(5-	angiotensin II	hypertension; heart
	tetrazoyl)biphenyl-4-	antagonist	failure
	yl]methyl]-5H-	- Indiana	hannie
	ругаzolo[1,5-		
	b][1,2,4]triazole	Ì	
irbesartan +	Unspecified	angiotensin II	
hydrochlorothiazide;	Onspectified	, –	hypertension; kidney
hydrochlorothiazide +	_	antagonist; diuretic	disease
irbesartan;		·	
AVALIDE;			
COAPROVEL;			
KARVEZIDE			
losartan +	Unspecified		
hydrochlorothiazide;		angiotensin II	hypertension
HYZAAR;		antagonist; diuretic	
LOSACOR D			1
tasosartan +		angiotensin II	hypertension
hydrochlorothiazide;		antagonist; diuretic	
hydrochlorothiazide +			
tasosartan;			
VERDIA/HCTZ			
valsartan +	1 - 1	angiotensin II	hypertension
hydrochlorothiazide;		antagonist; diuretic	
nydrochlorothiazide +			
valsartan; CoDiovan;			
CO-DIOVAN;			
DIOVAN HCT;			
CoTareg; CO-			
TAREG; DIOVAN-D			

	Т		
candesartan; CV	2-ethoxy-1-[[2'-(1H-	angiotensin II	hypertension
11974	tetrazol-5-yl)[1,1'-	antagonist; imidazole	
	bipheny]-4-		}
	yl]methyl]-1H-		
	benzimidazole-7-]	
	carboxylic acid		
CV 11194; EP	2-butyl-1-[[2'-(1H-	angiotensin II	hypertension
425921A	tetrazol-5-yl)[1,1'-	antagonist; imidazole	1
	biphenyl]-4-		
	yl]methyl]-1H-		
	benzimidazole-7-		
	carboxylic acid		
LR B087; LRB 087	Unspecified	angiotensin II	hypertension
,		antagonist; imidazole	"
zolasartan; GR	1-[[3-bromo-2-[2-	angiotensin II	hypertension
117289; GR 117289C	(1H-tetrazol-5-	antagonist;	71,
	yl)phenyl]-5-	vasodilator	
	benzofuranyl]methyl]		
	-2-butyl-4-chloro-1H-		
·	imidazole-5-		
· n	carboxylic acid		
LA 360	Unspecified	anion transport	hypertension
		inhibitor	**
AP 539	1-(2-	ANP antagonist	hypertension
	naphthoxyacetyl)piper		
	idin-4-carbonyl-		·
	Nalfa-L-arginyl-		
	Nalfa-L-isoleucinyl-		
	Nalfa-L-aspartyl-		
	Nalfa-L-arginyl-		
	Nalfa-L-		
	isoleucinylamide		
antihypertensive	Unspecified	Antihypertensive	hypertension
antihypertensive,	4-amino-2,4-dihydro-		hypertension
	5-(1-methylethyl)-3H-		
	1,2,4-triazol-3-one		
	hydrazone		
BR 9201	Unspecified	Antihypertensive	hypertension
BW 1045U85	Unspecified		hypertension
			hypertension
erythritol; NIK 242	1,2,3,4-butanetetrol		hypertension
IRLS DR09	Unspecified		hypertension
IRLS DR12			hypertension
			hypertension
	Chopconica	a minimypertensive	Typertension

LCB 2601	Unspecified	Antihypertensive	hypertension
millisrol; NK 843H;	Unspecified	Antihypertensive	hypertension;
NK 843L; NK 843			diagnosis
MYD 37	Unspecified	Antihypertensive	hypertension
PST 2238	(3beta,5beta,14beta)-		hypertension
	21,23-epoxy-24-		, , , , , , , , , , , , , , , , , , ,
	norchola-20,22-diene	-	
	3,14,17-triol		
RES 7011; RES 701-	Gly-Asn-Trp-His-	Antihypertensive	hypertension
1 .	Gly-Thr-Ala-Pro-		-21
	Asp-Trp-Phe-Phe-		
	Asn-Tyr-Tyr-Trp		
	cyclic (9-1)-peptide		
RS 89769	Unspecified	Antihypertensive	hypertension
TN 891	(S)-4-(2-hydroxy-3-	Antihypertensive	hypertension
	isopropylaminopropo		7
	xy)phenylacetamide		
UH 334	Unspecified	Antihypertensive	hypertension
antihypertensive	1-((3-	Antihypertensive;	hypertension
	methylphenyl)piperaz	central site	
	in-1-yl)-3-(thio(4-	and the second	
	acetamido)phenyl)-pr	·	
	opane		
APCI	Unspecified	atrial peptide	hypertension
	·	clearance receptor	
		inhibitor	
candoxatril; UK		atriopeptidase	hypertension; heart
79300	1 -	inhibitor	failure
	yl)oxy]-2 - [(2-		
	methoxyethoxy)meth		
	y1]-3-		
	oxopropyl]cyclopenty		
	l]carbonyl]amino]-	•	
	cyclohexanecarboxyli		
<u>.</u>	c acid		
candoxatrilat; UK			hypertension
73967	carboxycyclohexyl)ca	inhibitor	
•	rbamoyl]-alfa-[(2-		
	methoxyethoxy)meth		
	yl]cyclopentanepropio		
	nic acid		
SCH 42945			hypertension
	·	inhibitor	

adimolol; imidolol;	1,3-dihydro-1-[3-[[2-	beta adrenergic	hypertension
MEN 935	hydroxy-3-(1-	antagonist	, pertension
	naphthalenyloxy)prop	, –	
	yl]amino]-3-		
	methylbutyl]-2H-		
	benzimidazol-2-one		
arotinolol; S 596;	(+,-)-5-[2-[[3-[(1,1-	beta adrenergic	glaucoma;
ALMARL;	dimethylethyl)amino]	_	hypertension
ANBROTH;	-2-		
ACEMAIL;	hydroxypropyl]thio]-		
ALOCHINON;	4-thiazolyl]-2-		
AMOPSOL;	thiophenecarboxamid		
AROTINOIL;	e		
ASTONIL;			
LISTERIA			
betaxolol; betaxolol	1-[4-[2-	beta adrenergic	glaucoma;
hydrochloride; SL	(cyclopropylmethoxy)		hypertension; angina
75212; MCI 144;	ethyl]phenoxy]-3-[(1-	gomot	lipportonsion, angina
ABAXON;	methylethyl)amino]-		
KERLONE;	2-propanol		
BETOPTIC:	From the second		i
KERLONG;			
GLAUTAXOL;			
BERTOCIL;			İ
OPTIPRES;			٧.
BETASEL; BEOF			
NICOLICH;			
LOKREN		•	
bevantolol;	(+,-)-1-[(3,4-	beta adrenergic	hypertension
bevantolol	dimethoxyphenethyl)a		
hydrochloride; CL	mino]-3-(m-		
775; NC 1400;	tolyloxy)-2-propanol		
VANTOL;	3 - 3 / P - P	•	
CALVAN;	·		
RANESTOL			
bisoprolol; bisoprolol	1-[(1-	beta adrenergic	hypertension; heart
	1 - 1	antagonist	failure
· ·	3-[4-[[2-(1-		
	methylethoxy)ethoxy]		
	methyl]phenoxy]-2-		
•	propanol		
ISOTEN; SOPROL;	r - r		
DETENSIEL;			
MAINTATE;			
SOBLOC; ZEBETA			

hamindalata I.T.	(1) 1 ((1)		· · · · · · · · · · · · · · · · · · ·
bopindolol; LT	(+,-)-1-[(1,1,-	beta adrenergic	hypertension
31200;	dimethylethyl)amino]	antagonist	
SANDONORM	-3-[(2-methy]-1H-		
	indo-4-yl)oxy]]-2-		
	propanol, benzoate		
carvedilol; karvedilol;		beta adrenergic	hypertension; angina;
BM 14190; DQ 2466;	yloxy)-3-[[2-(2-	antagonist	heart failure
	methoxyphenoxy)ethy	1	
DILATREND;	l]amino]-2-propanol]	
DIMITONE;			
ARTIST;			
EUCARDIC;			
QUERTO;			
COROPRES;			
DILBLOC			
cetamolol; ICI 72222;	2-[2-[3-[(1,1-	beta adrenergic	hypertension
AY 27303; AJ 27303;	dimethylethyl)amino])portonoion
BETACOR	-2-	0	
	hydroxypropoxy]phen		
	oxy]-N-		
	methylacetamide	,	
drug delivery system,		beta adrenergic	hypertension
HALO labetolol;	•	antagonist	
labetolol HALO			. [
drug delivery system,	Unspecified	beta adrenergic	hypertension
HALO metoprolol;	•	antagonist	in portension
metoprolol HALO			1
drug delivery system,	Unspecified	beta adrenergic	hypertension
HALO oxprenolol;	•	antagonist	I portonsion
oxprenolol HALO		8011100	
	Unspecified	beta adrenergic	hypertension
HALO timolol;	<u> </u>	antagonist	nypertension
timolol HALO			
drug delivery system,	Unspecified	beta adrenergic	hypertension
MICROPUMP oral		antagonist	ary per terision
controlled release			
atenolol; atenolol			· I
MICROPUMP;			
ATENAX			
drug delivery system,	Unspecified	oeta adrenergic	hypertension
transdermal	- 1	intagonist	nypertension
mepindolol;		magomst	
transdermal soft disc,			
mepindolol;			
mepindolol B10 TSD	į		

esatenolol; atenolol, (S)-; (S)-atenolol; (-)- atenolol	(S)-4-[2-hydroxy-3- [(1- methylethyl)amino]pr opoxy]benzeneacetam		hypertension
esmolol; ASL 8052; ASL 8123; BREVIBLOC	ide 4-[2-hydroxy-3-[(1-methylethyl)amino]pr opoxy]benzenepropan oic acid methyl ester	, –	hypertension; arrhythmia
levobunolol; W 7000A; AG 901; BETAGAN; VISTAGEN; GOTENSIN; VISTAGAN; LEVOGAN	(-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone	beta adrenergic antagonist	hypertension; glaucoma
ridazolol; CAS 413	4-chloro-5-[[2-[[3-(2-chlorophenoxy)-2-hydroxypropyl]amino]ethyl]amino]-3(2H)-pyridazinone	beta adrenergic antagonist	hypertension
2395; ARTEX; ARTENSIL	(+,-)-1-[(3,4-dihydro- 2H-1-benzothiopyran- 8-yl)oxy]-3-[(1,1- dimethylethyl)amino] -2-propanol		hypertension
atenolol + lisinopril; lisinopril + atenolol		beta adrenergic antagonist; ACE inhibitor	hypertension
	4-[[[[4-[2-hydroxy-3- [(1- methylethyl)amino]pr	beta adrenergic antagonist;	hypertension

carteolol; OPC 1085;		beta adrenergic	glaucoma;
ABBOTT 43326; A	dimethylethyl)amino	antagonist; beta	hypertension
43326; ARTEOPTIC	; -2-hydroxypropoxy]-	adrenergic antagonist	**
CARTEOL;	3,4-		
CARTROL;	dihydroquinolinone		
ENDAK;			
MERCATOA;			
MIKELAN;			
ORUKALOL;			
PALSIT; TENALET;		,	
TENALIN			
metoprolol, (S)-; (S)-	(28)-1-[4-(2-	beta adrenergic	
metoprolol	methoxyethyl)phenox		angina; hypertension;
and to proto to	y]-3-[(1-		arrhythmia
	methylethyl)amino]-	adrenergic antagonist	
nehivolol: nerhivololi	2-propanol		
nebivolol; narbivolol; R 67555; R 65824;		beta adrenergic	hypertension;
	alpha,alpha'-	antagonist; beta1	migraine; heart failure
67145. D. 065024	[iminobis(methylene)	adrenergic antagonist;	
67145; R 065824;		nitric oxide activator;	
NEBILET;		vasodilator	±
LOBIVON	benzopyran-2-		ľ
1	methanol]		
drug delivery system,	Unspecified		hypertension
HALO sustained		antagonist; beta2	
release propranolol;		adrenergic antagonist	
propranolol HALO			
sustained release		_ ;	
	N'-[3-acetyl-4-[3-	beta adrenergic	hypertension;
	[(1,1-	antagonist; beta2	nephritis
5320A; SELECTOL;	dimethylethyl)amino]	adrenergic partial	•
CELECTOL		antagonist;	
	hydroxypropoxy]phen		
	yl]-N,N-diethylurea	-	
		beta adrenergic	hypertension
chlortalidone;	- 1	antagonist; diuretic	-75 21101011
chlortalidone +		5011100, 010110010	1
betaxolol;			
KERLEDEX		1	

bisoprolol +	Unspecified	beta adrenergic	hamoutomai -
hydrochlorothiazide;	Chopconica	1	hypertension
hydrochlorothiazide		antagonist; diuretic	
, ·			
bisoprolol; EMD			
47378; ZIAC;			
CONCOR PLUS;			İ
EMCORECTIC;			
FONDRIL;			
MONOZIDE			
tienoxolol; UP 78842	2-[3-[(1,1-	beta adrenergic	hypertension
	dimethylethyl)amino]	antagonist; diuretic	
	-2-hydroxypropoxy]-		
	5-[(2-		
[thienylcarbonyl)amin		
	o]benzoic acid ethyl		
•	ester	••	
bendacalol;	[2R*[S*[R*(S*)]]]-	beta adrenergic	hypertension
bendacolol; CGS	alpha,alpha-	antagonist;	hypertension
10078B	[iminobis(methylene)		
	bis[2,3-dihydro-1,4-	V asourrator	
	benzodioxin-2-		
	methanol]	1	
tilisolol; N 696;	4-[3-[(1,1-	beta adrenergic	himomorphica
DAIM; SELECAL	dimethylethamino)]-	antagonist;	hypertension
Diam, DEDECTE	2-hydroxypropoxy]-2		. [
	methyl-1(2H)-	vasoulialoi	
1	isoquinolinone		
TS 702		1	
13 702	Unspecified	beta adrenergic	hypertension
		antagonist;	
4-1:1-1	/. / \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	vasodilator	
	(+/-)-N-cyclohexyl-	_	hypertension;
		antagonist; beta	myocardial infarction;
•		adrenergic antagonist	cardiovascular disease
	-2-		
	hydroxypropoxy]phen		
	yl]urea		
UT 26	Unspecified	biotechnology;	pulmonary
			hypertension
		oligonucleotide	
nesiritide; nesiritide			heart failure;
1 - 1		•••	hypertension
natriuretic peptide;		populo	- Deimon
BNP; NATRECOR			
,			

antisense	Unspecified	biotechnology;	hypertension
oligonucleotide,	opownou	mRNA translation	hypertension
angiotensinogen		inhibitor; antisense;	
		oligonucleotide	
zatebradine; ULFS 49	3-[3-[[2-(3-4	bradycardic agent	
Europiadine, OLI, 5 4.	dimethoxyphenyl)eth	bradycardic agent	angina; hypertension
	yl]methylamino]prop		
	yl]-1,3,4,5-tetrahydro	1	
	7,8-dimethoxy-2H-		
NIDI (4220	benzazepin-2-one		
WIN 64338	(S)-[[4-[[2-	bradykinin antagonist	hypertension
	[[bis(cyclohexylamin		
	o)methylene]amino]-		
	β-(2-naphthalenyl)-1-		
	oxopropyl]amino]phe		
	nyl]methyl]tributylph		
	osphonium chloride		
CP 0364	Unspecified	bradykinin antagonist;	hypertension;
		NSAID	inflammation
AHR 12742	4-(bis(4-	calcium antagonist	hypertension
·	fluorophenylmethyl)-		•
	7-(3-(4-		
	chlorophenoxyl)propy		
	Ipiperidine (E)-2-		
et a per	butenedioate		
amlodipine analogue	4-(2,3-	calcium antagonist	hypertension
	dichlorophenyl)-1,4-		
The state of the s	dihydro-2-[(2-		
	hydroxyethoxy)methy		
	l]-6-methyl-3,5-		
	pyridinedicarboxylic		
	acid 3-ethyl 5-methyl		
,	ester		
amlodipine besilate;		calcium antagonist	hypertension
1	aminoethoxy)methyl]	calcium angagomst	itypertension
NORVASC; ISTIN	-4-(2-chlorophenyl)-		
TORVADO, IDIA			
	1,4-dihydro-6-methyl- 3,5-		
1			
	pyridinedicarboxylic		
i i	acid, 3-ethyl 5-methyl		-
	ester		
	monobenzenesulfonat		
	e		

amlodipine, (S)-; (S)- (S)-2-[(2- calcium antagonist hypertension amlodipine; (-)-	
amingining (-i- jamingethovy)methylli	
amlodipine; (-)- amlodipine; l4-(2-chlorophenyl)-	
amlodipine 1,4-dihydro-6-methyl-	
3,5-	
pyridinedicarboxylic	
acid, 3-ethyl 5-methyl	
ester	
antihypertensive, ethyl isopropyl 4- calcium antagonist hypertension	
Kanebo (benzothiazol-2-	
yl)benzylphosphonate	
aranidipine; MPC 1,4-dihydro-2,6- calcium antagonist hypertension	
1304; SAPRESTA; dimethyl-4-(2-	
BEC BM; BEC nitrophenyl)-3,5-	
MARUKO; BEC pyridinedicarboxylic	İ
acid, methyl 2-	
oxopropyl ester	
azelnidipine; CS 905; (+,-)-2-amino-1,4- calcium antagonist hypertension	
RS 9054 dihydro-6-methyl-4-	
(3-nitrophenyl)-3,5-	
pyridinedicarboxylic	
acid 3-[1-	- 1
(diphenylmethyl)-3-	
azetidinyl] 5-(1-	- 1
methylethyl) ester	
belfosdil; SR 7037; [2-(2-phenoxyethyl)- calcium antagonist hypertension	
BMY 21891 1,3-	
propanediyl]bisphosp	1
honic acid tetrabutyl	- 1
ester	- 1
BN 50394 Unspecified calcium antagonist hyperlipidemia;	
hypertension	- 1
calcium antagonist (6R)-1- calcium antagonist hypertension	
(aminocarbonyl)-	- 1
1,2,3,6-tetrahydro-4-	
methyl-6- (3-	- 1
nitrophenyl)-2-oxo-5-	
pyrimidinecarboxylic	
acid, 1-methylethyl	
ester	

calcium antagonist,	5-	calcium antagonist	hypertension
Suntory	isopropyloxycarbony		in portension
}	-2-chloro-3-		
	methoxycarbonyl-6-		
	methyl-4-(3-		
	nitrophenyl)-1,4-	·	
	dihydropyridine		
CGP 28861	Unspecified	calcium antagonist	hypertension
CHF 1978	Unspecified	calcium antagonist	hypertension
cilnidipine;	(E)-(+,-)-1,4-dihydro-		hypertension
cinaldipine; FRC	2,6-dimethyl-4-(3-		71
8653; SISCARD;	nitrophenyl)-3,5-		
CINALONG;	pyridinedicarboxylic		
ATELEC	acid 2-methoxyethyl		
	3-phenyl-2-propenyl		
	ester		
clevidipine	4-(2,3-	calcium antagonist	hypertension
į	dichlorophenyl)-1,4-		''
	dihydro-2,6-dimethyl-		
	3,5-		
	pyridinedicarboxylic		
	acid methyl (1-		
	oxobutoxy)methyl		
	ester		
cronidipine; LF	[8-(4-chlorophenyl)-	calcium antagonist	hypertension
20254	1,4-dioxa-8-		
	azaspiro[4.5]dec-2-	,	
	yl]methyl methyl 1,4-		
	dihydro-2,6-dimethyl-		
	4-(3-nitrophenyl)-3,5-		
	pyridinedicarboxylate		
darodipine;	4-(4-benzofurazanyl)-	calcium antagonist	hypertension
dazodipine; PY	1,4-dihydro-2,6-		
108068; PY 108; PY	dimethyl-3,5-		ŀ
10868; PLIMO	pyridinedicarboxylic		
	acid diethyl ester		
diltiazem analogue	Unspecified	calcium antagonist	hypertension

drug delivery system, COER-24 oral verapamil; verapamil COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA drug delivery system, controlled release diltiazem; diltiazem Calcium antagonist hypertension; ang	ina
COER-24; OROS verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA drug delivery system, Controlled release Unspecified calcium antagonist hypertension; ang	
verapamil; COER-24 verapamil; COVERA-HS; CHRONOVERA; CRONOVERA drug delivery system, Unspecified calcium antagonist hypertension; ang	
verapamil; COVERA-HS; CHRONOVERA; CRONOVERA drug delivery system, Unspecified calcium antagonist hypertension; ang	
verapamil; COVERA-HS; CHRONOVERA; CRONOVERA drug delivery system, Unspecified calcium antagonist hypertension; ang	
CHRONOVERA; CRONOVERA drug delivery system, Unspecified calcium antagonist hypertension; ang controlled release	
CRONOVERA drug delivery system, Unspecified calcium antagonist hypertension; ang controlled release	
drug delivery system, Unspecified calcium antagonist hypertension; ang controlled release	
controlled release	
controlled release	ina
diltiazem: diltiazem	
partituzioni, unituzioni	
controlled release;	
TIAZAC; VIAZEM	
drug delivery system, Unspecified calcium antagonist hypertension; ang	na
controlled release	
nifedipine; nifedipine	
drug delivery system, Unspecified calcium antagonist hypertension	
controlled release	
verapamil; verapamil	
drug delivery system, Unspecified calcium antagonist hypertension	
HALO nicardipine;	
nicardipine HALO	
drug delivery system, Unspecified calcium antagonist hypertension	
HALO nifedipine;	•
nifedipine HALO	
drug delivery system, Unspecified calcium antagonist hypertension	
HALO sustained	
release diltiazem;	
diltiazem HALO	
sustained release	
drug delivery system, Unspecified calcium antagonist hypertension	
HALO verapamil;	
verapamil HALO	
drug delivery system, Unspecified calcium antagonist hypertension; angi	na
OSAT nifedipine;	
nifedipine sustained	
release	_
drug delivery system, Unspecified calcium antagonist hypertension	\neg
sustained release	l
diltiazem malate;	
diltiazem malate	
sustained release	

4-11	77	T	T
drug delivery system,	Unspecified	calcium antagonist	hypertension
sustained release			ĺ
diltiazem; diltiazem		,	
sustained release;			
DILACOR XR			
drug delivery system,	Unspecified	calcium antagonist	hypertension
sustained release			
diltiazem; diltiazem			
sustained release;			
DILTELAN;			
CARDIZEM CD;			
HERBESSER R;			
DILZEM OD;			
TIAZEM SR			
drug delivery system,	Unspecified	calcium antagonist	angina; hypertension
sustained release		ditagonist	angma, hypertension
nifedipine; nifedipine			
once daily; INDAS			
nifedipine;			
NIFENSAR XL;			
ADALAT SR;			
UNIDIPINE;			
NIFELAN; ADALAT			
OROS			
	5-(5,5-dimethyl-1,3,2-	calcium antagonist	hymontonoises and
selefodipine; NZ 105;		Calcium amagomst	hypertension; angina; cerebrovascular
1	yl)-1,4-dihydro-2,6-		disease
1	dim ethyl-4-(3-		uisease
	nitrophenyl)-3-		
	pyridine-carboxylic		
	acid, 2-		
	•		
	[phenyl(phenylmethyl		
)amino] ethyl ester, P- oxide		
flosatidil; SL 851016		calcium antagonist	angina; hypertension
	(dimethylamino)ethyl		·
][2-[[2-		
	(methylthio)phenyl][[·
	3-		
	(trifluoromethyl)phen		
	yl]methyl]amino]-2-		
	oxoethyl]carbamic		
	acid 2-methylpropyl		
	ester		

EDI (0100	4.50 11 6.0		
FPL 62129	4-[3-chloro-6-fluoro-	calcium antagonist	hypertension; angina
·	2-		
	(trifluoromethyl)phen		
	yl]-2-(fluoromethyl)-		
	1,4-dihydro-6-methyl	-	
	3,5-		
	pyridinedicarboxylic		
	acid 3-methyl 5-(1-		
	methylethyl) ester		
furnidipine; CRE 319	1,4-dihydro-2,6-	calcium antagonist	hypertension; angina;
	dimethyl-4-(2-		reperfusion injury
	nitrophenyl)-3,5-		1
	pyridinedicarboxylic		
	acid methyl		
	(tetrahydro-2-		
	furanyl)methyl ester		
gallopamil; D 600;	5-[(3,4-	calcium antagonist	hypertension; angina;
PROCORUM;	dimethoxyphenethyl)		arrhythmia
CORAPAMIL;	methylamino]-2-		
ALGOCOR	isopropyl-2-(3,4,5-		1
A per a de destructura de la compans	trimethoxyphenyl)val		: .
	eronitrile		
GOE 6070; PD	(+)-2-(N-methyl-N-	calcium antagonist	hypertension
406070	phenylmethylamino)-		7,
	ethyl 1,4-dihydro-5-		
i	isopropoxy-2-methyl-		
	4-(2-		
{	trifluoromethylphenyl		' ' '
·)-1,6-naphthyridine-3-		
	carboxylate		ļ
GYKI 46544		calcium antagonist	hypertension
HP 406		calcium antagonist	hypertension
	fluorophenyl)butyl]-		,,
	7-fluoro-2-		
	methylspiro[(2H)-1,4-		
	benzodioxepin-		
1	3(5H),4'-piperidine]		
	hydrochloride		

iganidipine; 1,4-dihydro-2,6- calcium antagonist hypertension; ang kirenidipine dimethyl-4-(3-hydrochloride; NKY nitrophenyl)-2,2- dimethyl-3-[4-(2-propenyl)-1-piperazinyl]propyl	na
hydrochloride; NKY nitrophenyl)-2,2- 722 dimethyl-3-[4-(2- propenyl)-1-	
722 dimethyl-3-[4-(2- propenyl)-1-	
propenyl)-1-	
hipperazinylipropyl i	
3,5-	
pyridinedicarboxylic	
acid methyl ester	
isradipine; isrodipine; 4-(4-benzofurazanyl)- calcium antagonist hypertension; ang	na
PN 200110; PN 1,4-dihydro-2,6-	
205033; PN 205034; dimethyl-3,5-	
PRESCAL; LOMIR; pyridinedicarboxylic	
DynaCirc; VASCAL; acid methyl 1-	
ICAZ methylethyl ester	
LCB 2514 Unspecified calcium antagonist hypertension	
lercanidipine; 1,4-dihydro-2,6- calcium antagonist hypertension	
masnidipine; REC dimethyl-4-(3-	
152375; R 75; TJN nitrophenyl)pyridine-	
324; ZANIDIP; 3,5-dicarboxylic acid	
LERDIP; ZANEDIP; 2-[(3,3-	
LERCADIP, diphenylpropyl)methy	
CARDIOVASC; lamino]-1,1-	
LERZAM dimethylethyl methyl	
ester	
leualacin cyclo(beta-alanyl-4- calcium antagonist hypertension	
methyl-2-	
hydroxypentanoylleuc	
yl-4-methyl-2-	- 1
hydroxypentanoyl-N-	
methylphenylalanyl)	
nilvadipine; 2-cyano-1,4-dihydro- calcium antagonist hypertension; angir	a
nivadipine; FK 235; 6-methyl-4-(3-	.
FR 34235; SKF mitrophenyl)-3,5-	
102362; CL 287389; pyridinedicarboxyli c	
NIVADIL; ESCOR acid 3-methyl 5-(1-	
methylethyl) ester	

nisoldipine; BAY k	1,4-dihydro-2,6-	calcium antagonist	angina; hypertension
5552; SULAR;	dimethyl-4-(2-	outorain antagomst	angina, nypenension
SYSCOR;	nitrophenyl)-3,5-		
BAYMYCARD;	pyridinedicarboxylic		
CORASOL;	acid methyl 2-		
CORNEL;	methylpropyl ester		
NISODIPEN;	J. Propy and		
NISOCOR;			
ZADIPINA			
nitrendipine, (S)-;	(4S)-1,4-dihydro-2,6-	calcium antagonist	hypertension
(S)-nitrendipine	dimethyl-4-(3-	outclass antagonist	hypertension
(-)	nitrophenyl)-3,5-		
	pyridinedicarboxylic	·	
	acid ethyl methyl		
	ester		
nitrendipine; BAY e	1,4-dihydro-2,6-	calcium antagonist	hypertension
5009;	dimethyl-4-(3-	- and an anagomst	l'ypertension
BAYOTENSIN;	nitrophenyl)-3,5-		
BAYPRESS;	pyridinedicarboxylic		
NIRAPEL;	acid ethyl methyl		
NITRENDIL;	ester		
NITRENDIPINA;			
HYPERDIPINA;			
HIPERTENOL;			
PORTIONAL;			
NELCONIL;			
RETENCAL			
NPK 1868	2-	calcium antagonist	hypertension
	[[(aminocarbonyl)oxy		, personoiox
	[methyl]-4-(2,3-		
	dichlorophenyl)-1,4-		
	dihydro-6-methyl-3,5-		
	pyridinedicarboxylic		
	acid dimethyl ester		
olradipine; S 11568;		calcium antagonist	hypertension
S 12968	aminoethoxy)ethoxy]		, postonorom
}	methyl]-4-(2,3-		·
1	dichlorophenyl)-1,4-		
· ·	dihydro-6-methyl-3,5-		1
	pyridinedicarboxylic		
	acid 3-ethyl 5-methyl		
	ester		
·		<u></u> L	

			
OPC 8490	3,4-dihydro-6-[4-(4-oxo-4-phenylbutyl)-1-piperazinyl carbonyl]-2(1H)-quinolinone	-	hypertension
1 IOD 032		 	
oxodipine; IQB 837	ethyl methyl 1,4-	calcium antagonist	hypertension
	dihydro-2,6-dimethyl-	•	
	4-[2,3-		
	(methylenedioxy)phe		
	nyl]-3,5-		
	pyridinedicarboxylate		
palonidipine; TC 81	(+,-)-3-	calcium antagonist	hypertension
	(benzylmethylamino)-		,,
	2,2-dimethylpropyl		
	methyl 4-(2-fluoro-5-		
	nitrophenyl)-1,4-		
	dihydro-2,6-dimethyl-		
	3,5-		
	pyridinedicarboxylate		
PCA 50982	Unspecified	calcium antagonist	humantanaianu anaina
pranidipine; OPC	(E)-1,4-dihydro-2,6-	calcium antagonist	hypertension; angina
13340, ACALAS	dimethyl-4-(3-	Calcium amagomst	hypertension; angina
15540; MCALAB	nitrophenyl)-3,5-		
	pyridinedicarboxylic		
	acid methyl 3-phenyl-		
. 1:	2-propenyl ester	<u> </u>	
riodipine; ryodipine;	4-[2-	calcium antagonist	hypertension; angina
PP 1466; FURIDONE	(difluoromethoxy)phe		
	nyl]-1,4-dihydro-2,6-		
	dimethyl-3,5-		
	pyridinedicarboxylic		
	acid dimethyl ester		
RS 5773	((2S,3S)-3-acetoxy-8-	calcium antagonist	angina; hypertension
	benzyl-2,3-dihydro-5-		
	(2-		
	(dimethylamino)ethyl	,	
)-2-(4-		
	methoxyphenyl)-1,5-		
	benzothiazepine-4-		
	(5H)-one		i
	hydrochloride		
	r., aroundide		

S 12967	(+)-2-[[2-(2-	calcium antagonist	h
5 12/0/	aminoethoxy)ethoxy]	Calcium amagomst	hypertension
	methyl]-4-(2,3-		
	dichlorophenyl)-1,4-		
	dihydro-6-methyl-3,5-	1	
	pyridinecarboxylic		
	acid 3-ethyl 5-methyl		
	ester	<u> </u>	
siratiazem; LR A113	(2S-cis)-3-	calcium antagonist	angina; hypertension
	(acetyloxy)-2,3-		
	dihydro-2-(4-		
	methoxyphenyl)-5-[2-		
	[methyl(1-		
	methylethyl)amino]et		
	hyl]-1,5-		
	benzothiazepin-	'	
	4(5H)-one		
SM 6586	1,4-dihydro-2,6-	calcium antagonist	hypertension
	dimethyl-5-[3-		
	[[methyl(phenylmethy		
	l)amino]methyl]-		
	1,2,4-oxadiazol-5-yl]-		
	4-(3-nitrophenyl)-3-		
	pyridinecarboxylic		
	acid methyl ester		
teludipine; taludipine;	(E)-2-	calcium antagonist	hypertension; angina
GR 53992B; GR	(dimethylamino)met	J	,
53992X	hyl]-4-[2-[3-(1,1-		
	dimethylethoxy)-3-		
ļ	oxo-1-		
	propenyl]phenyl]-1,4-		
	dihydro-6-methyl-3,5-		
	pyridinedicarboxylic		
	acid diethyl ester		
TMB 8		calcium antagonist	hypertension
	trimethoxybenzoic) P
	acid 8-		
	(diethylamino)octyl		
	ester		
L	VOICE		

	· · · · · · · · · · · · · · · · · · ·		
vatanidipine; watanidipine; AE 0047; GJ 0956; CALBREN	2-((2-((4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl) - 6-methyl-1,4-dihydropyrid-2-yl)methoxy)ethyl)amino)acetamide 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid, 2-[4-[4-(diphenylmethyl)-1-	calcium antagonist	hypertension; angina hypertension
	piperazinyl]phenyl]et hyl methyl ester		
Y 20835	Unspecified	calcium antagonist	hypertension
YM 161511; YM	(+-)-1,4-dihydro-4-[2-		hypertension; angina
16151-1 	[4-[(2-hydroxy-3- phenoxypropyl)amino]butoxy]-5- nitrophenyl]-2,6- dimethyl-3,5- pyridinedicarboxylic acid dimethyl ester monohydrochloride		
LU 49938	(n-hexyl)]amino-2- (3,4,5- trimethoxyphenyl)-2- isopropylvaleronitrile hydrochloride	calcium antagonist; 5HT antagonist	hypertension
amlodipine + benazepril; benazepril + amlodipine; CGP 24267A; LOTREL	Unspecified	calcium antagonist; ACE inhibitor	hypertension
diltiazem malate + enalapril; enalapril + diltiazem malate; TECZEM		calcium antagonist; ACE inhibitor	hypertension
felodipine + enalapril; enalapril + felodipine; LEXXEL	•	calcium antagonist; ACE inhibitor	hypertension

felodipine + ramipril; ramipril + felodipine; HOE 9869; UNIMAX; TAZKO	Unspecified	calcium antagonist; ACE inhibitor	hypertension
monatepil; monatepil	(+,-)-N-(6,11-	calcium antagonist;	hypertension; angina;
maleate; monasedin	dihydrodibenzo[b,e]th		
maleate; AJ 2615;	iepin-11-yl)-4-(4-	, ,	hyperlipidemia
AD 2615		antagonist; alpha1	
AD 2013	fluorophenyl)-1-	adrenergic antagonist	
C 1 1' ' .	piperazinebutanamide		
felodipine +	Unspecified	calcium antagonist;	hypertension; angina
metoprolol;		beta adrenergic	
metoprolol +		antagonist	
felodipine;			
LOGIMAX			ĺ
YM 154301; YM 430		calcium antagonist;	hypertension; angina
	dihydro-2,6-dimethyl-	beta adrenergic	/ 5
	4-(3-nitrophenyl)-3,5-		
	pyridinecarboxylic		
	acid, 4-[(2-hydroxy-3-		
	phenoxypropyl)amino		
	butyl methyl ester		
CD 349		calcium antagonist;	hypertension; asthma;
			angina
4	nitrophenyl)-3,5-		
4	pyridinedicarboxylic		
	acid 2-		
1	(nitrooxy)propyl 3-	•	
	(nitrooxy)propyl ester	* *	
AHR 16462B		calcium antagonist;	<u></u>
1	fluorophenyl)methyl]-		hypertension
1	1-(2-	vasouliator	
1	,		İ
	naphthalenylmethyl)p		
1	iperidine		
	hydrochloride		
1			hypertension;
1	dihydro-2,6-dimethyl-	vasodilator	ischemia
	4-(3-nitrophenyl)-3,5-		ĺ
	pyridinedicarboxylic		
OLDECA	acid methyl 1-		
	(phenylmethyl)-3-		
	pyrrolidinyl ester		
	·		

benidipine;	(R*,R*)-(+,-)-1,4-	ooloisuus auto sa ii t	<u>, </u>
nakadipine;		calcium antagonist;	hypertension; angina
nacadipine; KW	dihydro-2,6-dimethyl	i i	
	4-(3-nitrophenyl)-3,5	-[
3049; CONIEL	pyridinedicarboxylic		
	acid methyl 1-	·	
	(phenylmethyl)-3-		
	piperidinyl ester		
clentiazem;	(2S-cis)-3-	calcium antagonist;	hypertension; angina
clentiazem maleate;	(acetyloxy)-8-chloro-	vasodilator	, ,
TA 3090; LOGNA	5-[2-		
	(dimethylamino)ethyl		
]-2,3-dihydro-2-(4-		
	methoxyphenyl)-1,5-		
	benzothiazepin-		
	4(5H)-one		
elgodipine; IQB 875	(+,-)-4-(1,3-	calcium antagonist;	angina; hypertension;
·	benzodioxol-4-yl)-	vasodilator	heart failure
	1,4-dihydro-2,6-		Troute landio
	dimethyl-3,5-		
	pyridinedicarboxylic		
	acid 2-[[(4-		·
	fluorophenyl)methyl]		
	methylamino ethyl 1-		
	methylethyl ester		
lomerizine; KB 2796;		calcium antagonist;	hypertension;
TERRANAS TAB;	fluorophenyl)methyl]-		migraine
MIGSIS	4-[(2,3,4-	V abounator	ingrame
	trimethoxyphenyl)met		
•	hyl]piperazine		
manidipine;		calcium antagonist;	h
manidipine		vasodilator	hypertension
hydrochloride; CV	nitrophenyl)-2-[4-	vasounator	
4093; CALSLOT;	(diphenylmethyl)-1-	:	-
MADIPINE;	piperazinyl]ethyl 3,5-		
	pyridinedicarboxylic		
	acid methyl ester		
		calaium anta assist	1
	dimethoxyphenyl)eth		hypertension
		vasouliator	
	yl]-5-methoxy-N,alfa-		}
	dimethyl-2-		
	(phenylethynyl)benze		
	nepropanamine		

D 10/0	h (1 0 2 4	T	
P 1268	2-(1,2,3,4-	calcium antagonist;	hypertension
	tetrahydroisoquinolin	vasodilator	
	e-2-yl)ethyl-1,4-		
	dihydro-2,6-		
	dimethyl-4-(3-		
	nitrophenyl)-5-		
	methoxycarbonylpyri		
	dine-3-carboxylate,		
	monohydrochloride		
	l(R)-2-[2-[3-[[2-(1,3-	calcium antagonist;	angina; hypertension
fumarate; SD 3211;	benzodioxol-5-	vasodilator	0 , 31
DQ 4823; DS 4823	yloxy)ethyl]methylam	n	
	ino]propoxy]-5-		
	methoxyphenyl]-4-		
	methyl-2H-1,4-		
	benzothiazin-3(4H)-		
	one		
TJN 220	(1beta)-7-ethoxy-	calcium antagonist;	hypertension
	6,6',12-trimethoxy-	vasodilator	J. Portonolon
	2,2'-	1	. [
	dimethylberbaman		
felodipine; H 15482;	4-(2,3-	calcium antagonist;	hypertension; angina;
HOE 869; CGH 869;		vasodilator; diuretic	heart failure;
	dihydro-2,6-dimethyl-	,	atherosclerosis
VASOPINE;	3,5-		
SPLENDIL;	pyridinedicarboxylic		
MUNOBAL;	acid ethyl methyl		200 800
FLODIL	ester		
drug delivery system,	Unspecified	calcium channel	hypertension
OROS oral controlled	_	blocker	
release isradipine;			
isradipine OROS;			
DynaCirc CR			
lacidipine; GR 43659;	(E)-4-[2-[3-(1.1-	calcium channel	hypertension
GR 43659X; SN 305;		blocker	Portoitoit
1	oxo-1-		
1 ' '	propenyl]phenyl]-1,4-		
L	dihydro-2,6-dimethyl-		
l	3,5-		
	pyridinedicarboxylic		
	acid diethyl ester		
APONIL; ZASCAL;	mora aroury roster		
LACIMEN			
	Inchecitied	ooloissaa ahaaaa 1	h •
	<u>-</u>	calcium channel blocker	hypertension

RWJ 22726	N-benzyl-N-methyl-	landain 1	L
AC 17 J 22 / 20	aminoethyl 10-(2,3-	calcium channel blocker	hypertension
	dichlorophenyl)-	DIOCKCI	
	3,4,5,6,7,10-		1
	hexahydro-8-methyl-]
	1,1-dioxo-2H-		
	thiacycloocteno(3,2-		
	b)pyridine-		
	carboxylate		
verapamil, (S)-; (S)-	(S)-alpha-[3-[[2-(3,4-	calcium channel	hypertension;
verapamil;	dimethoxyphenyl)eth		arrhythmia; angina
levoverapamil; D	yl]methylamino]prop	DIOCKCI	arriiyuuma, angma
2024	yl]-3,4-dimethoxy-		
	alpha-(1-		
	methylethyl)benzenea		ĺ
	cetonitrile		
Z 6568	Unspecified	calcium channel	hypertension
		blocker	
meoxan	Unspecified	calcium channel	hypertension;
		blocker; alpha	thrombosis; eye
- · ·		adrenergic antagonist;	
		alphal adrenergic	·
		antagonist; platelet	
		antiaggregant	
S 2150		calcium channel	hypertension
	chloro-2,3-dihydro-2-	blocker; alpha	·
		adrenergic antagonist;	
	1 .	alphal adrenergic	
		antagonist	
	piperazinyl]propyl]-		
	1,5-benzothiazepin-		
I D man	4(5H)-one citrate		,
veroxan; VUFB	1 -		hypertension;
18814		blocker; alpha	thrombosis; eye
		adrenergic antagonist;	disease
		alphal adrenergic	1
	i i	antagonist; platelet	
·		antiaggregant	

77 (22 (22)	b 5 11 1 27 50 550		
ZM 224832	3,5-diamino-N-[2-[[2		hypertension
	[[(6-bromo-2,3-	blocker; diuretic	
	dihydro-5-hydroxy-		
•	1,1-dimethyl-1H-	ľ	
	inden-4-		
	yl)methyl]amino]ethy	,	
	l]methylamino]ethyl]	-	
	6-		
	chloropyrazinecarbox		
	amide		
LAS 30538	1-[2-(2,6-	calcium channel	hypertension
	dimethylphenoxy)eth	blocker; vasodilator	-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	yl-alpha,alpha-bis(4-	,	
	fluorophenyl)-4-		
	piperidinemethanol		
mibefradil; mibefradi		calcium channel	hypertension; angina;
dihydrochloride; Ro	(1S-cis)-2-[2-[[3-(1H-		heart failure
405967; Ro	benzimidazol-2-	The state of the	licate famule
405967001;	yl)propyl]methylamin		
POSICOR; CERATE	o]ethyl]-6-fluoro-		
	1,2,3,4-tetrahydro-1-	1.0	
,	(1-methylethyl)-2-		
	naphthalenyl ester		
SQ 33351	[3R-	calcium channel	hypertension
	[1(S*),3alfa,4alfa]]-3-		
	(acetyloxy)-1,3,4,5-	, , , , , , , , , , , , , , , , , , , ,	
	tetrahydro-4-(4-		
	methoxyphenyl)-1-(2-		
	pyrrolidinylmethyl)-		
	6-(trifluoromethyl)-		
	2H-1-benzazepin-2-		
	one		
	monohydrochloride		
SQ 33537		calcium channel	hypertension
	<u> </u>	blocker; vasodilator	
	1,3,4,5-tetrahydro-3-		
	hydroxy-4-(4-		
3	methoxyphenyl)-1-(2-		
	pyrrolidinylmethyl)-		
	6-(trifluoromethyl)-		
	2H-1-benzazepin-2-		
	one		·
	monohydrochloride		
	полонушостопае	<u>-</u>	

DF 100	4-(3,5-dimethyl-1H-pyrazol-1-yl)-2,5-dihydro-1H-pyridazino[4,5-b]indol-1-onehydrazonemonohydrochloride	Calcium influx modulator	hypertension
AM 522	Unspecified	cardiac glycoside	hypertension; heart failure
AM 524	Unspecified	cardiac glycoside	heart failure; hypertension
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure; hypertension
antihypertensive	Unspecified	Catecholamine metabolism	hypertension
JMV 236	N-[(1,1- dimethylethoxy)carbo nyl]-O-sulfo-L- tyrosyl-L- norleucylglycyl-L- tryptophyl-L- norleucyl-L-alpha- aspartyl-L- phenylalaninamide	cholecystokinin agonist	hypertension
besulpamide; E 3050	l-(4-chloro-3- sulfamoylbenzamido) -2,4,5- trimethylpyridinum hydroxide	diuretic	hypertension
cicletanine; cycletanide; BN 1270; RU 270; WIN 90000; TENSTATEN; JUSTAR	3-(4-chlorophenyl)- 1,3-dihydro-6- methylfuro[3,4- c]pyridin-7-ol	diuretic	hypertension
drug delivery system, furosemide; furosemide delivery system; HYAL DI4151	Unspecified	diuretic	hypertension
hattalin	2,3-dibenzylbutane- 1,4-diol	diuretic	hypertension

PCT/US00/01392

TCI 101027	(D + D +) (+) 0 t0 t0	1,	T
ICI 181037	(R*,R*)-(+,-)-2-[2-[2	!-diuretic	hypertension
	(dimethylamino)-1-		
	[5-(1,1-		
• [dimethylethyl)-2-		
	methoxyphenyl]-1-		
	hydroxypropyl]pheno		
	xy]acetamide		
ICI 206970	3,5-diamino-N-[2-[N	-diuretic	hypertension
1	[2-(3-bromo-5-tert-		
	butyl-2-		1
	hydroxybenzylamino)	
	ethyl]-N-		
	methylamino]ethyl]-		
	6-chloropyrazine-2-		
	carboxamide		
ICI 207828	N-(2-(3-bromo-5-tert-	diuretic	hypertension
	butyl-2-		
	hydroxybenzylamino)		
	ethyl)-3-(N-2-(3,5-		
	diamino-6-		
	chloropyrazin-2-		
	ylcarboxamido)ethyl)		
	N-		
	methylamino)propion	ļ	
	amide		
MD 31; M 17055	N-[7-chloro-2,3-	diuretic	hypertension
	dihydro-1-(2-		31
	methylbenzoyl)-		
	4(1H)-		
	quinolinylidene]hydro		
	xylamine-O-sulfonic		
	acid potassium salt		
PF 886	Unspecified	diuretic	hypertension
SC 46279	1-(5-amino-7-		hypertension
	phenyl[1,2,4]triazolo[1	-7 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -
	1,5-c]pyramidine-8-		
	yl)-1,2-ethanediol		•
	V / ->	<u> </u>	

	hy seed	T.:	
torasemide;	N-[[(1-	diuretic	hypertension; heart
torsemide; JDL 464;	methylethyl)amino]c	a	failure
BM 02015; AC 4464;	,		
GJ 1090; UNAT;	methylphenyl)amino]	-	
PRESARIL;]3-		
TORREM, TOREM,	pyridinesulfonamide		
ZEMIDE;			
DEMADEX;			
TORADIUR;			
DIURESIX;			
LUPRAC		1	
telmisartan +	Unspecified	diuretic; angiotensin	hypertension
hydrochlorothiazide;		II antagonist	
hydrochlorothiazide +			
telmisartan			
MCC 134	1-[4-(1H-imidazol-1-	diuretic; potassium	hypertension
	yl)benzoyl]-N-	channel activator	71
	methylcyclobutanecar		
	bothioamide		
quinelorane;	(5aR-trans)-	dopamine agonist	Parkinson disease;
quinelorane	5,5a,6,7,8,9,9a,10-		hyperprolactinemia;
hydrochloride; LY	octahydro-6-		hypertension
163502	propylpyrido[2,3-		
	g]quinazolin-2-amine		l
RD 211; (+-)-RD 211	2-(dipropylamino)-	dopamine agonist	hypertension
	2,3-dihydro-5-methyl-		,,
	1 H-inden-4-ol		
Z 15040	Unspecified	dopamine agonist	hypertension
A 68930	(1R,3S)-1-	dopamine agonist;	hypertension;
	aminomethyl-5,6-	dopamine D1 agonist	
	dihydroxy-3-		
	phenylisochroman		
	ethylcarbamic acid,	dopamine agonist;	hypertension
	(R)-6-chloro-2,3,4,5-	dopamine D1 agonist	J
	tetrahydro-1-(4-		·
1	hydroxyphe nyl)-1H-		
1	3-benzazepin-7,8-diyl		·
1	ester		
	monohydrochloride		
		dopamine agonist;	hypertension
1		dopamine D1 agonist;	, portonsion
		dopamine D1 agonist;	
		vasodilator	
1	1,2-naphtolenediol	v asoutiatoi	<u> </u> -
,	dihydrochloride		
L	amydrocinoride		

E 4010	4 ff(2 ablass 4	11.	T
E 4010	4-[[(3-chloro-4-	dopamine agonist;	pulmonary
	methoxyphenyl)meth	1	hypertension; sexual
	y]amino]-1-(4-	phosphodiesterase	dysfunction
	hydroxy-1-piperid	inhibitor;	
	inyl)-6-	phosphodiesterase V	
	phthalazinecarbonitril	inhibitor	
	e monohydrochloride		
fenoldopam;	6-chloro-2,3,4,5-	dopamine agonist;	hypertension;
fenoldopam mesylate	tetrahydro-1-(p-	dopamine D1 agonist;	
SKF 82526; SKF	hydroxphenol)-1H-3-	vasodilator: diuretic	disease; heart failure
825263;	benzazepine-7,8-diol		-100-200, mount landro
CORLOPAM			
carmoxirole; EMD	3-[4-[3,6-dihydro-4-	dopamine agonist;	hypertension
45609	phenyl-1(2H)-	dopamine D2 agonist	
	pyridinyl]butyl]-1H-	'	
	indole-5-car boxylic		
	acid		
ZK 112566		dopamine agonist;	hypertension
		dopamine D2 agonist;	rty per terision
	2,6-dimethyl-ergolin-		
	8-yl]-N,N-die	antagonist; alpha2	
	thylurea	adrenergic antagonist;	
		vasodilator	
fosopamine; SIM	4-[2-		hypertension
2055; Z 2055		vasodilator	ilypertension .
[1,2-benzenediol 1-	Vasouliator	
	(dihydrogenphosphate		
	(diriyarogenphosphate	* .	
MDL 43925	Unspecified	dopamine beta	hypertension
10,25		monooxygenase	hypertension
		inhibitor	
endothelin A			by montangia and laid and
antagonist	-		hypertension; kidney
antagoinst		antagonist; endothelin	uisease
FR 139317; FK		antagonist endothelin A	
			hypertension;
	* · · · · · · · · · · · · · · · · · · ·	antagonist; endothelin	scnemia
		antagonist	
	yl)carbonyl]-L-		
	leucyl]-1-methyl-D-		
	tryptophyl]-3-(2-		
	pyridinyl)-D-alanine		

(carboxymethoxy)-4- methoxyphenyi]-1- (3,4- methylenedioxypheny i])-5-propoxyindane-2- carboxylic acid TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N- (3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonist peride endothelin antagonist hypertension hypertension hypertension hypertension hypertension hypertension endothelin antagonist hypertension endothelin antagonist hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension	SB 209670	(+)-(1S,2R,3S)-3[2-	endothelin A	kidney disease;
methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt 5-(dimethylamino)-N- (3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl-5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin Unspecified unspecified unspecified unspecified antagonist [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		(carboxymethoxy)-4-		hypertension
(3,4- methylenedioxypheny			1 • .	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D)-5-propoxyindane-2-carboxylic acid				
D)-5-propoxyindane-2-carboxylic acid		methylenedioxypheny	/	
Carboxylic acid TAK 044 Cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt S-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonami de EMD 94246 N-2,1,3-benzodiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt endothelin Unspecified endothelin antagonist hypertension benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt endothelin Unspecified endothelin antagonist hypertension hypertension hypertension hypertension hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension			· 1	
TAK 044 cyclo[4-oxo-4 (4-phenyl-1-piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonami de EMD 94246 N-2,1,3-benzodiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfo namide, potassium salt endothelin Unspecified Unspecified Unspecified Total pha-aspartyl disodium salt endothelin antagonist hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension hypertension				
phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin Unspecified unspecified saltagonist; endothelin disease; myocardial infarction; brain private endothelin antagonist; endothelin antagonist endothelin antagonist endothelin antagonist endothelin antagonist endothelin antagonist endothelin antagonist endothelin antagonist en	TAK 044		endothelin A	hypertension: kidney
piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N- (3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin Unspecified cndothelin antagonist hypertension hypertension bypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist hypertension cndothelin antagonist	1	1		
aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N- (3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin Unspecified unspecified condothelin antagonist hypertension endothelin antagonist hypertension antagonists J 104132; L 753037 [5S-[Salpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		Г -		
alpha-aspartyl-D-2- (2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N- (3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin Unspecified antagonists Unspecified antagonists J 104132; L 753037 [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid				
(2-thienyl)glycyl-L- leucyl-D-tryptophyl- D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N- (3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin Unspecified Unspecified endothelin antagonist Unspecified endothelin antagonist pendothelin antagonist pendothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension				i i i i i i i i i i i i i i i i i i i
leucyl-D-tryptophyl-D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified indothelin antagonist Unspecified endothelin antagonist bypertension hypertension hypertension endothelin antagonist hypertension endothelin antagonist hypertension hypertension hypertension hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension endothelin antagonist hypertension				
D-alpha-aspartyl] disodium salt BMS 182874 5-(dimethylamino)-N-endothelin antagonist hypertension (3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide EMD 94246 N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt endothelin antagonists Unspecified Unspecified cendothelin antagonist hypertension index pendothelin antagonist hypertension pendothelin antagonist hypertension index pendothelin antagonist hypertension				<u> </u>
disodium salt BMS 182874 5-(dimethylamino)-N-endothelin antagonist hypertension (3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide EMD 94246 N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt endothelin antagonists Unspecified Unspecified EMD 94246 Comparison Comparison EMD 94246 N-2,1,3-benzothiadiazol-5-yl-5-(dimethylamino)-1-naphthalenesulfonamide, potassium salt endothelin antagonists J 104132; L 753037 [SS-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxy-propyl)-4-methoxyphenyl]-6,-dihydro-5H-cyclopbenta[b]pyrindine-6-carboxylic acid				
(3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt Unspecified antagonists Unspecified antagonists J 104132; L 753037 [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid				
(3,4-dimethyl-5- isoxazolyl)-1- naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified Unspecified endothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid	BMS 182874	5-(dimethylamino)-N-	endothelin antagonist	hypertension
naphthalenesulfonami de EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified antagonists J 104132; L 753037 [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		(3,4-dimethyl-5-		
EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified EMD 94246 Unspecified endothelin antagonist hypertension pendothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		isoxazolyl)-1-		
EMD 94246 N-2,1,3- benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified unspecified Endothelin antagonist pendothelin antagonist hypertension hypertension hypertension hypertension hypertension pendothelin antagonist hypertension hypertension hypertension antagonist for alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		naphthalenesulfonami		
benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified endothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid				
benzothiadiazol-5-yl- 5-(dimethylamino)-1- naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified endothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid	EMD 94246	N-2,1,3-	endothelin antagonist	hypertension
naphthalenesulfo namide, potassium salt endothelin antagonists Unspecified endothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		benzothiadiazol-5-yl-		-1
namide, potassium salt endothelin antagonists Unspecified endothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		5-(dimethylamino)-1-		
salt endothelin antagonists J 104132; L 753037 [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		naphthalenesulfo		
endothelin antagonists Unspecified endothelin antagonist hypertension [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxy-propyl)-4-methoxyphenyl]-6,-dihydro-5H-cyclopbenta[b]pyrindine-6-carboxylic acid		namide, potassium	· .	·
antagonists [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxy-propyl)-4-methoxyphenyl]-6,-dihydro-5H-cyclopbenta[b]pyrindine-6-carboxylic acid		salt		
antagonists J 104132; L 753037 [5S-[5alpha, 6beta, 7alpha (R*)]]-2-butyl-5-(1,3-benzeodioxol-5-yl)-7-[(2-carboxy-propyl)-4-methoxyphenyl]-6,-dihydro-5H-cyclopbenta[b]pyrindine-6-carboxylic acid	endothelin	Unspecified	endothelin antagonist	hypertension
7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid	antagonists			51
7alpha (R*)]]-2-butyl- 5-(1,3-benzeodioxol- 5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid	J 104132; L 753037	[5S-[5alpha, 6beta,	endothelin antagonist	hypertension
5-yl)-7-[(2-carboxy- propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid				
propyl)-4- methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		5-(1,3-benzeodioxol-		
methoxyphenyl]-6,- dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		5-yl)-7-[(2-carboxy-		. 1
dihydro-5H- cyclopbenta[b]pyrindi ne-6-carboxylic acid		propyl)-4-		
cyclopbenta[b]pyrindi ne-6-carboxylic acid		methoxyphenyl]-6,-		. 1
ne-6-carboxylic acid		dihydro-5H-		
		cyclopbenta[b]pyrindi		
		ne-6-carboxylic acid		•
	Т 0115		endothelin antagonist	oulmonary
hypertension				-

DD 156707 DD			PC1/US00/(
PD 156707; PD	alpha-[2-(4-	endothelin antagon	ist; ischemia; reperfusi
156123	methoxyphenyl)-2-	endothelin A	injury; pulmonary
	oxo-1-[(3,4,5-	antagonist	hypertension
	trimethoxyphenyl)r	net	hypertension
	hyl]ethylidene]1,3-		
	benzodioxole-5-ace	tic	
	acid sodium salt		
SB 247083	Unspecified		
	Chispochicu	endothelin antagoni	
		endothelin A	hypertension
YM 598	notarain (D) 37 FG	antagonist	
1111 570	potassium(E)-N-[6-	endothelin antagoni	st; hypertension
	methoxy-5-(2-	endothelin A	1
	methoxyphenoxy)-2	- antagonist	
	(pyrimidin-2-yl)-		į
	pyrimidin-4-yl]-2-		
	phenylenthenesulfor	a	
	midate		
ecadotril; sinorphan;	(S)-N-[2-	enkephalinase	
3P 1.02; BAY y	(acetylthio)methyll	inhibitor	hypertension; heart
432; S 049; BP 102	1-oxo-3-	111111111111	failure; cirrhosis
	phenylpropyl]glycine		
•	phenyl methyl ester		
Y 203647	1-[2-hydroxy-3-		
***	propyl-4-[4-[2-[4-	leukotriene D4	hypertension; asthma
	(1H-tetrazol-5-	antagonist;	
		leukotriene antagonis	it
	yl)butyl]-2H-tetrazol-	•	
	D-		
	yl]butoxy]phenyl]eth:	a	
monotriles DNs0	none	·	
mapatrilat; BMS	[4S-	matrix	hypertension; heart
36716	[4alpha(R*),7alpha,1	metalloproteinase	failure
	[0abeta]]-octahydro-4-	inhibitor; ACE	
	[(2-mercapto-1-oxo-	inhibitor: neutral	
		endopeptidase	1
	phenylpropyl)amino]-	inhibitor proteiness	
	5-oxo-7H-pyrido[2,1-	inhihitor	
	b][1,3]thiazepine-7-	Partito I fol	
	carboxylic acid		
agonists	*	mineralocorticoid	hypertension
		antagonist	
diovascular disease rapy		Myosin motor	hypertension; heart
rahy	·	~· I	failure
70.0016		filaments	· -
CC 0216	Unspecified	neuropeptide Y	obesity; hypertension
		antagonist	insperiension

AXC 1829	Unspecified	neuropeptide Y	PC1/US00/0
		antagonist	obesity; hypertensio
neuropeptide Y	Unspecified	neuropeptide Y	obosit. 1
antagonist, Alanex		antagonist	obesity; hypertensio
SR 120819A	[alpha R-	neuropeptide Y	himortoni
	[N[R*(cis)],alpha	antagonist-	hypertension; obesit
	R*]]-N-[1-[[4-[[[[4-	neuropentide VI	eating disorder
	(dimethylamino)me	et antagonist	
	nyi jeyelohexyl metl	nvl	
	[]amino]iminomethy	/11	
	phenyl]methyl]-2-		
	oxo-2-(1-		
	pyrrolidinyl)ethyl]-		
	alpha-[(2-		
	naphthalenylsulfonyl)	
•	amino]benzenep		
10 2115	ropanamide		
SC 3117	N,N'-bis-[2-N-(0-2,6-	neuropentide V	<u> </u>
	dichiorobenzyl-L-	antagoniet-	hypertension
	tyrosyl)aminoethylgu	neuropentide V2	
	MILVIEVSIAMINA	antagonist	
rug delivery system,	Unspecified	Neurotransmitter	hamorton
heraDerm-MTX		modulation	hypertension
ansdermal			l
onidine; clonidine			.
heraDerm-MTX			
GS 24128	N-[3-[1,1'-biphenyl]-	neutral endopeptidase	himorton
- 2 ¹¹ 1 - 1	1. 2	inhibitor	hypertension
	(phosphonomethyl)al		
3C 24502	anyl]beta-alanine		
GS 24592	N-[3-[1,1'-biphenyl]-	neutral endopeptidase	hypertension
	4-yl-N-	nhibitor	Aberrensiou
	(phosphonomethyl)-		
	L-alanyl]beta-alanine		
58 25155 	[2S-	neutral endopeptidase	Vnertension
	·· (ααιο/,>Ο]]-1- [[nhibitor	Abou (CH210II
	[[9-		
	(acetylthio)methyl]de		
	cahydro-10-oxo-2-		
	zecinyl]carbonyl]-4-	. 1	
	ydroxy-L-proline		
fn	henylmethyl ester	i	j

	•	PC170500
N-[3-[1,1'-bipheny	l]- neutral endopeptic	lase hypertension
[· J1-11-	annibitor	add hypertension
[(diphenoxyphospl	nin	
yl)methyl]-L-alany	· I]-	
beta-alanine	1	
[S-(R*,R*)]-N-[N-	(1- neutral endonentid	
carboxy-3-	inhihitor	ase hypertension
	in in to to t	
phenylalanyll-2-	İ	
hydroxy-beta-alanir	ne l	
N-[2(S)-		
	ileutral endopeptida	ase hypertension
(2-methylphonyl)	innibitor	
	neutral endopeptida	se hypertension
(uncreaptomethyl)-1.	- Inhibitor	
· -		
pnenylpropyljamino]	
$[S-(R^*,R^*)]$ -alpha-	neutral endopeptidas	se heart failure
[[[(3-butoxy-2-	inhibitor; ACE	hypertension
hydroxy-3-	inhibitor	-J Portonsion
oxopropyl)(2-		
methylpropyl)amino]	d	.
arbonyl]amino]-2-		
naphthalenepropanoi	e	
acid		
Unspecified	neutral endonentidas	o by months in the
	inhibitor: ACE	e hypertension; heart
	inhibitor	failure
N-[2-		
-	inhibitor: diversis	nypertension
0X0-3-phenylnronyll	and tollor, diurenc	
beta-alanine		
	L:	
V 7		angina; hypertension
1 -		pulmonary
		hypertension
, - ,	nitric oxide donor;	angina; hypertension
		1
Unspecified	Noradrenergic release	hypertension
 	inhibitor	- J P or correctors
F -		
Unspecified	PAF antagonist	hymertensis
l ' f		hypertension; thrombosis
	[(diphenoxyphosphyl)methyl]-L-alanybeta-alanine [S-(R*,R*)]-N-[N-carboxy-3-phenylpropyl)-L-phenylalanyl]-2-hydroxy-beta-alanin N-[2(S)-acetylthiomethyl-3-(2-methylphenyl)-propanoyl-L-methionine ethyl est 7-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]aminoheptanoic acid [S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]arbonyl]amino]-2-naphthalenepropanoic acid Unspecified N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine Unspecified Unspecified Unspecified Unspecified	[(diphenoxyphosphin yl)methyl]-L-alany l]-beta-alanine [S-(R*,R*)]-N-[N-(1-neutral endopeptid inhibitor phenylpropyl)-L-phenylalanyl]-2-hydroxy-beta-alanine N-[2(S)-acetylthiomethyl-3-(2-methylphenyl)-propanoyl-L-methionine ethyl ester 7-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]heptanoic acid [S-(R*,R*)]-alpha-[[[(3-butoxy-2-hydroxy-3-oxopropyl)(2-methylpropyl)amino]carbonyl]amino]-2-naphthalenepropanoic acid Unspecified Unspecified N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine Unspecified nitrate Unspecified nitrate Unspecified nitric oxide donor; NSAID Unspecified Noradrenergic release inhibitor

LA 228	Unspecified	montido	<u> </u>
LA 230		peptide	hypertension
LA 230	Unspecified	peptide	hypertension;
LA 231	T In an and C = 1	<u> </u>	hyperlipidemia
SNAP 1156	Unspecified	peptide	hypertension
BNAP 1130	Unspecified	peptide	anxiety; hypertension
CGS 19281A	T I	 	obesity; addiction
CGS 19281A	Unspecified	phenylethanolamine	hypertension
		N methyl transferase	
KT 2734	2-phenyl-8-	inhibitor	
K1 2754	ethoxycycloheptimid	phosphodiesterase	hypertension
	zole	аниноног	
SCH 59498	Unspecified	mhoonh - Jirota	
5017 55 150	Onspectifica	phosphodiesterase inhibitor;	hypertension
		phosphodiesterase I	
		inhibitor;	
		phosphodiesterase V	
		inhibitor	
E 4021; ER 21355	1-[4[(1,3-	phosphodiesterase	hypertension; angina;
	benzodioxol-5-	inhibitor;	heart failure
].	ylmethyl)amino]-6-	phosphodiesterase V	
	chloro-2-	inhibitor	
	quinazolinyl]-4-		
	piperidinecarboxylic		
	acid, monosodium		.
	salt		
BF 385; GP 385;	Unspecified	phosphodiesterase	hypertension;
BF/GP 385; ONO		· ·	thrombosis
BF11301; ONO 1505		phosphodiesterase V	
		inhibitor;	
		thromboxane	
	·	synthetase inhibitor;	
onones etc 1.	(57011 1111	platelet antiaggregant	
epoprostenol;	(5Z,9alpha,11alpha,1	platelet antiaggregant;	- 1
epoprostenol sodium; prostacyclin;	1		hypertension;
prostacyclin; prostaglandin X;		prostanoid	thrombosis
prostaglandin I2;	dihydroxyprosta-5,13- dien-1-oic acid		
vasocyclin; UN	mich-1-oic acid		
53217A; U 53217;			Ī
FLOLAN; CYCLO-			
PROSTIN			
T.COZAII.		<u></u>	

diethylhomospermin	ne N,N'-bis[4-	polyamine analogue	diarrhea;
; DEHOP; DE 444	(ethylamino)butyl]-	i sy = maioguo	hypertension; cancer;
	1,4-butanediamine		psoriasis; ulcerative
			colitis
AL 0670	(+)-N-(6-amino-3-	potassium channel	hypertension
	pyridyl)-N'-	activator	
	[(1S,2R,4R)-bicyclo-		
	[2.2.1]hept-2-yl]-N"-		
	cyanoguanidine		
AL 0671	(1S-endo)-N-(6-	potassium channel	hyperlipidemia;
	amino-3-pyridinyl)-	activator	hypertension
	N'-bicyclo[2.2.1]hept		
	2-yl-N"-	1	
KC 515	cyanoguanidine		
ICC 313	N-(2-cyanoethyl)-2,2		hypertension
	bis(fluoromethyl)-6-	activator	
	(pentafluoroethyl)- 2H-1-benzopyran-4-		
	carboxamide.		·
KP 403	6-cyano-2,2-		
103	dimethyl-4-[(N-	potassium channel activator	hypertension
.e 77 s	cyano-	activator	
	acetoimidoyl)amino]-		
	2H-benzo[b]p yran		
KP 4603	Unspecified	potassium channel	hypertension
		activator	hypottonsion
KRN 4884	5-amino-N-[2-(2-	potassium channel	hypertension
·		activator	portonation
	N'-cyano-3-		
	pyridinecarboximida		
	mide		
evcromakalim;		potassium channel	hypertension
emakalim;	3-hydroxy-2,2-	activator	
cromakalim, (-); BRL	dimethyl-4-(2-oxo-1-		
38227; BRL 34915;	pyrrolidinyl)-2H-1-	•	
BRL 38226;	benzopyran-6-	·	
LEVANEX	carbonitrile		
NIP 121			hypertension
		activator]
	6,6-dimethyl-6H-		
	pyrano[2,3-f]-2,1,3-		
	benzoxadiazol-8-yl)-		
	2-piperidinone		

DD 40256	1 1 1 1 1		
RP 49356	tetrahydro-N-methyl- 2-(3-pyridinyl)-2H- thiopyran-2- carbothioamide 1- oxide	activator	hypertension
RWJ 26629	trans-(+,-)-1-(6,7- dihydro-6-hydroxy- 5,5-dimethyl-2-nitro- 5H-thieno[3,2- b]pyran-7-yl)-2- piperidinone	potassium channel activator	hypertension
SKP 450; KR 30450	(R)-1-[2-(1,3- dioxolan-2-yl)-2- methyl-6-nitro-2H-1- benzopyran-4-y l]-2- pyrrolidinone	potassium channel activator	hypertension; heart ischemia
TAK 636	Unspecified	potassium channel activator	hypertension; angina
TCV 295	2-(6-bromo-7-chloro- 2,2-dimethyl-2H-1,3- benzoxazin-4-	potassium channel activator	hypertension
	yl)pyridine N-oxide		A 1411
UR 8218	Unspecified	potassium channel activator	hypertension
UR 8267	Unspecified	potassium channel activator	hypertension
Y 27152	(3S,trans)-N-(6- cyano-3,4-dihydro-3- hydroxy-2,2- dimethyl-2H-1- benzopyran-4-yl)-N- (phenylmethoxy)aceta mide		hypertension; angina
CL 891902	_	potassium channel activator; bronchodilator	asthma; hypertension
	(3S-trans)-3,4- dihydro-3-hydroxy-	potassium channel activator; bronchodilator	hypertension; heart failure; asthma; peripheral vascular disease

potassium channel	4 (() 6 ()		01/0500/0.
activator	4-[(1,6-dihydro-1-	potassium channel	hypertension; asthm
	methyl-6-oxo-3-	activator;	
	pyridazinyl)oxy]-3,4	- bronchodilator	
	dihydro-3-hydroxy-		
	2,2-dimethyl-2H-1-		
	benzopyran-6-		
Ro 316930	carbonitrile		
KO 210930	2,2-dimethyl-4-(2-	potassium channel	hypertension; asthm
	pyridinyl)-2H-1-	activator;	population, astinii
	benzopyran-6-	bronchodilator	
004.40	carbonitrile N4-oxide		
SCA 40	6-bromo-8-	potassium channel	hypertension; asthma
•	(methylamino)-	activator;	arypertension, asthma
	imidazo[1,2-	bronchodilator	
	a]pyrazine-2-		
	carbonitrile		
symakalim; EMD	4-[(1,6-dihydro-1-	potassium channel	himartonei
57283	methyl-6-oxo-3-	activator;	hypertension;
	1	bronchodilator	coronary artery
	dihydro-3-hydroxy-		disease; asthma
	2,2-dimethyl-2H-1-		
	benzopyran-6-		
	carbonitrile		, and the second
JR 8225	1,2-dihydro-4-(1,2-	potassium channel	
		activator;	hypertension; asthma;
	pyridyl)-2,2-dimethyl-	hronchodilator	urinary incontinence
	1-oxonaphthalene-6-	or offiction (1)	
	carbonitrile		
M 934	3,4-dihydro-2,2-	potassium channel	
	dimethyl-6-nitro-4-(2-	ectivator:	hypertension; asthma,
		pronchodilator	urinary incontinence
	benzoxazine N-oxide	Monenognator	
likalim; WAY	(0.0	ootassium channel	
0491	1		hypertension
	2,2-dimethyl-6-	ctivator; vasodilator	
	(trifluoromethoxy)-		
	2H-1-benzopyran-4-		
	yl]-2,3-dihydro-1H-		
	isoindol-1-one		

DY 9708	F		5 0 17 0 5 0 0 7 0
DY 9708	[1R-[1	potassium channel	hypertension; angin
	alpha,2(3S*,4R*),6a	l activator; vasodilato	or
	pha]]-3,4-dihydro-3-	.	
	hydroxy-2,2-dimethy	/	
	1-4-[(5-oxo-3,4-	•	
·	diazabicyclo[4.1.0]h	e	
	pt-2-en-2-yl)oxy]-2H	[-	
	1-benzopyran-6-		
	carbonitrile		
pinacidil; P 1134;	N-cyano-N'-(4-	potassium channel	
PINDACIL;	pyridinyl)-N"-(1.2.2-	blocker	hypertension
PINDAL; PINDAC;	trimethylpropyl)guan	i	
THERAPRESS	dine		
U 37883A	N-cyclohexyl-N'-	potassium channel	
	tricyclo[3.3.1.13,7]de	blocker	hypertension
	c-1-yl-4-	DIOCKCI	•
	morpholinecarboximi		
	damide	1	
	monohydrochloride		
CL 115999	(9alfa,11alfa,13E)-	prostanoid	
	6,9-epoxy-16-ethenyl-	prostatioid	hypertension
-	11,16-dihydroxy-5-		
	iodoprost-13-en-1-oic		·
	acid methyl ester		
beraprost; TRK 100;		program - id day 1	
RU 55100; ML 1129;	h	prostanoid; platelet	peripheral vascular
MDL 201129;	hydroxy-4-methyl-1-	antiaggregant	disease; thrombosis;
DORNER;	octen-6-ynyl)-1H-		ischemia; pulmonary
PROCYLIN	cyclopenta[b]benzofu	. 1444	hypertension;
	ran-5-butanoic acid	·	diabetes; neuropathy
ZK 110841	F 4 =		
	<u>,</u> -		glaucoma;
	[lalfa(Z),2beta(1E,3S		hypertension;
	chloro-2-(3-		thrombosis
			İ
	cyclohexyl-3-		
	hydroxy-1-propenyl)-		·
E			
· [3-	1	
	nydroxycyclopenyl]- 5-heptenoic acid		

ZK 118182	T1D	T	
KK 110102	[1R-	prostanoid; platelet	thrombosis;
	[lalfa(Z),2beta(1E,35	antiaggregant	hypertension
	*),3alfa,5alfa]]-[[4-		
	[5-chloro-2-(3-		
	cyclohexyl-3-		
	hydroxy-1-propenyl)-	·	
	β-		
	hydroxycyclopentyl]-		
	2-butenyl]oxy]acetic		
	acid		
UT 15	Unspecified	prostanoid;	pulmonary
		vasodilator	hypertension
alprostadil; lipo-	(11alpha,13E,15S)-	prostanoid;	hepatitis; thrombosis;
prostaglandin E1;	11,15-dihydroxy-9-	vasodilator;	peripheral vascular
lipo-PGE1; U 10136;	oxoprost-13-en-1-oic	cicatrizant	disease; sexual
PGE1; CAVERJECT	;acid		dysfunction;
PALUX; LIPLE;			pulmonary
PROSTIN; EDEX;			hypertension; skin
MUSE			ulcer; hearing loss
Y 27632	[4(R)-trans]-4-(1-	protein kinase	hypertension; asthma;
	aminoethyl)-N-4-	inhibitor	cancer
	pyridinylcyclohexane		
	carboxamide		
staurosporine; (+)-	(9S,10R,11R,13R)-	protein kinase	hypertension
staurosporine;	2,3,10,11,12,13-	inhibitor; protein	i portonsion
staurosporin;	•	kinase C inhibitor	
antibiotic 230; AM	oxy-9-methyl-11-		
2282	(methylamino)-9,13-		
	epoxy-1H,9H-		
	diindolo[1,2,3-		
	gh:3',2',1'-		
	lm]pyrrolo[3,4-		
	j][1,7]benzodiazonin-		
1	1-one		
SCH 34826	N-[N-[2-[(2,2-	proteinase inhibitor;	nain: hymertonsian
		analgesic	pain; hypertension
	dioxolan-4-		
;	yl)methoxy]-2-oxo-1-		į
	(phenylmethyl)ethyl]-		İ
	L-phenylalanyl]-beta-		
1	alanine		

A 62198	S spide 11-1 1		T
JA 02198	5-azido-1-cyclohexyl	proteinase inhibitor;	hypertension
	1,2,5-trideoxy-2-	renin inhibitor	
	[[N[N-(2-methyl-1-		
	oxopropyl)-L-		
	phenylalanyl]-L-		
	histidyl]amino-L-		
'	arabinitol		
A 65317	T5S-	proteinase inhibitor;	hypertension
	[5R*[1R*[R*(S*)],2S		ary per terision
	*]]]-N1-[2-[[1-		
	(cyclohexylmethyl)-2		
	1	-	
	(3-ethyl-2-oxo-5-		
	oxazolidinyl)-2-		
	hydroxyethyl]amino]-		
	1-(1H-imidazol-4-		
	ylmethyl)-2-		
	oxoethyl]-N4-[2-[(2-		
	methoxyethoxy)meth		
	oxy]ethyl]-N4-		
	methyl-2-		
	(phenylmethyl)butane		
	diamide	·	
A 74273	[alphaS-	proteinase inhibitor;	hypertension
	[alphaR*,gammaR*,d		hypertension
	eltaR*[R*(R*)]]]-	reinii iimioitor	
	- 1222		·
	gamma-hydroxy-		·
	delta-[[2-[2-[4-		
·	(methoxymethoxy)-1-	,	
	piperidinyl]-2-oxo-1-		
	(phenylmethyl)ethoxy		
]-1-oxohexyl]amino]-		
	alpha-(1-		
	methylethyl)-N-[3-(4-		
	morpholinyl)propyl]c		
	yclohexanehexanamid		,
	b contraction of the contraction of		
BW B633C	N-((2Rs,3S)-3-(L-	protoiness inhihit	h
שוניטע זו ש			hypertension
		renin inhibitor	
	phenylalanyl-L-		
	histidyl)-amino-2-		
	hydroxy-5-		
	methylhexyl)-L-valyl-		
	L-isoleucyl-L-phenyl-	ļ	
	alanine methyl ester		.
	hemiacetate		
	pioniacotato		

CG 38560	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
CGP 60536B; CGS	[alphaS-	proteinase inhibitor;	hypertension
CGP 60536B; CGS 60536	(alphaR*,gammaR*,deltaR*,zetaR*)]-delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-	renin inhibitor	hypertension
	methylethyl)benzeneo ctanamide		
CI 992; PD 134672	[1S-(1R*,2S*,3R*)]-	proteinase inhibitor; renin inhibitor	hypertension
	2,3-dihydroxy-5- methylhexyl]-L- alaninamide		
ciprokiren; Ro 449375	[1S- [1R*[R*(R*)],2S*,3R *]]-N-[1- (cyclohexylmethyl)-3- cyclopropyl-2,3- dihydroxypropyl]- .alpha[[2-[[[1,1- dimethyl-2-(4- morpholinyl)-2- oxoethyl]sulfonyl]met hyl]-1-oxo-3- phenylpropyl]amino]-	proteinase inhibitor; renin inhibitor	hypertension
	1H-imidazole-4- propanamide		

CD 51960	5 25	·	
CP 71362	[2R-(2R*,4S*,5S*)]- N-[N2-[6-cyclohexyl- 5-[[N-[N-[(1,1- dimethylethoxy)carbo nyl]-L-phenylalanyl]- L-histidyl]amino]-4- hydroxy-2-(2- methylpropyl)-1- oxohexyl]-L-lysyl]-L- phenylalanine		hypertension
ditekiren; U 71038	[1S- [1R*,2R*,4R*(1R*,2 R*)]]-1-[(1,1- dimethylethoxy)carbo nyl]-L-prolyl-L- phenylalanyl-N-[2- hydroxy-5-methyl-1- (2-methylpropyl)-4- [[[2-methyl-1-[[(2- pyridinylmrthyl)amin o]carbonyl]butyl]ami no]carbonyl]bexyl]- Nalfa-methyl-L- histidinamide		hypertension
EMD 56133	Unspecified	proteinase inhibitor; renin inhibitor	hypertension
enalkiren; A 64662	-	1	hypertension; glaucoma

ES 6864	[S-(R*,S*)]-5-	proteinase inhibitor;	hypertension
L3 0004	cyclohexyl-2,4,5-	renin inhibitor	riypertension
	trideoxy-N-[2-(4-		,
	morpholinyl)ethyl]-4-		
	[[2-[[4-(4-		
	morpholinyl)-2-(1-		
1	naphthalenylmethyl)-		
-	1,4-		
	dioxobutyl]amino]-1-		
	oxo-3-(4-		<u> </u>
	thiazolyl)propyl]amin		
	o]-L-threo-		
	pentonamide		
ES 8891	5-cyclohexyl-2,4,5-	proteinase inhibitor;	hypertension
	trideoxy-N-hexyl-4-	renin inhibitor	
	[[N-[3-(1-		
	naphthalenyl)-N-(4-		
	morpholinylacetyl)-L-		·
	alanyl]-3-(4-		
	thiazolyl)-L-		
	alanyl]amino]-L-		
	threo-pentonamide		
FK 906; FR 115906	N-methyl-N-[2(S)-		hypertension
	[N-methyl-N-[2-[N-	renin inhibitor	
	methyl-N-	, and a	
,	(morpholinocarbonyl)		
	amino]ethyl]carbamo		
	yloxy]-3-		
	phenylpropionyl]-L-		•
	histidine 1(S)-		
·	(cyclohexylmethyl)-		
	2(S)-hysroxy-5-		
	methylhexylamide		
	hydrochloride		
ICI 213878	Unspecified	proteinase inhibitor;	hypertension
	1 -	renin inhibitor	
ICI 219623	Unspecified	proteinase inhibitor;	hypertension
	1 -	renin inhibitor	J1
	<u> </u>	<u> </u>	

KRI 1314	[alfaR-	proteinase inhibitor;	hypertension
	[alfaR*,betaS*[S*(R*		-) Portoniololi
']]]-alfa-hydroxy-		
	beta-[[3-(1H-		
	imidazol-4-yl)-2-[[4-		
	(4-morpholinyl)-2-(1-		
	naphthalenylmethyl)-		
	1,4-		
	dioxobutyl]amino]-1-	İ	
	oxopropyl]amino]cycl		
	ohexanebutanoic acid		
	1-methylethyl ester		
PD 132002		proteinase inhibitor;	hypertension
		renin inhibitor	,,,
	morpholinylsulfonyl)-		
	L-phenylalanyl-N-[1-		
	(cyclohexylmethyl)-		
	2,3-dihydroxy-5-		
	methylhexyl]-O-		
	methyl-3-oxo-DL-		
	serinamide		
remikiren; Ro 425892	[1S-	proteinase inhibitor;	hypertension
	[1R*[R*(R*)],2S*,3R	renin inhibitor	
	*]]-N-[1-		
	(cyclohexylmethyl)-3-		,
	cyclopropyl-2,3-		
. ar	dihydroxypropyl]-		
	alfa-[[2-[[(1,1-		
	dimethylethyl)sulfony		
	l]methyl]-1-oxo-3-		
	phenylpropyl]amino]-		
	1H-imidazole-4-		į
	propanamide		

renin inhibitor	[1S-		<u> </u>
, 511111 111111111111111111111111111111	[1S- [1R*,2S*,4S*(1R*,2	proteinase inhibitor; renin inhibitor	hypertension
	[1K ,25 ,43 (1K ,2 R*)]]-[4-[[[1-	remn innibitor	
]	(cyclohexylmethyl)-2	, †	
	hydroxy-4-[[(2-	7	
	methylpropyl)amino]		
	arbonyl]-4-	9	
	pentenyl]amino]carbo		
	nyl]-2-hydroxy-1-	1	
	(phenylmethyl)-		
	nonenyl]-carbamic		
	acid, 1,1-		
1	dimethylethyl ester.		
renin inhibitor	isopropyl (2R,3S)-3-	proteinase inhibitor;	bymartanaia
	((N-((2R)-3-	renin inhibitor	hypertension
	(morpholino-	Total minotor	
	carbonyl)-2-(1-		
	naphthylmethyl)propi		
	onyl)-L-histidyl)-		
	amino)-4-cyclohexyl-		
	2-hydroxybutyrate		
RPEP 27	Unspecified	proteinase inhibitor;	hypertension
		renin inhibitor	-ypo.combion
S 2864	N-[N-(3-(4-amino-1-	proteinase inhibitor;	hypertension
	piperidinyl-carbonyl)-	renin inhibitor	
	2(R)-		
	benzylpropionyl)-L-		1 1
	histidinyl]-		
;	(2S,3R,4S)-1-		
	cyclohexyl-3,4-		
	dihydroxy-6(2-		
	pyridyl)-2-hexyl-		
00.45005	amide-acetate		
SC 45075	[R-(R*,S*)]-N-[(1,1-	proteinase inhibitor;	hypertension
	dimethylethoxy)carbo	renin inhibitor	
	nyl]-L-phenylalanyl-		
	N-[1-		·
	(cyclohexylmethyl)-		
	2,3-dihydroxypropyl]-		
	L-leucinamide		

SC 46944	4-	proteinase inhibitor;	hypertension
1	morpholinecarboxyli	renin inhibitor	hypertension
	acid, [1S-	- Junio Itol	
	[1R*[R*(R*)],2S*,3I	2	1
	*]]-2-[[1-[[[1-]	
	(cyclohexylmethyl)-		
	2,3-dihydroxy-5-		
	methylhexyl]amino]c		
	arbonyl]-3-		
	methylbutyl]amino]-		
	2-oxo-1-		
	(phenylmethyl)ethyl		
	ester		
SC 56525	N2-[2(S)-benzyl-3-(4	proteinase inhibitor:	hypertension
	methylpiperazin-1-	renin inhibitor	7,7
	ylsulfonyl)propionyl]-		
	N1-[1(S)-		
	(cyclohexylmethyl)-		
<u> </u>	2(R),3(S)-dihydroxy-		
	5-methylhexyl]-2(S)-		
	(2-		
	propynyl)glycinamide		
SQ 33800	Unspecified	proteinase inhibitor;	hypertension
		renin inhibitor	
SQ 34017	Unspecified	proteinase inhibitor;	hypertension
		renin inhibitor	
U 70714E		proteinase inhibitor;	hypertension
	(N-acetyl-1-formyl-L-	renin inhibitor	
	tryptophyl)-L-prolyl]-		
!	L-phenylalanyl]-L-		
	histidyl]amino]-3-		
	phenylpropyl]-L-		
	phenylalanyl-L-valyl-		
	L-tyrosinamide		

zankiren; zankiren	TIS-	proteinase inhibitor;	
hydrochloride; A	[1R*[R*(R*)],2S*,3F	proteinase inhibitor;	hypertension
72517;	*]]-N-[1-	deimi numbhor	
, 2217,	(cyclohexylmethyl)-		
	2,3-dihydroxy-5-		
	methylhexyl]-alfa-		
	[[2-[[(4-methyl-1-		
	piperazinyl)sulfonyl]		
	methyl]-1-oxo-3-		
	phenylpropyl]amino]-		
	I -		
- 1.41:	thiazolepropanamide		
cyclothiazomycin	cyclothiazomycin	proteinase inhibitor;	hypertension
		renin inhibitor;	
		antibiotic	
ES 1005		proteinase inhibitor;	hypertension
		renin inhibitor;	
	1	peptide	
	amino-6-		,
	hydroxyhexyl)amino]		
	carbonyl]-3-		
	methylbutyl]amino]-		
	2-hydroxy-1-(2-		
	methylpropyl)-4-		
	oxobutyl]-alfa-[[3-(1-		
	naphthalenyl)-2-(1-		
	naphthalenylmethyl)-	,	
	l-oxopropyl]amino]-	· - ·	'
	1H-imidazole-4-		
	propanamide		·
	dihydrochloride		
terlakiren; CP 80794	[R-(R*,S*)]-N-(4-	proteinase inhibitor;	hypertension
	morpholinylcarbonyl)	renin inhibitor;	21
	-L-phenylalanyl-N-[1-	peptide	
	(cyclohexylmethyl)-2-	· •	
	hydroxy-3-(1-		
	methylethoxy)-3-		
	oxopropyl]-S-methyl-		j
	L-cysteineamide		

KB 5246	6-fluoro-5-(4-methyl	quinolone; antibiotic	
12.10	1-piperazinyl)-8-oxo		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1	3H,8H-4-oxa-1-thia-		hypertension; HIV
	9b-		infection;
			gastrointestinal ulcer;
	azacyclopenta[cd]pho		hyperlipidemia;
	nalene-9-carboxylic		bacterial infection
	acid		
	monohydrochloride		
renin inhibitor	Unspecified	renin inhibitor;	hypertension
		proteinase inhibitor	
U 75875	(1(1S,2S),5(S))-6-	renin inhibitor;	hypertension; HIV
	cyclohexyl-2,5,6-	proteinase inhibitor;	infection
	trideoxy-5-((3-(1H-	HIV proteinase	
	imidzol-4-y l)-2-(((1-		
	naphthalenyloxy)acet		
	yl)amino)-1-		
	oxopropyl)amino)-2-		
	(1-methylethyl)-N-		
	(2-methyl-1-(((1-		
	pyridinylmethyl)amin		
1	o)carbonyl)butyl,-L-		
	idonamide	100	,
BIBU 308; DTTX 30		thromboxane	
DE 500, DI IX 50	(hydroxyamino)-2-	1	pulmonary
	oxoethyl]methylamin	•	hypertension;
	o]carbonyl]cyclohexa	annaggregam	peripheral vascular
	necarboxylic acid	[disease
terbogrel; BIBV 308		41 7	
SE		5	pulmonary
DL .	[[(cyanoamino)[(1,1-	antagonist;	hypertension;
	dimethylethyljaminoj	thromboxane synthase	
	methylene]amino]phe	inhibitor	disease
	nyl]-6-(3-pyridinyl)-		
AVD 111	5-hexenoic acid		
AIT 111	unspecified	Unspecified	angina; arrhythmia;
			hypertension
laennec		Unspecified	hypertension; liver
	hydrolysate		disease
S 8666		uricosuric; diuretic	hypertension; gout
	[(dimethylamino)sulf		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
•	onyl]-2,3-dihydro-2-		ł
	benzofurancarboxylic		
	acid		1
vaccine, angiotensin,		vaccine	nypertension
vaccine, hypertension			Abortonsion
acome, hypertension			

LP 805	0		
LP 803	8-tert-butyl-6,7- dihydropyrrolo[3,2- e]-5- methylpyrazolo[1,5a	vasodilator	hypertension; angina
	pyri midine-3-	'	
1	carbonitrile		
MER A2026A; Mer-		vasodilator	1
A 2026A	3,7,9,11,13-	vasounator	hypertension
	pentamethyl-2,5,7,11	_	
	tetradecatetraenyl)-6-		
	methoxy-3-methyl-4-		
	pyridinol		
MER A2026B; Mer-		vasodilator	hypertension
A 2026B	3,7,9,11-tetramethyl-		ilypertension
	2,5,7,11-		
	tridecatetraenyl)-6-		
	methoxy-3-methyl-4-		
	pyridinol		
metipamide	3-(aminosulfonyl)-4-	vasodilator	hypertension
	chlorobenzoic acid 2-		
	methyl-2-		
	phenylhydrazide		
NY 008	3-octyl-1(3H)-	vasodilator	hypertension
	isobenzofuranone		
U 92352	N-cyano-N'-(3,4-	vasodilator	hypertension
	dichlorobenzyl)-N"-		
	(4-		'
121	pyridinyl)guanidine		
vasodilator	N-(2,3-dihydro-6,7-	vasodilator	hypertension
	dimethoxy-1-methyl-		
	3-0x0-4-		
	isoquinolinyl)-N'-2-		
phentolamine	propenyl-urea		
r		vasodilator; alpha	sexual dysfunction;
1	l '	adrenergic antagonist; muscle relaxant	nypertension
Γ	methylphenyl)amino]	muscle relaxant	. 1
VASOMAX; Z-	phenol		
MAX; VASOFEM	P-10101	·	·
prostanit	Unspecified	vasodilator;	hamortonoion
	<u>-</u>	prostaglandin agonist	hypertension
		prostagianum agomst	

	T		
SKF 105494	O-ethyl-D-tyrosyl-L-		hypertension
	phenylalanyl-L-valyl-	antagonist	
	L-asparaginyl-5-[1-		
	(carboxymethyl)cyclo		
	hexyl]-L-norvalyl-L-		
,	arginyl-D-		
	argininamide cyclic		
	(5->1)peptide		
OPC 21268	1-[1-[4-(3-	vasopressin	hypertension; heart
	acetylaminopropoxy)	antagonist; diuretic	failure
	benzoyl]-4-piperidyl]-		
	3,4-dihydro-2(1H)-		
	quinolinone		
SR 121463	cis-N-(1,1-	vasopressin	heart failure;
	dimethylethyl)-4-[[5'-		hypertension
	ethoxy-4-[2-(4-		-J
	morpholinyl)ethoxy]-		
	2'-		
	oxospiro[cyclohexane		
	-1,3'-[3H]indol]-	,	· .
	1'(2'H)-yl]sulfonyl]-3-		
	methoxy-benzamide		
_	(E)-2-butenedioate		
	(1:1)		
SR 49059	[2R-	vasopressin	gynecological;
	[2alfa(S*),3beta]]-1-	antagonist; diuretic	cancer; hypertension;
	[[5-chloro-3-(2-		heart failure; emesis
	chlorophenyl)-1-		
	[(3,4-		
	dimethoxyphenyl)sulf		
	onyl]-2,3-dihydro-3-		
	hydroxy-1H-indol-2-		
	yl]carbonyl]-2-		
	рупоlidinecarboxami		
	de		

Table 61. Current Candidate Therapeutic Interventions for the Treatment of Hypotension

Product Name	Chemical Name	Action	Indication
ICI D4398; ZM 241385	4-[2-[[7-amino-2-(2- furanyl)[1,2,4]triazolo [1,5-a][1,3,5]triazin- 5- yl]amino]ethyl]pheno l	adenosine A2 antagonist	peripheral vascular disease; hypotension

midodrine; midodrine hydrochloride; A 4020 LINZ; St Peter 224; St 1085; METLIGENE; MIDON; GUTRON; AMATINE; MIDAMINE; ProAmatine;	e (+,-)-2-amino-N- (beta-hydroxy-2,5- dimethoxyphenethyl) cetamide	alpha adrenergic agonist a	hypotension; urinary incontinence; sexual dysfunction
HYPERTAN; MIDRON; NATILDINE; SHUPRASE OHARA			
M 6434	2-[(5-chloro-2- methoxyphenyl)azo]- 1H-imidazole	alpha adrenergic agonist; alphal adrenergic agonist; imidazole	anaphylactic shock; hypotension
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3- dihydro-1H-inden-2- yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxyl ic acid 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl(te trahydro-2H-pyran-2-yl)methy ester	calcium agonist	hypotension; anaphylactic shock
	•	Calcium channel activator	hypotension
arginase		enzyme depletion of arginine leading to reduction of NO leading to increase in BP	hypotension

neuropeptide Y	unspecified	neuropeptide Y	hypotension; obesity;
antagonists		antagonist;	depression
		neuropeptide Y2	dopression
		antagonist	
hemoglobin-based	unspecified		er hypotension; cancer
scavenger;			a rispotension, cancer
ENDOGLOBIN-HT;			
ENDOGLOBIN-CT			
hemoglobin-based	unspecified	nitric oxide scavenge	rcancer; hypotension;
therapy		l sur surgo	septic shock
pyridoxylated	pyridoxylated	nitric oxide scavenge	r cancer; hypotension;
hemoglobin	hemoglobin	- State sourcinge	septic shock
polyoxyethylene			septic shock
conjugate; PHP-HT;			
РНР-СТ	1		
nitric oxide	unspecified	NSAID	hypotension; cancer;
modulators			rheumatoid arthritis
BN 50739	6-(2-chlorophenyl)-9-	PAF antagonist	hypotension; septic
	[2-[(3,4-	_	shock; stroke
	dimethoxyphenyl)thio		SHOCK, SHOKE
]-1-thioxoethyl]-	221420 464 4 46 4	
	7,8,9,10-tetrahydro-1-		
	methyl-4H-		
	pyrido[4',3':4,5]thieno		
	[3,2-		·
	f][1,2,4]triazolo[4,3-		
	a][1,4]diazepine		
ocepafant; BN 50730		PAF antagonist	hypotension;
į	7,10-dihydro-N-(4-	_	cytoprotectant;
	methoxyphenyl)-1-		asthma
	methyl-4H-		
	pyrido[4',3':4,5]thieno		İ
	[3,2-		
	f][1,2,4]triazolo[4,3-	Į.	
	a][1,4]diazepine-	}	
	9(8H)-carbothioamide		
	Arginine-free amino	Peptide induced	lypotension
į	acid product i	ncrease of blood	
		pressure	

amezinium	4-amino-6-methoxy-	Sympathomimetic	hypotension
metilsulfate;	1-phenylpyridazinium		
amezinium	methyl sulfate		
methylsulfate; LU			
1631; RISUMIC;			•
REGULTON;			
TENFORTAN;			
CROVARIL;			
SUPRATONIN			
INO 4743	unspecified	sympathomimetic	hypotension
INO 5042	unspecified	sympathomimetic	hypotension

Table 62. Current Candidate Therapeutic Interventions for the Treatment of Myocardial Ischemia

Ischemia	<u> </u>		
Product Name	Chemical Name	Action	Indication
CM 57493	3,6-dihydro-4-[3-	5HT agonist; 5HT1	ischemia
	(trifluoromethyl)phen	agonist	
	yl]-1(2H)-		
	pyridinepropanenitrile	,	
ITF 1570	Salicylester	5HT1A and	peripheral vascular
		bradykinin receptor	disease;
		ligands	cerebrovascular
			disease; heart
			ischemia
adenosine A3	unspecified	adenosine A3 agonist;	ischemia; myocardial
agonists			infarction
		adenosine agonist	
adenosine agonists	unspecified	adenosine agonist	ischemia
GP 3521	unspecified	adenosine regulating	ischemia
		agent	
adenosine regulating	unspecified	adenosine regulating	ischemia
agents, ischemia		agent; anti-ischemic	
GP 531			ischemia; thrombosis
	5-	agent; anti-ischemic	
	[phenylmethyl)amino	. ,	
	-beta-D-		
	ribofuranosyl-1H-		
	imidazole-4-		
	carboxamide		
acadesine; AICA-	5-amino-1-beta-D-	adenosine regulating	cardiovascular
riboside; AR 100; GP			disease; thrombosis;
			ischemia
		ischemic	
PROTARA			İ
		·	

mivazerol; UCB	2-hydroxy-3-(1H-	alpha adrenergic	ischemia
22073	imidazol-4-	agonist; alpha2	ischemia
	ylmethyl)benzamide	adrenergic agonist	
LY 293558	T3S-	AMPA antagonist;	honet inchession
273330	r-	glutamate antagonist	heart ischemia;
	,8aalpha)]-decahydro-		epilepsy
	6-[2-(1H-tetrazol-5-		
	yl)ethyl]-3-		
	isoquinolinecarboxyli		
	c acid		
prasterone;	(3beta)-3-	androgen; vaccine	systemic lupus
dehydroepiandrostero	hydroxyandrost-5-en-		erythematosus;
ne; DHEA; GL 701;	17-one	replacement therapy;	hormone deficiency;
NBI 106; PB 007;		corticosteroid	Alzheimer disease;
ASTENILE;	j		reperfusion injury;
DEANDROS;			ischemia
DIANDRON			
vascular endothelial	unspecified	angiogenesis inducer	coronary artery
growth factor B; AM			disease; ischemia
133			
Del-1 angiogenic	unspecified	angiogenesis	cancer; ischemia;
protein based		inhibitor;	restenosis
therapies		angiogenesis inducer	
hypoxia therapy	unspecified	antihypoxic	heart ischemia; stroke
AMP deaminase	unspecified	anti-ischemic	ischemia
inhibitors	_		
FR 76830	2-methyl-N-(2-(4-	anti-ischemic	ischemia
	morpholinyl)ethyl)-4-		
	(3-nitrophenyl)-6-		
	phenyl-3-		
	pyridinecarboxamide	į	
TEI 2306	gamma-L-glutamyl-	anti-ischemic	heart ischemia;
	L-cysteine ethyl ester		reperfusion injury
ST 520	(R)-N,N,N-trimethyl-		ischemia
	4-oxo-2-(1-		
	oxopropoxy)-4-[(2-		
	sulfoethyl)amino]-1-		
	butanaminium inner		
	salt		
		anti-ischemic;	heart ischemia;
,			reperfusion injury
		exchange inhibitor	cherrasion infacta
	indole-2-carboxamide	evenuise initipitot	
	monomethanesulfonat		
ı			
L	e ;		

delphinidin; ephdine;	D 5 7 milesdans 2	lamaia mida de C	· · ·
delphinidol;		antioxidant; free	ischemia
1 -	(3,4,5-	radical scavenger	
delfinidol;	trihydroxyphenyl)-1-		
delphinidine;	benzopyrilium		
delphinidin chloride;	chloride		
IDB 1056			
LXR 015; LXR 015-	Unspecified	apoptosis inhibitor	reperfusion injury;
2; ELIREX			heart ischemia;
			ischemia
LXR 017	unspecified	apoptosis inhibitor	heart ischemia
LXR 1035	unspecified	apoptosis inhibitor	ischemia; heart
			ischemia
bak; cell death	unspecified	apoptosis inhibitor;	heart ischemia;
inhibitor-1; Cdi-1		chemoprotectant;	ischemia; reperfusion
		cytoprotectant; gene	injury
MAb, C5 single	unspecified	biotechnology;	inflammation;
chain; MAb,		complement inhibitor;	myocardial infarction;
complement C5;		monoclonal antibody;	
5G1.1-SC		NSAID	,
sudismase;	N-acetylsuperoxide	biotechnology; free	respiratory disease;
superoxide dismutase	dismutase (human	radical scavenger;	ischemia; rheumatoid
copper zinc complex;		NSAID	arthritis:
CuZnSOD;	copper-zinc subunit		inflammation
OxSODrol	protein moiety		
	reduced)		,
F 3226	3-[3-[[2-(3,4-	calcium antagonist	ischemia
	dimethoxyphenyl)eth		,
	yl]methylamino]prop		•
	yl]-2,3-dihydro-6,7-		
	dimethoxy-4H-1,3-		
li e	benzoxazin-4-one		
K 201	2,3,4,5-tetrahydro-7-	calcium antagonist	ischemia
	methoxy-4-[1-oxo-3-	0	
	[4-(phenylmethyl)-1-		
	piperidinyl]propyl]-		
	1,4-benzothiazepine		
KP 840	diethyl 1,4-dihydro	calcium antagonist	ischemia; depression
	2,6-dimethyl-4-(3-		depression
	ethynyl phenyl)-3,5-		
	pyridine-dicarboxylic		
Į :	acid		
L	acid		

R 56865	N-[1-[4-(4-	calcium antagonist	F1
IC 30803	fluorophenoxy)-	calcium antagonist	ischemia
	butyl]-4-piperidinyl]-		
	N-methyl-2-		ĺ
CO 21496	benzothiazolamine	<u> </u>	
SQ 31486	(3R-cis)-3-	calcium antagonist	ischemia
	(acetyloxy)-1-[2-		1
· ·	(dimethylamino)ethyl		
]-1,3,4,5-tetrahydro-		
1	4-(4-methoxyphenyl)	-{	
	7-(trifluoromethyl)-		
	2H-1-benzazepin-2-		
	one		
	monohydrochloride		
barnidipine;	[S-(R*,R*)]-1,4-	calcium antagonist;	hypertension;
mepirodipine; YM	dihydro-2,6-dimethyl-		ischemia
09730; YM 097305;	4-(3-nitrophenyl)-3,5-		
YM 730; HYPOCA;	pyridinedicarboxylic		
OLDECA	acid methyl 1-		
	(phenylmethyl)-3-		
	pyrrolidinyl ester		and the second section of the section of the second section of the secti
CP 060S	(S)-3-[3-[[2-(1,3-	calcium channel	heart ischemia;
	benzodioxol-5-	blocker	angina
	yloxy)ethyl]methylam		
	ino]propyl]-2-[3,5-		
	bis(1,1-		
,	dimethylethyl)-4-		
	hydroxyphenyl]-4-		
	thiazolidinone (E)-2-		
	butenedioate (1:1)		
DP 16	Acylglycerol	Calcium chelator	epilepsy; stroke; heart
	derivative of BAPTA		ischemia
thiazohalostatin	4,5-dihydro-2-[8-	Calcium overload-	ischemia
	I	induced death	asciiciiia
	1	inhibition	
	(3,4,5-trichloro-1H-	HILLOIGON	
	pyrrol-2-yl)-7-		
	octenyl]-4-methyl-4-		
	thiazolecarboxylic		
	acid		
FCE 24265		-1-:	
CD 24203	4		ischemia
		inhibitor;	
		thromboxane	
	phenyl) -pyridine-3,5-	synthetase inhibitor	
·	dicarboxylate		

T.NT. 200	(2)	T	
LNF 209	(3beta,5beta,14beta,1	cardiac glycoside	ischemia
1	7beta)-14-amino-3-		
	[(6-deoxy-alfa-L-		
	mannopyranosyl)oxy		
	androstane-17-		
	carboxylic acid		
	methyl ester		
	hydrochloride		
R 59494	N-methyl-N-(1-(4-	cardiac glycoside	ischemia
	phenoxybutyl)-3-		
	pyrrolidinyl)-2-		
	benzothiazolamine		
PERFUSOL;	unspecified	chelating agent	trauma; ischemia;
MYOSOL			reperfusion injury
LY 178002	5-[[3,5-bis(1,1-	COX inhibitor; 5	inflammation;
	dimethylethyl)-4-	lipoxygenase	ischemia
	hydroxyphenyl]methy		
	lene]-4-thiazolidinone		
FR 139317; FK	N-[N-[N-		hypertension;
139317	[(hexahydro-1H-	antagonist; endothelin	
	azepin-1-	antagonist	
	yl)carbonyl]-L-		
	leucyl]-1-methyl-D-		
	tryptophyl]-3-(2-		
	pyridinyl)-D-alanine		
L 749329	4-[1-(1,3-	endothelin A	ischemia; reperfusion
	benzodioxol-5-yl)-2-	antagonist; endothelin	
,	[[[4-(1-	antagonist	initian y
	methylethyl)phenyl]s	umugomst	
	ulfonyl]amino]-2-		
	oxoethoxy]-3-		
	propylbenzoic acid		·
PD 159433	unspecified	endothelin A	cardiovascular
10 107400	, -		
		antagonist; endothelin	
TAK 044			ischemia
1 A.K. 044	1		hypertension; kidney
		antagonist; endothelin	
			infarction; brain
		endothelin antagonist;	ischemia
		peptide	
	(2-thienyl)glycyl-L-		
	leucyl-D-tryptophyl-		
	D-alpha-aspartyl]		
	disodium salt		· .

endothelin antagonist	lungnosified	d-41-11	
endomenn antagonisi	unspecified	endothelin antagonist	
			ischemia;
			inflammatory bowel
DD 156707, DD	11 50 74		disease; asthma
PD 156707; PD	alpha-[2-(4-	endothelin antagonist	; ischemia; reperfusion
156123	methoxyphenyl)-2-	endothelin A	injury; pulmonary
	oxo-1-[(3,4,5-	antagonist	hypertension
	trimethoxyphenyl)met	t	
	hyl]ethylidene]1,3-		
	benzodioxole-5-acetic		
	acid sodium salt		
TBC 11251; IPI 1251	1	endothelin antagonist;	heart failure;
	methyl-5-isoxazolyl)-	endothelin A	pulmonary
		antagonist	obstructive disease;
ļ	benzodioxol-5-		brain ischemia
	yl)acetyl]-3-		
	thiophenesulfonamide		
DCC 9364	unspecified	free radical scavenger	ischemia
disulfiram; CPC 501;	bis(diethylthiocarbam	free radical scavenger	alcoholism: heart
ANTABUSE	oyl)disulfide		ischemia
MDL 73404	3,4-dihydro-6-	free radical scavenger	ischemia
	hydroxy-	Ü	"
	N,N,N,2,5,7,8-		
	heptamethyl-2H-1-		
	benzopyran-2-		
	ethanaminium 4-		
	methylbenzenesulfon		
	ate		-
MDL 74270	6-(acetyloxy)-3,4-	free radical scavenger	ischemia
	dihydro-	J	
	N,N,N,2,5,7,8-		
,	heptamethyl-2H-1-		
	benzopyran-2-	,	
	ethanaminium 4-		
	methylbenzenesulfon		
	ate	,	
pegorgotein;	unspecified	free radical scavenger	ischemia: reperfusion
polyethylene glycol		-	injury
superoxide dismutase;		1	injury
PEG-SOD;			
superoxide dismutase			
macrogol; WIN			
22118; PEG-SOD;]
DISMUTEC			
	L		

superoxide	unspecified	free radical scavenger	heart ischemia:
dismustase, human;		area ramour souveriger	reperfusion injury
hSOD			
YM 21170; Q 1047H	-11-hydroxy-4,6,8,10-	free radical scavenger	heart ischemia
A; Q 1047H-A-A; Q			
1047H-A-B	azabicyclo[10.3.1]hex		
	adeca-8,12,15-triene-		
	3,5,14,16-tetrone		
•	stereoisomer		
superoxide dismutase	unspecified	free radical	ischemia; arthritis
B, manganese		scavenger; NSAID	
complex; Mn-SOD-B		<u></u>	
superoxide dismutase	unspecified	free radical	ischemia; rheumatoid
manganese complex;		scavenger; NSAID;	arthritis;
hMNSOD		immunosuppressant	inflammation;
			reperfusion injury
glycoprotein IIb/IIIa	unspecified	glycoprotein IIb/IIIa	thrombosis; heart
antagonist,P246		antagonist; peptide;	ischemia; stroke
		platelet antiaggregant	
JP 7	unspecified	Hemoglobin allosteric	cancer; surgery; heart
			ischemia; stroke
ribose; MGI 330	D-ribose	Hemoglobin allosteric	heart ischemia;
			diagnosis
RSR 13		Hemoglobin allosteric	surgery; heart
	dimethylphenyl)amin	modifier	ischemia; stroke
	o]-2-		
	oxoethyl]phenoxy]-2-		
202	methylpropanoic acid		
RSR 4	2-[4-[2-[(3,5-	Hemoglobin allosteric	
	dichlorophenyl)amino	modifier	ischemia; stroke
]-2-		
	oxoethyl]phenoxy]-2-		
	methylpropanoic acid		
RSR 46		Hemoglobin allosteric	
		modifier	ischemia; stroke
	yl)amino]-2-		
	oxoethyl]phenoxy]-2-		
	methylpropanoic acid		

monophosphoryl lipic A; TLC 3; RDE; MPL; MPL-C; MPL- S	deoxy-2-[[1-oxo-3- [(1- oxododecyl)oxy]tetra decyl]amino]-3-O-[1- oxo-3-[(1- oxotetradecyl)oxy]tetradecyl]-4-O-		heart ischemia; bacterial infection; infectious disease; reperfusion injury
	phosphono-beta-D-glucopyranosyl]-2- [(3-hydroxy-1- oxotetradecyl)amino]- alfa-D-glucopyranose 3-(3- hydroxytetradecanoat e)		·
soluble complement receptor type 1; sCR1, TP 10; TP 10HD; BRL 55730; YM 55730	unspecified	complement inhibitor	respiratory distress syndrome; heart ischemia; transplant rejection
MAb, E/P-selectin, humanized; MAb, SMART E/P-selectin			respiratory distress syndrome; ischemia; reperfusion injury
GM 1998		cell adhesion inhibitor, NSAID	inflammation; respiratory distress syndrome; heart ischemia; reperfusion injury
CEN 100		integrin antagonist; peptide; P selectin	ischemia; inflammation; reperfusion injury
TBC 427		selectin antagonist; immunosuppressant; cell adhesion inhibitor	ischemia; psoriasis; respiratory distress syndrome; transplant rejection; reperfusion injury

tirilazad; tirilazad	21-[4-(2,6-di-1-	lazaroid	L
mesylate; trilazad; U	pyrrolidinyl-4-	lazatoiu	brain ischemia;
74006F; FREEDOX	pyrimidinyl)-1-		stroke; trauma; heart
74000F, FREEDOX	F *		ischemia; kidney
	piperazinyl]-16-		disease
	alpha-me thyl-pregn-		
	1,4,9-(11)-triene-		
	3,20-dione		
H 29051; H 290/51	cis-7-methyl-9-	Lipid peroxidation	heart ischemia;
	methoxy-5,5a,b,10b-	inhibitor	reperfusion injury
	tetrahydroindeno(2,1-		
	6 indole		
MAb, 60-3; MAb,	unspecified	Monoclonal antibody	septic shock; heart
CD18/CD11			ischemia; reperfusion
			injury
MAb, CD18; R15.7	unspecified	monoclonal antibody	ischemia
MAb, beta2 integrin;	unspecified	monoclonal antibody;	ischemia: reperfusion
LDP 01			injury
		integrin antagonist;	
		cell adhesion inhibitor	
MAb, P-selectin; CY	unspecified	monoclonal antibody;	
1748; CY 1747	•	integrin antagonist; P	
		selectin antagonist;	
		cell adhesion inhibitor	
MAb, CD11b; MAb,	unspecified	monoclonal antibody;	inflammation: heart
m60.1; m60.1; LY	1 -		ischemia; reperfusion
303932			injury
ITF 1129	2,3-dihydro-6-methyl-		heart ischemia;
	3-[2-(nitrooxy)ethyl]-	(.·	angina
	4H-1,3-benzoxazin-4-		шібіна
	one		
TTF 1697		NSAID; peptide	septic shock;
	Chispochica		inflammation; heart
	,		ischemia;
		1	, ,
·			inflammatory bowel
recombinant DCCI 1			disease
recombinant PSGL 1, PSGL 1	1 -	P selectin antagonist;	
rogr I		E selectin antagonist;	
		L selectin antagonist;	
			injury
		NSAID	

BN 50726	6 (2 oblovenhamil) O	DAE	F
BN 30720	6-(2-chlorophenyl)-9	- PAr antagonist	ischemia;
	(hexadecylsulfonyl)-		cytoprotectant
	7,8,9,10-tetrahydro-1	-	
	methyl-4H-		
	pyrido[4',3':4,5]thien	o	
	[3,2-		
	f][1,2,4]triazolo[4,3-		
	a][1,4]diazepine		
nupafant; nupafant	(S)-N-[1-	PAF antagonist	ischemia; reperfusion
hydrochloride; BB	(ethoxymethyl)-3-	_	injury
960; BB 2113	methylbutyl]-4-[(2-		
	methyl-1H-		
	imidazo[4,5-		
	c]pyridin-1-		
	yl)methyl]benzenesul	f	
	onamide		
UR 12670	4-[(2-methyl-1H-	PAF antagonist;	kidney disease;
	imidazo [4,5-c]	platelet antiaggregant	
	pyridin-1-yl)methyl]-	p-more annuage ceame	pancreatitis
	1-(1-oxo-3,3-		Panercatitis
	diphenylpropyl)-		
	piperidine	· · · · · · · · · · · · · · · · · · ·	
CEN 294	unspecified	peptide; NSAID	inflammation;
	<u> </u>	,,	ischemia; reperfusion
			injury
kappa-conopeptides	unspecified	peptide; potassium	heart ischemia;
	1	channel blocker	arrhythmia;
			gastrointestinal
			disorder
ER 3826	N-(1-benzyl-4-	phospholipase	ischemia
	piperidinyl)-4-(N-	inhibitor	isonoi, ita
	methyl-N-((E)-3-(4-		
	(methylsulfony	·	
	l)phenyl)-2-		·
	propenoyl)amino)ben		
	zenesulfonamide		
EF 12		platelet antiaggregant;	hoort igal amia.
	-	antiproliferative agent	
aprikalim; RP 52891;	tatrahydra N mathyl		
APRIM	-		heart ischemia
T TOTAL	thiopyran-2-	activator	
	carbothioamide 1-		
·			•
	oxide		

BMS 191095	(2D trong) 4 [(4	hotopium shaard	
BIMP 131032	(3R-trans)-4-[(4-	potassium channel	ischemia
	chlorophenyl)(1H-	activator	
	imidazo-2-		
-	ylmethyl)amino]-3,4-		
ļ ·	dihydro-3-hydroxy-		
	2,2-dimethyl-2H-1-		
	benzopyran-6-		
	carbonitrile		
NS 004; NS 4	1-(5-chloro-2-	potassium channel	ischemia
	hydroxyphenyl)-1,3-	activator	
	dihydro-5-		
	(trifluoromethyl)-2H-		
	benzimidazol-2-one		
SKP 450; KR 30450	(R)-1-[2-(1,3-	potassium channel	hypertension; heart
	dioxolan-2-yl)-2-	activator	ischemia
	methyl-6-nitro-2H-1-		1301101111a
	benzopyran-4-y 1]-2-		
	pyrrolidinone		
U 89232	trans-N-cyano-N'-(6-	notaccium channal	ischemia
0 07232	cyano-3,4-dihydro-3-		ischemia
	hydroxy-2,2-	activator	
	dimethyl-2H-1-		
•			
1	benzopyran-4-yl)-N"-		
	(1,1-dimethylpropyl)-		
CD 47062	guanidine		
SR 47063	4-(2-cyanoimino-1,2-		heart ischemia;
	dihydropyrid-1-yl)-6-	•	asthma
		bronchodilator	·
	2H-1-benzopyran		
azimilide; azimilide		potassium channel	ischemia; arrhythmia
		blocker; class III	
azilimide; NE 10064;	furanyl]methylene]am	antiarrhythmic	
STEDICOR	ino]-3-[4-(4-methyl-		
	1-piperazinyl)butyl]-		
	2,4-		
	imidazolidinedione		
tedisamil; KC 8857	3',7'-	potassium channel	heart ischemia
	bis(cyclopropylmethy		
	l)spiro[cyclopentane-		
	1,9'-		
	[3,7]diazabicyclo[3.3.		
,	1]nonane]		

	·		
RU 55100; ML 1129 MDL 201129; DORNER; PROCYLIN	2,3,3a,8b-tetrahydro- 2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid	prostanoid; platelet antiaggregant	peripheral vascular disease; thrombosis; ischemia; pulmonary hypertension; diabetes; neuropathy
SPC 100271	unspecified	protein kinase inhibitor; protein kinase C inhibitor	ischemia; reperfusion injury
SPC 101591	unspecified	protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury
SPC 100270	unspecified	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	ischemia; transplant rejection; reperfusion injury
SPC 100840	unspecified	protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury
argatroban;	(2R,4R)-1-[(2S)-5-	proteinase inhibitor;	thrombosis;
argatrovan;	[(aminoiminomethyl)	platelet antiaggregant;	
argipidine;	amino]-1-oxo-2-	thrombin inhibitor	ischemia; angina;
argopidine;	[[(1,2,3,4-tetrahydro-		brain ischemia;
algipidine; DK 7419;	3-methyl-8-		thrombocytopenia
MCI 9038; MD 805;	quinolinyl)sulfonyl]a		
OM 805; GN 1600;	mino]pentyl]-4-	,	* ***
NOVASTAN;	methyl-2-		
SLONNON	[piperidinecarboxylic acid		
Recombinant	unspecified	Recombinant	ischemia
hemoglobin mutant		hemoglobin mutant	
p-38-2 inhibitor			inflammation;
	, -	_	ischemia
superoxide dismutase mimetics, SOD mimetics,		SOD mimetic	ischemia; reperfusion injury
NO-SOD mimetics, nitrosylated superoxide dismutase mimetics		oxide donor	asthma; respiratory distress syndrome; ischemia; reperfusion injury
FR 183998	· · · · · · · · · · · · · · · · · · ·		heart ischemia

HOE 694	N-	sodium/hydrogen	hoost inch
1.020,	(aminoiminomethyl)-		heart ischemia;
	3-(methylsulfonyl)-4-		reperfusion injury
	(1-		
	N		
	piperidinyl)benzamid		
	e mesilate		
KBR 9032; KB-R	N-	sodium/hydrogen	arrhythmia; heart
9032	(aminoiminomethyl)-	exchange inhibitor;	ischemia; reperfusion
	3,4-dihydro-2,2-	anti-ischemic	injury
	dimethyl-4-(1-		
	methylethyl)-3-oxo-		
	2H-1,4-benzoxazine-		
	6-carboxamide		
	monomethanesulfonat		
	e		
transforming growth	unspecified	TGFbeta receptor	brain ischemia;
factor beta;		pathway; growth	trauma; stroke;
		factor	neurodegeneration
NF-kappaB inhibitor	unspecified	transcription factor	inflammation;
		regulator; NSAID	ischemia; cancer;
		r ogulutor, rtorin	autoimmune disease
hemorrhagic shock	Unspecified	unspecified	cardiovascular
therapy	o aspesimou	anspecticu	disease; ischemia;
F 7			
PKH 135	Lipid-colchicine	Unspecified	reperfusion injury
11011133	conjugate		cancer; ischemia;
vascular endothelial	unspecified	VICCE 4.6	reperfusion injury
growth factor; VEGF;		VEGF, growth factor;	
rhVEGF165			disease; ischemia;
	4.4.4		restenosis; skin ulcer
Ro 315460		xanthine oxidase	ischemia; reperfusion
		inhibitor	injury
	1-carboxaldehyde		
torbafylline; HWA	7-ethoxymethyl-1-(5-	xanthine; vasodilator	ischemia
448	hydroxy-5-		
	methylhexyl)-3-	•	
	methylxanthine		

Table 63. Current Candidate Therapeutic Interventions for the Treatment of Heart Failure

Product Name	Chemical Name	Action	Indication
	6-(12-hydroxy-5,10 dodecadiynyl)-2,3,5- trimethyl-1,4- benzoquinone	5 lipoxygenase inhibitor	asthma; heart failure

captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL; LOPIRIN; TENSOBON	methyl-1-oxopropyl)- L-proline		hypertension; kidney disease; heart failure; diabetes
drug delivery system, SODAS captopril; captopril SODAS	Unspecified	ACE inhibitor	heart failure; hypertension
imidapril; TA 6366; EMD 61800; EMD 63100; TANATRIL; NOVALOC; NOVAROK; TANAPRESS; NORTEN	4S-[3-[R*(R*)],4R*]- 3-[2-[[1- (ethoxycarbonyl)-3- phenylpropyl]amino]- 1-oxopropyl]-1- methyl-2-oxo-4- imidazolidinecarboxy lic acid		hypertension; heart failure; diabetes
lisinopril; MK 521; L 154826; MK 522; PRINIVIL; ZESTRIL; TENSOPRIL-D; ADICANIL;		ACE inhibitor	hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease
SED 9490; MCN A2833109; DW 7950; COVERSYL;	(2S,3aS,7aS)-1-[(2S)- 2-[[(1S)-1- (ethoxycarbonyl)butyl]amino]-1- oxopropyl]octahydro- 1-1H-indole-2- carboxylic acid		hypertension; coronary artery disease; heart failure
COVEREX; COVERSIL			·

			
ramipril; HOE 498;		ACE inhibitor	hypertension; heart
ALTACE; TRIATEC	;N-[(S)-1-carboxy-3-		failure
PRAMACE;	phenylpropyl]alanyl]d		
RAMACE;	ctahydrocyclopenta[b]	
TRITACE;	pyrrole-2-carboxylic		
CARASEL; ACOVIL	acid 1-ethyl ester		
utibapril; FPL 63547	(S)-2-tert-butyl-4-	ACE inhibitor	hypertension; heart
	[(S)-N-[(S)-1-		failure
	carboxy-3-		
	phenylpropyl]alanyl]-		
	delta2-1,3,4-		
	thiadiazoline-5-		
	carboxylic acid, 4-		
	ethyl ester	Ì	
fosinopril +	Unspecified	ACE inhibitor;	hypertension; heart
hydrochlorothiazide;		diuretic	failure
hydrochlorothiazide +			lanuro
fosinopril;			
TENSOZIDE;			
MONOPRIL-HCT;			
FOSICOMP		1	
BMS 189921	[S-(R*,R*)]-	ACE inhibitor; matrix	hypertension: heart
	hexahydro-6-[(2-	metalloproteinase	failure
	mercapto-1-oxo-3-	inhibitor; neutral	
	phenylpropyl)amino]-		
		inhibitor; proteinase	•
		inhibitor	
ER 3295	Unspecified		hypertension; heart
	• -	neutral endopeptidase	
		inhibitor	
sampatrilat; UK	2-[[1-[[[1-carboxy-2-		hypertension; heart
81252	=	neutral endopeptidase	,
4.4	hydroxyphenyl)ethyl]		
1	amino]carbonyl]cyclo		
1	pentyl]methyl]-N-		
	N2-(methylsulfonyl)-		
	L-lysyl]-beta-alanine		
	[S-(R*,R*)]-		
Z 13752A		ACE inhibitor;	hypertension; heart
	•	neutral endopeptidase	
		inhibitor	1411410
<u> </u>			

MDL 100240; MDL	[4S-	ACE inhibitor;	hand Cili
100173 pro	[4alpha,7alpha(R*),1	neutral endopeptidase	heart failure;
100175 p10	2bbeta]]-7-[[2-	inhibitor; diuretic	lippertension
	(acetylthio)-1-oxo-3-	innibitor, druictic	
	phenylpropyl]amino]-	<u> </u>	
	1,2,3,4,6,7,8,12b-		
	octahydro-6-oxo-		
	pyrido[2,1-		
	a][2]benzazepine-4-	1	
	carboxylic acid		
trandolapril; CI 907;	[2S-	ACE inhibitor;	hypertension; heart
RU 44570; RU 570;	[1[R*(R*)],2alpha,3a	vasodilator	failure; myocardial
ODRIK; UDRIK;	alpha,7abeta]]-1-[2-		infarction
GOPTEN; TRAPRIL	[[1-(ethoxycarbonyl)-	<u> </u>	
ODRIC; MAVIK	3-		
	phenylpropyl]amino]-		
	1-		
	oxopropyl]octahydro-		·
	1H-indole-2-		
CLUT 400	carboxylic acid		
CVT 429	Unspecified	adenosine A1 agonist;	
CV /T. COO			failure
CVT 609	Unspecified	adenosine A1 agonist;	
A1	TI		failure
adenosine A1	Unspecified	l l	heart failure
antagonists		antagonist; diuretic;	
adenosine A2a	I Imamoni End	adenosine antagonist	1
agonists		adenosine A2 agonist;	neart failure
RPR 100579		adenosine agonist	<u> </u>
KG K 100577	Onspecified		hypertension; heart failure;
			hyperlipidemia
CVT 427	Unspecified		arrhythmia; heart
0.1 (2)		adenosine A1 agonist	
CVT 510			arrhythmia; heart
3,1210	1 -	adenosine A1 agonist	
CVT 741			arrhythmia; heart
, = · · ·	1 •	adenosine A1 agonist	•
SDZ WAG994; SDZ			heart failure;
WAG 994	1 -	adenosine A1 agonist	•
WRC 0342		adenosine antagonist	
WRC 0571		adenosine antagonist	
HMR 4902		adenosine antagonist;	
			disease
	1	antagonist	

KW 3902	8-(noradamantyl-3-	adenosine antagonist;	heart failure
	yl)-1,3-	adenosine A1	
	dipropylxanthine	antagonist; diuretic	
CVT 124; BG 9719;	3,7-dihydro-8-(3-	adenosine antagonist;	heart failure:
ADENTRI	oxatricyclo[3.2.1.0	diuretic; adenosine	hypertension
	2,4]oct-6-yl)-1,3-	Al antagonist	riypertension
	dipropyl-1H-purine-	i i unugomst	
	2,6-dione		
FR 113453		adenosine antagonist;	heart failure
	(2-	vasodilator; diuretic	
	phenylpyrazolo[1,5-	, assument, didiono	
	a]pyridin-3-yl)-5-(1-		
	piperidinyl)-1-penten-		
	3-one		
eplerenone;	(7.alpha.,11.alpha.,17.	aldosterone	heart failure;
epoxymexrenone;	alpha.)-9,11-epoxy-	antagonist	hypertension
CGP 30083; SC	17-hydroxy-3-	- Borne	in perionsion
66110	oxopregn-4-ene-7,21-		
	dicarboxylic acid		
	.gammalactone		
	methyl ester	for a common section	
moxonidine; BE		alpha adrenergic	hypertension; heart
5895; BDF 5895; LY	dihydro-1H-imidazol-		failure; diabetes
326869; CYNT;		adrenergic agonist;	,
PHYSIOTENS		imidazoline agonist	
	pyrimidinamine	J	
metazosin; metasozin;	1-(4-amino-6,7-	alpha adrenergic	hypertension;
metazocin;	dimethoxy-2-		glaucoma; benign
KENOSIN	quinazolinyl)-4-(2-	adrenergic antagonist	
	methoxy-1-		heart failure
	oxopropyl)piperazine		
XB 513	2-amino-1,4-dihydro-	alpha adrenergic	heart failure
	4-[2-[[4-[4-(2-	antagonist; alpha1	
	methoxyphenyl)-1-	adrenergic antagonist;	
		calcium agonist	
	butyl]sulfinyl]phenyl]	_	
	-6-methyl-5-nitro-3-		
	pyridinecarboxylic		·
	acid methyl ester		

	KI 3 2 4 4 555	· · · ·	
	(+,-)-2-ethoxy-1-[[2'-	1 -	hypertension; heart
TCV 116; H 21291;	(1H-tetrazol-5-	antagonist	failure; restenosis;
BLOPRESS;	yl)[1,1'-biphenyl]-4-	1	kidney disease
ATACAND; AMIAS			
KENZEN	benzimidazole-7-		
·	carboxylic acid 1-		
	[[(cyclohexyloxy)carl	b	
	onyl]oxy]ethyl ester		
irbesartan; SR 47436;	2-butyl-3-[[2'-(1H-	angiotensin II	hypertension; kidney
BMS 186295;	tetrazol-5-yl)[1,1'-	antagonist	disease; heart failure
APROVEL;	biphenyl]-4-		,
KARVEA; AVAPRO	yl]methyl]-1,3-		
	diazaspiro[4.4]non-1-		ł
	en-4-one		
losartan; losartan	2-butyl-4-chloro-1-	angiotensin II	hypertension; anxiety;
potassium; DUP 753;		antagonist	stroke; heart failure;
MK 954; DUP 89; E	yl)[1,1'-biphenyl]-4-	3	myocardial infarction
3340; AVASTAR;	yl]methyl] -1H-		in your dial infunction
COZAAR;	imidazole-5-methano	1	
LOORTAN;			İ
NULOTAN			
UR 7247	3-(1-methylethyl)-1-	angiotensin II	hypertension; heart
	propyl-5-[[2'-(1H(-	antagonist	failure
	tetrazol-5-yl)[1,1'-	<i>S</i>	1011010
	biphen yl]-4-		
	yl]methyl]-1H-		
	pyrazole-4-carboxylic		'
	acid		
valsartan; CGP	N-(1-oxopentyl)-N-	angiotensin II	hypertension; heart
48933; DIOVAN	[[2'-(1H-tetrazol-5-	antagonist	failure
	yl)[1,1-biphenyl]-4-	g	
	yl]meth yl]-L-valine		
YM 358		angiotensin II	hypertension; heart
	·	antagonist	failure
	yl]methyl]-5H-		iaiiuio
	pyrazolo[1,5-		
	b][1,2,4]triazole		
fructose-1,6-		anti-ischemic	heart failure;
i '	phosphate) D-fructose		myocardial infarction;
111; CORDOX	pricopilato, Directosc		sickle cell anemia;
, 5513571			septic shock
apoptosis inhibitors	Unspecified	anantagia inhihita-	
apoptosis illilloitois	Onspecificu	apoptosis inhibitor	neuropathy; HIV
			infection; heart failure

cardiovascular disease	Unspecified	apoptosis inhibitor;	cardiovascular
therapy		caspase inhibitor	disease; myocardial infarction; heart failure
OPC 31260	N-[4-[[5- (dimethylamino)- 2,3,4,5-tetrahydro- 1H-1-benzapin-1- yl]carbonyl]phenyl]- 2-methylbenzamide	aquaretic; vasopressin antagonist	heart failure
candoxatril; UK 79300	4-[[[1-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-cyclohexanecarboxylic acid		hypertension, heart failure
Т 0509	(R)-4-[2-[[2-(3,4-dimethoxyphenyl)eth yl]amino]-1-hydroxyethyl]-1,2-benzenediol	beta adrenergic agonist; beta1 adrenergic agonist	heart failure
xamoterol; ICI 118587; CORWIN; SEPAN	(+,-)-N-[2-[[2- hydroxy-3-(p- hydroxyphenoxy)prop yl]amino]ethyl]-4- morpholinecarboxami de	agonist; betal adrenergic agonist; beta adrenergic partial	heart failure
BIB 16S	Unspecified		heart failure
33512; CL 297939; CONCOR; EMCOR; EMCORE;	methylethyl)amino]- 3-[4-[[2-(1-	antagonist	hypertension; heart failure

carvedilol; karvedilol; l-(9H-carbazol-4-BM 14190; DQ 2466; yloxy)-3-[[2-(2-methoxyphenoxy)ethy DILATREND; DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- alpha,alpha'- alpha,alpha'- alpha,alpha'- alpha, serior oxide activator; hypertension; ang heart failure heart	
DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*(S*)]]]- nebivolol; narbi	ure
DILATREND; DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- R 67555; R 65824; ME 3255; R 67138; R [iminobis(methylene) 67145; R 065824;]bis[6-fluoro-3,4- NEBILET; dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2- I]amino]-2-propanol beta adrenergic antagonist; nitric oxide activator; vasodilator heart failure antagonist; phosphodiesterase phosphodiesterase inhibitor	ure
DIMITONE; ARTIST; EUCARDIC; QUERTO; COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- nebivolol; narbivolol; [2R*[R*(S*)]]]- nebivolol; narb	ure
EUCARDIC; QUERTO; COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- R 67555; R 65824; alpha,alpha'- ME 3255; R 67138; R [iminobis(methylene) 67145; R 065824;]bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- nethanol] GI 104313 (S)-2-[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	ure
QUERTO; COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- alpha,alpha'- alpha,alpha'- [iminobis(methylene) 67145; R 065824;]bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- hypertension; migraine; heart failure hypertension; migraine; heart failure heart failure heart failure	ure
COROPRES; DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]]- R 67555; R 65824; alpha,alpha'- ME 3255; R 67138; R [iminobis(methylene) 67145; R 065824;]bis[6-fluoro-3,4- NEBILET; dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- hydroxypropyl]amino]-2- hypertension; migraine; heart failure heart failure heart failure	ure
DILBLOC nebivolol; narbivolol; [2R*[R*[R*(S*)]]- R 67555; R 65824; alpha,alpha'- ME 3255; R 67138; R [iminobis(methylene) 67145; R 065824;]bis[6-fluoro-3,4- dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- nitric oxide activator; vasodilator beta adrenergic antagonist; nitric oxide activator; vasodilator beta adrenergic antagonist; phosphodiesterase pyridazinyl)phenoxy]- inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	ure
mebivolol; narbivolol; [2R*[R*[R*(S*)]]]- R 67555; R 65824; alpha,alpha'- ME 3255; R 67138; R [iminobis(methylene) 67145; R 065824;]bis[6-fluoro-3,4- NEBILET; dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- hypertension; migraine; heart failure antagonist; nitric oxide activator; vasodilator beta adrenergic antagonist; nitric oxide activator; vasodilator hypertension; migraine; heart failure antagonist; nitric oxide activator; vasodilator hypertension; migraine; heart failure antagonist; nitric oxide activator; vasodilator hypertension; migraine; heart failure antagonist; nitric oxide activator; vasodilator hypertension; migraine; heart failure antagonist; nitric oxide activator; vasodilator hypertension; migraine; heart failure antagonist; nitric oxide activator; vasodilator	ure
R 67555; R 65824; alpha,alpha'- ME 3255; R 67138; R [iminobis(methylene) adrenergic antagonist; heart far far far far far far far far far far	lure
R 67555; R 65824; alpha,alpha'- ME 3255; R 67138; R [iminobis(methylene) adrenergic antagonist; heart far far far far far far far far far far	lure
ME 3255; R 67138; R [iminobis(methylene) adrenergic antagonist; 67145; R 065824;]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol] GI 104313 (S)-2-[2-chloro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenoxy]-hydroxypropyl]amino]-2-	
67145; R 065824; bis[6-fluoro-3,4- nitric oxide activator; NEBILET; dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- hydroxypropyl]amino -2- hydroxypropyl]amino -2-	
NEBILET; dihydro-2H-1- benzopyran-2- methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]-inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2- vasodilator beta adrenergic antagonist; phosphodiesterase phosphodiesterase inhibitor	
methanol] GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	
GI 104313 (S)-2-[2-chloro-4- (1,4,5,6-tetrahydro-6- oxo-3- pyridazinyl)phenoxy]- inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2- beta adrenergic antagonist; phosphodiesterase inhibitor	
(1,4,5,6-tetrahydro-6- oxo-3- phosphodiesterase pyridazinyl)phenoxy]-inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	
(1,4,5,6-tetrahydro-6- oxo-3- phosphodiesterase pyridazinyl)phenoxy]-inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	i
pyridazinyl)phenoxy]-inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	
pyridazinyl)phenoxy]-inhibitor N-[2-[[3-(2- cyanophenoxy)-2- hydroxypropyl]amino]-2-	
cyanophenoxy)-2- hydroxypropyl]amino]-2-	ĺ
hydroxypropyl]amino]-2-	
]-2-	
	.
methylpropyl]acetami	- [
de	
bucindolol; 2-[2-hydroxy-3-[[2- beta adrenergic heart failure;	\neg
bucindolol (1H-indol-3-yl)-1,1- antagonist; myocardial infarct	on
hydrochloride; MJ dimethylethyl]amino] vasodilator	
131051; BEXTRA propoxy]benzonitrile	
drug delivery system, Unspecified beta adrenergic heart failure	
controlled release antagonist;	
GEOMATRIX vasodilator	
bucindolol;	
bucindolol	
GEOMATRIX	
nesiritide; nesiritide Brain natriuretic biotechnology; heart failure;	_
citrate; brain peptide-32 hormone; peptide hypertension	\dashv
natriuretic peptide;	-
BNP; NATRECOR	

carperitide; human atrial natriuretic	l-de-L-leucine-2-de- L-alanine-3-	biotechnology; hormone; peptide;	heart failure
peptide; ANP;	deglycine-4-de-L-	diuretic	
HANP; atriopeptin-28			
(human); SUN 4936;			
HANP	methionine-		
	atriopeptin-33 (rat)		
etanercept; tumor	Unspecified	biotechnology; TNF	rheumatoid arthritis;
necrosis factor		inhibitor;	heart failure; diabetes;
receptor; TNFr; TNR		immunosuppressant;	pain; endometriosis;
001; ENBREL		NSAID; analgesic	autoimmune disease
BAY y 5959	(-)-2-amino-5-cyano-	calcium agonist	heart failure
	1,4-dihydro-6-methyl-		
	4-(3-phenyl-5-		
	quinolinyl)-3-		
t i	pyridinecarboxylic	ļ	
•	acid 1-methylethyl		
ł	ester		·
LY 249933	(R)-1,4-dihydro,2,6-	calcium antagonist	heart failure
	dimethyl-5-nitro-4-	8	
I .	thieno[3,2-c]pyridin-		
	3-yl-3-	•	·
	pyridinecarboxylic		
	acid, 1-phenylethyl		
	ester		
SIM 6080	N-[3,3-bis(4-	calcium antagonist	heart failure
]	fluorophenyl)propyl]-		
	N,N'-dimethyl-N'-		
	[(3,4,5-		
	trimethoxyphenyl)met		
	hyl]-1,2-	'	
	ethanediamine		
SR 33805	Unspecified	calcium antagonist	heart failure;
			atherosclerosis
		calcium antagonist	heart failure
	difluorophenyl)-5-	-	
	methyl-4,7-		·
	dihydropyrazolo-(1,5-		
	a)pyrimidine-6-	ļ	
	carboxylate		

elgodipine; IQB 875	(+,-)-4-(1,3-	coloium antanaist	
orgodipine, 1QD 075	benzodioxol-4-yl)-	calcium antagonist; vasodilator	angina; hypertension;
	1,4-dihydro-2,6-	vasounator	heart failure
	dimethyl-3,5-		
	pyridinedicarboxylic		
	acid 2-[[(4-		
	fluorophenyl)methyl]	1	
	methylamino]ethyl 1-		
6-1- dimina. II 16400.	methylethyl ester	 	
felodipine; H 15482;	1 \ '	calcium antagonist;	hypertension; angina;
HOE 869; CGH 869;	1 1 1	vasodilator; diuretic	heart failure;
HYDAC; PLENDIL;	1 '	•	atherosclerosis
VASOPINE;	3,5-		
SPLENDIL;	pyridinedicarboxylic		,
MUNOBAL;	acid ethyl methyl		
FLODIL	ester		
mibefradil; mibefradi	1	calcium channel	hypertension; angina;
dihydrochloride; Ro	(1S-cis)-2-[2-[[3-(1H-	blocker; vasodilator	heart failure
405967; Ro	benzimidazol-2-		
405967001;	yl)propyl]methylamin	·	
POSICOR; CERATE	o]ethyl]-6-fluoro-	,	
	1,2,3,4-tetrahydro-1-		
	(1-methylethyl)-2-		
	naphthalenyl ester		
MCI 154	6-(4-(4-	calcium sensitizer	heart failure
	pyridinylamino)pheny		İ
	1)-4,5-dihydro-3(2H)-		
	pyridazinone		
	monohydrochloride		
AM 522	Unspecified	cardiac glycoside	hypertension; heart
			failure
AM 524	Unspecified	cardiac glycoside	heart failure;
			hypertension
digitalis-like	Unspecified	cardiac glycoside	heart failure
compound 1; DLC-	•	<i>G.</i> ,	
CL3			
digitoxigenin-PC	Unspecified	cardiac glycoside	heart failure;
			hypertension
NE 11040	Unspecified		heart failure
			heart failure
-		activity; cardiosteroid	moart ranuic
1	methyl-1-oxo-2-	won vity, cardiosiciold	
1	butenyl)oxy]-19-		
	oxobufa-20,22-		·
	dienolide		
	arvioliuc		

acetamide	Unspecified	Cardiac stimulant	heart failure
mildronate; MET 88		Cardiostimulation	heart failure
	1,1,1-trimethyl-		
	hydrazinium, inner		
	salt		
DAC 7684	Unspecified	cardiotonic	heart failure
P 877692	Unspecified	Cardiotonic	heart failure
UP 10023	Unspecified	Cardiotonic	heart failure
VA 5	6-(2,5-	Cardiotonic	heart failure; cancer
İ	dimethoxyphenyl)-		,
	2,3-		
	dihydroimidazo[2,1-		
	b]thiazole		
GP 2128	1-(3,4-	catecholamine	heart failure
	dihydroxyphenyl)-2-		
	[3-(4-		
	carbamoylphenyl)-1-		
	methylpropylamino]e	t	
	hanol		
dexrazoxane;	(+)-(S)-4,4'-	chemoprotectant;	cancer; heart failure
razoxane (+), (S);	propylenedi-2,6-	cytoprotectant	2 - 3
ICRF 187; NSC	piperazinedione		
169780; ADR529;			
ICI 59118;			
CARDIOXANE;			•
EUCARDION;			
RAZOXIN;			
ZINECORE;	·		
ZINECARD;	·		
ANTRAGARD			
ICRF 197	Unspecified	chemoprotectant;	cancer; heart failure
4 OD 4 741		cytoprotectant	
AQRA 741		cholinergic	heart failure
	(diethylamino)butyl]-	antagonist;	
,	l-piperidinyl]acetyl]-		
		antagonist;	
	F = " .	muscarinic M2	
	b][1,4]benzodiazepin-	antagonist	
MCC 126	6-one		
	. * `	Contractile	heart failure;
		dysfunction	myocardial infarction
i	1	amelioration].
	monohydrate		<u> </u>

'1 PLE	b 11 5 (17)	T.: :	1
azosemide; PLE	2-chloro-5-(1H-	diuretic	heart failure
1053; SK 110;	tetrazol-5-yl)-4-[(2-		
LURET; DIART;	thienylmethyl)amino]		
URETIN	benzenesulfonamide		
C 2921	4-(bicyclo[2.2.1]hept	-diuretic	heart failure
<u> </u>	1-ylamino)-N-[[(1-		
	methylethyl)amino]ca		
	rbonyl]-3-		
	pyridinesulfonamide		
JDL 961	4-(cyclooctylamino)-	diuretic	heart failure
	N-		
	[(ethylamino)carbony	i	
	1-3-		
1	pyridinesulfonamide		
piretanide: HOE 118.	3-(aminosulfonyl)-4-	diuretic	heart failure
S 734118; ARELIX;	phenoxy-5-(1-		ileart faiture
ARLIX; TAULIZ;	pyrrolidinyl)benzoic		
EURELIX:	acid		
PIRENEX			
	N-[[(1-	diuretic	hypertension; heart
•	methylethyl)amino]ca		failure
BM 02015; AC 4464;	rhonvill-4-[(3-		hanure
	methylphenyl)amino]-		
PRESARIL;	3-		
TORREM; TOREM;	r		
ZEMIDE;	pyriumesunonamide		:
DEMADEX;			ementa in i
TORADIUR:	•		والمراجع المرا
DIURESIX;			
LUPRAC			٠,
	(15)		
niravoline; niravolin;			trauma; heart failure;
F .		agonist; kappa agonist	cirrhosis
	pyrrolidinyl)-1H-	,	·
	inden-1-yl]-N-methyl-		·
	3-		
	nitrobenzeneacetamid		
	e		
		diuretic; sulfonylurea	heart failure
	(bicyclo[2.2.1]hept-2-		
	ylamino)-N-[[(1-	İ	·
	methylethyl)amino]ca]	
	rbonyl]-5-		
	pyrimidinesulfonamid		
	e		

PNU 80873A	Unspecified	diuretic; vasopressin antagonist	heart failure
dopexamine; FPL 60278; FPL 60278AR; CARDURA; DOPACARD	4-[2-[[6-[(2- phenylethyl)amino]he xyl]amino]ethyl]-1,2- benzenediol	dopamine agonist; beta adrenergic agonist; beta2 adrenergic agonist; vasodilator	heart failure
ibopamine; SB 7506; AF 3104; SKF 100168; INOPAMIL; SCANDINE; ESCANDINE; ERFOLGAN; TRAZYL	acid 4-[2- (methylamino)ethyl]- 1,2-phenylene ester	dopamine agonist; dopamine D1 agonist; vasodilator	heart failure; eye disease
fenoldopam prodrug	Unspecified	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	heart failure
fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM	6-chloro-2,3,4,5- tetrahydro-1-(p- hydroxphenol)-1H-3- benzazepine-7,8-diol	dopamine agonist; dopamine D1 agonist; vasodilator; diuretic	hypertension; glaucoma; kidney disease; heart failure
		dopamine D2 agonist; alpha adrenergic agonist; alpha2	heart failure
CHF 1255	Unspecified	dopamine agonist; vasodilator	heart failure
8704; TA 870; TANADOPA	[2-[[2-(acetylamino)- 4-(methylthio)-1- oxobutyl]amino]ethyl]-1,2-phenylene diethyl ester	vasodilator	heart failure
	dihydroxyphenyl)-	dopamine antagonist; dopamine D1 antagonist	heart failure
BMS 193884	Unspecified	endothelin antagonist endothelin antagonist	

hosentan: Ro 470203	· 4-(1 1-dimethylethyl)	-endothelin antagonist	h 6 1
Ro 470203/039	N-[6-(2-	-chdometin antagonisi	neart failure
100 47 02037037	hydroxyethoxy)-5-(2-		1
	methoxyphenoxy)[2,2		
		4	
	'-bipyrimidin]-4-		
	yl]benzenesulfonamio	1	
TA 0201	01/6/2/5	<u> </u>	
1 A 0201	(N-(6-(2-(5-	endothelin antagonist	1
	bromopyrimidin-2-		myocardial infarction
	yloxy)ethoxy)-5-(4-		
	methylphenyl)pyrimic	1	
	in-4-yl)-4-(2-		
	hydroxy-1,1-		
	dimethyl)benzensulfo		
	mide sodium salt)		
ZD 1611	Unspecified	endothelin antagonist	heart failure
ZD 2574	Unspecified	endothelin antagonist	heart failure
ZD 4054	Unspecified	endothelin antagonist	heart failure
Ro 485695	2-pyridinyl-carbamic	endothelin antagonist;	heart failure
	acid, 2-[[5-(2-	endothelin A	
	methoxyphenoxy)-6-	antagonist	
	[[[4-(1-		
	methylethyl)phenyl]s		
	ulfonyl]amino]-2-(4-		
:	morpholinyl)-4-		·
	pyrimidinyl]oxy]ethyl		
	ester		
TBC 11251; IPI 1251	N-(4-chloro-3-	endothelin antagonist;	heart failure:
·		T	pulmonary
	2-[(6-methyl-1,3-		obstructive disease;
	benzodioxol-5-	, -	brain ischemia
	yl)acetyl]-3-		
	thiophenesulfonamide	,	
ecadotril; sinorphan;			hypertension; heart
BP 1.02, BAY y	r , ,	L ⁻ .	failure; cirrhosis
7432; S 049; BP 102	1-oxo-3-		aniuro, chritosis
. ,	phenylpropyl]glycine	·	,
	phenyl methyl ester		
ThGRF 129- H 9506-	N-(2-aminoethyl)-1,2-	grouth harmons	hant Gilion 1
ThGRF 1-29			heart failure; hormone
	i		deficiency
		analogue	

BU E75; BU-E 75	N-[3-(3,4- difluorophenyl)-3-(2- pyridinyl)propyl]-N'- [3-(1H-imidazol-4- yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
BU E76; BU-E 76	N-[3-(3,5- difluorophenyl)-3-(2- pyridinyl)propyl]-N'- [3-(1H-imidazol-4- yl)propyl]guanidine	histamine agonist; histamine H2 agonist	heart failure
HE 30582	N-(3-(1H-imidazol-4-yl)propyl)-4-(2 nitro-4-(1,4,5,6- tetrahydro-4-methyl-6-oxo-2-pyridizinyl)phenyl)-1-piperazine carboximidamide	histamine H2 agonist	heart failure
anaritide; atrial	N-L-arginyl-8-L-	hormone; ANP	heart failure; kidney
natriuretic factor 4-	methionine-21a-L-	agonist; peptide	disease
28; ANF 4-28; atrial	phenylalanine-21b-L-		
natriuretic peptide;	arginine-21c-L-		•
anaritide acetate; WY	1 -		
47663; AURICULIN	21 (rat)		
BM 500430	4,5-dihydro-5-methyl- 6-[2-(pyridin-4-yl)- 1H-indol-5-yl]- pyridazin-3(2H)-one	Inotropic agent	heart failure
CL 284027	Unspecified	Inotropic agent	heart failure
digitalis-like steroids	\$	Inotropic agent	heart failure
DLC-CL3	 		heart failure
DLC-CL3		Inotropic agent	heart failure
GYKI 12735	2-methyl-4-((2-4-morpholinyl)ethyl)am ino-1H-pyrimido(5,4- 6)-(1,4) oxazin- 7(6H)-one		heart failure
KF 15832	6-(4-benzylamino-7- quinazinolinyl)-4,5- dihydro-5-methyl- 3(2H)-pyridazinone hydrochloride	Inotropic agent	heart failure
LAS 31180	Unspecified	Inotropic agent	heart failure
LAS 31270	Unspecified	Inotropic agent	heart failure

DO 12152	(2)	L	
RG 12152	6-(3'-cyano-6'-methyl	-Inotropic agent	heart failure
	2'-oxo-(1H)-pyridin-		
	5'-yl)-1-methyl-2H-		
	pyri do (3,2-b)-1,4-		
	oxazin-3(4H)-one		
RWJ 24517	6-[1-[1-bis(4-	Inotropic agent	heart failure
	fluorophenyl)methyl]		
	piperazin-4-yl]-2-		
	hydroxy-3-pro panyl-		
	thiopurine		
UK 66838	6-(4-acetyl-2-methyl-	Inotropic agent	heart failure
	1H-imidazol-1-yl)-8-		
	methyl-2(1H)-		
	quinolinone		
vasotrope	Unspecified	Inotropic agent	heart failure
meribendan; EMD	4,5-dihydro-5-methyl-		heart failure
49931	6-(2-pyrazol-3-yl-5-	cardiotonic	
	benzimidazolyl)-		
	3(2H)-pyridazinone		
omapatrilat; BMS	[4S-	matrix	hypertension; heart
186716	[4alpha(R*),7alpha,1	metalloproteinase	failure
	0abeta]]-octahydro-4-		
	[(2-mercapto-1-oxo-		
	3-	endopeptidase	
tu v T	phenylpropyl)amino]-		. 1
	5-oxo-7H-pyrido[2,1-		
·	b][1,3]thiazepine-7-		
And the second	carboxylic acid	·	
matrix	Unspecified	matrix	heart failure
metalloproteinase	_	metalloproteinase	
inhibitor, coronary		inhibitor; proteinase	
heart failure		inhibitor	
cardiovascular disease	Unspecified	Myosin motor and	hypertension; heart
therapy		actin filaments	failure
••		modulation	
SA 7060		neutral endopeptidase	heart failure
	- ' '		hypertension
	[·	inhibitor	A L account of
	oxopropyl)(2-		
	methylpropyl)amino]c		ļ
	arbonyl]amino]-2-		
	naphthalenepropanoic		
	acid		
	acid		

SCH 50690	Unspecified	neutral endopeptidase inhibitor; ACE	hypertension; heart failure
SLV 306	[S-(R* S*)]-3-[[[1-[2-	inhibitor neutral endopeptidase	heart failure
	(ethoxycarbonyl)-4- phenylbutyl]cyclopen yl]carbonyl]amino]-	inhibitor; diuretic	icait failuic
	2,3,4,5-tetrahydro-2- oxo-1H-1- benzazepin-1-aceti c		,
nitric oxide	acid		
vasodilators	Unspecified	nitric oxide donor; vasodilator	angina; heart failure
VX 745	Unspecified	transduction inhibitor	neurological; heart
BRL 52656	S(-)-2-(1- pyrrolidinylmethyl)- 1-(4- trifluoromethylphenyl)acetylpiperidine hydrochloride		heart failure
BRL 53114		opiate agonist; kappa agonist; diuretic	heart failure
oxytocin antagonist	Unspecified	diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
amrinone; WIN 40680; YM 10310; INOCOR; WINCORAN; VESISTOL; AMCORAL; CARTONIC	5-amino-[3,4'- bipyridin]-6(1H)-one	phosphodiesterase	heart failure
BRL 40696		phosphodiesterase inhibitor	heart failure

EMD 52000	(1) (1) 1 (
EMD 53998	6-(3,6-dihydro-6-	phosphodiesterase	heart failure
	methyl-2-oxo-2H-	inhibitor	
ļ	1,3,4-thiadiazin-5-yl)) -	
	1-(3,4-		
	dimethoxybenzoyl)-		
	1,2,3,4-		
	tetrahydroquinoline		
indolidan; LY 19511		phosphodiesterase	heart failure
	dimethyl-5-(1,4,5,6-	inhibitor	
	tetrahydro-6-oxo-3-		
	pyridazinyl)-2H-		
	indol-2-one		
N 3601	2-[[(4,6-	phosphodiesterase	heart failure
	dimethylpyridin-2-	inhibitor	
	yl)methylamino]carbo		
	xy]-3-[2-[4-(3,4-		
	dimethoxybenzoyl)pi		
	perazin-1-yl]ethyl]-3-		
	aza-2,3-dihydro-1H-		
	indole		
olprinone; loprinone;		phosphodiesterase	heart failure
E 1020; CORETEC	imidazo[1,2-	inhibitor	
	a]pyridin-6-yl-6-		
	methyl-2-oxo-3-]	
	pyridinecarbonitrile		
TZC 5665	4-chloro-2-[3-[[1,1-	phosphodiesterase	heart failure
	dimethyl-	inhibitor	
	2[[4(1,4,5,6-		
	tetrahydro-4-methyl-		·
	6-oxo-3-		
	pyridazinyl)phenyl]a		
	mino]ethyl]amino]-2-		
	hydroxypropoxy]benz	1, 1, 1	
	onitrile, compd. with		
	(Z)-2-butenedioic]
	acid, monoethyl ester,		
	(1:1)		
ZSY 39	4-methyl-5-(4-	phosphodiesterase	heart failure
		inhibitor	
	thiazolecarboxamide		
	iniazolecarboxamide		

EMD 57033; (+)-	(+)-6-(3,6-dihydro-6-	phosphodiesterase	heart failure
EMD 53998	methyl-2-oxo-2H-	inhibitor;	
	1,3,4-thiadiazin-5-yl)	phosphodiesterase III	
	1-(3,4-	inhibitor	
	dimethoxybenzoyl)-		
	1,2,3,4-		
	tetrahydroquinoline		
isomazole; LY	2-[2-methoxy-4-	phosphodiesterase	heart failure
175326; EMD 52750	(methylsufinyl)pheny	linhibitor;	
]-1H-imidazo[4,5-	phosphodiesterase III	
	c]pyridine	inhibitor	
NSP 804	4,5-dihydro-6-[4-[(2-	phosphodiesterase	heart failure
	methyl-3-oxo-1-	inhibitor;	
		phosphodiesterase III	
	phenyl]-3(2H)-	inhibitor	
	pyridazinone		
NSP 805; TZN 01	4,5-dihydro-5-methyl-		heart failure
	6-[4-[(2-methyl-3-	inhibitor;	
	oxo-1-	phosphodiesterase III	
	cyclopentenyl)amino]	inhibitor	
	phenyl]-3(2H)-		
	pyridazinone		
revizinone; R 801222	(E)-N-cyclohexyl-N-		heart failure
	methyl-2-	inhibitor;	
	[[[phenyl(1,2,3,5-	phosphodiesterase III	,
	tetrahydro-2-	inhibitor	
	oxoimidazo[2,1- b]quinazolin-7-		
	yl)methylene]amino]o		
	xy]acetamide		
	4,5-dihydro-5-methyl-	nhoenhodiesterese	heart failure
13232		inhibitor;	nicatt latture
	[(phenylmethyl)amino		
		inhibitor;	
		phosphodiesterase V	
	` '	inhibitor; vasodilator	
ORG 10325			heart failure
1	•	inhibitor;	itoart taituic
	•	phosphodiesterase III	
t I		inhibitor;	
		phosphodiesterase IV	
		inhibitor	

ORG 30029	N-hydroxy-5,6-	phosphodiesterase	the same College
ORG 30029	dimethoxy-	inhibitor;	heart failure
	benzo[b]thiophene-2-	phosphodiesterase III	
	carboximidamide	inhibitor;	
		phosphodiesterase IV	
		inhibitor	
ORG 9731	4-fluoro-N-hydroxy-	phosphodiesterase	heart failure
	5,6-dimethoxy-	inhibitor;	
		phosphodiesterase III	
	carboximidamine	inhibitor;	
	methyl sulfonic acid	phosphodiesterase IV	
		inhibitor	
E 4021; ER 21355	1-[4[(1,3-	phosphodiesterase	hypertension; angina;
	benzodioxol-5-	inhibitor;	heart failure
	ylmethyl)amino]-6-	phosphodiesterase V	
	chloro-2-	inhibitor	
	quinazolinyl]-4-		
	piperidinecarboxylic		
	acid, monosodium		
	salt		
IC 351; GF 196960;	Unspecified	phosphodiesterase	heart failure; angina;
GG 960		inhibitor;	sexual dysfunction;
		phosphodiesterase V	psoriasis
		inhibitor	
SKF 95654	4,5-dihydro-6-(4-(1,4-		thrombosis; heart
	dihydro-4-oxopyridin-	, · ·	failure
		antiaggregant	
, ,	methyl- 3(2H)-		
	pyridazinone		
pimobendan; UDCG		phosphodiesterase	thrombosis; heart
115; UDCG 115A;		inhibitor; platelet	failure
UDCG 115BS;	benzimidazolyl)-5-	antiaggregant;	
ACARDI 🛷	methyl-3-(2H)-	vasodilator	
	pyridazinone		
simendan	[[4-(1,4,5,6-	phosphodiesterase	heart failure;
	tetrahydro-4-methyl-	inhibitor; platelet	thrombosis
		antiaggregant;	
	6-oxo-3- pyridazinyl)phenyl]hy	vasodilator	
	6-oxo-3-	vasodilator	

levosimendan; OR 1259; SIMDAX	[[4-(1,4,5,6- tetrahydro-4-methyl- 6-oxo-3- pyridazinyl)phenyl]hy drazono]propanedinitiile	rsensitizer	heart failure; thrombosis
toborinone; OPC 18790	(+,-)-6-[3-[[(3,4- dimethoxyphenyl)met hyl]amino]-2- hydroxypropoxy] 2(1H)-quinolinone	phosphodiesterase inhibitor; potassium channel blocker	heart failure
vesnarinone; piperanometozine; OPC 8212; ARKIN- Z; ARKIN	l-(1,2,3,4-tetrahydro- 2-oxo-6-quinolyl)-4- veratroylpiperazine	phosphodiesterase inhibitor; potassium channel blocker	heart failure; HIV infection
bemoradan; ORF 22867	7-(1,4,5,6-tetrahydro- 4-methyl-6-oxo-3- pyridazinyl)-2H-1,4- benzoxazin-3(4H)- one	phosphodiesterase inhibitor; vasodilator	heart failure
BW 349U85	2(1H)-quinolinone monohydrochloride	phosphodiesterase inhibitor; vasodilator	heart failure
enoximone; fenoximone; phenoximone; MDL 17043; RMI 17043; PERFAN; PERFLAN; PERFANE	1,3-dihydro-4-methyl- 5-[4- (methylthio)benzoyl]- 2H-imidazol-2-one	phosphodiesterase inhibitor; vasodilator	heart failure
milrinone; WIN 47203; WIN 472032; YM 018; CORATROPE; PRIMACOR; MILRILA	1,6-dihydro-2-methyl- 6-oxo-[3,4'- bipyridine]-5- carbonitrile	phosphodiesterase inhibitor; vasodilator	heart failure
MS 857	-	phosphodiesterase inhibitor; vasodilator	heart failure

saterinone: BDF 863	4 (+,-)-1,2-dihydro-5-	nhoonhodiasta	h . c ::
Batermone, BB1 803	[4-[2-hydroxy-3-[4-	phosphodiesterase inhibitor; vasodilator	heart failure
	(2-methoxy-phenyl)-	inimibitor, vasodilator	
	12-methoxy-phenyly-		
	ninerozinullanemuula		
	piperazinyl]propxy]p		
	henyl]-6-methyl-2- oxo-3-		
16alpha-gitoxin;	pyridinecarbonitrile		
gitoxin	Unspecified	Positive inotropic	heart failure
emakalim; EMD	(20 +) 2 4	action	
56431	(3S-trans)-3,4-	potassium channel	hypertension; heart
50431	dihydro-3-hydroxy-	activator;	failure; asthma;
	2,2-dimethyl-4-(2-	bronchodilator	peripheral vascular
	oxo-1(2H)-pyridinyl)-		disease
	2H-1-benzopyran-6-	ĺ	
	carbonitrile		
nicorandil; SG 75;	N-[2-(nitrooxy)ethyl]-	AT .	angina;
EMD 36385; U	β-	activator; nitrate;	cerebrovascular
64417; SIGMART;	pyridinecarboxamide	vasodilator	disease; heart failure
PERISALOL;			
DANCOR; IKOREL;		se un e	
ADANCOR;			·
CORDONE;			
KALIDIL			
BW 15AU81; BW			heart failure
15AU; U 62840;	[1alpha(S*),2beta,3aa	vasodilator	
15AU81	lpha,9aalpha]]-		
	[[2,3,3a,4,9,9a-		
	hexahydro-2-		
	hydroxy-1-(3-		·
	hydroxyoctyl)-1H-		
	benz[f]inden-5-		
T) (7) 50005	yl]oxy]acetic acid		
	L		neart failure
		renin inhibitor	
	phenylalanyl-L-		İ
	histidyl-(4S-amino-		
N	3S-hydroxy-5-		
	cyclohexyl)-		
	pentancarbonyl)-L-		
	isoleucyl-(2-		
	amidomethyl)-tetrazol		

BDF 9148	4-[3'-(1-benzhydryl-	sodium channel	hoost Cilium
BD1 7140	azetidin-3-oxy)-2'-	activator	heart failure
	hydroxylpropoxy]-	activator	
	1H-indole-2-		
	carbonitrile		
BM 20	N-[[-4-	au16aau16biau	1 4 6 11
DIVI 20	1	sulfonylthiourea;	heart failure
	(cyclooctylamino)pyri	diuretic	
	din-3-yl]sulfonyl]-N'- ethylthiourea		
daltroban; BM 13505		411	1
SKF 96148		thromboxane	heart failure;
DKF 90146	chlorophenyl)sulfonyl		thrombosis
1]amino]ethyl]benzene acetic acid	antiaggregant	
BW A746C	Unspecified	I Improvided	1 4 C:1
CM 3		Unspecified	heart failure
congestive heart	Unspecified	Unspecified	heart failure
failure therapy	Unspecified	Unspecified	heart failure
CK 2289	4 -41-3 1 2 1:1-1-	1.1	
CK 2209	4-ethyl-1,3-dihydro- 5-[4-(1H-imidazol-1-	vasodilator	heart failure
	1 - '		
	yl)benzoyl]-2H- imidazol-2-one		
FK 664	† · · · · · · · · · · · · · · · · · · ·		
FK 004	6-(3,4-	vasodilator	heart failure
	dimethoxyphenyl)-1-		
	ethyl-3,4-dihydro-3-		
	methyl-4-[(2,4,6-	•	
	trimethylphenyl)imin		
	o]-2(1H)-		
flosequinan; BTS	pyrimidinone 7-fluoro-1-methyl-3-		2 4 C 1
49465; MANOPLAX		vasodilator	heart failure
43403, MAINOFLAA			
HN 10200	4(1H)-quinolinone	1.1	
mn 10200	1 ``	vasodilator	heart failure
	methylsulfinyl)-2-		
	thienyl)-1-H-		
	imidazo(4,5-]
	c)pyridine		
T TY	hydrochloride	4**	
nanterinone; UK	. ` '	vasodilator	heart failure
61260; UK 6126027	imidazol-1-yl)-8-		
	methyl-2(1H)-		
· · ·	quinolinone	<u> </u>	
piroximone; MDL	1 -	vasodilator	heart failure
19205	isonicotinoyl-4-		
	imidazolin-2-one		

prinoxodan; RGW	2 A dibudeo 2 mothul	Logadilatan	h 4 C 11
2938; RG 2938	3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-		heart failure
2930, KG 2930			
	6-oxo-3-pyridazinyl)-		
16	2-(1H)-quinazolinone	 	
colforsin dapropate;	6-[3-	vasodilator;	heart failure; asthma;
NKH 477; ADEHL	(dimethylamino)propi	bronchodilator	musculoskeletal
	onyl]forskolin		disorder
propionylcarnitine, L-	, ,	vasodilator;	peripheral vascular
; propionyl-L-	oxopropoxy)-N,N,N-	cicatrizant	disease; angina; heart
carnitine;	trimethyl-1-		failure; skin ulcer
levocarnitine	propanaminium		
propionyl; ST 261;	hydroxide, inner salt		
DROMOS			
VPA 985	N-[3-chloro-4-(5H-	vasopressin	heart failure
	pyrrolo[2,1-	antagonist; aquaretic	
	c][1,4]benzodiazepin-		
	10(11H)-		
	ylcarbonyl)phenyl]-5-		
	fluoro-2-		
	methylbenzamide		
WAY 140288	Unspecified	vasopressin	heart failure
	·	antagonist; aquaretic	
OPC 21268	1-[1-[4-(3-	vasopressin	hypertension; heart
	acetylaminopropoxy)	antagonist; diuretic	failure
	benzoyl]-4-piperidyl]-		·
	3,4-dihydro-2(1H)-		
	quinolinone		
SR 121463	cis-N-(1,1-	vasopressin	heart failure;
***	dimethylethyl)-4-[[5'-	antagonist; diuretic	hypertension
	ethoxy-4-[2-(4-	-	
	morpholinyl)ethoxy]-		
	2'-		
	oxospiro[cyclohexane		
	-1,3'-[3H]indol]-		
	1'(2'H)-yl]sulfonyl]-3-		
	methoxy-benzamide		
	(E)-2-butenedioate		
	(1:1)		

SR 49059	[2R-	vasopressin	gynecological;
	[2alfa(S*),3beta]]-1-	antagonist; diuretic	cancer; hypertension;
	[[5-chloro-3-(2-	, aranono	heart failure; emesis
	chlorophenyl)-1-		mourt failure, efficies
	[(3,4-		
	dimethoxyphenyl)sulf	F	
	onyl]-2,3-dihydro-3-		
•	hydroxy-1H-indol-2-		
	yl]carbonyl]-2-		
	pyrrolidinecarboxami		
	de		
vasopressin	Unspecified	vasopressin	anxiety; depression;
antagonist		antagonist; diuretic	obsessive compulsive
			disorder; epilepsy;
			heart failure
YM 087	N-[1,1'-biphenyl]-2-	vasopressin	heart failure
	yl-4-[(4,5-dihydro-2-	antagonist; diuretic	
	methylimidazo[4,5-		
	d][1]benzazepin-		
	6(1H)-yl)carbonyl]-		
	benzamide	·	
YM 471		vasopressin	heart failure
		antagonist; diuretic	
	piperidinyl]-2-		
	oxoethylidene]-4,4-		
	difluoro-2,3,4,5-		
	tetrahydro-1H-1-		
	benzazepin-1-		
	yl]carbonyl]phenyl]-		
	[1,1'biphenyl]-2-		
	carboxamide,		
	monohydrochloride		1

Table 64. Current Candidate Therapeutic Interventions for the Treatment of Thrombosis

Product Name	Chemical Name	Action	Indication
DV 7028	3-[2-[4-(4- fluorobenzoly)piperid in-1-yl]ethyl]-6,7,8,9- tetrahydro-2H- pyrido[1,2-a]-1,3,5- triazine-2,4(3H)- dione maleate		thrombosis

eplivanserin; SR	(1Z,2E)-1-(2-	5HT antagonist;	hahiran harris
46349; SR 46349B	fluorophenyl)-3-(4-	5HT2 antagonist;	schizophrenia;
DO545, SK 40545B	hydroxyphenyl)-2-		insomnia; thrombosis
	1	platelet antiaggregant	
	propen-1-one (2E)-2-		
LY 215840	butenedioate (2:1) sal		ļ <u></u>
LY 213840	[8beta(1S,2R)]-N-(2-		thrombosis; angina
	hydroxycyclopentyl)-		
	6-mrthyl-1-(1-	platelet antiaggregant	
	methylethyl)ergoline-	İ	
	8-carboxamide		
MDL 28133A	N-[4-[[1-[2-(4-	5HT antagonist;	thrombosis
	fluorophenyl)-2-	5HT2 antagonist;	
	oxoethyl]-4-	platelet antiaggregant	
	piperidinyl]carbonyl]		
	phenyl]methanesulfor	ų.	
	amide	·	
	monohydrochloride		
S 14280	3-[2-[3-[2-(4-	5HT antagonist;	thrombosis
	fluorophenyl)-2-	5HT2 antagonist;	
	oxoethyl]pyrrolidin-	platelet antiaggregant	
	l-yl]ethyl]-		
	2,4(1H,3H)-		
	quinazolinedione		
sarpogrelate;	butanedioic acid	5HT antagonist;	thrombosis
sarpogrelate	mono[2-	5HT2 antagonist;	
hydrochloride; MCI	(dimethylamino)-1-	platelet antiaggregant	
9042; ANPLAG	[[2-[2-(3-		
	methoxyphenyl)ethyl]		•
	phenoxy]methyl]ethyl		•
	ester		
AT 1015	unspecified	5HT antagonist;	thrombosis
		5HT2A antagonist;	
		platelet antiaggregant	
GP 531			ischemia; thrombosis
		agent; anti-ischemic	diomodolo
	[phenylmethyl)amino	8,	
	-beta-D-		
	ribofuranosyl-1H-		
	imidazole-4-		
:	carboxamide		
acadesine; AICA-		adenosine regulating	cardiovascular
riboside; AR 100; GP	l		
1110; GP 11100;			disease; thrombosis; ischemia
ARASINE;	1 1	ischemic	ischemia
PROTARA	Cai DOXAIIIIAE	ISCHEIIIIC	
TINOIMINA	·		

AT 112	2,3-dihydro-2-[(4-	alpha adrenergic	thrombosis;
	phenyl-1-	antagonist; alphal	hypertension
	piperazinyl)methyl]i	adrenergic antagonist	
	midazo[1,2-	platelet antiaggregant	
	c]quinazolin-5(6H)-	,	
·	one		
thrombospondin 1	unspecified	angiogenesis	cancer; diagnosis;
inhibitor, TSP-1		inhibitor; platelet	thrombosis
inhibitor,		antiaggregant;	
		radiodiagnostic;	
		contrast medium	
avidinorubicin	unspecified	antibiotic;	thrombosis
		anthracycline; platelet	
		antiaggregant	
placetin A	unspecified	antibiotic; platelet	thrombosis; bacterial
		antiaggregant	infection; cancer
placetin B	unspecified	antibiotic; platelet	thrombosis; bacterial
		antiaggregant	infection; cancer
RP 12986; RG 12986	1	anticoagulant	thrombosis
	Willebrand factor		
	fragment		• • •
staphylokinase	Recombinant	anticoagulant	thrombosis
	staphylokinase		
thrombomodulin; MR	unspecified	Anticoagulant	thrombosis
33; MB 015			
1	Protein isolated from	anticoagulant	thrombosis
anticoagulant, natural;	human placenta		
VAC, natural			
hirudin, natural	unspecified		thrombosis
	unspecified	antithrombin; platelet	thrombosis
hirudin; PEG-hirudin;		antiaggregant	
hirudin macrogol FK 633	NT 54 54		
FK 033	N-[4-[4-	Antithrombotic	thrombosis
	(aminoiminomethyl)p		
	henoxy]-1-oxobutyl]-		
	L-alpha-aspartyl-L-		
	valine		
	unspecified		thrombosis
	unspecified		hrombosis
LU 208791	unspecified	antithrombotic	hrombosis

M 19791; U 68215	IT I D	1	T
WI 19791; U 08213	[1R-	antithrombotic	thrombosis
	[lalpha(R*),2beta,3aa		
	lpha,9aalpha]]-[[1-(3-		
	cyclohexyl-3-hydro		1
	xypropyl)-2,3,3a,4,9a	1	
	hexahydro-2-		
	hydroxy-1H-		
	benz[f]inden-5-		İ
	yl]oxy]-acetic acid		
protein C	unspecified	antithrombotic	thrombosis
protein C natural,	unspecified	antithrombotic	thrombosis
activated; activated			
protein C, natural;			
APC			
protein C; CTC 111	unspecified	antithrombotic	thrombosis
thrombin receptor	unspecified	antithrombotic	thrombosis
inhibitors			111011100313
thrombomodulin;	Recombinant	antithrombotic	thrombosis
ART 123	Thrombomodulin	antitinomodic	unombosis
thrombosis therapy	unspecified	antithrombotic	thrombosis
TMD 1105		antithrombotic	thrombosis
	recombinant	·	unonioosis
	thrombomodulin		}
V 20R	unspecified	antithrombotic	thrombosis
V 21	unspecified	antithrombotic	thrombosis
GS 522		aptamer; thrombin	thrombosis
00 322	Į.	inhibitor; proteinase	ulloilibosis
	į .	inhibitor	
nematode			thus
anticoagulant protein	l "	biotechnology; blood clotting factor VIIa	thrombosis
c2, recombinant;		inhibitor; proteinase	
NAPc2; AcAPc2;		inhibitor	
rNAPc2		HIRHOROL	'
tick-derived	unspecified	hiotophysle 11- 1	411
	, - ,	biotechnology; blood	unrombosis
anticoagulant peptide; TAP		clotting factor Xa	
IAC		inhibitor; peptide;	
4:-4-4: A (F)(0)		proteinase inhibitor	
antistatin; ATS;		biotechnology; blood	thrombosis
ghilanten		clotting factor Xa	
	1	inhibitor; proteinase	
		inhibitor	

factor Xa inhibitor, leech; FACTOREX	unspecified	biotechnology; blood clotting factor Xa inhibitor; proteinase	thrombosis
		inhibitor	
nematode	unspecified	biotechnology; blood	thrombosis
anticoagulant protein		clotting factor Xa	
5, recombinant;		inhibitor; proteinase	
rNAP5; NAP5		inhibitor	
TP 9201	N-acetyl-L-cysteinyl-	biotechnology;	thrombosis
	L-asparaginyl-L-	glycoprotein IIb/IIIa	
	prolyl-L-	antagonist; platelet	
	arginylglycyl-L-	antiaggregant	
	alpha-aspartyl-O-		
	methyl-L-tyrosyl-L-		
	arginyl-L-		
İ	cysteinamide cyclic		
	(1-9)-disulfide		
CX 397	unspecified	biotechnology;	thrombosis
		hirudin analogue	
MAb, AP-1	unspecified	biotechnology;	thrombosis
	and the same and a second	monoclonal antibody	
MAb, fibrin beta	unspecified	biotechnology;	thrombosis
chain plus hirudin;		monoclonal antibody	
HAF			
MAb, platelet	unspecified	biotechnology;	thrombosis
receptor IIb/IIIa +		monoclonal antibody	
hirudin; HAP; HAP			
MAb, RWR; MAb,	unspecified	biotechnology;	thrombosis
alpha2-plasmin		monoclonal antibody	
MAb, thrombosis;	unspecified	biotechnology;	thrombosis; septic
12D10; CORSEVIN		monoclonal antibody	shock; angina
M		,	
MAb, factor IX;	unspecified	biotechnology;	thrombosis
MAb, BC 2; SB		monoclonal antibody;	
249417		blood clotting factor	•
		IXa inhibitor	
MAb, FAb, 7E3	unspecified	biotechnology;	thrombosis
		monoclonal antibody;	
		glycoprotein IIb/IIIa	
		antagonist; platelet	•
		antiaggregant	

	·		
MAb, glycoprotein IIb/IIIa; MAb, GP IIb/IIIa	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAb, glycoprotein Пь/Ша; YM 337	unspecified	biotechnology; monoclonal antibody; glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
MAb, AJvW2; MAb, von Willebrand factor; AJvW2; humanized AJvW2	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAb, M735 and P14G11 urokinase conjugate; bispecific antibody, platelet antiaggregant; ATC 3; ATC (3)	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	thrombosis
MAb, platelet, humanized; SMART anti-platelet	unspecified	biotechnology; monoclonal antibody; platelet antiaggregant	cardiovascular disease; thrombosis
AAMP-1 derived peptides; cell adhesion peptides	unspecified	biotechnology; peptide	thrombosis
KPI Xa	unspecified	biotechnology; peptide; proteinase inhibitor; thrombolytic; fibrinolytic; serine proteinase inhibitor	thrombosis
D K2P	unspecified	biotechnology; plasminogen activator; thrombolytic	thrombosis
FK2P; U 84793	unspecified	· · · · · · · · · · · · · · · · · · ·	thrombosis
hybrid B; plasminogen activator	unspecified	· · · · · · · · · · · · · · · · · · ·	thrombosis

monteplase; tissue	84-L-	biotechnology;	h1
plasminogen	serineplasminogen	plasminogen	thrombosis
activator, second	activator (human	activator;	
generation; tPA	tissue-type protein		
P .	1	thrombolytic	
second generation; E	moiety reduced)		
6010; CLEACTOR			
reteplase; tissue	173-L-serine-174-L-	biotechnology;	thrombosis;
plasminogen	tyrosine-175-L-	plasminogen	myocardial infarction
activator; tPA; BM	glutamine-173-527-	activator;	
06022; RAPILYSIN;	plasminogen activator	thrombolytic	
RETAVASE;	(human tissue type)		
RETEVASE;			
ECOKINASE			
tissue plasminogen	unspecified	biotechnology;	thrombosis
activator variants;		plasminogen	
tPA variants		activator;	·
		thrombolytic	
tissue plasminogen	unspecified	biotechnology;	thrombosis
activator, FK(2)P24;	*	plasminogen	
tPA second		activator;	
generation; FK		thrombolytic	
(2)P24			
BIO-LASE	unspecified	biotechnology;	thrombosis; kidney
	•	platelet antiaggregant	
calen; calin; EMD	unspecified	biotechnology;	thrombosis
66800	l -	platelet antiaggregant	
human von			thrombosis
Willebrand fragment	_	platelet antiaggregant	,
protein C activator			thrombosis
	-	platelet antiaggregant	
tifacogin; tissue factor			thrombosis; septic
		platelet antiaggregant	shock
, , , , , , , , , , , , , , , , , , , ,	LACI (human clone	Pratotot aritiabbiobatic	SHOCK
	lambdaP9 protein		
	moiety reduced)	* .	
		biotechnology;	thrombosis
apyrases	- 1		HILDINOSIS
		platelet antiaggregant;	İ
		enzyme	

abciximab; abcirximab; MAb, F(ab')2 fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment antihuman glycoprotein IIb/IIIa receptor), disulfide with humanmouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.light chain		stroke; myocardial infarction
antiurombin iii		biotechnology; proteinase inhibitor	thrombosis
KPI 185	unspecified	*	thrombosis
LEX 026			thrombosis; inflammation
lepirudin; HBW 023; REFLUDAN	threonine-63-desulfo-		thrombosis, restenosis
BB 10153		biotechnology; thrombolytic	thrombosis
hirudin, recombinant		biotechnology; thrombolytic	thrombosis
hirudin; rHV2-Lys47; rt HV2		biotechnology; thrombolytic	thrombosis
LU 52369	1 -	biotechnology; thrombolytic	thrombosis
plasminogen mutants	unspecified		thrombosis
hementin; EMD 66777	unspecified		thrombosis

5711 15	· · · ·	1	T
MAb, bispecific	unspecified	biotechnology;	thrombosis
F(ab')2 fibrin and u-		thrombolytic;	
PA + scu-PA; scu-		monoclonal antibody	
PA/MA-FUI-			
74F(ab')2			
MAb, bispecific	unspecified	biotechnology;	thrombosis
fibrin tissue	}	thrombolytic;	
plasminogen; MAb,		monoclonal antibody	
bispecific tPA fibrin			
MAb, chimeric	unspecified	biotechnology;	thrombosis
plasminogen		thrombolytic;	
activator; K12G2S32		monoclonal antibody	
MAb, D3-ATF; MAb,	unspecified	biotechnology;	thrombosis
thrombosis; MAb,		thrombolytic;	
human tissue factor		monoclonal antibody	
DSPA; alpha-DSPA;	unspecified	biotechnology;	thrombosis
rDSPAalpha1; ZK		thrombolytic;	
152387; SH 576		plasminogen activator	·
duteplase; tPA; tissue	245-L-methionine	biotechnology;	thrombosis
1 -	plasminogen activator		
		plasminogen activator	
	chain form protein	ĺ	
	moiety)		
SOLCLOT			
lanoteplase; novel	N-[N2-(N-glycyl-L-	biotechnology;	thrombosis
- · ·		thrombolytic;	
		plasminogen activator	
	L-methionine-(1-5)-	3 3	·
	(87-527)-plasminogen		
T .	activator (human		
	tissue-type protein		
1	moiety)		
LY 210825		biotechnology;	thrombosis
	•	thrombolytic;	
	•	plasminogen activator	
nateplase; tissue			thrombosis
plasminogen		thrombolytic;	
activator; tPA; MMR		plasminogen activator	
701; MILYZER;		Production of the contract of	
TEPASE			
pamiteplase; YM 866;	(1-126)-(209-562)-	biotechnology;	thrombosis
_	plasminogen activator		un villousis
		plasminogen activator	
	(human tissue-type	piasinimogen activator	
1	precursor reduced)		
L	produsor reduced)		

prourokinase; PUK;	unspecified	h.:	
FCE 26177	unspecified	biotechnology;	thrombosis
CL 20177		thrombolytic;	
prourokinase; PUK;	unspecified	plasminogen activator	
rProUK; A 74187;	unspecified	biotechnology;	thrombosis; stroke
PROLYSE		thrombolytic;	
	1	plasminogen activator	
saruplase; CG 4509	prouro-(human clone	biotechnology;	thrombosis
	pUK4/pUK18) kinase	- 1	
niltanlara tianu	(enzyme activating)	plasminogen activator	
silteplase; tissue plasminogen	unspecified	biotechnology;	thrombosis
activator; tPA; TD		thrombolytic;	
		plasminogen activator	
2061; DR 3200; PLASMINER			
tissue plasminogen activator	unspecified	biotechnology;	thrombosis
activator		thrombolytic;	
		plasminogen activator	
tissue plasminogen	unspecified	biotechnology;	thrombosis
activator, K2tuPA;		thrombolytic;	}
tPA, K2tuPA		plasminogen activator	
tissue plasminogen			thrombosis
activator,		thrombolytic;	
unglycosylated; rtPA; BM 06021		plasminogen activator	
tPA analogue	unspecified		thrombosis;
			myocardial infarction
-141		plasminogen activator	
alteplase; tissue			thrombosis; skin
plasminogen			ulcer, stroke
activator; tPA;		plasminogen	
ACTIVASE;		activator; cicatrizant	
ACTILYSE;			e e
ACTIVACIN;			
GRTPA			
draculin		blood clotting factor	thrombosis
		IXa inhibitor; blood	
		clotting factor Xa	J
		inhibitor; proteinase	
TD (001		inhibitor	
VM 201			thrombosis; stroke
	ŀ	IXa inhibitor;	
		proteinase inhibitor	
factor VIIa inhibitor	unspecified	blood clotting factor	thrombosis
		VIIa inhibitor;	
		proteinase inhibitor	

<u></u>			
factor VIIa inhibitor,	unspecified	blood clotting factor	thrombosis
injectable;		VIIa inhibitor;	
CORSEVIN AS		proteinase inhibitor	
factor VIIa inhibitor,	unspecified	blood clotting factor	thrombosis
oral, Corvas;		VIIa inhibitor;	
CORSEVIN AS		proteinase inhibitor	
factor VIIa inhibitors	unspecified	blood clotting factor	thrombosis
		VIIa inhibitor;	
		proteinase inhibitor	
factor VIIa inhibitors	unspecified	blood clotting factor	thrombosis
		VIIa inhibitor;	
		proteinase inhibitor	
antithrombotic agents	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
	İ	proteinase inhibitor	
DPC 423	unspecified	blood clotting factor	thrombosis
	i -	Xa inhibitor;	
		proteinase inhibitor	·
DX 9065a	[S-(R*,R*)]-7-	blood clotting factor	thrombosis
	(aminoiminomethyl)-	Xa inhibitor:	
	alpha-[4-[[1-(1-	proteinase inhibitor	
	iminomethyl)-3-		
	pyrrolidinyl]oxy]phen		
	yl]-2-		
	naphthalenepropanoic		
	acid		
1	monohydrochloride,		
	pentahydrate		
factor Xa inhibitor	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
		proteinase inhibitor	
factor Xa inhibitor	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	·
		proteinase inhibitor	
factor Xa inhibitor	unspecified	blood clotting factor	thrombosis; stroke;
		Xa inhibitor;	myocardial infarction
		proteinase inhibitor	
	unspecified	blood clotting factor	thrombosis
injectable;		Xa inhibitor;	
CORDECIN AS		proteinase inhibitor	
			thrombosis
CORDECIN AS		Xa inhibitor;	
		proteinase inhibitor	

factor Xa inhibitors	unspecified	blood clotting factor	thrombosis
	1	Xa inhibitor;	in olifoosis
		proteinase inhibitor	
factor Xa inhibitors	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
		proteinase inhibitor	
factor Xa inhibitors	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
		proteinase inhibitor	
factor Xa/thrombin	unspecified	blood clotting factor	thrombosis
inhibitors		Xa inhibitor;	
		proteinase inhibitor	
JTV 803	unspecified	blood clotting factor	stroke; myocardial
		Xa inhibitor;	infarction; thrombosis
7675 A 1411		proteinase inhibitor	
KFA 1411	unspecified	blood clotting factor	thrombosis
·		Xa inhibitor;	
CII 644. CII 620	·~ .	proteinase inhibitor	
SH 544; SH 630	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
YM 60828	[[[7-	proteinase inhibitor	
11141 00020	(aminoiminomethyl)-	blood clotting factor	thrombosis
	7-	proteinase inhibitor	
	naphthalenyl]methyl][P	
	4-[[1-(1-iminoethyl)-		
	4-		
	piperidinyl]oxy]pheny		
	l]amino]sulfonyl]aceti		
	c acid		
	dihydrochloride		
ZD 4927	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
		proteinase inhibitor	
SR 34006	unspecified	blood clotting factor	thrombosis
		Xa inhibitor;	
		proteinase inhibitor;	,
		oligosaccharide	

Tr. 4 000	T. () 2 () 1	T : :	T
TA 993		calcium antagonist;	thrombosis
	5-[2-	platelet antiaggregant	
	(dimethylamino)ethyl		1
]-2,3-dihydro-8-	1	
	methyl-2-(4-		
	methylphenyl)-1,5-		
	benzothiazepin-		
	4(5H)-one		
meoxan	unspecified	calcium channel	hypertension;
		blocker; alpha	thrombosis; eye
		adrenergic antagonist;	
		alpha1 adrenergic	
	}	antagonist; platelet	
		antiaggregant	
veroxan; VUFB	unspecified		hypertension;
18814			thrombosis; eye
}		adrenergic antagonist;	
		alphal adrenergic	
		antagonist; platelet	
		antiaggregant	
clinprost;	[3aS		thrombosis; skin
lipoisocarbacyclin;	[3aalpha,5beta,6alpha	· '	ulcer; peripheral
isocarbacyclin methyl		-	vascular disease
ester; TEI 9090	1,3a,4,5,6,6a-	35 5	
	hexahydro-5-		
	hydroxy-6-(3-		
	hydroxy-1-octenyl)-2-		
	pentalenepentanoic		
	acid methyl ester	·	
MRX 408	unspecified	contrast medium;	diagnosis; thrombosis
,	-	echo contrast	,
		medium;	
		thrombolytic	
FR 122047	1-[(4,5-bis(4-		thrombosis
		platelet antiaggregant	-
	thiazoyl)carbnonyl]-		
1	4-methylpiperazine		
	hydrochloride		
		COX inhibitor;	thrombosis
-	•	platelet antiaggregant	
	(trifluoromethyl)thiaz	1	İ
	ole		
	<u> </u>		I

KC 764	(2-	COX inhibitor;	thrombosis
	methylpyrazolo[1,5-	platelet antiaggregant	
	a]pyridin-3-	practice annaggiegant	
	yl)(1,4,5,6-tetrahydro		
	3-		ł
	pyridinyl)methanone		
trifenagrel; BW 325U	2-[2-(4,5-diphenyl-	COX inhibitor;	inflammation;
	1H-imidazole-2-	platelet antiaggregant;	
	yl)phenoxy]-N,N-	NSAID	
	dimethylethanamine		
ST 681	N-(2-fluorophenyl)-	COX inhibitor;	thrombosis
	4,5-dihydro-1H-	thromboxane	
	imidazol-2-amine	synthetase inhibitor;	
	mononitrate	platelet antiaggregant	
pamicogrel; KBT	2-[4,5-bis(4-		thrombosis;
3022; KB 3022; TO	methoxyphenyl)-2-	1 '	peripheral vascular
192	thiazolyl]-1H-pyrrole-	antiaggregant	disease
	1-acetic acid ethyl		
	ester		
Ro 462005		endothelin A	thrombosis
***	hydroxy-ethoxy)-5-	antagonist; endothelin	
		B antagonist;	
	phenoxy)-4-	endothelin antagonist;	
	pyrimidinyl]-	platelet antiaggregant	
	benzenesulphonamide		
	unspecified	endothelin antagonist;	thrombosis
610612		platelet antiaggregant	
PD 145065		endothelin antagonist;	thrombosis
	(10,11-dihydro-5H-	platelet antiaggregant	
	dibenzo[a,d]cyclohept		
	en-5-yl)glycyl-L-		
4.	leucyl-L-alpha-		
	aspartyl-L-isoleucyl-		-
	L-isoleucyl-L-		
	tryptophan disodium		
	salt		
		fibrinogen antagonist; t	hrombosis
KLERVAL		glycoprotein IIb/IIIa	
		antagonist; platelet	
		antiaggregant	·

GR 144053	4-[4-[4-	fibrinogen antagonist	thrombosis
		platelet antiaggregan	, 41011100313
	henyl]-1-piperazinyl]		[]
	1-piperidineacetic		
	acid		
	monohydrochloride	·	
GR 233548	Unspecified	fibrinogen antagonist	thrombosis
		platelet antiaggregant	
UR 12947	unspecified	fibrinogen antagonist	
		platelet antiaggregant	
GR 83895	N-[(6S-amino-5-oxo-	fibrinogen antagonist	thrombosis
	8aR-hexahydro-5H-	platelet antiaggregant	
İ	thiazolo[3,2-	peptide	
	a]pyridin-3R-yl)-		
1	carbonyl]-L-arginyl-	ĺ	
	L-glycyl-L-aspartyl-		
	L-phenylalanine,		
	cyclic(4>1)-		·
	peptide,		
	monotrifluoroacetate		
bitistatin .	unspecified	fibrinogen antagonist;	thrombosis
,		venom; platelet	
		antiaggregant	
fibrolase	Agkistrodon	fibrinolytic;	thrombosis
	concortrix venom	thrombolytic; venom	
	metalloproteinase		
M4	unspecified	fibrinolytic;	thrombosis
		thrombolytic; venom	
glycoprotein IIb/IIIa	unspecified	glycoprotein IIb/IIIa	thrombosis; heart
antagonist; P246		antagonist; peptide;	ischemia; stroke
		platelet antiaggregant	ŕ
C 6822	unspecified	glycoprotein IIb/IIIa	thrombosis
		antagonist; platelet	
		antiaggregant	
CGH 400			thrombosis
•		antagonist; platelet	
	,	antiaggregant	
cromafiban			thrombosis; stroke
		antagonist; platelet	
		antiaggregant	

DMP 728	N-[3- (aminomethyl)benzoy l]-D-2- aminobutanoyl-N2- methyl-L- arginylglycyl-L- aspartic acid cyclic (41->1)-peptide monomethanesulfona	antiaggregant	thrombosis
DMP 802	3-[[[(5R)-3-[4- (aminoiminomethyl)p henyl]-4,5-dihydro-5- isoxazolyl]acetyl]ami no]-N-[(3,5-dimethyl- 4- isoxazolyl)sulfonyl]- L-alanine	antiaggregant	thrombosis
EMD 122347; YM 028	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
glycoprotein IIb/Ша antagonist	unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
glycoprotein IIb/IIIa inhibitors	,	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis
	(S)-[[1-[2-[[4- (aminoiminomethyl)b enzoyl]amino]-3-(4- hydroxyphenyl)-1- oxopropyl]-4- piperidinyl]oxy]acetic acid	glycoprotein IIb/IIIa	thrombosis
	bipiperidin]-1-	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis

ME 3277	0 21 114 1114 5 6 7	-1 t TRI GY	
IVIE 3277	2,2'-[[4-[[[4,5,6,7-	glycoprotein IIb/IIIa	thrombosis
	tetrahydrothieno[3,2-	, · · ·	
	c]pyridin-2-	antiaggregant	
	yl)carbonyl]amino]ac		
	etyl]-1,2-		
	phenylene]bis(oxy)]b	i	
	sacetic acid		
MK 852; L 367073	N-acetyl-L-cysteinyl-	glycoprotein IIb/IIIa	stroke; thrombosis
	L-asparaginyl-(4R)-	antagonist; platelet	
1	5,5-dimethyl-4-	antiaggregant	
	thiazolidinecarbonyl-		
	4-(aminomethyl)-L-		
1	phenylalanylglycyl-L-		
İ	alpha-aspartyl-L-		
	cysteine, cyclic (1-7)-		
	disulfide		
Ro 435054	N-[N-[N-[4-	glycoprotein IIb/IIIa	thrombosis
	(aminoiminomethyl)b		
	enzoyl]-beta-alanyl]-		
<u>'</u>	L-alfa-aspartyl]-L-	38 -8	
,	phenylalanine		
	mono(trifluoroacetate		
Ro 438857; Ro 43-	2,2'-[[4-[[[4-	glycoprotein IIb/IIIa	thrombosis
8857	(aminoiminomethyl)b	antagonist: platelet	
	enzoyl]methylamino]	antiaggregant	
	acetyl]-1,2-	88. 48	
	phenylene]bis(oxy)]bi		
	sacetic acid		
roxifiban; DMP 754		glycoprotein IIb/IIIa	thrombosis
,	(aminoiminomethyl)p		anomoosis
	henyl]-4,5-dihydro-5-		
	isoxazolyl]acetyl]ami	and a general control	
	nol-N-		
	(butoxycarbonyl)-L-		
	alanine methyl ester		
	monoacetate		
RPR 110173		alvanratain IIb/III-	· · · · · · · · · · · · · · · · · · ·
IC ICIIVI/J	1 -		thrombosis
		antagonist; platelet	
	<u> </u>	antiaggregant	

			_
SB 208651	(+,-)-8-[[[4-	glycoprotein IIb/IIIa	thrombosis
	(aminoiminomethyl)p	antagonist; platelet	
	henyl]methylamino]c	antiaggregant	
	arbonyl]-2,3,4,5-		
	tetrahydro-3-oxo-4-		
	(2-phenylethyl)-1H-		
	1,4-benzodiazepine-		
	2-acetic acid		
SC 47643	(S)-3-[[8-	glycoprotein IIb/IIIa	thrombosis
	[(aminoiminomethyl)		an omoobis
	amino]-1-	antiaggregant	
	oxooctyl]amino]-4-		
	[[2-(4-		
	methoxyphenyl)ethyl]		
	amino]-4-		
	oxobutanoic acid		
SC 49992	8-guanadino-	glycoprotein IIb/IIIa	thrombosis
	octanoyl-Asp-Phe	antagonist; platelet	difonioosis
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	antiaggregant	
SC 52012A	N-[N-[5-[4-	glycoprotein IIb/IIIa	thrombosis
	(aminoiminomethyl)p		
		antiaggregant	.
	L-alpha-aspartyl]-L-		
	phenylalanine		
SC 54701	(S)-3-[[4-[[4-	glycoprotein IIb/IIIa	thrombosis
	(aminoiminomethyl)p		
		antiaggregant	1
	dioxobutyl]amino]-4-		·
	pentynoic acid		
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa	thrombosis; stroke
	_	antagonist; platelet	,
		antiaggregant	
sibrafiban; Ro			thrombosis
483657; RO	[amino(hydroxyimino	antagonist; platelet	
483657001; XUBIX;	methyl]benzoyl]amin	antiaggregant	
ZUBIX	o]-1-oxopropyl]-4-	35 5	
	piperidinyl]oxy]acetic	·	
	acid ethyl ester		

SR 121787	A TTA CA	alaman A ' YE GYY	T
SK 121707	4-[[4-[4-	glycoprotein IIb/IIIa	thrombosis
	[[(ethoxycarbonyl)an	nantagonist; platelet	
	ino]iminomethyl]phe	antiaggregant	
	nyl]-2-thiazolyl] (3-		İ
	ethoxy-3-		}
	oxopropyl)amino]-1-	li .	
	piperidineacetic acid,		
	ethyl ester		
T 250	(-)-4-[3-(4-	glycoprotein IIb/IIIa	thrombosis
	(aminoiminomethyl)p	antagonist; platelet	
	henoxy]propyl]-2,3-	antiaggregant	1
	dioxo-beta-3-py		
	ridinyl-1-		
	piperazinepropanoic		
	acid		
TAK 029	4-[[[4-	glycoprotein IIb/IIIa	thrombosis
	(aminoiminomethyl)b	antagonist: platelet	
	enzoyl]amino]acetyl]-		
	2-oxo-1,3-		
	piperazinnediacetic		
	acid alpha3-methyl		·
	ester		
tirofiban; tirofiban	N-(butylsulfonyl)-O-	glycoprotein IIb/IIIa	thrombosis; angina
hydrochloride; MK	[4-(4-	antagonist; platelet	and moosis, angma
383; L 700462;	piperidinyl)butyl]-L-	antiaggregant	
AGGRASTAT	tyrosine	86.48	
TRM 147	unspecified	glycoprotein IIb/IIIa	thrombosis
	•	antagonist; platelet	
		antiaggregant	
xemilofiban; SC	ethyl 3-[[4-[[4-	glycoprotein IIb/IIIa	thrombosis
54684A; SC 54684;	(aminoiminomethyl)p		
CS 551		antiaggregant	
	dioxobutyl]amino]-4-	and a grant	
	pentynoate		
contortrostatin; CN		glycoprotein IIb/IIIa	cancer; thrombosis
	· •	antagonist; platelet	cancer, unumbusis
		antiagonist, platelet antiaggregant;	
		biotechnology	
	<u> </u>	ororecimology	

eptifibatide;	N6-	alvoquestain III-/III	
INTEGRILIN;	(aminoiminomethyl)-	glycoprotein IIb/IIIa	thrombosis; angina;
INTEGRELIN	N2-(3-mercapto-1-	71	myocardial infarction
INTEGREEN	oxopropyl)-L-	antiaggregant; peptide	restenosis
	lysylglycyl-L-alpha-		
	aspartyl-L-tryptophyl	-	
	L-prolyl-L-		
	cysteinamide cyclic		
C 4120	(1->6)-disulfide		
G 4120	N-(mercaptoacetyl)-	glycoprotein IIb/IIIa	thrombosis
	D-tyrosyl-L-	antagonist; platelet	
	arginylglycyl-L-	antiaggregant; peptide	
	alpha-aspartyl-L-		
	cysteine cyclic (1-5)-		
	sulfide S-oxide		
kistrin	kistrin (Agkistrodon	glycoprotein IIb/IIIa	thrombosis
	rhodostoma reduced)	antagonist; platelet	
		antiaggregant; venom	÷ ,
aprosulate sodium;	N,N'-1,3-	Heaprin cofactor;	thrombosis
LW 10082	propanediylbis[4-O-	serine proteases	
turisti i ti	(2,3,4,6-tetra-O-sulfo-		
	beta-D-		
į	galactopyranosyl)-D-		
	gluconamide],		
	2,2',3,3',5,5',6,6'-	•	
	octakis(hydrogen		
·	sulfate)		•
	hexadecasodium salt		
dermatan sulfate;	dermatan, hydrogen	heparin cofactor II	thrombosis
chondroitin sulfate B;	sulfate (ester)	activator	
chondroitinsulfuric			
acid B; MF 701; DS			
435			
alpha idosone	unspecified	heparinoid	thrombosis
ardeparin sodium;	unspecified	heparinoid	thrombosis
WY 90493;		=	
NORMIFLO			
bemiparin sodium;	unspecified	heparinoid	hrombosis
HIBOR	•		
BF 611	unspecified	heparinoid	hrombosis
C4 CY 216			hrombosis
certoparin sodium;			hrombosis
ALPHAPARIN	•	•	

1. 1. 1.	<u>, </u>		
dalteparin sodium;	heparin, sodium salt	heparinoid	thrombosis; coronary
low molecular weight		Ì	artery disease; angina
heparin; heparin, low		·	
molecular weight;			
tedelparin;			
tedelparine; KABI			
2165; K 2165; FR		1	
860; FRAGMIN;			
FRAGMINE;			
BOXOL			
1 -	unspecified	heparinoid	thrombosis;
danaparoid;			thrombocytopenia
glycosamino glycan;			
ORG 10172; KB 101;			
ORGARAN;			
LOMOPARAN;			
RESTART			
drug delivery system,	unspecified	heparinoid	thrombosis
BEODAS heparin;	j		
heparin BEODAS			
drug delivery system,	unspecified	heparinoid	thrombosis
LDS microemulsion			
low molecular weight			
heparin; heparin, low			
molecular weight,			·
LDS microemulsion			
drug delivery system,	unspecified	heparinoid	thrombosis
nanosphere oral			
heparin; heparin oral;			
HEPORAL			
drug delivery system,	unspecified	heparinoid	thrombosis
oral low molecular			
weight heparin;			
heparin delivery	•		
system	· · · · · · · · · · · · · · · · · · ·		
drug delivery system,	unspecified	heparinoid	thrombosis
submicron emulsion	,	-	
low molecular weight			
heparin; low			
molecular weight			
heparin SME			

drug delivery system, transmucosal low	unspecified	heparinoid	thrombosis
molecular weight			
heparin; heparin, low			
molecular weight,			
transmucosal		İ	
enoxaparin sodium;	heparin sodium salt	heparinoid	thrombosis; angina;
low molecular weight		inoparmora.	stroke; myocardial
heparin; enoxaparin;		•	infarction
enoxaparine; PK			maichon
10169; RPY 005; RP		·	
54563; LOVENOX;			
CLEXAN;			
CLEXANE			
GM 2000	unspecified	heparinoid	thrombosis; restenosis
heparin sulfate	unspecified	heparinoid	thrombosis
analogue; HHS 5	1 1		inomoosis
ITF 1331	heparin compound	heparinoid	thrombosis
	with bis[4-	1	
	(dibutylamino)butyl]		
	carbonate	the most as a second	
ML 009723; CIRICIN	unspecified	heparinoid	thrombosis
	unspecified	heparinoid	thrombosis
low molecular weight		1	
heparin; heparin, low			
molecular weight; CY			
216; FRAXIPARIN;			
FRAXIPARINE;	,		
FRAXIPARINA;			• •
SELEPARIN		<u></u>	
naroparcil; LF 90055	p-(p-((5-thio-beta-D-	heparinoid	thrombosis
	xylopyranosyl)thio)be		
	nzoyl)benzonitrile		
Language 11 11 1			
	heparin	heparinoid	thrombosis
parnaparin; low	heparin	heparinoid	thrombosis
parnaparin; low molecular weight	heparin	heparinoid	thrombosis
parnaparin; low molecular weight heparin; heparin, low	heparin	heparinoid	thrombosis
parnaparin; low molecular weight heparin; heparin, low molecular weight;	heparin	heparinoid	thrombosis
parnaparin; low molecular weight heparin; heparin, low molecular weight; LHG 500; FLUXUM;	heparin	heparinoid	thrombosis
pamaparin sodium; parnaparin; low molecular weight heparin; heparin, low molecular weight; LHG 500; FLUXUM; MINIDALTON; LOHEPA	h epari n	heparinoid	thrombosis

F	T		
reviparin sodium;	unspecified	heparinoid	thrombosis
reviparin; low			
molecular weight			
heparin; heparin, low			
molecular weight; LU	J.		
47311; CLIVARIN			
S 5	unspecified	heparinoid	thrombosis
supersulfated low	unspecified	heparinoid	thrombosis;
molecular weight			hyperlipidemia
heparin; ssLMWH			
tinzaparin sodium;	unspecified	heparinoid	thrombosis
tinzaparin; low			
molecular weight			
heparin; heparin, low			
molecular weight;			
LHN 1; LOGIPARIN	,	İ	
INNOHEP			
ultra low molecular	unspecified	heparinoid	thrombosis
weight heparin;	•		11101100313
heparin, ultra low			
molecular weight; CY			
222			
ZYN-LINKER	unspecified	heparinoid	restenosis; thrombosis
conjugated heparin	•	1	
fondaparin sodium;	methyl O-2-deoxy-6-	heparinoid: blood	thrombosis;
		clotting factor Xa	peripheral vascular
31540; SR 90107A	(sulfoamino)-alfa-D-		disease
	glucopyranosyl-(1-4)-		
		oligosaccharide	
	glucopyranuronosyl-	8	
	(1-4)-O-2-deoxy-3,6-		
	di-O-sulfo-2-		
1	(sulfoamino)-alfa-D-		
r e	glucopyranosyl-(1-4)-		
	O-2-O-sulfo-alfa-L-		
	idopyranuronosyl-(1-		
	4)-2-deoxy-2-		
	(sulfoamino)-alfa-D-		
1	glucopyranoside 6-		
1	(hydrogen sulfate)		
L	(iryurogen surrate)		

Ca=O== 22701 - CD	L-4-1001	h :	
SanOrg 32701; SR 32701	methyl O-2-deoxy-6-		thrombosis
B2701	O-sulfo-2-	clotting factor Xa	
	(sulfoamino)-alpha-	inhibitor; proteinase	
	D-glucopyranosyl-(1-	1	
	4)-O-beta-D-	oligosaccharide	
	glucopyranuronosyl-		
	(1-4)-O-2-deoxy-3,6-		·
	di-O-sulfo-2-		
	(sulfoamino)-alpha-		
	D-glucopyranosyl-(1-		
1	4)-O-2-O-sulfo-alpha		
	L-idopyranuronosyl-		
	(1-4)-2-deoxy-2-		
	(sulfoamino)-alpha-		
	D-glucopyranoside		
	3,6-bis(hydrogen		[
	sulfate)		
	undecasodium salt		·
ITF 1300	Unspecified	heparinoid; class III	thrombosis;
		antiarrhythmic	arrhythmia
GM 1077;	unspecified	heparinoid; platelet	thrombosis; restenosis
ASTENOSE		antiaggregant	
MDL 28050	N-[N-[N-[N-[1-	hirudin analogue	thrombosis
	[N-[1-[N-[N-(3-	_	
	carboxy-1-		.
	oxopropyl)-L-		
	tyrosyl]-L-alfa-		
	glutamyl]-L-prolyl]-		
	L-isoleucyl]-L-		
	prolyl]-L-alfa-		
	glutamyl]-L-alfs-		
	glutamyl]-L-alanyl]-		
	3-D-glutamic acid		
hirudin peptide	unspecified	hirudin analogue;	thrombosis
analogue; P 79		peptide; thrombin	
	1	inhibitor; proteinase	
		inhibitor	
antibody-mediated	· · · · · · · · · · · · · · · · · · ·		gynecological; stroke;
stroke inhibitor		biotechnology	thrombosis;
			myocardial infarction
drug delivery system,	unspecified	integrin antagonist;	thrombosis
ANCHOR platelet	1 ^	cell adhesion inhibitor	
inhibitor		con auticoton miniotol	
	l		

PKSI 527	[1(S)-trans]-4-[[2-	kallikrein inhibitor;	contin sha-l-
1	[[[4-	NSAID	septic shock;
	(aminomethyl)cycloh	ł .	inflammation;
	1	•	thrombosis
	exyl]carbonyl]amino]		
	-1-oxo-3-		
·	phenylpropyl]amino]		
	benzeneacetic acid		
	monohydrochloride		
linsidomine; SIN 1;	3-(4-	nitric oxide donor;	thrombosis
CORVASAL;		platelet antiaggregant	
CORVATON	imine		
NCX 4016	2-(acetyloxy)benzoic	NSAID; nitric oxide	thrombosis; pain
	acid, 2-	donor; platelet	1
	[(nitrooxy)methyl]pho		İ
	nylester	analgesic	
OP 2000	unspecified	oligosaccharide	inflammatory bowel
	•		disease; thrombosis
ORG 31550; SR	unspecified	oligosaccharide	thrombosis
80027		ongosaccilariac	un omioosis
SR 123781	unspecified	oligosaccharide	thrombosis
VASOFLUX	unspecified	oligosaccharide;	thrombosis;
		thrombin inhibitor;	myocardial infarction
		proteinase inhibitor	
lexipafant; BB 882;	N-methyl-N[[4-(2-	PAF antagonist	thrombosis; endotoxic
DO 6; GR 167089;	methyl-1H-	i Ai aitagonist	shock; pancreatitis;
ZACUTEX	imidazo[4,5-		eye disease; multiple
S. T. COTE A.	c]pyridin-1-		sclerosis
	yl)methyl]phenyl]sulf		Scierosis
	onyl]-L-leucine ethyl		
	ester	·	
LA 213		DAF	
LA 215	unspecified		hypertension;
,	1	r - · · ·	thrombosis
do a for to DD 49740		antiaggregant	
dacopafant; RP 48740			asthma; thrombosis
	1H,3H-pyrrolo[1,2-	platelet antiaggregant	
	c]thiazole-7-		
	carboxamide		
epiyangambin			thrombosis
		platelet antiaggregant	
	bis(3,4,5-		
	trimethoxyphenyl)-		
	1H,3H-furo[3,4-		
	c]furan		
F 1850		PAF antagonist;	thrombosis; asthma
	-	platelet antiaggregant	
		practice aircragglegailt	

ginkgolide B; BN	hexacyclic trilactone	PAF antagonist;	thrombosis;
52021		platelet antiaggregant	dermatitis; asthma:
·			multiple sclerosis;
			septic shock
KO 286011	N-[1-(9-ethoxy-6-	PAF antagonist;	thrombosis
	hydroxy-6-oxido-	platelet antiaggregant	
	5,7,11-trioxa-6-		
	phosphaheptacos-1-		
	yl)-4(1H)-		
	pyridinylidene]-N-		•
	methylmethanaminiu		
	m inner salt		
L 659989	trans-(+,-)-tetrahydro-	PAF antagonist	asthma; thrombosis
1	2-[3-methoxy-5-	platelet antiaggregant	distanta, tiliomoosis
	(methylsulfonyl)-4-	- BB. Gant	
	propoxyphenyl]-5-	·	
	(3,4,5-		
	trtimethoxyphenyl)fur		
	an		
minopafant; E 5880	(R)-1-ethyl-2-[[(2-	PAF antagonist;	thrombosis
	1	platelet antiaggregant	
·	methoxy-3-[[[4-	,	·
	[[(octadecylamino)car		
ĺ	bonyl]oxy]-1-		
	piperidinyl]carbonyl]		
,	oxy]propoxy]carbonyl		
	[amino]methyl]pyridi		
	nium chloride		
R 74654	3-(6-(0-(2R,2S)-(3-	PAF antagonist;	asthma; thrombosis
	heptadecylcarbamoyl		and the first the state of the
·	oxytetrahydropyran-		
	2-yl)met		
	hyl)phosphonoxy)hex	,	
	ylthiazolium		1
R 74717		PAF antagonist;	asthma; thrombosis
	heptadecylcarbamoylt	platelet antiaggregant	,
	hiotetrahydropyran-2-	,	
	yl)me		
	thyl)phosphonoxy)pe		
•	ntylthiazolium		
	r, 10110220110111		

Ro 244736; Ro 24-	5-[3-[4-(2-	PAF antagonist;	thrombosis; asthma;
4736	chlorophenyl)-9-	platelet antiaggregant	sentic shock
	methyl-6H-	platolet antiaggicgant	Septic Shock
	thieno[3,2-]
	f][1,2,4]triazolo [4,3-		
	a][1,4]diazepin-2-yl]-		
	2-propynyl]-6(5H)-		
	phenanthridinone		
SDZ 64412; SDZ 64-	*	PAF antagonist;	asthma; thrombosis
412	(3,4,5-	platelet antiaggregant	assuma, unomoosis
	trimethoxyphenyl)eth		
	yl]phenyl]imidazo[2,1		
	-a]isoquinoline		
	monohydrochloride		
SM 12502	(2R-cis)-3,5-	PAF antagonist;	thrombosis
	dimethyl-2-(3-	platelet antiaggregant	
	pyridinyl)-4-		
	thiazolidinone,		
·	monohydrochloride		
SR 27388	4-[2-[[2-	PAF antagonist;	thrombosis; asthma;
		platelet antiaggregant	
](3-		•
	pyridinylmethyl)amin		
	o]-4-thiazolyl]-2,6-		
,	bis(1,1-		
	dimethylethyl)phenol		
UK 74505		PAF antagonist;	thrombosis; asthma
•	1,4-dihydro-6-methyl-	platelet antiaggregant	
•	2-[4-(2-methyl-1H-		
	imidazo[4,5-		
	c]pyridin-1-		
	yl)phenyl]-5-[(2-		
	pyridinylamino)carbo		
	nyl]-3-		
	pyridinecarboxylic		
	acid ethyl ester		
		PAF antagonist;	asthma; anaphylactic
	8,9-dihydro-1-methyl-	platelet antiaggregant	shock; thrombosis
	N,N-dipropyl-4H,7H-		1
	cyclopenta[4,5]thieno		
	[3,2-		į
	f][1,2,4]triazolo[4,3-		
	a][1,4]diazepine-8-		
	carboxamide		

YM 264	1-(3-methyl-3-	PAF antagonist;	thrombosis; asthma
		-platelet antiaggregant	amonioosis, astiinia
Ì	pyridinyl)-4-	practice anniaggiogani	
	thiazolidinyl]carbony	1	
·	piperazine (E)-2-		
	butenedioate (1:1)		
SDZ 64619	(+,-)-2-[6-methoxy-2-	PAE antagonist:	thmo
		platelet antiaggregant	thrombosis; asthma
	dioxo-4,8-dioxa-2,10		
	diazaoctacosan-1-yl)-		
	1-methylpyridinium		
	iodide		İ
CV 6209	2-(2-acetyl-6-	PAF antagonist;	through a size
0, 020	methoxy-3,9-dioxo-	platelet antiaggregant;	thrombosis;
	4,8-dioxa-2,10-	NSAID	umation
	diazaoctacos-1-yl)-1-	INDAID	
	ethylpyridinium		
	chloride		
UR 11353	2-	PAF antagonist;	thrombosis;
	[[acetyl[[[tetrahydro-	platelet antiaggregant;	
	5-(octadecyloxy)-3-	NSAID	initalinialion ·
	furanyl]methoxy]carb	,	
	onyl]amino]methyl]-		
	l-ethylpyridinium		,
	chloride		
XR 334 series; XR	(Z,Z)-3-[(4-	PAI inhibitor;	thrombosis; angina
334	Methoxyphenyl)meth		,
	ylene]-6-		
	(phenylmethylene)-		
	2,5-pipe razinedione		
XR 5118	(Z,Z)-3-[[5-[[2-	PAI inhibitor;	thrombosis
	(dimethylamino)ethyl		
]thio]-2-		
•	thienyl]methylene]-6-		•
•	(phenylmethylene)-		
	2,5-piperazinedione		
	monohydrochloride		
anticoagulant, Erfurt	D-phenylalanyl-L-	peptide	thrombosis
Medical Academy	prolyl-L-arginine	- -	
	nitrile		
entithrombotic	unspecified	peptide t	hrombosis

C1 . 1 1	· · · ·	1 :.	
fibrolase and	unspecified	peptide	thrombosis
thrombus targeting			İ
peptides; fibrolase			
and P734			
LU 58463	unspecified	peptide	thrombosis
AS 101;	unspecified	peptide; contrast	diagnosis; thrombosis
METASCAN	,	medium;	
		radiodiagnostic	
GPIIb/IIIa peptide	unspecified	peptide; platelet	thrombosis
antagonist		antiaggregant	
MOL 144	unspecified	peptide; thrombin	thrombosis
	•	inhibitor; proteinase	
		inhibitor	
MOL 171	unspecified	peptide; thrombin	thrombosis
		inhibitor; proteinase	III OIIIOOSIS
		inhibitor	[
triflusal; UR 1501;	unspecified	phosphodiesterase	thrombosis
DISGREN;		inhibitor; COX	UII OHIOOSIS
TECNOSAL;		inhibitor; platelet	
TRIFLUX; AFLEN		antiaggregant	
NM 702	4-bromo-6-[3-(4-	phosphodiesterase	thrombosis
	chlorophenyl)propoxy	inhihitor	unomoosis
]-5-[(3-	phosphodiesterase III	
ļ	pyridinylmethyl)amin		
	o]-3(2H)-	phosphodiesterase V	
	pyridazinone	inhibitor;	
	monohydrochloride	thromboxane	,
	mononydrocmonde		
		synthetase inhibitor;	
cilostazol; OPC	6-[4-(1-cyclohexyl-	platelet antiaggregant	411
13013; PLETAL;	1 - '	phosphodiesterase	thrombosis
PLETAAL	j	inhibitor;	
LLIAAL	yl)butoxy]-3,4-	phosphodiesterase III	
,		inhibitor; platelet	
	quinolinone	antiaggregant;	
DE 205 CE 205		vasodilator	
BF 385; GP 385;			hypertension;
BF/GP 385; ONO			thrombosis
BF11301; ONO 1505		phosphodiesterase V	
		inhibitor;	
		thromboxane	
	1	synthetase inhibitor;	
		platelet antiaggregant	

AY 31390	5-bromo-6-[[(5-	mhoomhadiant	1,2 , .
KT 31350	bromo-3-	phosphodiesterase	thrombosis
	pyridinyl)methyl]ami	inhibitor; platelet	1
		antiaggregant	
	no]-2-methyl-4(1H)-		
	pyrimidinone		
D) (V 01100	monohydrobromide	<u> </u>	
BMY 21190	7-[4-	phosphodiesterase	thrombosis
	(cyclohexylamino)bu		
ļ	oxy]-1,3-dihydro-2H-	antiaggregant	
•	imidazo[4,5-	}	
	b]quinolin-2-one		·
BMY 21638	1,3-dihydro-7-[4-	phosphodiesterase	thrombosis
	(phenylsulfonyl)butor	dinhibitor; platelet	
	y]-2H-imidazo[4,5-	antiaggregant	
	b]quinolin-2-one		
BMY 43351	7-(4-(4-	phosphodiesterase	thrombosis; angina
	(cyclohexylmethyl)-1		,
	piperazinyl)-4-	antiaggregant	
	oxobutoxy)-1,3-	1 55 5	
	dihydro-2H-		
	imidazo(4,5-		
	b)quinolin-2-one		i
R 69082	unspecified	phosphodiesterase	thrombosis
		inhibitor; platelet	
		antiaggregant	·
SKF 95654	4,5-dihydro-6-(4-(1,4-		thrombosis; heart
	dihydro-4-oxopyridin-		failure
	1-yl)phenyl)-5-	antiaggregant	
	methyl- 3(2H)-	308	
	pyridazinone		
pimobendan; UDCG	<u> </u>	phosphodiesterase	thrombosis; heart
115; UDCG 115A;	1	inhibitor; platelet	failure
UDCG 115BS;		antiaggregant;	imiuic
ACARDI	methyl-3-(2H)-	vasodilator	
	pyridazinone	Vasodifator	
simendan	f ·	phosphodiesterase	heart failure;
		I	thrombosis
		antiaggregant;	шш ОППОО\$1\$
	pyridazinyl)phenyl]hy		
	drazono]propanedinitr		
	ile		
	ите	<u> </u>	

levosimendan; OR	[[4-(1,4,5,6-	phosphodiesterase	heart failure;
1259; SIMDAX	tetrahydro-4-methyl-	inhibitor: platelet	thrombosis
i zos, om i zor	6-oxo-3-	antiaggregant;	unombosis
	pyridazinyl)phenyl]hy		
	drazono]propanedinit		
	ile		
U 73122	1-[6-[[(17 beta)-3-		
0 73122	1	phospholipase	inflammation;
	methoxyestra-	inhibitor; platelet	thrombosis
	1,3,5(10)-trien-17-	antiaggregant;	
tonostonlass, TNI/	yl]amino]hexyl]	NSAID	
tenecteplase; TNK-	plasminogen activator		thrombosis;
tPA; TNK	(human tissue type),		myocardial infarction
	103-L-asn-117-L-gln-		
	296-L-ala-297-L-ala-	thrombolytic	
	298-L-ala-299-L-ala-		
fu-PA	unspecified	plasminogen	thrombosis
		activator;	
		thrombolytic	
anagrelide; anagrelide	1 *	platelet antiaggregant	thrombosis; cancer
hydrochloride; BL	dihydroimidazo[2,1-		
4162A; AGRYLIN;	b]quinazolin-2(3H)-		
AGRELIN	one	·	
antiaggregant,	4,5-bis(4-	platelet antiaggregant	thrombosis
Kanebo	methoxyphenyl)-2-		
	(1,5-dimethyl-2-		
the field was the of	pyrrolyl)thiazole		
anticoagulant	hexadecasodium	platelet antiaggregant	thrombosis
2,50	N,N'-		
.: .	dimethylethylenebis(4		
	-O-beta-D-		
	galactopyranosyl-D-		
	gluconoylamino		
	octasulfate)		
anticoagulant		platelet antiaggregant	thrombosis
_	trimethylenebis (4-O-	L268	and Brooks
	beta-		
	galactopyranosyl-D-		•
PI CONTRACTOR OF THE CONTRACTO	gluconoylamino		
	octasulfate)		
		platelet antiaggregant	thrombosis
67085; FPL 67085XX		higieiei amiaggiegant	THOUTOOSIS
	monoanhydride with		
	(dichloromethylene)bi		
<u> </u>	s[phosphonic acid]		

			
aspalatone;		platelet antiaggregant	thrombosis
asparatone; BK 111	acid 2-methyl-4-oxo-		
	4H-pyran-3-yl ester		
BIBU 251	unspecified	platelet antiaggregant	
BIS-TMPP	2,2'-(1-propene-1,3-	platelet antiaggregant	thrombosis
	diyl)bis[3,5,6-		
	trimethylpyrazine]		
BMY 21259	methyl-4-((2,3-	platelet antiaggregant	thrombosis
	dihydro-2-oxo-1H-		
	imidazo(4,5-		
	b)quinolin-7-yl)-oxy)		
	butanoate		
BMY 21260	4-[(2,3-dihydro-2-	platelet antiaggregant	thrombosis
	oxo-1H-imidazo[4,5-		
	b]quinolin-7-		
	yl)oxy]butyric acid		
BP 16	potassium 6-chloro-	platelet antiaggregant	thrombosis
	alpha-		المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة المارة
	cyanopyrazineacetic		
	acid ethyl ester ion(1-		
. ga waga™ara ayaan	•)		***
C 894095	5-amino-3-(3,3-	platelet antiaggregant	thrombosis
	dimethyl-1,1-dioxido-		
	4-thiomorpholinyl)-		
,	1,2,3-oxadiazolium		
	chloride		
CK 53	2-[[4-(2-	platelet antiaggregant	thrombosis
	chlorophenyl)-1-		
	piperazinyl]methyl]-		
	2,6-		
	dihydroimidazo[1,2-		
	c]quinazolin-5(3H)-	·	
	one		
clopidogrel;	(S)-alfa-(2-	platelet antiaggregant	thrombosis: stroke:
clopidogrel bisulfate;			ischemia
	dihydrothieno[3,2-	ļ	
25990C; DV 7314;	c]pyridine-5(4H)-		
	acetic acid methyl		
25990B; SR 25990A;	1		
SR 25990D; SR			
25990E; PLAVIX;			
ISCOVER			
	unspecified	platelet antiaggregant	hrombosis
		platelet antiaggregant	

dicranin	9,12,15- octadecatrien-6-ynoic	platelet antiaggregant	thrombosis
	acid		
drug delivery system,	unspecified	platelet antiaggregant	
argatroban;			myocardial infarction
argatroban drug			
delivery system			
drug delivery system,	unspecified	platelet antiaggregant	thrombosis
oral heparin; heparin,			
oral delivery system			
drug delivery system,	unspecified	platelet antiaggregant	thrombosis
oral low molecular		<u> </u>	
weight heparin; low			
molecular weight			
heparin oral			
echicetin	unspecified	platelet antiaggregant	
ethyl	ethyl all-cis-	platelet antiaggregant	
eicosapentaenoate;	5,8,11,14,17-		hyperlipidemia
ethyl icosapentate;	eicosapentaenoate		
EPA-E; MND 21;			
EPADEL			
fradafiban; BIBU 52	(3S,5S)-5-[(4'-	platelet antiaggregant	thrombosis
	amidino-4-		
	biphenylyl)oxymethyl		
]-2-oxo-3-		
2 600	pyrrolidineacetic acid		
G 619	4-methoxy-N3-(3-	platelet antiaggregant	thrombosis
	pyridinylmethyl)-1,3-		
	benzenedicarboxamid	!	
	e	,	
glaucocalyxin A		platelet antiaggregant	thrombosis
	dihydroxy-kaur-16-		
C2 6 1 1 1 5	ene-3,15-dione		
GM 1115	unspecified		thrombosis; restenosis
GM 1445		platelet antiaggregant	
GM 9005	unspecified	platelet antiaggregant	
GT 12		platelet antiaggregant	thrombosis
	(N,N-		
	diethylcarbamoyl)pip		į
	eridino]-p-xylene		
	dihydrobromide		
IBI P05006; IBI-P	2-amino-6-	platelet antiaggregant	thrombosis
05006	hexylcyclohexanehept		
	anoic acid		

indobufen; K 3920;	(+,-)-2-[p-(1-oxo-2-	platelet antiaggregant	thrombosis
IBUSTRIN	isoindolinyl)phenyl]b		LIII OII IDOSIS
	utyric acid		
KK 117	2-hydroxy-1,2,3,3-	platelet antiaggregant	thrombosis
	tetrahydro-3H-		in on oos
	pyrano(3,2-		
	f)quinoline-8(7H)-one		
L 367073; MK 0852		platelet antiaggregant	thrombosis
	L-asparaginyl-5,5-	000	
	dimethyl-L-4-		
	thiazolidinecarbonyl-		-
	4-(aminomethyl)-L-		
	phenylalanylglycyl-L-		
	alfa-aspartyl-L-		
	cysteine cyclic (1-7)-		
	disulfide		
L 703014	unspecified	platelet antiaggregant	thrombosis
LF 1351	4-[hydroxy(4-	platelet antiaggregant	
	mitrophenyl)methyl]p		
	henyl-beta-D-	j	
	xylopyranoside		<u> </u>
ME 3229	unspecified	platelet antiaggregant	thrombosis
mycololide B	unspecified	platelet antiaggregant	thrombosis
P1		platelet antiaggregant	thrombosis
	Cys(3-nitro-2-		·
,	pyridinesulfenyl)-		
	Gly-NH2		
PI 200		platelet antiaggregant	
PI 201		platelet antiaggregant	thrombosis
RC 3911	2-(diethylamino)-7-	platelet antiaggregant	thrombosis
	hydroxy-4H-1-		
	benzopyran-4-one		
RGDY		platelet antiaggregant	thrombosis
SC 52905	unspecified	platelet antiaggregant	thrombosis
SKF 106760	N-acetyl-L-cysteinyl-	platelet antiaggregant	thrombosis
•	N2-methyl-L-		
	arginylglycyl-L-		
	alpha-aspartyl-3-		
	mercapto-L-		
	valinamide cyclic (1-		
	5)-disulfide		

	· · · · · · · · · · · · · · · · · · ·		
thiofedrine	3-[(2-hydroxy-1-	platelet antiaggregant	thrombosis
1	methyl-2-		
	phenylethyl)amino]-		
	1-(thien-2-yl)-1-		
	propanone		
trombodipine;	1,4-dihydro-2,4,6-	platelet antiaggregant	thrombosis
thrombodipine; PCA	trimethyl-3,5-		
4230	pyridinedicarboxylic		
	acid ethyl 2-(3-oxo-		
	1,2-benzisothiazol-		,
	2(3H)-yl)ethyl ester		
	S,S-dioxide		
TY 11223	[1S-	platelet antiaggregant	thrombosis
	[lalpha(R*),2beta,3aa		
Ì	lpha,7aalpha]]-[2-		ĺ
	[2,3,3a,6,7,7a-		
	hexahydro]e-hydroxy-		
	1-(3-hydroxy-4,4-		
	dimethyl-1,6-		
1	nonadiynyl)-1H-		
	inden-5-		
	yl]ethoxy]acetic acid		
V 20	unspecified	platelet antiaggregant	thrombosis
EF 12		platelet antiaggregant;	
		antiproliferative agent	
ticlopidine;		platelet antiaggregant;	
	chlorophenyl)methyl]		, , , , , , , , , , , , , , , , , , , ,
hydrochloride; 5332	-4,5,6,7-	β	
C; 4 C 32; PCR 5332;			
PICLODIN;	c]pyridine		
PICLONADINE;	117		
PROPACALL;			
TICLID;			
PANALDINE;			
ROBETARL;			·
RONDORIN			
L 734217	[R-(R*,R*)]-3-[[[2-	platelet antiaggregant;	thrombosis
		fibrinogen antagonist	
	piperidinyl)ethyl]-1-	in in the second	
	piperidinyl]acetyl]ami		
	no-butanoic acid	·	
	no-outailoic aciu		

lefradafiban; BIBU	(3S-trans)-5-[[[4'-	platalat antigagement	. 411
	1	platelet antiaggregant	inromoosis
104; BIBU 104XX	[imino[(methoxycarb	P= -	
	onyl)amino]methyl][1	antagonist	
	,1'-biphenyl]-4-yl]		
	oxy]methyl]-2-oxo-3-		
	pyrrolidineacetic acid		
	methyl ester		
MS 180	3,4-dihydro-6-[[4-	platelet antiaggregant	thrombosis
	(imino-4-	glycoprotein IIb/IIIa	
	morpholinylmethyl)be	antagonist	İ
	nzoyl]amino]-2H-1-		
	benzopyran-3-acetic		
	acid ethyl ester		
	monohydrochloride		
orbofiban; SC	(S)-N-[[[1-[4-	platelet antiaggregant	thrombosis
57099B; CS 511	(aminoiminomethyl)p		
	henyl]-2-oxo-3-	antagonist	
1	pyrrolidinyl]amino]ca		
	rbonyl]-beta-alanine		
	ethyl ester		
RWJ 53308		platelet antiaggregant;	thrombosis
	[1-oxo-3-(4-	glycoprotein IIb/IIIa	
Ì	piperidinyl)propyl)-3-		
	piperidin	30	
	yl]carbonyl]amino]-3-		
	pyridinepropanoic		
	acid	·	, .
SC 46749	unspecified	platelet antiaggregant;	thrombosis
00 10/12	unspecified	glycoprotein IIb/IIIa	tinoinoosis
		antagonist	
SR 121566	4-[[4-[4-	platelet antiaggregant;	thrombosis
DK 121500	(aminoiminomethyl)p		unomoosis
	henyl]-2-thiazolyl](2-		
		amagomsi	
·	carboxyethyl)amino]-		
	1-piperideneacetic		
1 1 1 11 1	acid trihydrochloride		
platelet adhesion	unspecified	platelet antiaggregant;	thrombosis
inhibitors		platelet antiaggregant	
S 18886		platelet antiaggregant;	thrombosis
	•	thromboxane	
ſ		antagonist	1

dana daliman, austana	I		
drug delivery system,	unspecified	platelet antiaggregant	
MICROPUMP oral		thromboxane	inflammation
controlled release		synthetase inhibitor;	
aspirin; aspirin		analgesic; NSAID	ļ
MICROPUMP;			
ASACARD			
cloricromen;	[[8-chloro-3-[2-	platelet antiaggregant;	агтhythmia;
cloricromene; AD 6;	(diethylamino)ethyl]-	vasodilator	thrombosis
PROENDOTEL	4-methyl-2-oxo-2H-		
	1-benzopyran-7-		
	yl]oxy]acetic acid		·
	ethyl ester		
vintoperol; RGH	(3alpha,16alpha)-21-	platelet antiaggregant;	peripheral vascular
2981	nor-1,14-		disease; thrombosis
	secoeburnamein-20-ol		,
epoprostenol;	(5Z,9alpha,11alpha,1	platelet antiaggregant;	pulmonary
epoprostenol sodium;	3E,15S)-6,9-epoxy-		hypertension;
prostacyclin;	11,15-		thrombosis
prostaglandin X;	dihydroxyprosta-5,13-		
prostaglandin I2;	dien-1-oic acid		
vasocyclin; UN			
53217A; U 53217;			
FLOLAN; CYCLO-			
PROSTIN			
triflavin	triflavin (trimeresurus	platelet antiaggregant;	thrombosis
		venom	
albolabrin	unspecified	platelet antiaggregant;	thrombosis
	ł ⁻	venom; peptide	
echistatin		platelet antiaggregant;	thrombosis
		venom; peptide	
BMY 42393	2-[3-[2-(4,5-diphenyl-		hvnerlinidemia:
		platelet antiaggregant	
	oxazolyl)ethyl]pheno	Piatorot antiaggrogant	unomoosis
	xy] acetic acid		
		prostaglandin agonist;	thrombosis
2.,,00	[1alfa,2beta(Z),3alfa(unonino212
	1E,3R*),4alfa]]-7-[3-	pratoret antraggregatit	
	(3-cyclohexyl-3-		
	hydroxy-1-propenyl)-		
	ovahiovolo[2 2 1]hant		
	oxabicyclo[2.2.1]hept		
	-2-yl]-5-heptenoic		
	acid		

DVV 102006 102006	5 /2	nrostoglandin media	k1
BW 192C86; 192C86	1 -		thrombosis
	carboxypropylthio)-1-	1 -	
	1-	antiaggregant	
	hydroxyethylideneami	1	
	no)-3-ethyl-		
	hexahydrocyclopenta-		
	(d) imidazol-2(1H)-		
	one		
ataprost;	[3aS-	prostanoid; platelet	thrombosis
tepoprostenol; ONO	[2E,3aalfa,4alfa(1E,3	antiaggregant	
41483; OP 41483	R*),5beta,6aalfa]]-5-		
	4-(3-cyclopentyl-3-		
	hydroxy-1-		
	propenyl)hexahydro-		
	5-hydroxy-2(1H)-		
	pentalenylidene]penta		
	noic acid		
beraprost; TRK 100;		prostanoid; platelet	peripheral vascular
RU 55100; ML 1129;		antiaggregant	disease; thrombosis;
MDL 201129;	hydroxy-4-methyl-1-	antiaggi ogant	ischemia; pulmonary
DORNER;	octen-6-ynyl)-1H-		hypertension;
PROCYLIN	cyclopenta[b]benzofu		diabetes; neuropathy
ROCILIN	ran-5-butanoic acid		diabetes, neuropatity
BMY 45778	unspecified	prostanoid; platelet	thrombosis
DIVIT 45/1/6	unspecified	antiaggregant	
ciprostene; ciprostene	[308	prostanoid; platelet	thrombosis; restenosis
calcium; U 61431F	[2Z,3aalfa,5beta,6alfa	r	illioilloosis, restellosis
Calcium, O 014317	IF.	amaggiegam	
	(1E,3R*),6aalfa]]-5- [hexahydro-5-	٠.	
	hydroxy-6-(3-	ļ	
	hydroxy-1-octenyl)-		
	3a-methyl-2(1H)-		
	pentalenylidene]penta		
	noic acid		
drug delivery system,		p	thrombosis; stroke
lipid microsphere,	[3aalpha,5beta,6alpha	antiaggregant	
clinprost; clinprost	(1E,3R*),6aalpha]]-		•
lipid microsphere;	1,3a,4,5,6,6a-		
TTC 909; ARTEON	hexahydro-5-		
	hydroxy-6-(3-		
	hydroxy-1-octenyl)-2-		·
	pentalenepentanoic	l	
l .	acid methyl ester	1	

naxaprostene; CG	[3aS-	prostanoid; platelet	thrombosis
4305	[2E,3aalfa,4alfa(1E,3	antiagoregant	III OHIOOSIS
	R*),5beta,6aalfa]]-3-		
	[[4-(3-cyclohexyl-3-		
	hydroxy-1-		
	propenyl)hexahydro-		
	5-hydroxy-2(1H)-		
	pentalenylidene meth		
	yl]benzoic acid		
ONO NT012	5(Z)-7-	prostanoid; platelet	thrombosis
	[(1S,2S,3S,5R)-3-	antiaggregant	in on loosis
	(trans-beta-		
	styren)sulfonamido-		
	6,6-		
	dimethylbicyclo[3.1.1		
,	.]hept-2-yl]-5-		
	heptenoic acid		
ZK 110841	[1R-	prostanoid; platelet	glaucoma;
	[lalfa(Z),2beta(1E,3S	antiaggregant	hypertension;
	*),3alfa,5beta]]-7-[5-		thrombosis
	chloro-2-(3-		
	cyclohexyl-3-		
	hydroxy-1-propenyl)-		
	3-		
	hydroxycyclopenyl]-		·
777 110100	5-heptenoic acid		
ZK 118182		prostanoid; platelet	thrombosis;
	[1alfa(Z),2beta(1E,3S	antiaggregant	hypertension
	*),3alfa,5alfa]]-[[4-		
	[5-chloro-2-(3-		
	cyclohexyl-3-		
	hydroxy-1-propenyl)-		
	3-		
	hydroxycyclopentyl]-	<u>.</u>	
	2-butenyl]oxy]acetic	÷	
	acid		

KP 10614	[3aS-	amostomoid 1 t 1 :	10 1
10014	-	prostanoid; platelet	thrombosis;
	[2(Z),3aalfa,5beta,6al		peripheral vascular
	fa(1E,3R*,4R*),6aalf	vasodilator	disease
	a]]-5-1,3a,4,5,6,6a-		
	hexahydro-5-		
	hydroxy-6-(3-		
	hydroxy-4-methyl-1-	1	
	nonen-6-ynyl)-2-		
	pentalenyl]-4-		
	pentenoic acid		
taprostene; CG 4203	alpha-	prostanoid; platelet	peripheral vascular
	((2Z,3aR,4R,5R,6aS)-	antiaggregant;	disease; thrombosis
	4-((1E,3S)-3-	vasodilator	
	cyclohexyl-3-		
	hydroxypropenyl)hex		
	ahydro-5-hydroxy-		
	2H-		
	cyclopenta(beta)furan		1
	-2-ylidene)-meta-	•	
	toluic acid		
iloprost; ciloprost; ZK	5-[hexahydro-5-	prostanoid; platelet	peripheral vascular
36374; E 1030; SH	1	antiaggregant;	disease; thrombosis;
401; ILOMED;	hydroxy-4-methyl-1-	vasodilator; NSAID	thrombocytopenia;
ENDOPROST;	octen-6-ynyl)-2(1H)-		rheumatoid arthritis
L	pen		
	talenylidene]pentanoi		
,	c acid		
alprostadil; lipo-		prostanoid;	hepatitis; thrombosis;
	1 1	vasodilator;	peripheral vascular
lipo-PGE1; U 10136;		•	disease; sexual
PGE1; CAVERJECT;			dysfunction;
PALUX; LIPLE;			pulmonary
PROSTIN; EDEX;			hypertension; skin
MUSE			ulcer; hearing loss
	[3aS-		thrombosis;
	[2E,3aalpha,4alpha(3	-	
	R*,4R*),5beta,6aalph	· -	peripheral vascular disease; cancer
i i	a]]-[2-[hexahydro-5-	वारावप्रद्वाटप्रवार	uiscase, cailcer
l ·	hydroxy-4-(3-		
	hydroxy-4-methyl-		
	1,6-nonadiynyl)-		
	2(1H)-		
	pentalenylidene]ethox		
	y]acetic acid		

protein kinase	unspecified	protein kinase	asthma; thrombosis
activators		activator; protein	asuma, anomousis
		kinase A activator	
ONO 3307	4-	proteinase inhibitor	thrombosis
	[(aminoiminomethyl)	r	rinomoosis
	amino]benzoic acid 4	3	
	(aminosulfonyl)pheny	1	
	l ester	$^{\prime}$	
	monomethanesulfona	•	
	pronomentanesuriona	ų 	
proteinase inhibitors	unspecified	proteinase inhibitor	thrombosis
HMR 2906	unspecified	proteinase inhibitor;	thrombosis
		blood clotting factor	LIMOINDOSIS
	·	Xa inhibitor	
ZK 807191	N-[2-[5-	proteinase inhibitor;	thrombosis
	(aminoiminomethyl)-	blood clotting factor	TITI OTHOOSIS
	2-hydroxyphenoxy}-	Xa inhibitor	
	6-[3-(4,5-dihydro-1-	A IIIIIOIOI	
	methyl-1H-imidazol-		
	2-yl)phenoxy]-3,5-	İ	
. Landing age of the	difluoro-4-pyridinyl]-		
	N-methylglycine		
bivalirudin; BG 8967;		proteinase inhibitor;	thrombosis; angina;
HIRULOG		hirudin analogue;	myocardial infarction
	prolylglycylglycylglyc		inyocardiai imarction
	ylglycyl-L-	in different minorior	
	asparaginylglycyl-L-		
	alphaaspartyl-L-		
	phenylalanyl-L-	·	
	alphaglutamyl-L-		
	.alphaglutamyl-L-		
	isoleucyl-L-prolyl-L-		
	.alphaglutamyl-L-		
	alphaglutamyl-L-	*=	
-	tyrosyl-L-leucine		
GL 522		proteinase inhibitor;	thrombosis
		platelet antiaggregant	
nafamostat;	6-amidino-2-naphthyl		thrombosis;
· ·	p-guanidinobenzoate		
nafamostat mesilate;	- S	Procession minagerogant	anaphylactic shock
FUT 175; FUTHAN			anaphysactic SHOCK
ΓORII; FUTHAN	•		j

SDZ 217766; SDZ	[3aS-	proteinase inhibitor;	thrombosis
217-766	-	platelet antiaggregant	
	6beta,7aalpha]]N-	peptide	'
	[(1,1-	peptide	
	dimethylethoxy)carbo		
	nyl]-3-	'	
	(trimethylsilyl)-L-		
	alanyl-N-[4-		
	[(aminoiminomethyl)		
	amino]-1-(hexahydro-		
	3a,5,5-trimethyl-4,6-		
	methano-1,3,2-		
	benzodioxaborol-2-	·	
	yl)butyl]-L-		
	prolinamide	· ·	
argatroban;	(2R,4R)-1-[(2S)-5-	proteinase inhibitor;	th
argatrovan;	[(aminoiminomethyl)	platelet antiaggregant;	thrombosis;
argipidine;	amino]-1-oxo-2-	thrombin inhibitor	ischemia; angina;
argopidine;	[[(1,2,3,4-tetrahydro-	momom minorior	brain ischemia;
1	3-methyl-8-		thrombocytopenia
MCI 9038; MD 805;	quinolinyl)sulfonyl]a		unomocytopenia
OM 805; GN 1600;	mino]pentyl]-4-		
NOVASTAN;	methyl-2-		
SLONNON	[piperidinecarboxylic	·	
	acid		•
proteinase inhibitors,	unspecified	proteinase inhibitor;	thrombosis
SIDR		serine proteinase	
		inhibitor; peptide	
BCH 2763	unspecified		thrombosis
	1 *	thrombin inhibitor	
CCI 1004	unspecified		thrombosis
	1	thrombin inhibitor	
CL 03135	unspecified		thrombosis
) * .	thrombin inhibitor	and offices is
ORG 37940	N-(carboxymethyl)-3-		thrombosis
1	cyclohexyl-D-alanyl-	r ' 1	
·	N-[5-amino-1-		
	(carboxycarbonyl)pen		
	tyl]-L-prolinamide		
PPACK		proteinase inhibitor;	thrombosis
		thrombin inhibitor	um 011100313
			thrombosis
	•	thrombin inhibitor	TITOHIO0212
		anomom manonor	

CD7 01 (744	1	T : : : : : : : : : : : : : : : : : : :	T
SDZ 216744	unspecified	F	thrombosis
		thrombin inhibitor;	
		platelet antiaggregant	
thrombin receptor	unspecified		thrombosis
inhibitors, oral		thrombin inhibitor;	
		platelet antiaggregant	
thrombin receptor	unspecified	proteinase inhibitor;	thrombosis
inhibitors, parenteral		thrombin inhibitor;	
		platelet antiaggregant	
AR 69931; AR	N-[2-	purinoceptor	thrombosis;
C69931MX	(methylthio)ethyl]-2-		myocardial infarction
	[(3,3,3-	antiaggregant	,
	trifluoropropyl)thio]-		
	5'-adenylic acid		
	monoanhydride with	·	
	(dichlorophosphonom		
	ethyl)phosphonic acid	1	
purinoceptor 2T	unspecified		thrombosis
antagonists	'	antagonist; platelet	
		antiaggregant	
Buthus Martensii	unspecified		thrombosis
Karsch venom; BMK	•	thrombolytic	
venom; scorpion			
venom			
ACITIC	[3-[(7-amino-4-	serine proteinase	thrombosis
	:	inhibitor; proteinase	
	i e	inhibitor	
	yl)oxy]propyl]thioure		
	a		
LEX 026 analogues	unspecified	serine proteinase	thrombosis
	_	inhibitor; proteinase	
		inhibitor	
BIBR 1048			thrombosis
	· · · · · · · · · · · · · · · · · · ·		thrombosis
1		biotechnology;	
1	l`	proteinase inhibitor	
hirudin; CGP 39393;	100101111111111	protestiase minoriti	
REVASC; HIRUDIN			
FEET TOC, THRODIN		<u></u>	

CVS 995	N-(1-oxo-2-	thrombin inhibitor;	thrombosis
C V 5 775	propylpentyl)-L-	peptide; proteinase	IIII OHIOOSIS
	alpha-aspartyl-L-	inhibitor	
	prolyl-N6-		
	(aminoiminomethyl)-	ļ	
	2-oxo-(S)-3,6-	į	
	diaminohexanoylglyc		
	ylglycylglycylglycylgl		
	ycyl-L-		
	asparaginylglycyl-L-		
	aplpha-aspartyl-L-		
	phenylalanyl-L-alpha-		
	glutamyl-L-alpha-		
	glutamyl-L-isoleucyl-		
	L-prolyl-L-alpha-		
	glutamyl-L-tyrosyl-L-		
	leucine		
DUP 714	(S)-N-acetyl-D-	thrombin inhibitor;	thrombosis
	phenylalanyl-N-[4-	peptide; proteinase	
	(*)	inhibitor	
	amino]-1-		
	boronobutyl]-L-		
	prolinamide		
P 8714	N-acetyl-D-	thrombin inhibitor;	thrombosis
	phenylalanyl-N-[4-	peptide; proteinase	·
3 Jan 1997	[(aminoiminomethyl)	inhibitor	
	amino]-1-		
	boronobutyl]-L-		
,	prolinamide		
S 18326	Ac-D-Phe-N-	thrombin inhibitor;	thrombosis
	cyclopentylglycine-	peptide; proteinase	
	boroArg	inhibitor	
napsagatran; Ro	(S)-N-[N4-[[1-	thrombin inhibitor;	thrombosis
466240	(aminoiminomethyl)-	platelet antiaggregant;	
	3-	proteinase inhibitor	
	piperidinyl]methyl]-		
ł	N2-(2-		
	naphthalenylsulfonyl)		
	-L-asparaginyl]-N-		
	cyclopropylglycine	,	
3DP 4026		thrombin inhibitor;	thrombosis
	_	proteinase inhibitor	
L	L	E	

BMS 180742	N2-[N-[N-[N-[1-	thrombin inhibit	
DIVIS 100742			thrombosis
	[N-[1-[N-[N-(3-	proteinase inhibitor	
	carboxy-1-		
	oxopropyl)-L-		
	phenylalanyl]-L-		
	alpha-glutamyl]-L-		1
	prolyl]-L-isoleucyl]-		
	L-prolyl]-L-alpha-		
	glutamyl]-L-alpha-		
	glutamyl]-L-tyrosyl]-		
	3-cyclohexyl-L-		
	alanyl]-L-glutamine		
BMY 44621	[S-(R*,R*)]-N-[4-	thrombin inhibitor;	thrombosis
	[(aminoiminomethyl)		unomoosis
	amino]-1-	protoniase innibitor	
	formylbutyl]-1-(1-		
	oxo-3-phenylpropyl)-		
	b cycl-3-bijenathiopati-		
	narralidin asarbayani		
	pyrrolidinecarboxami de	1	
CORTURONDRI			
CORTHROMBIN	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
CRC 220; CRC 200	[S-(R*,S*)]-4-[[1-[[4-		thrombosis
Ì	(aminoiminomethyl)p	proteinase inhibitor	
	henyl]methyl]-2-oxo-		
·	1 2-(1-		
,	piperidinyl)ethyl]ami		İ .
	no]-3-[[(4-methoxy-		
	2,3,6-		
	trimethylphenyl)sulfo		
	nyl]amino]-4-		
	oxobutanoic acid		
CVS 1123		thrombin inhibitor;	thrombosis
	1 '	proteinase inhibitor	
•	alpha-aspartyl-N-		<u> </u>
	[(1S)-4-		
	[(aminoiminomethyl)		
	amino]-1-		
	formylbutyl]-L-	•	
	prolinamide methyl		
H 376; H 37695; H	ester		
H 1/0' H 1/641 H			
376/95		thrombin inhibitor; proteinase inhibitor	thrombosis

L 374087	N-[(6-amino-2-	thrombin inhibitor;	thrombosis
	methyl-3-	proteinase inhibitor	1111011100212
	pyridinyl)methyl]-6-	protomase minoritor	
	methyl-2-oxo-3-		
	[[(phenylmethyl)sulfo		
	nyl]amino]-1(2H)-		
	pyridineacetamide		
L 375378	N-[(6-amino-2-	thrombin inhibitor;	41
D 373376	methyl-3-	proteinase inhibitor	thrombosis
	pyridinyl)methyl]-6-	proteinase inhibitor	
	methyl-2-oxo-3-[(2-		
	phenylethyl)amino]-		-
<u> </u>	1(2H)-		
	pyrazineacetamide		
LB 30057	dihydrochloride		
LB 30037	(S)-4-[3-	thrombin inhibitor;	thrombosis
	(cyclopentylmethylam	proteinase inhibitor	,
	ino)-2-[(2-		
	naphthalenylsulfonyl)		
	amino]-3-oxopropyl]-		
	benzenecarboximidic		
	acid hydrazide		
LY 294291	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
LY 303496	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
MDL 73756	D-Phe-Pro-Arg-CF3	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
melagatran; H 31968		thrombin inhibitor;	thrombosis
	[[[[4-	proteinase inhibitor	
	(aminoiminomethyl)p		
	henyl]methyl]amino]c		
	arbonyl]-1-		·
	azetidinyl]-1-		
	cyclohexyl-2-		
	oxoethyl]glycine		
MOL 127		thrombin inhibitor;	thrombosis
	•	proteinase inhibitor	
MOL 376		<u> </u>	thrombosis
	1 - 1	proteinase inhibitor	
·	<u> </u>	protection manoritor	

Ro 091679; Ro 09-	[S-(E)]-N2-(3-	thrombin inhibitor;	k11
1679	carboxy-1-oxo-2- propenyl)-L-arginyl-	proteinase inhibitor	thrombosis
	N-[4- [(aminoiminomethyl)		
	amino]-1- formylbutyl]-L-		
	leucinamide	·	
SDZ MTH958; MTH		thrombin inhibitor;	41
958	silylalanine-Pro- borolysine	proteinase inhibitor	thrombosis
thrombin inhibitor	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
thrombin inhibitor	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
thrombin inhibitor	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
thrombin inhibitor	unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	
thrombin inhibitor,	unspecified	thrombin inhibitor;	thrombosis
injectable; CORTHROMBIN		proteinase inhibitor	
thrombin inhibitor,	unspecified	thrombin inhibitor;	thrombosis
systemic	l	proteinase inhibitor	infombosis
thrombin inhibitors	unspecified	thrombin inhibitor;	thrombosis
	i	proteinase inhibitor	unombosis
V 19	Unspecified	thrombin inhibitor;	thrombosis
		proteinase inhibitor	in omoosis
efegatran; efegatran	N-methyl-D-Phe-Pro-		thrombosis; angina;
sulfate; GYKI 14766;	Arg-H	proteinase inhibitor;	myocardial infarction
LY 294468		peptide	
S 17436	Ac-D-Phe-	thrombin inhibitor;	thrombosis
		proteinase inhibitor;	
		peptide	
	unspecified	thrombin inhibitor;	thrombosis
ANCHOR direct		proteinase inhibitor;	
thrombin inhibitor		serine proteinase	
		inhibitor	

UK 156406	[C (D * C*)] 1 [2 [2	the manufacture is 1 77 %	13 1 :
UK 130400	[S-(R*,S*)]-1-[3-[3-		thrombosis
	(aminoiminomethyl)p	r	
	henyl]-1-oxo-2-	serine proteinase	
1	1	inhibitor	
	2-methyl-7-		
	isoquinolinyl)sulfonyl		
]amino]propyl]-		
	1,2,3,6-tetrahydro-4-		
İ	methyl-2-		
	pyridinecarboxylic		
	acid		
A 76120	unspecified	thrombolytic	thrombosis;
			myocardial infarction
anistreplase;	anisoylated (human)	thrombolytic	thrombosis
acetylated	lys-plasminogen		
plasminogen	streptokinase		
streptokinase	_		
complex; APSAC;			
apsaplase; BRL			
26921; EMINASE			
antithrombotic agents,	unspecified	thrombolytic	thrombosis
Actinova			
BBNT 12	unspecified	thrombolytic	thrombosis
BRL 54912		thrombolytic	thrombosis
drug delivery system,	unspecified	thrombolytic	thrombosis
MACROMOL		·	
urokinase oral,			·
urokinase			
MACROMOL	·		
urokinase			
eliparcil; LF 40212	unspecified	thrombolytic	thrombosis
factor			thrombosis
Xa/prothrombinase	· •	•	
inhibitors	·		
factor Xai; factor Xa	unspecified	thrombolytic	thrombosis
GM 11001			thrombosis
			thrombosis
saruplase, natural;	•		
prourokinase;			
plasminogen pro-			
activator; proUK; GE			
0943;			
THROMBOLYSE;			
TOMIZE			
	unspecified	thrombolytic	thrombosis
rioriparon, Di 50050	unspecified	anomoorync	TH 011100212

oral factor Xa	unspecified	thrombolytic	thrombosis
inhibitors, Cor	1		
RWJ 27755	D-Phe-Pro-Arg- chloromethyl ketone (PPACK)	thrombolytic	thrombosis
saruplase, natural; single chain urokinase plasminogen activator; SCU-PA; SANDOLASE	unspecified e	thrombolytic	thrombosis
Thrombosis therapy	unspecified	thrombolytic	thrombosis
tisokinase; tissue plasminogen activator, natural; tPA, natural; AK 124 PLASVATA; HAPASE		thrombolytic	thrombosis; stroke
dermatan sulfate, low molecular weight; low molecular weight	sulfate (ester)	thrombolytic; fibrinolytic	thrombosis; restenosis
dermatan sulfate; low molecular weight chondroitin sulfate B; low molecular weight chondroitinsulfuric acid type B; DESMIN 370; DS 435			
nattokinase.	unspecified	thrombolytic; fibrinolytic	thrombosis
poloxamer 188; CRL 5861; FLOCOR; RheothRx	•	thrombolytic; fibrinolytic	thrombosis; cytoprotectant; sickle cell anemia
hementerin	unspecified	thrombolytic; fibrinolytic; biotechnology	thrombosis
	(1(S)-trans]-N-(4- acetylphenyl)-alpha- [[[4- (aminomethyl)cycloh exyl]carbonyl]amino] -4-(2- pyridinylmethoxy)ben zenepropanamide	thrombolytic; proteinase inhibitor; fibrinolytic	thrombosis

coprinin	2-methoxy-5-methyl-	thromboxane	L1 1 :
	1,4-benzoquinone	antagonist; platelet antiaggregant	thrombosis
daltroban; BM 13505;	4-[2-[[(4-	thromboxane	heart failure;
SKF 96148	chlorophenyl)sulfonyl	antagonist; platelet	thrombosis
]amino]ethyl]benzene		
	acetic acid		
domitroban; S 1452;	(+,-)-	thromboxane	asthma; rhinitis;
S 145; ANBOXAN	[1alfa,2alfa(Z),3beta,	antagonist; platelet	thrombosis
	4alfa]-7-[3-	antiaggregant	
	[(phenylsulfonyl)amir		
	o]bicyclo[2.2.1]hept-		
	2-yl]-5-heptenoic acid		
F 10171; L 0051	unspecified	thromboxane	thrombosis
	_	antagonist; platelet	
		antiaggregant	1
FR 106881	6-(2S,4R)-1-(4-	thromboxane	thrombosis
	chlorophenylsulfonyl)	antagonist; platelet	1
	-4-(4-	antiaggregant	
	chlorophenylsulfonyla		
	mi no)-pyrrolidine-2-	٠.	
	yl-(Z)-5-hexenoic		
	acid		
HA 29	2-[(3-	thromboxane	thrombosis
	methoxyphenyl)meth	antagonist; platelet	••
		antiaggregant	
	dimethylpyrano[2,3-		
	c]pyrazol-6(2H)-one		
ICI 185282	[2alfa,4alfa,5alfa(Z)]-	thromboxane	thrombosis; asthma
·	7-[4-(2-	antagonist; platelet	,
		antiaggregant	
	(trifluoromethyl)-1,3-		
	dioxan-5-yl]-5-		
	heptenoic acid		
		thromboxane	thrombosis; asthma
			,
			·
		J <i>G G</i>	
	· -		
·		antagonist; platelet antiaggregant	

WT 2062, KT 2 062	2 54 554	I	
KT 2962; KT 2-962	3-[4-[[(4-	thromboxane	stroke; asthma;
	chlorophenyl)sulfony		kidney disease;
]amino]butyl]-6-(1-	antiaggregant	thrombosis
	methylethyl)-1-		
	azulene sulfonic acid		
	monosodium salt		
KW 3635	(E)-11-(2-(5,6-	thromboxane	thrombosis
	dimethyl-1-	antagonist; platelet	
	benzimidazolyl)ethyli	antiaggregant	
	dine)-6,11-		
	dihydrodibenz(b,e)ox		
	epine-2-carboxylic		
	acid sodium salt		
L 670596	(-)-6,8-difluoro-	thromboxane	asthma; thrombosis
	2,3,4,9-tetrahydro-9-	antagonist; platelet	and the control of th
	[[4-	antiaggregant	
1	(methylsulfonyl)phen	88. 8	
	yl]methyl]-1H-		
	carbazole-1-acetic		
	acid		
LCB 2853	4-[[1-[[](4-	thromboxane	thrombosis
	chlorophenyl)sulfonyl		
]amino]methyl]cyclop		
	entyl]methyl]benzene		
	acetic acid		
	monosodium salt		
linotroban; HN		thromboxane	thrombosis
11500; CL 871501	benzenesulfonamidoe		III OHOOSIS
	•	antiaggregant	
	thienyl]oxy]acetic	amaggicgam	
	acid		
mipitroban; UP		thromboxane	thrombosis
11677		antagonist; platelet	unombosis
110//		antiaggregant	
	dimethyl-3H-	amaggiegam	
	imidazo[4,5-		
l.			
	b]pyridine-2-butanoic		
ON 579	acid	.,	
UN 3/9			thrombosis; asthma
	chlorophenylsulfonyla		
	, , , ,	antiaggregant	
	difluorophenoxya		
	cetic acid		

ONO 8809	[1S-	thromboxane	thrombosis, sath
0110 0007	[13- [1alfa,2alfa(Z),3beta,		thrombosis; asthma
	4alfa]]-6-[3-[[[(4-	antiaggregant	
	bromophenyl)sulfony		
]amino]methyl]bicycl		
	o[2.2.1]hept-2-yl]-5-		
	hexenoic acid decyl		
	ester	<u> </u>	
S 17732	unspecified	thromboxane	thrombosis
•		antagonist; platelet	1
		antiaggregant	
S 17733	unspecified	thromboxane	thrombosis
		antagonist; platelet	
		antiaggregant	
S 19167	6-[[(4-	thromboxane	thrombosis
	chlorophenyl)sulfonyl	antagonist; platelet	
]amino]-5,6,7,8-	antiaggregant	
	tetrahydro-3-methyl-		·
	1-		
	naphthalenepropanoic		
	acid -	**** ********* * *** * * * * * * * * * *	
SQ 30741	[1S-	thromboxane	thrombosis
	[1alpha,2alpha(Z),3al	antagonist; platelet	
	pha,4alpha]]-7-	antiaggregant	
	[3[[[[(1-		
	oxoheptyl)amino]acet		
	yl]amino]methyl]-7-		
	oxabicyclo[2.2.1]hept		
	-2-yl]-5-heptenoic		
	acid		
SQ 33261		thromboxane	thrombosis
`	[lalfa,2alfa(Z),3alfa,4		
		antiaggregant	.]
	[[[(phenylamino)carb	00 -0	
	onyi]hydrazono]meth		
	yl]-7-		
	oxabicyclo[2.2.1]hept	•	
	-2-yl]-4-hexenoic acid		
<u> </u>	-2-yijliexeliole aciu		<u> </u>

SQ 33552	[1S-	thromboxane	<u></u>
DQ 33332	[1alfa,2alfa(Z),3alfa,		thrombosis
	alfa]]-6-[3-[[[[(4-		
•		antiaggregant	
	chlorophenyl)amino]		
	arbonyl]hydrazono]m	1	
	ethyl]-7-		
	oxabicyclo[2.2.1]hep		
20.22061	-2-yl]-4-hexenoic acid		
SQ 33961	[1S-(exo,exo)]-2-[[3-		thrombosis;
	[4-[[(4-	antagonist; platelet	peripheral vascular
	cyclohexylbutyl)amin	antiaggregant	disease; asthma
	o]carbonyl]-2-		
	oxazolyl]-7-		
	oxabicyclo[2.2.1]hept		
	-2-		
	yl]methyl]benzenepro	,	
	panoic acid		
SQ 35091	[1S-	thromboxane	thrombosis
	[1alfa,2alfa,3alfa(E),4		
	alfa]]-2-[[3-	antiaggregant	
	[[[(phenylamino)carb		
	onyl]hydrazono]meth	·	
	yl]-7-		
	oxabicyclo[2.2.1]hept		
	-2-		. 1
	yl]methyl]benzenepro		
	panoic acid		
sulotroban; BM		thromboxane	thrombosis
13177; SKF 95587	(benzenesulfonamido)		tinoinoosis
,==== ,===,		antiaggregant	
•	acid	annaggiogain	
vapiprost; GR 32191;		thromboxane	thrombosis, Isidas
	[1alfa(Z),2beta,3beta,		thrombosis; kidney disease
		antiagonist, platelet antiaggregant	uiscase
	biphenyl]-4-	annaggregam	
	ylmethoxy)-3-		
	hydroxy-2-(1-		·
	piperidinyl)cyclopent		
	yl]-4-heptenoic acid		

ZK 151847	(5Z)-(8R,9S,12S)-9-		thrombosis
İ	(p-Phenylbenzyloxy)		
	11-desoxy-12-(p-	antiaggregant	
	fluorobenzene		
	sulfonylamino)-		
	13,14,15,16,17,18,19	,	
j	20-octanor-prost-5-		
	enoic acid		
ifetroban; ifetroban	[1S-	thromboxane	thrombosis; skin ulcer
sodium; BMS	(1alfa,2alfa,3alfa,4alf	antagonist; platelet	
18029102; BMS	a)]-2-[[3-[4-[(n-	antiaggregant;	
180291A; BMS	pentylamino)carbonyl	cicatrizant	
180291]-2-oxazolyl]-7-		
	oxabicyclo[2.2.1]hept	:	
	a-2-		
	yl]methyl]benzenepro		
	panoic acid		
CGS 22652	(+,-)-gamma-[4-[[(4-		thrombosis
	chlorophenyl)sulfonyl	antagonist; synthase	
]amino]butyl]-3-	inhibitor; platelet	
	pyridineheptanoic	antiaggregant	
	acid]
GR 85305	(E)-6-[3-[2-[[(4-	thromboxane	thrombosis
	iodophenyl)sulfonyl]a		
	mino]ethyl]phenyl]-6-	inhibitor; platelet	
		antiaggregant	
	hexenoic acid		
ICI D1542; ZD 1542	[2S-	thromboxane	thrombosis
	[2alfa,4alfa,5alfa(Z)]]	antagonist; synthetase	
	-6-[2-[1-methyl-1-(4-	inhibitor; platelet	ŀ
		antiaggregant	
	nitrophenoxy)ethyl]-		
	4-(3-pyridinyl)-1,3-		,
	dioxan-5-yl]-4-		
	hexenoic acid		
		thromboxane	thrombosis; restenosis
A2/prostaglandin H2	chlorophenyl)sulfonyl	antagonist; synthetase	
antagonist;]amino]ethyl]-5-(3-	inhibitor;	
hromboxane A2		prostaglandin	+
	enepropanoic acid	antagonist; platelet	
Pfizer.		antiaggregant	

KDI 792; FK 070; FI	8 [25-	thromboxane	41 1
12170	[2alpha,(Z),4beta]]-6		thrombosis;
12170		thromboxane	peripheral vascular
	[4-[[(4-		disease; asthma
		synthetase inhibitor;	
]amino]-1-(3-	platelet antiaggregant	:
	pyridinylmethyl)-2-		
	pyrrolidinyl]-5-		
TTD 020100	hexenoic acid		
TER 930180	4-[1-[[[(4-	thromboxane	thrombosis
	chlorophenyl)sulfony		
]amino]methyl]-4-(3-		
		synthetase inhibitor;	
	nepropanoic acid	platelet antiaggregant	
ONO 1301; AP	[[7,8-dihydro-5-[2-	thromboxane synthase	thrombosis
50002; ONO AP	[[(phenyl-3-	inhibitor; platelet	
50002	pyridinylmethylene)a	antiaggregant	·
	mino]oxy]ethyl]1-		
	naphthalenyl]oxy]ace	t	
	ic acid		
applaggin	unspecified	thromboxane	thrombosis
		synthetase inhibitor;	
·		platelet antiaggregant	
camonagrel;	(+,-)-5-(2-imidazol-1-		thrombosis
DEFIBROTIDE	ylethoxy)-1-	synthetase inhibitor;	
	indancarboxylic acid	platelet antiaggregant	·
FCE 27262	(E)-5-[[[1-cyclohexyl-		thrombosis
	2-(1H-imidazol-1-yl)-		
	β-	platelet antiaggregant	
	phenylpropylidene]a	,	
	mino]oxypentanoic		•
	acid		
isbogrel; CV 4151; A	(E)-7-phenyl-7-(3-	thromboxane	thrombosis; stroke
		synthetase inhibitor;	monioosis, shoke
		platelet antiaggregant	
KY 063	——————————————————————————————————————		thrombosis
		synthetase inhibitor;	nii OHIOOSIS
	1.	platelet antiaggregant	
	propionic acid	Practice anniaggregant	
nafagrel; DP 1904		thrombover	1
•			thrombosis; angina;
	,		asthma; restenosis
		platelet antiaggregant	
ll i	naphthalenecarboxyli		
	c acid		

	(m) 0 54 (177	T	
ozagrel; ozagrel	(E)-3-[4-(1H-	thromboxane	stroke; thrombosis;
sodium; OKY 046;	imidazol-1-	synthetase inhibitor;	asthma; cough
DOMENAN;	ylmethyl)phenyl]-2-	platelet antiaggregan	i
CATACLOT;	propenoic acid		
XANBON; VEGA			
platelet antiaggregan	t N-((1H-pyrazol-1-	thromboxane	thrombosis
	yl)butyl)benzoylamid	synthetase inhibitor;	
	е	platelet antiaggregant	
rolafagrel; FCE	5,6-dihydro-7-(1H-	thromboxane	thrombosis; kidney
22178	imidazol-1-yl)-2-	synthetase inhibitor;	disease
		platelet antiaggregant	
	c acid		
TEI 5178	IR-	thromboxane	nephritis; thrombosis
	[1alfa,2B(1E,3S*),3al		liopinius, unomoosis
	fa]]-6-[[2-(3-	platelet antiaggregant	
	cyclohexyl-3-	pratorot untruggrogant	
	hydroxy-1-propenyl)-		
	3-hydroxy-5-		
	oxocyclopentyl]thio]h		
	exanoic acid,		
	methylester		
Y 20811		thromboxane	thrombosis; asthma;
	1	synthetase inhibitor;	stroke
	methylphenyl)methyl)	nlatelet antigggregant	Shoke
	-3,5-dimethyl-benzoic	piateiet antiaggiegant	
	acid, monosodium		
	salt		
satigrel; E 5510		thromboxane	thrombosis
		synthetase inhibitor;	uiromoosis
		prostaglandin	
	r	endoperoxidase	
	1		
		inhibitor; platelet	
ZT 386		antiaggregant	
21 300	1 -	thromboxane	thrombosis; asthma
		synthetase inhibitor;	•
	1	thromboxane	
	1	antagonist; platelet	
		antiaggregant	
tricaprilin; tricaprylin;			thrombosis
NOF 005		antiaggregant	
vascular	unspecified	vascular anticoagulant	thrombosis
anticoagulant; VAC			

drotaverine	1,2,3,6-tetrahydro-	vasodilator;	thrombosis;
acephyllinate;	1,3-dimethyl-2,6-	antispasmodic	peripheral vascular
DEPOGEN	dioxo-7H-purine-7-		disease
	acetic acid cmpd.		
	with 1-[(3,4-		
	diethoxyphenyl)meth		
	ylene]-6,7-diethoxy-		
	1,2,3,4-		
	tetrahydroisoquinolin		
	e (1:1)		
eptaloprost; eptaprost;	3aS-	vasodilator;	thrombosis;
ZK 97959	[2E,3aalfa,4alfa(3R*,	prostanoid	peripheral vascular
	4R*)5beta,6aalfa]-4-		disease; cancer
	(2-hexahydro-5-		
	hydroxy-4-(3-		
,	hydroxy-4-methyl-		
	1,6-nonadiynyl-		
	2(1H)-		
	pentalenylidene)ethox		
	y-butanedioic acid		

Table 65. Current Candidate Therapeutic Interventions for the Treatment of Renal Disease, Disorder, or Dysfunction

Product Name	Chemical Name	Action	Indication
captopril; SQ 14225; ACENORM; ACEPRIL; ANTIPRESS; CAPLOLANE; CAPOTEN; CAPOZIDE; CAPTEA; CAPTORIL;	 	ACE inhibitor	hypertension; kidney disease; heart failure; diabetes
PRINIVIL;	(S)-1-[N2-(1- carboxy-3- phenylpropyl)-L- lysyl]-L-proline		hypertension; heart failure; myocardial infarction; retinopathy; diabetes; kidney disease

FK 352	(D) (E)) 1 (1)	T :	
JF N 332	[R-(E)]-1-[1-oxo-3- (2-	adenosine antagonist;	kidney disease
	phenylpyrazolo[1,5-	adenosine A1	
	a]pyridin-3-yl)-2-	antagonist	
	propenyl]-2-		
•	piperidineacetic acid		
HMR 4902		 	
11WIK 4902	Unspecified	adenosine antagonist;	
		adenosine A1	disease
midanifallia . IDEI	0.41	antagonist	
midaxifylline; IRFI	8-(1-	adenosine antagonist;	
111/	aminocyclopentyl)-	adenosine A1	depression; kidney
	3,7-dihydro-1,3-	antagonist	disease
	dipropyl-1H-purine-		
A T TO 0.46	2,6-dione		
ALT 946	Pimagedine	Advanced	diabetes; neuropathy;
1	derivative	glycosylated end-	retinopathy; kidney
		products formation	disease
DOT 1001		inhibitor	
BST 4001;	Vitamin B6 derivative	1	diabetes; kidney
PYRIDORIN		glycosylated end-	disease
,		products formation	
		inhibitor	
pimagedine;	Aminoguanidine	Advanced	diabetes; kidney
pimagedine			disease; retinopathy;
hydrochloride;		products inhibition	atherosclerosis;
aminoguanidine;			neuropathy; stroke
GER 11; YM 585			e executive to
epalrestat; ONO			neuropathy, kidney
2235; KINEDAK	phenyl-2-	inhibitor	disease; eye disease;
	propenylidene)-4-		diabetes
	oxo-2-thioxo-3-		
	thiazolidineacetic		
	acid		
zopolrestat; CP	3,4-dihydro-4-oxo-3-	1	diabetes; neuropathy;
73850; ALOND	[[5-(trifluoromethyl)-	inhibitor	kidney disease
	2-		
	benzothiazolyl]methy		
	l]-1-phthalazineacetic		
	acid		

candesartan cilevetil	(+,-)-2-ethoxy-1-[[2'-	ongietamaia II	<u> </u>
TCV 116; H 21291;	(1H-tetrazol-5-	1 -	hypertension; heart
BLOPRESS;	1'	antagonist	failure; restenosis;
	yl)[1,1'-biphenyl]-4-		kidney disease
ATACAND; AMIAS			
KENZEN	benzimidazole-7-		
	carboxylic acid 1-		
	[[(cyclohexyloxy)carl		
	onyl]oxy]ethyl ester		
irbesartan; SR 47436;		angiotensin II	hypertension; kidney
BMS 186295;	tetrazol-5-yl)[1,1'-	antagonist	disease; heart failure
APROVEL;	biphenyl]-4-		,
KARVEA; AVAPRO	yl]methyl]-1,3-		
	diazaspiro[4.4]non-1-		
	en-4-one		
irbesartan +	Unspecified	angiotensin II	hypertension; kidney
hydrochlorothiazide;		antagonist; diuretic	disease
hydrochlorothiazide +	į	5,	
irbesartan;			
AVALIDE;			
COAPROVEL;		Ì	
KARVEZIDE			
A 68828	L-arginyl-L-cysteinyl-	ANP agonist	kidney disease
	3-cyclohexyl-L-	I I I agoinst	kidiley disease
	alanylglycylglycyl-L-		
	arginyl-L-isoleucyl-L-	•	
1	alfa-aspartyl-L-		
3	arginyl-L-isoleucyl-L-	·	
	phenylalanyl-L-		·
•	arginyl-L-	* *	
	cysteinamide cyclic	-	
	(2-13)-disulfide		
EXO 226	Unspecified	Antiglycation agent	diahatan laidaan
	Спаросписа	mingrycanon agent	diabetes; kidney disease
phensuccinal	beta-	antioxidant	
Ť :	phenylethylamide-2-		diabetes; kidney
			disease; retinopathy
	hydroxysuccinanylic acid		
	***	<u> </u>	
			cardiovascular
	hydroxy-N,N,N-		disease; kidney
	trimethyl-1-		disease; septic shock
	propanaminium		
	hydroxide inner salt		
CARNITOR			

hydroxyphenyl)ethyl]-dopamine D1 agonist 4-[2-[[6-[(2-phenylethyl)amino]he xyl]amino]ethyl]-1,2-benzenediol dihydrochloride fenoldopam; fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid BQ 123 Cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl) TAK 044 Cyclo[4-oxo-4 (4-phenyl-1-alpha-aspartyl-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L- alpha-aspartyl-D-2-(2-thienyl)glycyl-L- hydroxphenyl]-1-dopamine D1 agonist; hypertension; kidrapomist; dopamine D1 agonist; hypertension; kidrapomist; endothelin A antagonist; endothelin hypertension; kidrapomist; endothelin A antagonist; endothelin antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; endothelin antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; endothelin antagonist; endothelin disease; myocardia ppeptide	FPL 63012AR	3-[2-(3-	4	h · ·
4-[2-[[6-[(2-phenylethyl)amino]he xyl]amino]ethyl]-1,2-benzenediol dihydrochloride fenoldopam; fenoldopam mesylate; tetrahydro-1-(p-hydroxphenol)-1H-3-benzazepine-7,8-diol CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxypheny l])-5-propoxyindane-2-carboxylic acid BQ 123 Cyclo(D-alpha-aspartyl-L-leucyl-D-tryptophyl) TAK 044 4-[2-[[6-[(2-phenyl)glycyl-L-sleptide]] antagonist; hypertension; kidragonist; endothelin A antagonist; endothelin A antagonist; endothelin antagoni	11 L 03012AK			kidney disease
phenylethyl)amino]he xyl]amino]ethyl]-1,2-benzenediol dihydrochloride fenoldopam; 6-chloro-2,3,4,5-fenoldopam mesylate; tetrahydro-1-(p-hydroxphenol)-1H-3-benzazepine-7,8-diol CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl])-5-propoxyindane-2-carboxylic acid BQ 123 Cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl) TAK 044 phenyl-1 piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L- person of the final approach in farction; brain emotothelin antagonist; endothelin disease; myocardia peptide dopamine agonist; hypertension; kidney disease; heart failt disease; heart failt disease; heart failt disease; heart failt disease; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; peptide modothelin A antagonist; endothelin disease; heart failt disease; heart failt disease; heart failt disease; heart failt disease; heart failt disease; heart failt disease; heart failt disease; heart failt disease; endothelin A antagonist; endothelin A antagonist; endothelin disease; heart failt disease; heart f			-dopamine D1 agonist	
xyl]amino]ethyl]-1,2- benzenediol dihydrochloride fenoldopam; fenoldopam mesylate; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 Cyclo(D-alpha- aspartyl-L-prolyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L-		1		
benzenediol dihydrochloride fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 Cyclo(D-alpha- aspartyl-L-prolyl-D- tryptophyl) TAK 044 benzerenediol dihydrochloride 6-chloro-2,3,4,5- tetrahydro-1-(p- hydroxphenol)-1H-3- benzazepine-7,8-diol CORLOPAM endothelin A antagonist; endothelin A antagonist; endothelin A antagonist endothelin A antagonist; endothelin A antagonist; endothelin antagonist; endothelin antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin in antagonist; endothelin antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin in antagonist; endothelin infarction; brain endothelin antagonist; endothelin infarction; brain endothelin antagonist; endothelin infarction; brain endothelin antagonist; endothelin infarction; brain endothelin antagonist; endothelin infarction; brain endothelin antagonist; endothelin antagonist; endothelin infarction; brain endothelin infarction; brain endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist;				
dihydrochloride fenoldopam; fenoldopam mesylate; SKF 82526; SKF 825263; CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methoxypheny]]-1-(3,4-methylenedioxypheny l)-5-propoxyindane-2-carboxylic acid BQ 123 Cyclo(D-alpha-aspartyl-L-prolyl-D-tryptophyl) TAK 044 dihydrochloride fenoldopam; 6-chloro-2,3,4,5-dopamine agonist; hypertension; dopamine D1 agonist; glaucoma; kidney disease; heart failt disease antagonist; endothelin A antagonist endothelin A antagonist; endothelin antagonist hypertension; dopamine agonist; glaucoma; kidney disease; heart failt disease hypertension; kidney disease antagonist; endothelin A antagonist; endothelin antagonist; peptide endothelin A antagonist; endothelin antagonist; peptide piperazinyl)-L-2-aminobutanoyl-L-alpha-aspartyl-D-2-(2-thienyl)glycyl-L- dopamine agonist; hypertension; kidney disease; heart failt disease hypertension; kidney disease antagonist; endothelin A antagonist; peptide hypertension; kidney disease; heart failt disease antagonist endothelin A antagonist; endothelin antag				
fenoldopam; fenoldopam mesylate; tetrahydro-1-(p-hydroxphenol)-1H-3-benzazepine-7,8-diol CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2-(carboxymethoxy)-4-methylenedioxyphenyl]-1-(3,4-methylenedioxyphenyl]-5-propoxyindane-2-carboxylic acid BQ 123 Cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl) TAK 044 Fenoldopam mesylate; tetrahydro-1-(p-hydroxphenol)-1H-3-benzazepine-7,8-diol Unspecified endothelin A antagonist; endothelin A antagonist; endothelin A antagonist endothelin A antagonist; endothelin antagonist; endothelin antagonist; peptide Endothelin A kidney disease; hypertension; kidrantagonist; endothelin antagonist; peptide Endothelin A kidney disease antagonist; endothelin A antagonist; peptide Endothelin A antagonist; endothelin antagonist; endot				•
fenoldopam mesylate; tetrahydro-1-(p- SKF 82526; SKF 825263; benzazepine-7,8-diol CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 Cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 Cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L-				
SKF 82526; SKF 825263; CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 Cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 Cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- wasodilator; diuretic disease; heart fails wasodilator; diuretic disease; heart fails disease; heart fails disease; heart fails hypertension; kidr antagonist; endothelin A antagonist; peptide kidney disease kidney disease antagonist; peptide endothelin A antagonist; peptide rendothelin A antagonist; peptide hypertension; kidn antagonist; endothelin disease; myocardia bantagonist; endothelin antagonist; infarction; brain endothelin antagonist; infarction; brain peptide				
benzazepine-7,8-diol CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 Cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- bendothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin antagonist; endothelin A antagonist; endothelin antagonist; endothelin antagonist; endothelin A antagonist; endothelin antagonist				
CORLOPAM endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- tryptophyl) TAK 044 Cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- endothelin A antagonist; endothelin antagonist; endothelin antagonist; peptide kidney disease kidney disease antagonist endothelin A antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin A antagonist; endothelin antagonist; endothelin A phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L-	1		vasodilator; diuretic	disease; heart failure
endothelin A antagonist SB 209670 (+)-(1S,2R,3S)-3[2- endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin A antagonist; endothelin hypertension antagonist (3,4- methylenedioxypheny l)-5-propoxyindane-2-carboxylic acid BQ 123 Cyclo(D-alpha- endothelin A antagonist; endothelin valyl-L-leucyl-D- antagonist; peptide TAK 044 Cyclo[4-oxo-4 (4- endothelin A antagonist; endothelin piperazinyl)-L-2- aminobutanoyl-L-alpha-aspartyl-D-2- (2-thienyl)glycyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L-	1	benzazepine-7,8-diol		
antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- matagonist; endothelin A antagonist; endothelin A antagonist; peptide kidney disease antagonist; endothelin A antagonist; endothelin antagonist				
antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- antagonist; endothelin A kidney disease antagonist; endothelin A antagonist; endothelin A antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; endothelin A phypertension; kidn disease; antagonist antagonist endothelin A antagonist; endothelin disease; myocardia infarction; brain peptide	endothelin A	Unspecified	endothelin A	hypertension; kidney
antagonist SB 209670 (+)-(1S,2R,3S)-3[2- (carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- antagonist endothelin A kidney disease; hypertension antagonist; endothelin antagonist; endothelin antagonist; endothelin bidisease; myocardia infarction; brain endothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin A antagonist sendothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endothelin antagonist; endo	antagonist		antagonist; endothelin	
(carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- antagonist; endothelin antagonist; peptide kidney disease antagonist; peptide kidney disease antagonist; endothelin antagonist; peptide kidney disease antagonist; peptide kidney disease antagonist; peptide				
(carboxymethoxy)-4- methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- antagonist; endothelin hypertension kidney disease antagonist; peptide kidney disease hypertension; kidney disease antagonist; endothelin antagonist; endothelin antagonist; peptide	SB 209670	(+)-(1S,2R,3S)-3[2-	endothelin A	kidney disease:
methoxyphenyl]-1- (3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- antagonist endothelin A hypertension; kidn antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; peptide		(carboxymethoxy)-4-	l antagonist; endothelin	
(3,4- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid endothelin A antagonist; peptide kidney disease antagonist; peptide hypertension; kidn antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; peptide				, , , , , , , , , , , , , , , , , , ,
methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- methylenedioxypheny l)-5-propoxyindane-2- carboxylic acid endothelin A antagonist; peptide kidney disease antagonist; peptide kidney disease antagonist; peptide			J	
l)-5-propoxyindane-2- carboxylic acid BQ 123				
carboxylic acid BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- endothelin A antagonist; peptide hypertension; kidn antagonist; endothelin disease; myocardia infarction; brain peptide	•			
BQ 123 cyclo(D-alpha- aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- endothelin A antagonist; peptide hypertension; kidn antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; peptide				
aspartyl-L-prolyl-D- valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- phenyl-1- piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L- antagonist; endothelin disease; myocardia infarction; brain			endothelin A	kidney disease
valyl-L-leucyl-D- tryptophyl) TAK 044 cyclo[4-oxo-4 (4- endothelin A hypertension; kidn phenyl-1- antagonist; endothelin piperazinyl)-L-2- B antagonist; infarction; brain aminobutanoyl-L- endothelin antagonist; ischemia alpha-aspartyl-D-2- (2-thienyl)glycyl-L-	;			
tryptophyl) TAK 044 cyclo[4-oxo-4 (4- endothelin A hypertension; kidn phenyl-1- antagonist; endothelin disease; myocardia piperazinyl)-L-2- B antagonist; infarction; brain endothelin antagonist; alpha-aspartyl-D-2- (2-thienyl)glycyl-L-				
rak 044 cyclo[4-oxo-4 (4- endothelin A hypertension; kidn phenyl-1- antagonist; endothelin disease; myocardia infarction; brain endothelin antagonist; alpha-aspartyl-D-2- (2-thienyl)glycyl-L-	1 .	-	. populac	
phenyl-1- antagonist; endothelin disease; myocardia piperazinyl)-L-2- aminobutanoyl-L- alpha-aspartyl-D-2- (2-thienyl)glycyl-L-			endothelin A	hymertension: kidnou
piperazinyl)-L-2- B antagonist; infarction; brain aminobutanoyl-L- endothelin antagonist; ischemia alpha-aspartyl-D-2- peptide (2-thienyl)glycyl-L-				
aminobutanoyl-L- endothelin antagonist; ischemia alpha-aspartyl-D-2- peptide (2-thienyl)glycyl-L-	1			
alpha-aspartyl-D-2- peptide (2-thienyl)glycyl-L-	ľ	,		
(2-thienyl)glycyl-L-				ischemia
			peptide	
		leucyl-D-tryptophyl-		
D-alpha-aspartyl]				
disodium salt				
			. 1 .1 1	
endothelin antagonist unspecified endothelin antagonist kidney disease				
endothelin antagonist Unspecified endothelin antagonist kidney disease;	chaomenn antagonist	Unspecified		
ischemia;				-
· · · · · · · · · · · · · · · · · · ·				inflammatory bowel
disease; asthma	OD 004551			
SB 234551 Unspecified endothelin antagonist kidney disease				
VML 588; Ro 611790 Unspecified endothelin antagonist; kidney disease; bra	VML 588; Ro 611790	- 1		kidney disease; brain
endothelin A ischemia				ischemia
antagonist	ł	ļ	antagonist	

IxC1-62/47	T I	T	
IXC1-02/47	Unspecified	enzyme degradation	kidney disease;
		of oxalate, reduction	inflammatory bowel
]	in the formation of	disease; Crohn
		kidney stones	disease
OPC 15161; NF	6-(1H-indol-3-	free radical	inflammation; kidney
1616904	ylmethyl)-5-methoxy-		disease
	3-(2-methylpropyl)-2-	-	1
	(1H)-pyrazinone, 4-		
	oxide		
keratinocyte growth	Protein	growth factor;	cancer; mucositis;
factor 2; KGF 2; HG		cicatrizant;	skin ulcer; alopecia;
03400		chemoprotectant;	kidney disease
		cytoprotectant	
somatropin; human	Somatotropin	growth hormone	hormone deficiency;
growth hormone;	(human)		Turner syndrome;
hGH; SJ 0011;			growth disorder;
SAIZEN;		ļ.	cachexia; kidney
SEROSTIM			disease
anaritide; atrial	N-L-arginyl-8-L-	hormone; ANP	heart failure; kidney
natriuretic factor 4-	methionine-21a-L-	agonist; peptide	disease
28; ANF 4-28; atrial	phenylalanine-21b-L-	- Grands Francis	·
natriuretic peptide;	arginine-21c-L-		
anaritide acetate; WY			
47663; AURICULIN	21 (rat)		
mecasermin; insulin-	Human insulin-like	Hormone; growth	amyotrophic lateral
like growth factor-1;	growth factor I	factor	sclerosis; neuropathy;
IGF-1; CGP 35126;	e english.		kidney disease;
CEP 079; KW 6151;	in the second		osteoarthritis
IGF-1; CEP 151;			
MYOTROPHIN			
B 2036PEG; PEG-B	Unspecified	Human recombinant	retinopathy;
2036; TROVERT		growth hormone	acromegaly; cancer;
·	1	antagonist	diabetes; kidney
	,		disease
recombinant alpha3	Alpha 3 collagen	immunosuppressant	kidney disease
	chain	airooappioosant	and and an an an an an an an an an an an an an
3002			
	5-hydroxy-1-beta-D-	immunocupprecent	rheumatoid arthritis;
1	ribofuranosylimidazol		
ł	e-4-carboxamide		transplant rejection;
L	C-4-Calubxalliluc		kidney disease

phellodendrine; OB	(7S-cis)-5,8,13,13a-	immunosuppressant;	transplant rejection;
	tetrahydro-2,11- dihydroxy-3,10-	NSAID	inflammation; viral infection; asthma;
	dimethoxy-7-methyl- 6H- dibenzo[a,g]quinolizi		kidney disease
	nium		
recombinant alpha3 collagen chain; BST 3003	Alpha 3 collagen chain	Imunosuppressant	kidney disease; systemic lupus erythematosus
tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1- pyrrolidinyl-4- pyrimidinyl)-1- piperazinyl]-16- alpha-me thyl-pregn- 1,4,9-(11)-triene- 3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
ALT 420	Unspecified	macrophage stimulator	diabetes; neuropathy; retinopathy; kidney disease
macrophage stimulators	Unspecified	macrophage stimulator	diabetes; neuropathy, retinopathy; kidney disease
NEPHROSTAT	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor	kidney disease; diabetes
matrix metalloproteinase inhibitor	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis
MAb, migis-mIgA; Mab, B cell	unspecified	monoclonal antibody	kidney disease
targinine; 546C88; BW 546C88	N5- [imino(methylamino) methyl]-L-ornithine	nitric oxide synthase inhibitor; NSAID	septic shock; arthritis; kidney disease
UR 12670		PAF antagonist; platelet antiaggregant	kidney disease; ischemia; asthma; pancreatitis
C-peptide analogues		peptide	diabetes; kidney disease

ularitide; urodilatin;	l-threonyl-l-alanyl-l-	montida	h · 1
urodilatin (human)		peptide	kidney disease
urouriatini (numan)	prolyl-l-arginyl-l-		
	seryl-l-leucyl-l-arginy		
	-l-arginyl l-seryl-l-		
	seryl-l-cysteinyl-l-		
	phenylalanylglycylgly	/	
	cyl-l-arginyl-l-		
}	methionyl-l-aspartyl-		
	l-arginyl-l-		
	isoleucylglycyl-l-		
	alanyl-l-glutaminyl-l-		
	serylglycyl-l-		
	leucylglycyl-l-		
	cysteinyl-l-		
	asparaginyl-l-seryl-l-		
	phenyalanyl-l-arginyl-	-	
	l-tyrosine cyclic (11-	l	
	27) disulfide		
lanthanum carbonate; LAMBDA	Lanthanum carbonate	Phosphate binding	kidney disease
VML 252	High molecular	Phosphate binding	kidney disease
	weight, insoluble,	.	
	polymeric resin		
sevelamer; GT16-	2-propen-1-amine,	Phosphate binding	kidney disease
026A; PB 94;	· -	resin	
RenaGel	(chloromethyl)oxiran		
	le		
BIO-LASE	unspecified	platelet antiaggregant	thrombosis: kidney
		1	disease; eye disease
ALFA 366	Unspecified	platelet antiaggregant	
<u>.</u>	_		diabetes
ALFA 642	Unspecified	platelet antiaggregant	
	•	_	disease
TFC 612; TFC 6122	[1R-		liver disease; kidney
	[1alpha,2beta(1E,3S*,	f I	disease
	5R*),3alpha]]-6-[[3-		
	hydroxy-2-(3-		
	hydroxy-5-methyl-1-		
r .	nonenyl)-5-		
T T	oxocyclopentyl]thio]-		
	hexanoic acid methyl		
	ester		
		l	

	(E) (() 2 !!! !		·
mycophenolate mofetil; RS 61443	(E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofurany l)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester	purine synthesis inhibitor; immunosuppressant; NSAID	transplant rejection; rheumatoid arthritis; asthma; restenosis; kidney disease; systemic lupus erythematosus
LSL 90202	L-lysine monoeicosapentaenoa te (1:1)	Renal function improvement in nephrotoxicity associated with cyclosporine	kidney disease
KT 2962; KT 2-962	3-[4-[[(4- chlorophenyl)sulfonyl]amino]butyl]-6-(1- methylethyl)-1- azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
vapiprost; GR 32191; GR 32191B; SN 309	[1alfa(Z),2beta,3beta,5alfa]]-7-[5-([1,1'-biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid	thromboxane antagonist; platelet antiaggregant	thrombosis; kidney disease
rolafagrel; FCE 22178			thrombosis; kidney disease
TJ 8117	Unspecified	Unspecified	kidney disease
uteroglobin; CC 10	Unspecified	Uteroglobin	respiratory disease; kidney disease
CGP 22979	N-acetyl-L-glutamic acid 5-[2-(5-butyl-2- pyridinyl)hydrazide]		kidney disease
FULSTAN;	(1alfa,3beta,5Z,7E)- 26,26,26,27,27,27- hexafluoro-9,10- secocholesta- 5,7,10(19)-triene- 1,3,25-triol		osteoporosis; kidney disease; hyperparathyroidism; psoriasis

Table 66. Current Candidate Therapeutic Interventions for the Treatment of Nephritis

Product Name	Chemical Name	Action	Indication
melanocortin	unspecified	analgesic;	asthma; pain;
receptor-1		melanocortin agonist;	nephritis
modulators, Trega		melanocortin MC1	
Biosciences		agonist	
candesartan cilexetil;	(+,-)-2-ethoxy-1-[[2'-	angiotensin II	hypertension; heart
TCV 116; H 21291;	(1H-tetrazol-5-	antagonist	failure; restenosis;
BLOPRESS;	yl)[1,1'-biphenyl]-4-		kidney disease
ATACAND; AMIAS	;yl]methyl]-1-H-		,
KENZEN	benzimidazole-7-		
	carboxylic acid 1-		
	[[(cyclohexyloxy)cart		
	onyl]oxy]ethyl ester		
celiprolol; NPB 582;	N'-[3-acetyl-4-[3-	beta adrenergic	hypertension;
ST 1396; REV	[(1,1-	antagonist; beta2	nephritis
5320A; SELECTOL;	dimethylethyl)amino]	adrenergic partial	
CELECTOL	-2-	antagonist;	
	hydroxypropoxy]phen	vasodilator	·
	yl]-N,N-diethylurea		
recombinant alpha3	unspecified	biotechnology;	kidney disease;
collagen chain; BST	* * * * * * * * * * * * * * * * * * * *	immunosuppressant	systemic lupus
3003			erythematosus
decorin	unspecified	cicatrizant	nephritis; scleroderma
K 76 monocarboxylic		complement inhibitor;	
acid; K 76C00H; MX			inflammatory bowel
	octahydro-4,6',7'-		disease
	trihydroxy-2',5',5',8a'-		
	tetramethylspiro[benz	-	•
	ofuran-2(3H),1'(2'H)-		
	naphthalene]-7-		1
	carboxylic acid		
complement C5;		complement inhibitor;	
5G1.1		monoclonal antibody;	
PG1.1		immunosuppressant;	erythematosus
interleukin-1		NSAID	
antagonist,			nflammation
ImmunoPharmaceutic	·	NSAID	
k			
actarit; MS 932;	 4-	DMADD	
,	· .	DMARD;	heumatoid arthritis
l í	(acetylamino)phenyla		
	cetic acid	NSAID	

07577 77 4 0 0 0 0 0	T . T	T	
SKF-R 105058	ethylcarbamic acid, (R)-6-chloro-1-[4- [[(ethylamino)carbon yl]oxy]ph enyl]- 2,3,4,5-tetrahydro- 1H-3-benzazepine- 7,8-diyl ester	dopamine agonist; dopamine D1 agonist; vasodilator	nephritis
OPC 15161; NF 1616904	6-(1H-indol-3- ylmethyl)-5-methoxy- 3-(2-methylpropyl)-2- (1H)-pyrazinone, 4- oxide		inflammation; kidney disease
LJP 394	unspecified	immunosuppressant	systemic lupus erythematosus
MAb, CD40 ligand; 5C8; ANTOVA	unspecified	NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
SKF 105685	N,N-dimethyl-8,8- dipropyl-2- azaspiro[4,5]decane- 2-propanamine	immunosuppressant; NSAID	autoimmune disease; rheumatoid arthritis; HIV infection
bindarit; AF 2838	(phenylmethyl)-1H-		rheumatoid arthritis; nephritis
MAb, gamma interferon, humanized; SMART anti-gamma interferon	unspecified		systemic lupus erythematosus; multiple sclerosis
zolimomab aritox; MAb, H65 RTA; MAb, bone marrow- ricin A conjugate; CD5-T lymphocyte immunotoxin; MAb, CD5; XMMLY H65 RTA; XOMAZYME H65; XOMAZYME CD5+; ORTHOZYME CD5+; CD5 Plus	·	monoclonal antibody; immunotoxin; immunosuppressant	transplant rejection

	TEXT TO THE TEXT T		· · · · · · · · · · · · · · · · · · ·
TFC 612; TFC 6122	~	prostanoid	liver disease; kidney
	[1alpha,2beta(1E,3S*		disease
	5R*),3alpha]]-6-[[3-		
	hydroxy-2-(3-		
	hydroxy-5-methyl-1-		
	nonenyl)-5-		
	oxocyclopentyl]thio]-		
	hexanoic acid methyl		
	ester		
mycophenolate	(E)-6-(1,3-dihydro-4-		transplant rejection;
mofetil; RS 61443;	hydroxy-6-methoxy-	inhibitor;	rheumatoid arthritis;
CellCept	7-methyl-3-oxo-5-	immunosuppressant;	asthma; restenosis;
	isobenzofurany 1)-4-	NSAID	kidney disease;
	methyl-4-hexenoic		systemic lupus
	acid 2-(4-		erythematosus
	morpholinyl)ethyl		,
C14 6504	ester		
CV 6504	2,3,5-trimethyl-6-(3-		cancer
·	pyridinylmethyl)-2,5-		
	cyclohexadiene-1,4-	lipoxygenase inhibitor	
TEL 5170	dione		
TEI 5178	[1R-	thromboxane	nephritis; thrombosis
	[1alfa,2B(1E,3S*),3al		
	fa]]-6-[[2-(3-	platelet antiaggregant	
ļ	cyclohexyl-3-		,
	hydroxy-1-propenyl)-		15 (
	3-hydroxy-5-		ş ·
	oxocyclopentyl]thio]h		·
	exanoic acid,		
rolafagrel; FCE	methylester		
22178		thromboxane	thrombosis; kidney
22176	imidazol-1-yl)-2-		disease
	naphthalenecarboxyli c acid	platelet antiaggregant	
TJ 8014	Lyophylized extracts	unspecified	nephritis
	of 8 Japanese herbal	•	· •
	agents		İ
vaccine,	unspecified	vaccine	bacterial infection
Streptococcus	-		
pyogenes; rheumatic			
fever vaccine			
MAb, 3E10; vaccine,	unspecified	vaccine; monoclonal	nephritis
nephritis	*	antibody	P-MINIO

Table 67. Current Candidate Therapeutic Interventions for the Treatment of Restenosis

Product Name	Chemical Name	Action	Indication
Del-1 angiogenic	unspecified	angiogenesis	cancer; ischemia;
protein based	j	inhibitor;	restenosis
therapies		angiogenesis inducer	
RG 13577	(4-	angiogenesis	restenosis; multiple
	hydroxyphenoxy)aceti	inhibitor; FGF	sclerosis
		antagonist	
[formaldehyde		
	monoammoniate		
antiangiogenesis	Unspecified	angiogenesis	cancer; restenosis
agent	7	inhibitor; peptide	, , , , , , , , , , , , , , , , , , , ,
candesartan cilexetil;	(+,-)-2-ethoxy-1-[[2'-	angiotensin II	hypertension; heart
		antagonist	failure; restenosis;
BLOPRESS;	yl)[1,1'-biphenyl]-4-		kidney disease
ATACAND; AMIAS;	yl]methyl]-1-H-		,
KENZEN	benzimidazole-7-		
	carboxylic acid 1-		
	[[(cyclohexyloxy)carb		
	onyl]oxy]ethyl ester		
PN 271; PN 27,1;	unspecified	antibiotic; terpene	cancer; restenosis
AndroCar		•	·
CPG 603		antioxidant	restenosis
r ,	4,4'-	antioxidant	HIV infection;
	isopropylidenedithio-		hyperlipidemia;
	bis-2,6-di-t-		restenosis
	butylphenol		
SINLESTAL			
		antiproliferative agent	restenosis
		A	restenosis
	methoxyphenyl)meth		
		dependent kinase	
		inhibitor	
	purin-2-		
	yl]imino]bisethanol		•
	unspecified	antisense;	restenosis
oligonucleotide,		oligonucleotide	
restenosis			•
	unspecified	antisense;	restenosis
oligonucleotide,		oligonucleotide	
restenosis; TBC 395			- I

antisense	unspecified	antisense;	restenosis
oligonucleotide,	,	oligonucleotide	
smooth muscle cell			
proliferation;			
antisense		1	
oligonucleotide, SMC			
proliferation			
drug delivery system,	unspecified	antisense;	restenosis
HVJ liposome; drug	1 *	oligonucleotide	
delivery system,		l de la constant	
PCNA and cdc2]
kinase antisense			
oligonucleotides			
INX 3280; LR 3280;	unspecified	antisense;	restenosis
BW 4003W94; TA		oligonucleotide	
3280		8011401001140	
E2F inhibitors	unspecified	apoptosis inducer;	cancer; psoriasis;
	•	antiproliferative agent	viral infection:
			restenosis
RESTENEX	unspecified	calpastatin	restenosis
calpeptin	Benzyloxycarbonyl-	calpastatin; peptide	restenosis
	leu-norleucinal	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
inhibitor 1	acetyl-leu-leu-	calpastatin; peptide	restenosis
	norleucinal		
CT 1	Sulfated beta dextran	Cationic growth	restenosis
	monomer	factor binding and	
		inactivator	
heparinase III; IBT	unspecified	cicatrizant; enzyme	reperfusion injury;
9302		1	restenosis; skin ulcer
fibroblast growth	unspecified		skin ulcer; restenosis
factor, acidic; aFGF		factor	,
	9-methyl-3-(1H-	degranulation	asthma;
pemirolast potassium;			conjunctivitis;
BMY 26517; DE 068;	pyrido[1,2-		rhinitis; dermatitis;
BL 5617;	a]pyrimidin-4-one	1	restenosis
PEMILASTON;			
ALLEGYSAL			
	unspecified	DNA transcription	restenosis
oligonucleotide,	-	inhibitor; antisense;	
platelet derived		oligonucleotide	
growth factor; triple		J	
helix oligonucleotide,			
PDGF			

T. I. 125252, T. I.I.	(0) 11 5/46	T	
LU 135252; LU	(S)-alpha-[(4,6-	endothelin A	restenosis
127043; HMR 4005	dimethoxy-2-	antagonist; endothelir	1
	pyrimidinyl)oxy]-	antagonist	
	beta-methoxy-beta-		
	phenyl		
	benzenepropanoic		
	acid		
AZT 1993	1-[1-(3-	andathalin antaganist	
1021 1773	, - `	endothelin antagonist	resienosis
	ethoxyphenyl)propyl]		
	-4,5-dihydro-7-(5-		
	pyrimidinylmethoxy)		
	-1H-benz[g]indazole-		
	3-carboxylic acid		
	sodium salt	1	
ABT 627; A 127722;	[2S-	endothelin antagonist;	cancer; restenosis:
A 147627	(2alpha,3beta,4alpha)		myocardial infarction
]-4-(1,3-benzodioxol-		in your and in interest of
	5-yl)-1-[2-		
	(dibutylamino)-2-		
	oxoethyl]-2-(4-		
	methoxyphenyl)-3-		
	pyrrolidinecarboxylic		
<u> </u>	acid		
fibroblast growth	unspecified		restenosis; cancer
factor receptor		angiogenesis inhibitor	·
inhibitor; FGF			
receptor inhibitor			
TBC 2573	unspecified	FGF antagonist;	restenosis;
	-		rheumatoid arthritis;
			retinopathy
epidermal growth	unspecified		cancer; restenosis;
factor diphtheria toxin			
chimeric protein;			psoriasis
EGF diphtheria toxin		!	
chimeric protein;			
EGF fusion protein;			
DAB 389-EGF; DAB			
389-EGF			
mitotoxin fibroblast	unspecified	fusion toxin	cancer; restenosis; eye
growth factor-saporin;	-		disease
mitotoxin, FGF-			
saporin; PANTARIN	'		
cytochalasin B;	Cytochalasin	G(s)/odonylyl ovols	
-		G(s)/adenylyl cyclase	esienosis
BioStent		stimulation	j

JTV 806	unspecified	glycoprotein IIb/IIIa antagonist	angina; restenosis
eptifibatide; INTEGRILIN; INTEGRELIN	N6- (aminoiminomethyl)- N2-(3-mercapto-1- oxopropyl)-L- lysylglycyl-L-alpha- aspartyl-L-tryptophyl- L-prolyl-L- cysteinamide cyclic	glycoprotein IIb/IIIa antagonist; platelet antiaggregant; peptide	thrombosis; angina; myocardial infarction erestenosis
platelet derived growth factor; PDGF	(1->6)-disulfide unspecified	growth factor	restenosis
vascular endothelial growth factor; VEGF rhVEGF165	unspecified	growth factor; cicatrizant	coronary artery disease; ischemia; restenosis; skin ulcer
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	unspecified	growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
CL 03405	unspecified	heparinoid	restenosis
GM 1702	unspecified	heparinoid	restenosis
GM 2000	+	heparinoid	thrombosis; restenosis
ZYN-LINKER conjugated heparin			restenosis; thrombosis
GM 1077; ASTENOSE		heparinoid; platelet antiaggregant	thrombosis; restenosis
tranilast; MK 341; AINTERU; BESSARAL; CLANIST; LIZAMONT; RIZALAST; SYNBERNIA; TEIBLOCK; RIZABEN	2-[[3-(3,4- dimethoxyphenyl)-1- oxo-2- propenyl]amino]benz oic acid	Histamine and leukotriene release	asthma; allergy; conjunctivitis; rhinitis; restenosis
K 85; OMACOR	Unspecified	1	hyperlipidemia; restenosis
insulin-like growth factor-1 receptor inhibitor; IGF-1 JB3	1		restenosis; cancer

SB 223245	(S)-7-[[(1H-	integrin antagonist;	octoonomorio
OB 223243	benzimidazol-2-	cell adhesion inhibitor	osteoporosis;
	ylmethyl)methylamin	cen adhesion minibilo	restenosis; cancer
	o]carbonyl]-2,3,4,5-		
	tetrahydro-4-methyl-		
	3-oxo-1H-1,4-		
`			i
	benzodiazepine-2-		
	acetic acid	<u> </u>	
vitronectin receptor	unspecified	integrin antagonist;	osteoporosis; cancer;
antagonists		cell adhesion	restenosis
		inhibitor; alpha5	
		beta3 integrin	
		antagonist	
integrin-specific	unspecified	integrin antagonist;	osteoporosis; cancer;
peptides, Integra		cell adhesion	restenosis
LifeSciences		inhibitor;	
		angiogenesis inhibitor	
NE 1405	unspecified	integrin antagonist;	restenosis;
		oligosaccharide; P	reperfusion injury
		selectin antagonist;	
		cell adhesion inhibitor	
antiproliferative	Unspecified	Ion transport	cancer; restenosis;
agents		antiporliferative agent	
			atherosclerosis
sirolimus; rapamycin;	(3S,6R,7E,9R,10R,12		transplant rejection;
NSC 226080; AY	R,14S,15E,17E,19E,2	immunosuppressant;	autoimmune disease;
22989; RAPAMUNE	1S,23S,26R,27R,34a	antibiotic	restenosis
	S)-		
	9,10,12,13,14,21,22,2		
	3,24,25,26,27,32,33,3		
	4,34a-hexadecahydro-		
	9,27-dihydroxy-3-		
	[(1R)-2-[(1S,3R,4R)-		
	4-hydroxy-3-		
	methoxycyclohexyl]-		
	1-methylethyl]-10,21-		
	dimethoxy-		
	6,8,12,14,20,26-		
	hexamethyl-23,27-		
	epoxy-3H-pyrido[2,1-	į	
	c][1,4]oxaazacyclohe		
	ntriacontine-		1
	preriacontinic-	i	Į.
	1 5 11 28 20/41 41 2	I	i
	1,5,11,28,29(4H,6H,3 1H)-pentone		

MAb, thrombin	unspecified	monoclonal antibody	restenosis
receptor; MAb,		The section at an according	i CStCilosis
restenosis			
MAb, platelet derived	lunspecified	monoclonal antibody	cancer: restanceis
growth factor/basic		biotechnology	, cancer, resteriosis
fibroblast growth		o o como o gy	ł
factor; MAb			
PDGF/bFGF; SMA			
PDGF/bFGF			
MAb, platelet-derived	hunspecified	monoclonal antibody	restenosis
growth factor beta		platelet antiaggregant	
receptor; MAb,		practice armaggicgam	
PDGFr beta; CDP			
860			
leishmania	leishmania	Monocyte recruitmen	tinflommation
lipophosphoglycan	lipophosphoglycan	and infiltration	restenosis
- Francisco Bry Carr	i popiiospiiogiyomi	blockade	resteriosis
MSI 1436	Steroidal compound	Na+/H+ antiporter	viral infection;
	form dogfish shark	modulation	restenosis; diabetes;
			cancer
TAS 301	Unspecified	Neointimal hyperlasia	
		and late vascular	
		constrictive	
—		remodeling inhibition	
drug delivery system,	unspecified	nitric oxide donor	restenosis
vascular stent NMI			
393; NMI 393			
vascular stent			
NMI 220	unspecified	nitric oxide donor	restenosis
oligonucleotide	unspecified	oligonucleotide	restenosis
inhibitor, human non-			
muscle myosin IIB			
AVI 2221; Resten-	unspecified	oligonucleotide;	restenosis
NG	,	antisense	
CT 2	Sulfated beta	PDGF, IL-1, bFGF	restenosis
	cyclodextran polymer		
	Unspecified	PDGF, IL-1, bFGF	restenosis;
	•	inhibition	reperfusion injury
CT 2534	Unspecified		restenosis;
	•		reperfusion injury
somatoprim; PTR			pancreatitis; cancer;
	Trp-Lys-Val-Phe-	r - L	restenosis
	C3)Thr-NH2		
GM 1115		platelet antiaggregant	

EF 12	unspecified	platelet antiaggregant;	heart ischemia:
			thrombosis; restenosis
abciximab;	Immunoglobulin G1	platelet antiaggregant;	thrombosis
abcirximab; MAb,	(human-mouse	monoclonal antibody	
F(ab')2 fragment	monoclonal c7E3		stroke; myocardial
platelet; MAb, 7E3;	clone		infarction
c7E3 FAb; c7E3;	p7E3VHhC.gamma.1		i i i i i i i i i i i i i i i i i i i
ReoPro; CENTORX	Fab fragment anti-		
, , , , , , , , , , , , , , , , , , , ,	human glycoprotein		
	Ilb/IIIa receptor),		
	disulfide with human-		
	mouse monoclonal		
	c7E3 clone		
	p7E3V.kappa.hc.kapp		
	a.light chain		
polyclonal antibody,	unspecified	polyclonal antibody;	septic shock; malaria;
tumor necrosis factor		[* .	restenosis; Crohn
alpha; polyclonal			disease; graft versus
antibody, TNFalpha;	•		host disease
CytoTAb			nost discase
ciprostene; ciprostene	ſ3aS-	prostanoid; platelet	thrombosis; restenosis
calcium; U 61431F	[2Z,3aalfa,5beta,6alfa		
•	(1E,3R*),6aalfa]]-5-		
	[hexahydro-5-		
	hydroxy-6-(3-		-
	hydroxy-1-octenyl)-		
	3a-methyl-2(1H)-		
	pentalenylidene]penta		
	noic acid		
SERP 1	unspecified	proteinase inhibitor;	restenosis
	1 -	serine proteinase	
		inhibitor	
mycophenolate	(E)-6-(1,3-dihydro-4-		transplant rejection;
mofetil; RS 61443;		•	rheumatoid arthritis;
CellCept		ŕ	asthma; restenosis:
-	1 -		kidney disease;
	methyl-4-hexenoic	· · · · · · · · · · · · · · · · · · ·	systemic lupus
	acid 2-(4-	1	erythematosus
	morpholinyl)ethyl		-17
	ester		
ribozymes, restenosis,		ribozyme;	restenosis
Immusol; RestenASE	-	oligonucleotide	
ribozymes, restenosis			restenosis
, , , , , , , , , , , , , , , , , , , ,	•	oligonucleotide	COLORIOGIS
	<u> </u>	Bonacioonac	

aninarida: aarinarida	N	L 1: 0 1	T
cariporide; cariporide		sodium/hydrogen	arrhythmia;
mesilate; HOE 642;	(aminoiminomethyl)-	exchange inhibitor	myocardial infarction;
HOE 642A	4-(1-methylethyl)-3-		angina; restenosis
	(methylsulfonyl)benz		
	amide		
lanreotide; BIM	3-(2-naphthalenyl)-D-	somatostatin analogue	cancer; acromegaly;
23014; DC 13116;	alanyl-L-cysteinyl-L-		retinopathy; diabetes;
BIM 23014C; BN	tyrosyl-D-tryptophyl-		psoriasis; restenosis
52030;	L-lysyl -L-valyl-L-		
SOMATULINE;	cysteinyl-L-	· ·	
ANGIOPEPTIN;	threoninamide cyclic		
DERMOPEPTIN;	(2,7)-disulfide		
IPSTYL			
drug delivery system,	unspecified	taxane; microtubule	restenosis; cancer
vascular stent		assembly promoter	Cotonosis, cancer
paclitaxel; paclitaxel		promotor	·
vascular stent			
ZYN-LINKER	unspecified	taxane; microtubule	rogtonogia, comes-
conjugated paclitaxel	unopeemed	assembly promoter	restenosis; cancer
	1-L-leucine-2-L-	thrombin inhibitor;	
REFLUDAN			thrombosis; restenosis
KEILODAN	threonine-63-desulfo-	proteinase inhibitor	
	hirudin (hirudo		
	medicinalis isoform		
dama et au au l'Esta I au	HV1)		
dermatan sulfate, low		thrombolytic;	thrombosis; restenosis
molecular weight;	sulfate (ester)	fibrinolytic	
low molecular weight			
dermatan sulfate; low			
molecular weight			
chondroitin sulfate B;			
low molecular weight			
chondroitinsulfuric			
acid type B; DESMIN			
370; DS 435	·		
thromboxane	3-[2-[[(4-	thromboxane	thrombosis; restenosis
	chlorophenyl)sulfonyl		, , , , , , , , , , , , , , , , , , , ,
antagonist;		inhibitor:	
, ,	pyridinylmethyl)benz	,	
		antagonist; platelet	
Pfizer.		antiaggregant	
			thrombogies
] -	-		thrombosis; angina;
	,		asthma; restenosis
		platelet antiaggregant	
1	naphthalenecarboxyli	ļ	
	c acid		

NF-kappaB inhibitor	unspecified	transcription factor regulator; NSAID	asthma; inflammation;
		logulator, North	restenosis
AG 1296	6,7-dimethoxy-2-	tyrosine kinase	restenosis
	phenyl-quinoxaline	inhibitor	
PD 164199	6-(2,6-	tyrosine kinase	cancer;
	dichlorophenyl)-8-	inhibitor	atherosclerosis;
	methyl-2-		restenosis
	(phenylamino)pyrido[
	2,3-d]pyrimidin-		
	7(8H)-one		
PD 164771	6-(2,6-	tyrosine kinase	cancer;
	dichlorophenyl)-8-	inhibitor	atherosclerosis;
	methyl-2-(4-		restenosis
	pyridinylamino)pyrid		
	o[2,3-d]pyrimidin-		
	7(8H)-one	,	
PD 166285	6-(2,6-	tyrosine kinase	cancer;
	dichlorophenyl)-2-	inhibitor	atherosclerosis;
	[[4-[2-		restenosis
	(diethylamino)ethoxy		
]phenyl]amino]-8-		
	methylpyrido[2,3-		
	d]pyrimidin-7(8H)-		
	one		
KN 1022	4-(6,7-dimethoxy-4-	tyrosine kinase	restenosis
		inhibitor; PDGF	
	nitrophenyl)-1-	inhibitor	
	piperazinecarboxamid		
	е		
CT 3501	Unspecified	Unspecified	cancer; restenosis
PC 1122	Unspecified	Unspecified	restenosis;
		-	reperfusion injury

Table 68. Current Candidate Therapeutic Interventions for the Treatment of Peripheral Vascular Disease

Product Name	Chemical Name	Action	Indication
AHR 16303B	1-[4-[3-[4-[bis(4-fluorophenyl)hydroxy methyl]-1-piperidinyl]propoxy]phenyl]-2-methyl-1-propanoneethanedioate (1:1)		hypertension; angina

TTF 1570	Salicylester derivative	STITLA	1
µ1r 13/0	Sancylester derivative		peripheral vascular
		bradykinin antagonist	1
			cerebrovascular
			disease; heart
TOT D 4000 714	1.50.55	<u> </u>	ischemia
ICI D4398; ZM	4-[2-[[7-amino-2-(2-	adenosine antagonist;	
241385	furanyl)[1,2,4]triazolo		disease; hypotension
	[1,5-a][1,3,5]triazin-	antagonist	
	5-		
	yl]amino]ethyl]pheno		
	1		
ZD 9255	Unspecified	adenosine antagonist;	peripheral vascular
		adenosine A2	disease
		antagonist	
S 170891; S 18149	1,3',4',5-tetrahydro-7'-	alpha adrenergic	peripheral vascular
	methyl-spiro[4H-	agonist; alpha1	disease
	imidazole-4,2'(1'H)-	adrenergic agonist;	
	naphthalene]	alpha2 adrenergic	•
		agonist	
angiopoietin 1	Angiopoietin 1	angiogenesis inducer;	coronary artery
			disease; peripheral
			vascular disease
ranolazine; ranolazine	(+,-)-N-(2,6-	anti-ischemic	angina; peripheral
hydrochloride; RS	dimethylphenyl)-4-[2-		vascular disease
43285; KEG 1295	hydroxy-3-(2-		
	methoxyphenoxy)pro		
	pyl]-1-		
	piperazineacetamide		
antisense	Bcl-x oligonucleotide,	antisense	Peripheral vascular
oligonucleotide, bcl-x			disease
alifedrine; D 13625			peripheral vascular
			disease
	hydroxy-1-methyl-2-		-150450
	phenylethyl)amino]-		
	1-propanone		
trafermin; fibroblast		biotechnology;	skin ulcer;
			osteoporosis; stroke;
•	(human clone lambda	T. ' I	neuropathy;
	KB7/lambda HFL 1	í	peripheral vascular
	precursor reduced)		disease; coronary
CAB 2001; FIBLAST	production reduced,		
			artery disease

flunarizine; R 14950;	Unspecified	calcium entacemist	Inguintenni i
FLUZINA;	Chapternou	calcium antagonist; vasodilator	peripheral vascular
SIBELIUM;		vasounator .	disease;
ZINASEN;			cerebrovascular
SESNARBO;	j		disease; migraine;
			epilepsy
RIZENA;			
SINAZINE;	· ·		
HEADACHE;			
FLORIRATO;		j	
DIESPRUDEL			
elziverine; Ro 224839	1 ** .	calmodulin	peripheral vascular
	dimethoxyphenyl)met		disease; cognitive
	hyl]-6,7-dimethoxy-4	vasodilator	defect
	[[4-(2-		
	methoxyphenyl)-1-		
	piperazinyl]methyl]is		
	oquinoline	Ì	
clinprost;	[3aS-	cicatrizant;	thrombosis; skin
lipoisocarbacyclin;	[3aalpha,5beta,6alpha		ulcer; peripheral
isocarbacyclin methyl	(1E.3R*).6aalphall-	antiaggregant	vascular disease
ester; TEI 9090	1,3a,4,5,6,6a-	annaggi ogain	vasculai discase
	hexahydro-5-		
	hydroxy-6-(3-		
	hydroxy-1-octenyl)-2-		
	pentalenepentanoic		.
	acid methyl ester		
pamicogrel; KBT	2-[4,5-bis(4-	COX inhibitor;	thuamh a size
3022; KB 3022; TO		vasodilator; platelet	thrombosis;
192	thiazolyl]-1H-pyrrole-	enticegreent	peripheral vascular disease
	1-acetic acid ethyl	aimaggregam	uisease
	ester		
ZD 0892		-1	
CD 0092	i `	elastase inhibitor;	peripheral vascular
		proteinase inhibitor	disease
	valyl-N-[(1S)-3,3,3-	•	
1	trifluoro-1-(1-		
1	methylethyl)-2-		
	oxopropyl]-L-		
77: 01:	prolinamide		
			cancer; restenosis;
angiogenesis ligands,		cicatrizant; growth	retinopathy; skin
			ulcer; atherosclerosis;
			peripheral vascular
			disease

fondaparin sodium; SR 90107; ORG 31540; SR 90107A	methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alfa-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alfa-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alfa-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-alfa-D-glucopyranoside 6-(hydrogen sulfate)	clotting factor Xa inhibitor; proteinase inhibitor; oligosaccharide	thrombosis; peripheral vascular disease
BAY w 9798	Unspecified	leukocyte adhesion	peripheral vascular
		inhibitor; vasodilator	disease
MAb, AFS 98; AFS 98	Unspecified	monoclonal antibody	peripheral vascular disease
cilostazol; OPC	6-[4-(1-cyclohexyl-	phosphodiesterase	thrombosis
13013; PLETAL;	1H-tetrazol-5-	inhibitor;	
PLETAAL	yl)butoxy]-3,4-	phosphodiesterase III	
	dihydro-2(1H)-	inhibitor; platelet	
		antiaggregant; vasodilator	
indobufen; K 3920;		platelet antiaggregant	thrombosis
IBUSTRIN	isoindolinyl)phenyl]b utyric acid	,	
		platelet antiaggregant;	stroke: thrombosis
_	chlorophenyl)methyl]		
	-4,5,6,7-		
C; 4 C 32; PCR 5332;	tetrahydrothieno[3,2-		
1	c]pyridine		
PICLONADINE;			
PROPACALL;			
TICLID;			
PANALDINE;	·		
ROBETARL;			
RONDORIN			
vintoperol; RGH	(3alpha, 16alpha)-21-	platelet antiaggregant;	peripheral vascular
	1		disease; thrombosis
	secoeburnamein-20-ol		,

emakalim; EMD 56431	(3S-trans)-N-(4-chlorophenyl)-N'-cyano-N"-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-guanidine (3S-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-	potassium channel activator potassium channel activator; bronchodilator	angina hypertension; heart failure; asthma; peripheral vascular
	oxo-1(2H)-pyridinyl)- 2H-1-benzopyran-6- carbonitrile		disease
bimakalim; EMD 52692; SR 44866		potassium channel activator; vasodilator; bronchodilator	coronary artery disease; asthma; peripheral vascular disease
drug delivery system, transdermal alprostadil; alprostadil transdermal; prostaglandin E1 transdermal; OT 1404		prostaglandin	peripheral vascular disease
AS 013	(11alpha,13E,15S)- 11,15,dihydroxy-9-(1- oxobutoxy)prosta- 8,13-dien-1-oic acid butyl ester	prostanoid	peripheral vascular disease
ICI 199456			peripheral vascular disease
ONO 1608	Unspecified		peripheral vascular disease
SI 1702	Unspecified	*	peripheral vascular disease
limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid		cardiovascular disease; pain

hamment TDV 100.	h 2 20 9h 404-1-1-1	1	
	2,3,3a,8b-tetrahydro-	prostanoid; platelet	peripheral vascular
RU 55100; ML 1129; MDL 201129;	1 - `	antiaggregant	disease; thrombosis;
	hydroxy-4-methyl-1-		ischemia; pulmonary
DORNER;	octen-6-ynyl)-1H-		hypertension;
PROCYLIN	cyclopenta[b]benzofu		diabetes; neuropathy
	ran-5-butanoic acid	 	
ciprostene; ciprostene	F	prostanoid; platelet	thrombosis; restenosis
calcium; U 61431F	[2Z,3aalfa,5beta,6alfa	antiaggregant	
· .	(1E,3R*),6aalfa]]-5-		•
	[hexahydro-5-		
	hydroxy-6-(3-		
	hydroxy-1-octenyl)-		
	3a-methyl-2(1H)-		
	pentalenylidene]penta		
TCD 10614	noic acid		
KP 10614	[3aS-	prostanoid; platelet	thrombosis;
	[2(Z),3aalfa,5beta,6al		peripheral vascular
	fa(1E,3R*,4R*),6aalf	vasodilator	disease
	a]]-5-1,3a,4,5,6,6a-		
}	hexahydro-5-		
	hydroxy-6-(3-		
	hydroxy-4-methyl-1-		
	nonen-6-ynyl)-2-		
	pentalenyl]-4-		
	pentenoic acid		<u> </u>
taprostene; CG 4203		prostanoid; platelet	peripheral vascular
1	((2Z,3aR,4R,5R,6aS)-		disease; thrombosis
		vasodilator	
	cyclohexyl-3-		
	hydroxypropenyl)hex		
	ahydro-5-hydroxy-		
İ	2H-	,	
	cyclopenta(beta)furan		
	-2-ylidene)-meta-		
	toluic acid		
iloprost; ciloprost; ZK	(- ·	prostanoid; platelet	peripheral vascular
		antiaggregant;	disease; thrombosis;
	hydroxy-4-methyl-1-		thrombocytopenia;
ENDOPROST;	octen-6-ynyl)-2(1H)-		rheumatoid arthritis
•	pen		
	talenylidene]pentanoi		
	c acid		

alprostadil; lipo- prostaglandin E1; lipo-PGE1; U 10136; PGE1; CAVERJECT PALUX; LIPLE; PROSTIN; EDEX; MUSE cicaprost; cicaprost	(11alpha,13E,15S)- 11,15-dihydroxy-9- oxoprost-13-en-1-oic ;acid	prostanoid; vasodilator; cicatrizant prostanoid;	hepatitis; thrombosis; peripheral vascular disease; sexual dysfunction; pulmonary hypertension; skin ulcer; hearing loss thrombosis;
	[2E,3aalpha,4alpha(3 R*,4R*),5beta,6aalph a]]-[2-[hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl)- 2(1H)- pentalenylidene]ethox	vasodilator; platelet antiaggregant	peripheral vascular disease; cancer
BIBU 308; DTTX 30	(hydroxyamino)-2- oxoethyl]methylamin o]carbonyl]cyclohexa necarboxylic acid		pulmonary hypertension; peripheral vascular disease
SQ 33961	[1S-(exo,exo)]-2-[[3- [4-[[(4- cyclohexylbutyl)amin o]carbonyl]-2- oxazolyl]-7- oxabicyclo[2.2.1]hept -2- yl]methyl]benzenepro panoic acid	antagonist; platelet antiaggregant	thrombosis; peripheral vascular disease; asthma
SE	(5E)-6-[3- [[(cyanoamino)[(1,1- dimethylethyl)amino] methylene]amino]phe nyl]-6-(3-pyridinyl)- 5-hexenoic acid	thromboxane synthase	pulmonary hypertension; peripheral vascular disease
	[2alpha,(Z),4beta]]-6- [4-[[(4- chlorophenyl)sulfonyl	antagonist; thromboxane	thrombosis; peripheral vascular disease; asthma

WO 00/50639 PCT/US00/01392

vinpocetine; AY	(3alpha, 16alpha)-	vasodilator	naminala and
27255; CAVINTON;		vasouriator	peripheral vascular
CERACTON;	1		disease; cognitive
1	carboxylic acid ethyl		defect
AIRPACIL;	ester		
MEDICHILL;			
NAIKINOL TEISAN	;		
NAIKINOL IWAKI			
drotaverine	1,2,3,6-tetrahydro-	vasodilator;	thrombosis;
acephyllinate;	1,3-dimethyl-2,6-	antispasmodic	peripheral vascular
DEPOGEN	dioxo-7H-purine-7-		disease
	acetic acid cmpd.		
	with 1-[(3,4-		
	diethoxyphenyl)meth		
1	ylene]-6,7-diethoxy-		
	1,2,3,4-	•	
	tetrahydroisoquinolin	1	
	e(1:1)		
propionylcarnitine, L-		vasodilator;	peripheral vascular
; propionyl-L-	, ,	cicatrizant	disease; angina; heart
carnitine;	trimethyl-1-		failure; skin ulcer
levocarnitine	propanaminium		, 511111 41001
propionyl; ST 261;	hydroxide, inner salt		
DROMOS			
calcitonin gene	H-ala-cys-asp-thr-ala-	vasodilator: peptide	peripheral vascular
related peptide, alpha;		hormone	disease;
CGRP, alpha; CGRP,			cerebrovascular
human alpha	leu-ser-arg-ser-gly-		disease
·	gly-val-val-lys-asn-		
	asn-phe-val-pro-thr-		
	asn-val-gly-ser-lys-		
	ala-phe-NH2		,
eptaloprost; eptaprost;		vasodilator;	thrombosis;
ZK 97959	[2E,3aalfa,4alfa(3R*,		peripheral vascular
	4R*)5beta,6aalfa]-4-	F	disease; cancer
	(2-hexahydro-5-		uiscasc, caricti
	hydroxy-4-(3-		
	hydroxy-4-methyl-		
	1,6-nonadiynyl-		
	2(1H)-		
	pentalenylidene)ethox		
	y-butanedioic acid		

pimilprost; SM	[2R-	vasodilator;	peripheral vascular
10902; SKIPRON	[2.alpha.,3a.alpha.,4.alpha.(1E,3S*,5S*),5.beta.,6a.alpha.]]-[2-[octahydro-5-hydroxy-4-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]acetic acid methyl ester	prostanoid; cicatrizant	
pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL		1	peripheral vascular disease; stroke; atherosclerosis

Claims

What is claimed is:

5

10

15

1. A method for selecting a treatment for a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, disorder, or condition, comprising

determining whether cells of said patient contain at least one variance in a gene from a Table herein, wherein the presence or the absence of said at least one variance in said gene is indicative of the effectiveness of said treatment for said disease, disorder, or condition.

- 2. The method of claim 1, wherein disease, disorder, or condition is listed in an example or Table herein.
- 3. The method of claim 1, wherein the presence of said at least one variance is indicative that said treatment will be effective for said patient.
- 4. The method of claim 1, wherein the presence of said variance is indicative that said treatment will be ineffective or contra-indicated for said patient.
- 5. The method of claim 1, wherein said at least one variance comprises a plurality of variances.
 - 6. The method of claim 5, wherein said plurality of variances comprise a haplotype or haplotypes.
- 7. The method of claim 1, wherein said selecting a treatment further comprises identifying a compound differentially active in a patient bearing a form of said gene containing said at least one variance.
- 8. The method of claim 7, wherein said compound is a compound listed in a

 Table herein or that belongs to the same chemical class as a compound listed in a
 said Table.
- 9. The method of claim 1, wherein said selecting a treatment further comprises excluding or eliminating a treatment, wherein said presence or absence of said at least one variance is indicative that said treatment will be ineffective or contra-indicated.

10. The method of claim 1, wherein said treatment comprises a first treatment and a second treatment, said method comprising the steps of:

identifying a said first treatment effective to treat said disease, disorder, or condition; and

identifying a said second treatment which reduces a deleterious effect or promotes efficacy of said first treatment.

- 11. The method of claim 1, wherein said selecting a treatment further comprises selecting a method of administration of a compound effective to treat said disease in a patient, disorder or condition, wherein said presence or absence of said at least one variance is indicative of the appropriate method of administration for said compound.
- 15 12. The method of claim 11, wherein said selecting the method of administration comprises selecting a suitable dosage level or frequency of administration of a compound.
 - 13. The method of claim 1, further comprising determining the level of expression of said gene or the level of activity of a protein containing a polypeptide expressed from said gene,

wherein the combination of the determination of the presence or absence of said at least one variance and the determination of the level of activity or the level of expression provides a further indication of the effectiveness of said treatment.

25

30

35

20

. 5

10

14. The method of claim 1, further comprising determining the at least one of sex, age, racial origin, ethnic origin, and geopraphic origin of said patient,

wherein the combination of the determination of the presence or absence of said at least one variance and the determination of the sex, age, racial origin, ethnic origin, and geopraphic origin of said patient provides a further indication of the effectiveness of said treatment.

15. The method of claim 1, wherein said disease, disorder, or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central

nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

10

5

- 16. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises amplifying a segment of nucleic acid including at least one of said variances.
- 15 17. The method of claim 16, wherein said segment of nucleic acid is 500 nucleotides or less in length.
 - 18. The method of claim 16, wherein said segment of nucleic acid is 100 nucleotides or less in length.

20

25

- 19. The method of claim 16, wherein said segment of nucleic acid is 45 nucleotides or less in length.
- 20. The method of claim 16, wherein said segment includes a plurality of variances.
 - 21. The method of claim 17, wherein amplification preferentially occurs from one of the two strands of a chromosome.
- The method of claim 17, wherein said segment of nucleic acid is at least 500 nucleotides in length.
- 23. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises contacting nucleic acid comprising a variance site with at least one nucleic acid probe, wherein said at least one probe preferentially hybridizes with a nucleic acid sequence including said variance site and containing a complementary base at said variance site under selective hybridization conditions.

 $\gamma_{i,j} = \{ \gamma_{i,j}, \gamma_{i,j+1}, \ldots, \gamma_{i,j} \}$

- 24. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.
- 5 25. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.
- 26. The method of claim 1, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.
- 27. A method for selecting a method of treatment, comprising comparing at least one variance in at least one gene from Tables 1-6, 12-17, and 18-23 in a patient suffering from a neurological or psychiatric disease, druginduced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition with a list of variances or haplotypes in said at least one gene indicative of the effectiveness of at least one method of treatment.

30

35

- 28. The method of claim 27, wherein said list comprises at least 5 variances.
- 29. The method of claim 27, wherein said at least one variance comprises a plurality of variances.
- 25 30. The method of claim 27, wherein said list of variances comprises a plurality of variances.
 - 31. The method of claim 27, wherein at least one said method of treatment comprises the administration of a compound effective against said disease or condition to a patient.
 - 32. The method of claim 31, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

20

25

30

35

- 33. The method of claim 27, wherein the presence or absence of at least one variance or haplotype in said gene is indicative that said treatment will be effective in said patient.
- 5 34. The method of claim 27, wherein the presence or absence of at least one variance in said gene is indicative that said treatment will be ineffective or contraindicated.
 - 35. The method of claim 27, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.
- 36. The method of claim 27, wherein said at least one method of treatment is a plurality of methods of treatment.
 - 37. The method of claim 36, wherein said selecting comprises determining whether any of said plurality of methods of treatment will be more effective than at least one other of said plurality of methods of treatment.
 - 38. The method of claim 27, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia,
 - 39. A method for selecting a method of administration to a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation

angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis.

renal disease, restenosis, and peripheral vascular disease.

10

20

or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition for a compound or compounds effective to treat said condition or disease, comprising

determining whether at least one variance in a gene from Tables 1-6, 12-17, and 18-23 is present or absent in cells of said patient, wherein said presence or absence of said at least one variance is indicative of an appropriate method of administration for said compound.

- 40. The method of claim 39, wherein said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition is a disease or condition listed in the Detailed Description, an Example, or a Table herein.
- 15 41. The method of claim 39, wherein said selecting a method of administration comprises selecting a dosage level or frequency or frequency of administration of said compound.
 - 42. The method of claim 39, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.

Commence of the second

The method of claim 39, wherein said disease is selected from the group 25 43. consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system 30 toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, 35 infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia.

10

15

20

25

30

35

angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

44. A method for selecting a patient for administration of a treatment, comprising

comparing the presence or absence of at least one variance or haplotype in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition with a list of variances or haplotypes in said at least one gene, wherein the presence or absence of said at least one variance or haplotype in said cells is indicative that said treatment will be effective, more effective, less effective, ineffective, or contra-indicated in said patient; and

determining whether said patient will receive said treatment based on the presence or absence of said at least one variance in said cells.

- 45. The method of claim 44, wherein said list comprises at least 5 variances.
- 46. The method of claim 44, wherein said method of treatment comprises administration of a compound effective against said disease or condition.
 - 47. The method of claim 46, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.
 - 48. A method for identifying the presence or absence of at least one form of a gene from Tables 1-6, 12-17, and 18-23 in cells of an individual, comprising:

determining the presence or absence of at least one variance in said gene in said cells.

- 49. The method of claim 48, wherein said said at least one variance is a plurality of variances.
- 50. The method of claim 49, wherein said plurality of variances comprises a haplotype.

10

15

20

25

35

- 51. The method of claim 50, wherein said individual suffers from a disease or condition.
- 52. The method of claim 50, wherein the presence or absence of said at least one variance is indicative of the effectiveness of a therapeutic treatment in a patient having cells containing said at least one variance.
- 53. The method of claim 50, wherein said determining comprises amplifying a segment of nucleic acid including a site of at least one variance.
- 54. The method of claim 50, wherein said determining comprises contacting a nucleic acid sequence containing a variance site corresponding to a said variance with a probe which specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one said variance.
- 55. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises sequencing at least one nucleic acid sequence.
- 56. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises mass spectrometric determination of at least one nucleic acid sequence.
 - 57. The method of claim 50, wherein the detection of the presence or absence of said at least one variance comprises determining the haplotype of a plurality of variances in a gene.
 - 58. A pharmaceutical composition comprising a compound which has a differential effect in patients having at least one copy of a particular form of an identified gene from Tables 1-6, 12-17, and 18-23; and
- a pharmaceutically acceptable carrier or excipient or diluent,
 wherein said composition is preferentially effective to treat a patient with
 cells comprising a form of said gene comprising at least one variance.
 - 59. The method of claim 58, wherein said composition is adapted to be preferentially effective based on the unit dosage, presence of additional active components, complexing of said compound with stabilizing components, or inclusion of components enhancing delivery or slowing excretion of said compound.

10

15

20

25

30

35

- 60. The composition of claim 58, wherein said compound is deleterious to patients having said at least one copy or in patients not having said at least one copy, but not in both.
- 61. The composition of claim 58, wherein said patient suffers from a disease or condition selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.
 - 62. The pharmaceutical composition of claim 58, wherein said composition is subject to a regulatory restriction or recommendation for use of a diagnostic test determining the presence or absence of at least one variance or haplotype in said gene.
- 63. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation restricting or recommending restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance.
- 64. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is subject to a regulatory limitation or recommendation indicating said pharmaceutical composition is not to be used in patients having at least one copy of a form of a gene comprising at least one variance.
- 65. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and the packaging includes a label or insert restricting or

recommending the restriction of the use of said pharmaceutical composition to patients having at least one copy of a form of a gene comprising at least one variance or haplotype.

- 5 66. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is packaged, and said packaging includes a label or insert requiring or recommending the use of a test to determine the presence or absence of at least one variance in cells of a said patient.
- 67. A nucleic acid probe comprising a nucleic acid sequence 7 to 200 nucleotide bases in length that specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one variance in a gene from Tables 1-6, 12-17, and 18-23, or a sequence complementary thereto or an RNA equivalent.
- 68. The probe of claim 67, wherein said probe comprises a nucleic acid sequence 500 nucleotide bases or fewer in length.
 - 69. The probe of claim 67, wherein said nucleic acid sequence is 100 or fewer nucleotide bases in length.
- 70. The probe of claim 67, wherein said nucleic acid sequence is 25 or fewer nucleotide bases in length.
 - 71. The probe of claim 67, wherein said probe comprises DNA.
- 72. The probe of claim 67, wherein said probe comprises DNA and at least one nucleic acid analog.
 - 73. The probe of claim 67, wherein said probe comprises peptide nucleic acid (PNA).
- The probe of claim 67, further comprising a detectable label.
 - 75. The probe of claim 74, wherein said detectable label is a fluorescent label.
- 76. A method for determining a genotype of an individual, comprising analyzing at least one nucleic acid sequence from cells of said individual using mass spectrometric analysis,

10

20

35

wherein said nucleic acid sequence is a portion of a gene from Tables 1-6, 12-17, and 18-23 or a sequence complementary thereto.

- 77. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the presence or absence of a variance in said gene.
- 78. The method of claim 76, wherein said analyzing a nucleic acid sequence comprises determining the nucleotide sequence of said at least one nucleic acid sequence.
- 79. The method of claim 76, wherein said at least one nucleic acid sequence is 500 nucleotides or less in length.
- 80. The method of claim 76, wherein said at least one nucleic acid sequence comprises at least one variance site in said gene.
 - 81. An isolated, purified or enriched nucleic acid sequence of 15 to 500 nucleotides in length, comprising at least one variance site, wherein said sequence has the base sequence of a portion of an allele of a gene from Tables 1-6, 12-17, and 18-23.
 - 82. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence is 15 to 100 nucleotide bases in length.
- 83. The nucleic acid sequence of claim 81, wherein said nucleic acid sequence sequence is 15 to 25 nucleotide bases in length.
 - 84. A method for determining whether a compound has differential effects on cells containing at least one different form of a gene from Tables 1-6, 12-17, and 18-23, comprising:
- contacting a first cell and a second cell with said compound, wherein said first cell and said second cell differ in the presence or absence of at least one variance in said gene; and

determining whether the responses of said first cell and said second cell to said compound differ, wherein the difference in said response is due to the presence or absence of said at least one variance.

20

25

30

- 85. The method of claim 84, wherein said at least one variance comprises a haplotype.
- 86. The method of claim 84, wherein at least one of said first cell and said second cell are contacted *in vivo*.
 - 87. The method of claim 85, wherein at least one of said first cell and said second cell are contacted *in vitro*.
- 10 88. The method of claim 87, wherein at least one of said first cell and said second cell is contacted *in vivo* in a plurality of patients suffering from a disease or condition.
 - 89. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:
 - a) determining whether cells of said patient contain a form of a gene from Tables 1-6, 12-17, and 18-23 which comprises at least one variance, wherein the presence or absence of said at least one variance is indicative that a treatment will be effective in said patient; and
 - b) administering said treatment to said patient.
 - 90. The method of claim 89, wherein said gene is listed in Table 1 or is a gene in a pathway listed in Table 1 herein.
 - 91. The method of claim 89, wherein said disease or condition is a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition listed in the Detailed Description, Examples, or Tables herein.
 - 92. The method of claim 89, wherein said disease is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system

toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

10

15

20

25

30

35

- 93. The method of claim 89, wherein the presence of said at least one variance is indicative that said treatment will be effective in said patient.
- 94. The method of claim 93, wherein said treatment comprises the administration of a compound preferentially active for said condition or disease in a said patient having said at least one variance in said gene.
- 95. The method of claim 94, wherein said compound is selected from the group consisting of agonists, antagonists, blockers, partial agonists, partial antagonists, inhibitors, activators, modulators, negative antagonists, inverse agonists, mimetics, or factors that elicit pharmacological activity on a gene product of at least one gene or gene pathway listed in Table 1.
- 96. The method of claim 89, wherein the presence of said at least one variance in said gene is indicative of an appropriate dosage or frequency of administration of a compound in said treatment.
- 97. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:
- a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;
- b) selecting a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one

35

variance is indicative that said method of treatment will be effective in said patient; and

- c) administering said method of treatment to said patient.
- 5 98. The method of claim 97, wherein said at least one gene comprises a gene listed in Table 1 or comprises a gene in a pathway listed in Table 1 herein.
 - 99. The method of claim 97, wherein said condition or disease is a condition or disease listed in the Detailed Description, Examples, or Tables herein.
- 100. The method of claim 97, further comprising determining the presence or absence of said at least one variance in cells of said patient.
- 101. The method of claim 97, wherein said at least one variance comprises a plurality of variances.
 - 102. The method of claim 97, wherein said list of variances comprises a plurality of variances.
- 20 103. The method of claim 102, wherein said plurality of variances comprises a haplotype or haplotypes.
 - 104. The method of claim 97, wherein said method of treatment comprises the administration of a compound effective against said disease or condition.
- 25 105. The method of claim 97, wherein said treatment is a first treatment and the presence or absence of at least one variance in said gene is indicative that a second treatment will be beneficial to reduce a deleterious effect or promotes efficacy of said first treatment.
- 30 106. The method of claim 97, wherein said at least one method of treatment is a plurality of methods of treatment.
 - 107. The method of claim 97, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of

10

15

20

25

35

blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

- 108. A method of treating a patient suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition, comprising:
- a) comparing the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 in cells of a patient suffering from said disease or condition with a list of variances in said gene indicative of the effectiveness of at least one method of treatment;
- b) eliminating a method of treatment from said at least one method of treatment, wherein the presence or absence of at least one of said at least one variance is indicative that said method of treatment will be ineffective or contraindicated in said patient;
- c) selecting an alternative method of treatment effective to treat said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and
 - e. administering said alternative method of treatment to said patient.
- 30 109. The method of claim 108, further comprising determining the presence or absence of said at least one variance in cells of said patient.
 - 110. The method of claim 108, wherein said at least one gene comprises a gene in the acetylcholine pathway; the CNS lipid transport/membrane repair pathway; the prostaglandin, prostacylin and thromboxane pathway, or is a gene involved in Alzheimer's disease neurofibrillary plaque formation or in susceptibility to Alzheimer's disease.

10

15

20

25

30

35

- 111. The method of claim 108, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.
- 112. A method for producing a pharmaceutical composition, comprising:
- a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23;
- b) compounding said pharmaceutical composition by combining said compound and a pharmaceutically acceptable carrier or excipient or diluent in a manner adapted to be preferentially effective in patients having said at least one variance.
- 113. A method for producing a pharmaceutical agent, comprising:
- a) identifying a compound which has differential activity against a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in patients having at least one variance in a gene from Tables 1-6, 12-17, and 18-23; and
- b) synthesizing said compound in an amount sufficient to provide a pharmaceutical effect in a patient suffering from said neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition.
- 114. A method for determining whether a variance in a gene from Tables 1-6, 12-17, and 18-23 provides variable patient response to a method of treatment for a disease or condition, comprising:

determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition;

determining whether the presence or absence of at least one variance in said gene differs between said first patient or set of patient and said second patient or set of patients;

25

30

35

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

- 5 115. The method of claim 114, further comprising identifying at least one variance in a said gene.
 - 116. The method of claim 114, wherein a plurality of pairwise comparisons of treatment response and the presence or absence of at least one variance are performed for a plurality of patients.
 - 117. The method of claim 114, wherein said determining whether the presence or absence of at least one variance in at least one gene comprises comparing the response of at least one patient homozygous for said at least one variance with at least one patient homozygous for the alternative form of said at least one variance.
- 15 118. The method of claim 114, wherein said determining whether the presence or absence of said at least one variance in at least one gene comprises comparing the response of at least one patient heterozygous for said at least one variance with the response of at least one patient homozygous for said at least one variance.
- 20 119. The method of claim 114, wherein it is previously known that patient response to said method of treatment is variable.
 - 120. The method of claim 114, wherein said disease or condition is a disease or condition listed in the Detailed Description, Examples, or Tables herein.
 - 121. The method of claim 114, wherein said disease or condition is selected from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, spasticity, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia,

adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease.

- 122. The method of claim 114, wherein said method of treatment comprises administration of a compound effective to treat said disease or condition.
 - 123. A method of treating a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition in a patient, comprising
 - a) selecting a patient whose cells comprise an allele of a gene from Tables 1-6, 12-17, and 18-23, wherein said allele comprises at least one variance correlated with more effective treatment of said neurological or psychiatric disease, druginduced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or condition; and
 - b) altering the level of activity in cells of said patient of a product said allele, wherein said altering provides a therapeutic effect.
 - 124. A method for determining a method of treatment effective to treat a disease or condition in a sub-population of patients, comprising

altering the level of activity of a product of an allele of a gene from Tables 1-6, 12-17, and 18-23; and

determining whether said alteration provides a differential effect related to reducing or alleviating a disease or condition as compared to at least one alternative allele, wherein the presence of a said differential effect is indicative that said altering the level of activity comprises an effective treatment for said disease or condition in said sub-population.

- 125. A method for performing a clinical trial or study, comprising selecting or stratifying subjects using a variance or variances or haplotypes from one or more genes specified in Tables 1-6, 12-17, and 18-23.
- 126. The method of claim 125, wherein differential efficacy, tolerance, or safety of a treatment in a subset of patients who have a particular variance, variances, or haplotype in a gene or genes from Tables 1-6, 12-17, and 18-23, comprising

20

5

10

15

30

10

15

25

conducting a clinical trial and using a statistical test to assess whether a relationship exists between efficacy, tolerance, or safety with the presence or absence of any of said variances or haplotype in one or more of said genes.

wherein results of said clinical trial or study are indicative whether a higher or lower efficacy, tolerance, or safety of said treatment in said subset of patients is associated with any of said variance or variances or haplotype in one or more of said gene.

127. The method of claim 125 wherein normal subjects or patients are prospectively stratified by genotype in different genotype-defined groups, including the use of genotype as a enrollment criterion, using a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23, and subsequently a biological or clinical response variable is compared between the different genotype-defined groups.

128. The method of claim 125 wherein the normal subjects or patients in a clinical trial or study are stratified by a biological or clinical response variable in different biologically or clinically-defined groups, and subsequently the frequency of a variance, variances or haplotypes from Tables 1-6, 12-17, and 18-23 is measured in the different biologically or clinically defined groups.

- 129. The method of claim 127 or 128 where the normal subjects or patients in a clinical trial or study are stratified by at least one demographic characteristic selected from the goups consisting of sex, age, racial origin, ethnic origin, or geographic origin.
- 130. The method of claim 125, wherein said determining comprises assigning said patient to a group to receive said method of treatment or to a control group.
- 131. A method for determining whether a variance in a gene provides variable patient response to a method of treatment for a disease or condition, comprising determining whether the response of a first patient or set of patients suffering from a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or

20

25

30

35

renal disease, or proliferative disease or condition differs from the response of a second patient or set of patients suffering from said disease or condition:

determining whether the presence or absence of at least one variance in a gene from Tables 1-6, 12-17, and 18-23 differs between said first patient or set of patient and said second patient or set of patients;

wherein correlation of said presence or absence of at least one variance and the response of said patient to said treatment is indicative that said at least one variance provides variable patient response.

132. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or diagnosed with a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

identifying a said patient and determining the patient's genotype allele status for a gene from Tables 1-6, 12-17, and 18-23;

determining a treatment protocol using the patient's genotype status to provide a prediction of the efficacy and safety of a therapy in light of a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or an associated pathological condition.

133. A method for identifying a patient for participation in a clinical trial of a therapy for the treatment of neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease or disorder, comprising

identifying a patient with a disease risk and determining the patient's genotype, allele status for an identified gene from Tables 1-6, 12-17, and 18-23.

134. The method of claim 133, further comprising

determining the patient's allele status and selecting those patients having at least one wild type allele of said gene as candidates likely to develop a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

10

15

20

25

30

35

135. A method for treating a patient at risk for a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

identifying a patient with a risk for said disease;

determining the genotypic allele status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23; and

converting the genotypic allele status into a treatment protocol that comprises a comparison of the genotypic allele status determination with the allele frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

136. A method for treating a patient at risk for or diagnosed with having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

identifying a said patient;

determining the gene allele load status of the patient for at least one gene from Tables 1-6, 12-17, and 18-23 and converting the gene allele load status into a treatment protocol that includes a comparison of the allele status determinations with the allele frequency of a control population, thereby allowing a statistical calculation of the patient's risk for having having a neurological or psychiatric disease, druginduced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease.

137. A method for improving the safety of candidate therapies associated with having a neurological or psychiatric disease, drug-induced disease or toxicity, inflammation or immune disease, endocrine or metabolic disease, cardiovascular or renal disease, or proliferative disease, comprising

comparing the relative safety of the candidate therapeutic intervention in patients having different alleles in one or more than one of the genes listed in Tables 1-6, 12-17, and 18-23, thereby identifying subsets of patients with differing safety of the candidate therapeutic intervention.

138. A kit for determination of the presence or absence of at least one sequence variance in a gene identified in any of Tables 1-6, 12-17, and 18-23, comprising

at least one probe that preferentially hybridizes with a nucleic acid sequence corresponding to a portion of said gene or at least one primer comprising a nucleic acid sequence corresponding to a portion of said gene or a sequence complementary thereto or both said at least one probe and said at least one primer.

5

139. A method for determining whether there is a genetic component to intersubject variation in a surrogate treatment response, comprising:

10

a. administering said treatment to a group of related normal subjects and a group of unrelated normal subjects;

••

b. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;

15

c. performing a statistical test measuring the variation in response in said group of related normal subjects and, separately in said group or unrelated normal subjects;

d. comparing the magnitude or pattern of variation in response or both between said groups to determine if the responses of said groups are different, using a predetermined statistical measure of difference,

20

wherein a difference in response between said groups is indicative that there is a genetic component to intersubject variation in said surrogate treatment response.

25

140. The method of claim 129, wherein the size of the related and unrelated groups is set in order to achieve a predetermined degree of statistical power.

30

35

141. A method for evaluating the combined contribution of two or more variances to a surrogate drug response phenotype in subjects, comprising:

study of specific

- a. genotyping a set of unrelated subjects participating in a clinical trial or study of a compound for two or more variances to identify subjects with specific genotypes, wherein said two or more specific genotypes define two or more genotype-defined groups;
- b. administering a drug to subjects with two or more of said specific genotypes;

15

20

25

- c. measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in said subjects;
- d. performing statistical tests to measure response in said groups separately, wherein said statistical tests provide a measurement of variation in response with each said group;
- e. comparing the magnitude or pattern of variation in response or both between said groups to determine if said groups are different using a predetermined statistical measure of difference.
- 10 142. The method of claim 141, wherein said clinical trial or study is a Phase I clinical trial or study.
 - 143. The method of claim 141, wherein said specific genotypes are homozygous genotypes for two variances.
 - 144. The method of claim 141, wherein the comparison is between groups of subjects differing in three or more variances.
 - 145. A method for providing contract research services to a client, comprising:
 - a. enrolling subjects in a clinical drug trial or study unit for the purpose of genotyping said subjects in order to assess the contribution of one or more variances or haplotypes to variation in drug response;
 - b. genotyping said subjects to determine the status of one or more variances in said subjects;
 - c. administering a compound to said subjects and measuring a surrogate drug response variable;
 - d. comparing responses between two or more genotype-defined groups of said subjects to determine whether there is a genetic component to the interperson variability in response to said compound; and
 - e. reporting the results of said clinical drug trial or study unit to a contracting entity.

10

15

20

25

30

35

- 146. The method of claim 145, wherein said clinical drug trial or study unit is a Phase I drug trial or study unit.
- 147. The method of claim 145, wherein at least some of the subjects have disclosed that they are related to each other and said comparing includes comparison of groups of related individuals.
 - 148. The method of claim 147, wherein the related individuals are encouraged to participate by compensation in proportion to the number of their relatives participating.
 - 149. A method for recruiting a clinical trial or study population for studies of the influence of one or more variances or haplotypes on drug response, comprising soliciting subjects to participate in said clinical trial or study; obtaining consent of said subjects for participation in said clinical trial or study;

obtaining additional related subjects for participation in said clinical trial by compensating one or more of the related subjects for said participation at a level based on the number of related subjects participating or based on participation of at least a minimum specified number of related subjects.

from the group consisting of neoplastic disorders, amyotrophic lateral sclerosis, anxiety, dementia, depression, epilepsy, Huntington's disease, migraine, demyelinating disease, multiple sclerosis, pain, Parkinson's disease, schizophrenia, psychoses, and stroke, drug-induced diseases, disorders, or toxicities consisting of blood dyscrasias, cutaneous toxicities, systemic toxicities, central nervous system toxicities, hepatic toxicities, cardiovascular toxicities, pulmonary toxicities, and renal toxicities, arthritis, chronic obstructive pulmonary disease, autoimmune disease, transplantation, pain associated with inflammation, psoriasis, atherosclerosis, asthma, inflammatory bowel disease, and hepatitis, diabetes mellitus, metabolic syndrome X, diabetes insipidus, obesity, contraception, infertility, hormonal insufficiency related to aging, osteoporosis, acne, alopecia, adrenal dysfunction, thyroid dysfunction, and parathyroid dysfunction, anemia, angina, arrhythmia, hypertension, hypothermia, ischemia, heart failure, thrombosis, renal disease, restenosis, and peripheral vascular disease

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 31 August 2000 (31.08.2000)

(10) International Publication Number WO 00/50639 A3

(51) International Patent Classification7:	C12Q 1/68	(81) Designated States (national): AL, AM, AT, AU, AZ, BA,
		BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES,
(21) International Application Number:	PCT/US00/01392	FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
. ,		KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,
(22) International Filing Date: 20 January 2000 (20.01.2000)		MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
. ,		SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
(25) Filing Language:	English	YU, ZW.
(26) Publication Language:	English	(84) Designated States (regional): ARIPO patent (GH, GM,
(-,		KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(30) Priority Data:		
(DV) I I IVE ICY IVE ICE.		(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent

60/121,047 22 February 1999 (22.02.1999) US 60/139,440 15 June 1999 (15.06.1999) US 20 July 1999 (20.07.1999) 09/357,743 US

(71) Applicant (for all designated States except US): VARIA-GENICS, INC. [US/US]; 60 Hampshire Street, Cambridge, MA 02139-1562 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): STANTON, Vincent, Jr. [US/US]; 32 Royal Road, Belmont, MA 02173 (US).

(74) Agent: AMES, Wesley, B.; Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 (US).

(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,

GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 10 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

(57) Abstract: The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

INTERNATIONAL SEARCH REPORT

International Application No.

			10.703 00	7 01332		
A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68						
According to	o International Patent Classification (IPC) or to both national classific	cation and IPC				
B. FIELDS	SEARCHED					
Minimum do IPC 7	currentation searched (classification system tollowed by classification ${\tt C12Q}$	tion symbols)				
Documentat	tion searched other than minimum documentation to the extent that	such documents are incl.	ided in the fields s	earched		
	ata base consulted during the international search (name of data base)	ase and, where practical,	search terms used	1)		
MEDLIN	E, EPO-Internal, BIOSIS					
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the re-	elevant passages		Relevant to claim No.		
χ	MARSHALL ET AL.: "Getting the right drug 1 into the right patient"					
	NATURE BIOTECHNOLOGY, vol. 15, November 1997 (1997-11), pages 1249-1252, XPO02178096					
	page 1249, middle column -page 1 left-hand column 	250,				
χ	VUORISTO ET AL.: "Expression and	d		1		
	therapeutic response related to apolipoprotein E polymorphism in primary					
:	biliary cirrhosis"					
	JOURNAL OF HEPATOLOGY, vol. 27, no. 1, July 1997 (1997-07), pages					
	136-142, XP001024390					
	page 139, right-hand column -page 141, left-hand column					
		_/				
		,				
Further documents are listed in the continuation of box C. Patent family members are listed in annex.						
* Special categories of cited documents : 'T' later document published after the international filing date						
A document defining the general state of the art which is not considered to be of particular relevance or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention						
"E" earlier document but published on or after the international filing date "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone						
which is cited to establish the publication date of another citation or other special reason (as specified) 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the						
O document referring to an oral disclosure, use, exhibition or other means, such combined with one or more other such document, such combination being obvious to a person skilled in the art.						
"P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family						
Date of the a	Date of the actual completion of the international search Date of mailing of the international search report					
24	September 2001	09/10/20	001			
Name and m	ailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer				
	NL - 2280 HV Rijswijk. Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	van Klom	penburg, k	ı İ		

INTERNATIONAL SEARCH REPORT

Internal Application No
PC (/US 00/01392

			PC1/US 00/01392		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
X	ARRANZ ET AL.: "Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine" MOLCECULAR PSYCHIATRY, vol. 3, no. 1, January 1998 (1998-01), pages 61-66, XP001024470 abstract; tables 1-3 page 64, right-hand column -page 65, right-hand column page 61, left-hand column -page 62, left-hand column		1		
X	STEEN ET AL.: "The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness" PHARMACOGENETICS, vol. 8, no. 3, June 1998 (1998-06), pages 259-268, XP001024444 abstract; tables 1-3		1		

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 145-149

Claims 145-149 relate to methods for providing contract research and methods for recruiting a clinical trial or study population which are considered as methods for doing business under the provisions of Article 17(2)(a)(i) and Rule 39.1(iii), PCT. These methods are therefore excluded from search.

Continuation of Box I.2

Claims Nos.: 1-149

The present application relates to gene sequence variations which are useful in selecting suitable treatments of various diseases. The application provides extensive listings and tables relating to human genes, gene sequence variations, diseases and compounds. No individual links are provided between the gene sequence variations and the suitable compound for treating the corresponding disease.

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible.

Additionally, present claims 1-149 relate to an extremely large number of possible compounds and methods. In fact, the claims contain so many options and possible combinations of elements from the different tables, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Independently from the above, because of the large number of elements raising from the various tables, non-unity objections will almost certainly be made when in a later EP regional stage a search is required.

Present claims 58-66 also lack clarity (Article 6 PCT), since they relate to pharmaceutical compositions defined by reference to a desirable characteristic or property, namely having a differential effect in patients having at least one copy of a particular form of an identified gene.

An attempt is made to define the pharmaceutical compositions by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search of the claimed scope impossible.

Claims 89-110,123,124,131,132,135,136,139,141-144 relate to methods of treatment of the human body. Normally the search would be based and

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

performed on the alleged effects of the compounds. However, considering the shortcomings, especially the lack of conciseness and clarity mentioned above, no search could be performed.

Since for the reasons stated above a complete search was impossible, a limited search for the general principle underlying the first independent claim (claim 1), i.e. a method of selecting a treatment on basis of gene variance, was performed. The many documents retrieved also feature some of the genes mentioned in the many tables of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.